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Abstract 
Chronic meningeal inflammation is suggested to contribute to the progression of secondary 
progressive multiple sclerosis (SPMS) in part by driving cortical grey matter pathology. The 
presence of tertiary lymphoid organ-like (TLO) structures in a large proportion of SPMS cases 
is associated with faster clinical progression and more severe cortical pathology, suggesting 
that TLO neogenesis and chronic meningeal inflammation contribute to progression. Gene 
expression of the cytokine lymphotoxin-alpha (LTα), implicated in TLO formation and 
cytotoxicity, and the lymphoid chemokines CXCL13 and CCL21, was determined in post-
mortem SPMS meninges by qPCR. LTα was increased in SPMS, while substantially increased 
CXCL13 expression was associated with the presence of TLOs in SPMS. 
 
As LTα induces CXCL13 during inflammation, we investigated the hypothesis that LTα drives 
TLO formation and exacerbates cortical pathology in SPMS, using an animal model of cortical 
demyelination driven by meningeal inflammation. Subclinical experimental autoimmune 
encephalomyelitis was induced in female dark agouti rats by immunisation with 5-10μg of 
recombinant mouse myelin oligodendrocyte glycoprotein (rmMOG) in incomplete Freund’s 
adjuvant. Injection of LTα and the cytokine interferon-γ into the subarachnoid space 21 days 
post-immunisation induced substantial meningeal infiltration with B cell-rich areas, T cells, 
macrophages and channel formation reminiscent of early TLOs, accompanied by microglial 
activation, extensive demyelination, and remyelination within 21 days.   
 
To study chronic meningeal cytokine expression we injected a VSV-G pseudotyped lentiviral 
vector (LV) expressing green fluorescent protein (GFP) or human LTα (LVLTα) into the 
subarachnoid space. Meningeal GFP expression was induced up to 90 days post-injection. 
Human LTα expression was detected in rat brain and CSF, with widespread microglial 
activation and meningeal infiltrates of macrophages, B and T cells resembling TLOs, in naïve 
and rmMOG-immunised rats at 90 days post-LVLTα, while extensive demyelination was 
present only in rmMOG-immunised rats. This suggests that chronic meningeal LTα expression 
is sufficient for widespread microglial activation, but demyelination requires an anti-myelin 
response in this model. These findings support the hypothesis that chronic meningeal 
inflammation drives cortical pathology, and LTα / TLO neogenesis may represent a novel 
therapeutic target for SPMS.  
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1.1 Multiple sclerosis  
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) and is 
the leading cause of neurological disability in young adults (Hellings et al., 2002; Compston 
and Coles, 2008). The disease is characterised by the development of foci of inflammation, 
which are accompanied by loss of the insulating myelin sheath that surrounds axons 
(demyelination), astrogliosis and the formation of sclerotic plaques. Demyelinated lesions are 
disseminated throughout the CNS and are thought to develop via an auto-immune response 
against components of the myelin sheath. Reduction of conduction velocity through axons 
within the lesions, and axonal damage and loss, contribute to a reduction in neurological 
function, while dissemination of the lesions within the CNS gives rise to varied sensory, 
cognitive and motor symptoms.  
1.1.1 Epidemiology and aetiology 
MS is thought to result from a complex interaction between genetic susceptibility followed by 
an environmental trigger (Compston and Coles, 2008). The prevalence of MS varies with 
geographical location, with higher prevalence being associated with higher latitude, indicating 
an environmental component to the aetiology of the disease, which has yet to be 
comprehensively determined (Simpson et al., 2011). Meta-analysis of individual studies has 
yielded conflicting conclusions on this association however, depending on whether the data is 
adjusted for age and sex (Zivadinov et al., 2003), or the year the individual studies were 
completed, with a decreasing effect of latitude in post-1980 studies being ascribed to 
increasing incidence of MS at lower latitudes (Alonso and Hernan, 2008). All meta-analyses 
studies are subject to a certain amount of bias due to the lack of incidence studies conducted 
in Asia, Central or South America or Africa. 
Migration studies suggest that the risk of development of MS is influenced by the country of 
origin if migration occurs after 15 years of age, and that those younger than 15 years will adopt 
the MS risk of the country to which they migrate, supporting the case for environmental factors 
acting in early life to impact MS susceptibility (Dean and Elian, 1997; Handel et al., 2010). 
Reduced sun exposure has been suggested to link the association of higher latitudes with 
higher prevalence of MS, and increased outdoor activities during childhood is associated with 
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a decreased risk of MS (Kampman et al., 2007). It is not clear whether the effects of sun 
exposure on MS susceptibility reflects the effects of vitamin D levels, but high serum 
concentrations of the vitamin D precursor are protective against the development of MS, 
particularly under 20 years of age (Munger et al., 2006).   
A well-documented relationship exists between Epstein-Barr virus (EBV) seropositivity and 
susceptibility to MS, as 99.5% of MS patients have EBV antibodies (Bray et al., 1983; 
Sundstrom et al., 2004; Ascherio and Munger, 2007). In addition, anti-EBV antibody levels 
have been found to correlate with magnetic resonance imaging (MRI) activity and grey matter 
(GM) atrophy (Zivadinov et al., 2009; Kvistad et al., 2014). However, prevalence of EBV is 
high in age- and sex- matched controls (90-95%), so the majority of seropositive individuals do 
not develop MS, indicating that EBV may represent a necessary but not sufficient factor for MS 
(Ascherio and Munger, 2007; Handel et al., 2010).  
A recent meta-analysis of twin studies confirmed evidence for a significant contribution of 
genetic factors in MS susceptibility. Genetic variation was estimated to be responsible for 40-
60% of the difference in susceptibility to MS between individuals (Fagnani et al., 2015). 
Variation in the human leukocyte antigen (HLA) regions that encode glycoproteins involved in 
self- and non-self-antigen presentation has been known to be associated with increased MS 
susceptibility for over 40 years (Jersild et al., 1973), and supports the hypothesis that MS 
pathogenesis is primarily immune-mediated (Gourraud et al., 2012). Indeed, other non-HLA, 
MS-associated loci were found to be located close to or within genes for immune system 
components (Gourraud et al., 2012). A recent genome-wide association study (GWAS) 
confirmed that the HLA-DRB1*15:01 haplotype is the single strongest susceptibility locus in 
MS (Sawcer et al., 2011; Gourraud et al., 2012). The GWAS study also uncovered an MS 
association with CYP27B1, a gene involved in vitamin D metabolism, supporting an interaction 
between genetic and environmental factors in MS susceptibility (Sawcer et al., 2011; Gourraud 
et al., 2012). 
1.1.2 Diagnosis and clinical course 
Since the age of onset is variable in MS, it is possible that environmental factors may continue 
to impact MS susceptibility in early adulthood. Analysis of 431 cases from the population-
based cohort held in the UK MS Tissue Bank revealed the median age of disease onset to be 
31.5 years, age at progression to SPMS was 44, age of progression to wheelchair use was 50 
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and age at death was 62 (Reynolds et al., 2011). The median time to death from onset is 
approximately 30 years, with a reduction of life expectancy of 5-10 years (Bronnum-Hansen et 
al., 2004). The cause of death is attributed to MS in 60% of MS patients, with the remaining 
40% of deaths attributed to complications from infections and increased rates of suicide 
(Compston and Coles, 2008; Reynolds et al., 2011). In keeping with other auto-immune 
diseases the ratio of women affected compared to men is approximately 2:1, although this 
ratio varies and may be significantly higher depending on geographical location (Orton et al., 
2006).  
The symptoms of MS largely depend on the site of lesion pathology, but may include 
impairments in speech, swallowing, vision, bladder and/or sexual function, and cognitive 
and/or motor function. Weakness, pain and fatigue are also common. In addition, Uhtoff’s 
phenomenon (increased severity of MS symptoms upon bodily overheating due to weather, 
hot baths, exercise or fever) and Lhermitte’s symptom (electrical sensation following spine or 
neck flexion) are characteristic of MS (Compston and Coles, 2008).  
Diagnosis of MS requires exclusion of alternative conditions together with demonstration of 
dissemination of lesions in space and time, which can be made using clinical criteria alone, or 
increasingly supported by magnetic resonance imaging (MRI) of the CNS as set out in the 
revised McDonald criteria (Polman et al., 2011). Demonstration of dissemination of lesions in 
time can be achieved by observation of both gadolinium-enhancing and non-enhancing lesions 
in one MRI scan, or evidence of a new T2 lesion or clinical event in those patients who do not 
show evidence of both enhancing and non-enhancing lesions on a baseline MRI (Polman et 
al., 2011). Dissemination of lesions in space can be demonstrated by observation of a 
minimum of 1 T2 lesion in at least 2 of 4 locations that are considered to be characteristic for 
MS (juxtacortical, periventricular, infratentorial and the spinal cord) according to the original 
McDonald criteria (Polman et al., 2011). The presence of an increased immunoglobulin (Ig) 
index or at least 2 oligoclonal bands in the cerebrospinal fluid (CSF) is also used to support 
the diagnosis of MS, since a meta-analysis has shown that oligoclonal bands were found in 
87.7% of over 12,000 MS patients in 71 studies (Dobson et al., 2013). 
MS presents in 80% of patients as one acute episode of neurological dysfunction, known as 
clinically isolated syndrome (CIS). The isolated attack is followed by recovery (remission) and 
then further periods of neurological dysfunction (relapses), at which point the condition is 
termed relapsing-remitting MS (RRMS). Relapse frequency varies between individuals but has 
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been estimated to be approximately 1.5 per annum (Compston and Coles, 2008). Following 
this, approximately 65% of RRMS cases develop secondary progressive MS (SPMS), in which 
acute relapses are absent but where there is a gradual and progressive accumulation of 
disability due to incomplete recovery between relapses. In approximately 10-20% of MS 
patients, the disease course is progressive from the outset, lacks remission periods and is 
termed primary progressive MS (PPMS) (Reynolds et al., 2011). 
1.2 White matter pathology 
Historically MS has been considered a white matter (WM) disease, since the pathological 
hallmark of MS is the presence of multiple, focal, demyelinated WM lesions (WMLs) 
accompanied by oligodendrocyte loss, and perivascular infiltration of T lymphocytes and 
monocytes/macrophages (Compston and Coles, 2008; Reynolds et al., 2011). Evidence of 
astrocyte hypertrophy and damage has been observed surrounding perivascular infiltrates, 
and as an early event at the margins of acute lesions in the parenchyma, eventually leading to 
formation of astrocytic scars and the characteristic sclerotic plaques (Brosnan and Raine, 
2013). Lesions can arise throughout the CNS but are often associated with anatomical 
locations that are characteristic for MS (Polman et al., 2011). 
1.2.1 Pathogenesis of WMLs 
Pathology in early-stage RRMS has been suggested to mainly affect the white matter, 
although the difficulty of detecting GM lesions (GMLs) is a confounding factor (Lassmann, 
2014). Inflammation is closely associated with acute relapses, and active WMLs are 
accompanied by blood-brain barrier (BBB) leakage, neurodegeneration, demyelination, 
activated microglia and an accumulation of macrophages (Lassmann, 2014). Cytotoxic CD8+ 
T cells are the predominant cell type within inflammatory infiltrates, and are clonally expanded 
in active lesions (Babbe et al., 2000). Fewer B cells and CD4+ T cells are observed compared 
to CD8+ T cells, and they predominantly accumulate in the meninges and perivascular spaces 
(Serafini et al., 2004).  
Although MS lesions are characterised by primary demyelination, where myelin destruction 
occurs with relative preservation of axons, it is now accepted that axonal injury and loss 
accompanies the demyelinating pathology in early MS lesions. Transected axons are 
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commonly observed, and incidence is correlated with the degree of inflammation (Ferguson et 
al., 1997; Trapp et al., 1998). Demyelination of axons impairs conduction velocity through 
lesions, may result in spontaneous discharge and increases sensitivity to mechanical stimuli, 
resulting in distortion of senses and varied symptoms including Lhermitte’s symptom 
(Compston and Coles, 2008). Loss of axons is postulated to underlie the accumulation of 
irreversible disability (Reynolds et al., 2011). Several pathogenic processes are suggested to 
play a role in axonal degeneration, including loss of trophic support from oligodendrocytes, 
oxidative damage, energy failure and sodium ion accumulation within axons (Franklin et al., 
2012). Inflammation is closely correlated with axonal loss in all lesion types and at all disease 
stages of MS, and axonal damage is most prominent in early MS in active lesions with 
prominent inflammation, suggesting a key role of inflammation in disease progression (Trapp 
et al., 1998; Bitsch et al., 2000; Kuhlmann et al., 2002; Frischer et al., 2009). As MS 
progresses, inflammation is suggested to decrease in NAWM and lesions to levels seen in 
age-matched controls (Frischer et al., 2009). This is suggested to be accompanied by diffuse 
injury of NAWM and NAGM, widespread cortical demyelination and expansion of existing 
WMLs behind an intact BBB, resulting in brain atrophy (Kutzelnigg et al., 2005; Lassmann et 
al., 2012). However the sequence of events and mechanisms of disease progression remain 
speculative, due to the reliance on data from autopsy/biopsy material, which necessarily 
represents a single time-point and gives limited information on the development of pathology.  
The order of pathological events in WML formation and demyelination thus remains unclear in 
spite of extensive research. Demyelination is suggested to occur via autoimmune-mediated 
destruction of the myelin sheath (Lassmann et al., 2001). Autoreactive T helper (Th) CD4+ 
lymphocytes specific for myelin component self-antigens are proposed to be activated in the 
periphery, expand and migrate across the BBB (Hafler and Weiner, 1987). Highly activated T 
cells have been shown to cross the non-inflamed BBB in vivo (Vajkoczy et al., 2001; 
Laschinger et al., 2002; Englelhardt, 2010), or may enter via the choroid plexus which 
constitutively expresses adhesion molecules and chemokines (Steffen et al., 1996; Ransohoff 
et al., 2003; Reboldi et al., 2009). Controversy exists over whether migration of peripherally 
activated autoreactive CD4+ and cytotoxic CD8+ T lymphocytes across the BBB is secondary 
to oligodendrocyte apoptosis and microglial activation (Barnett and Prineas, 2004; Reynolds et 
al., 2011). Once in the CNS, autoreactive T cells are reactivated by local antigen presenting 
cells (APCs; perivascular macrophages and microglia) in the subarachnoid and perivascular 
spaces (Shrikant and Benveniste, 1996; Reboldi et al., 2009). Reactivation of autoreactive T 
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cells results in release of pro-inflammatory cytokines including interferon gamma (IFNγ) and 
tumour necrosis factor (TNF), leading to direct cytotoxicity to oligodendrocytes (Buntinx et al., 
2004), activation of the BBB and upregulation of adhesion molecules (Hellings et al., 2002; 
Compston and Coles, 2008). BBB activation is suggested by in vivo studies to induce a 
second wave of infiltration of other inflammatory cell types including B lymphocytes, plasma 
cells and monocytes, which accumulate in the meninges and form perivascular cuffs in the 
WM (Hellings et al., 2002; Serafini et al., 2004; Compston and Coles, 2008; Reboldi et al., 
2009). Myelin phagocytosis by macrophages may be enhanced by autoantibodies to myelin 
components including myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein 
(MBP), which have been found in MS CSF, and deposition of complement (Reindl et al., 1999; 
Breij et al., 2008; Sadaba et al., 2012; Ingram et al., 2014). 
Different mechanisms of demyelination may operate at different stages of the disease course, 
as heterogeneity of lesions has been noted in biopsies from early MS (Lucchinetti et al., 2000). 
Four patterns of demyelination were observed in early MS; patterns I and II were characterised 
by macrophage and T cell infiltration, with the additional observation of complement and 
antibody deposition in pattern II lesions. Pattern III lesions were characterised by apoptosis 
and loss of oligodendrocytes throughout the lesion, while loss of oligodendrocytes without 
signs of apoptosis was observed adjacent to the edge of active demyelination in pattern IV 
(Lucchinetti et al., 2000). In contrast, homogeneity of lesions was found in autopsy samples 
from cases with established MS, where antibody- and complement- mediated mechanisms of 
demyelination were found to predominate, suggesting that the heterogeneity of mechanisms 
that may be present in early disease may diminish with disease progression and converge to a 
unifying disease process (Breij et al., 2008). However, very few studies have been conducted 
using early stage MS tissue due to its limited availability, so the mechanisms of pathogenesis 
remain unclear, and suggestions are largely based on data from in vivo models. 
1.2.2 Classification of WMLs 
Several classification systems for stages of WML development have been created in an 
attempt to determine the time-course of pathogenic mechanisms, and since no single ideal 
system has been agreed on, use depends largely on the suitability of the material available 
(Van Der Valk and De Groot, 2000). WMLs are most often classified according to the extent of 
inflammation present and may be either active, chronic active or chronic inactive. Active 
lesions are characterised by macrophage infiltration throughout the lesion, while infiltration is 
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restricted to the lesion edge in chronic active lesions and is largely absent in chronic inactive 
lesions (Van Der Valk and De Groot, 2000). Identification of the degraded myelin proteins 
within infiltrating macrophages is also used as a marker of lesion stage. MOG and other minor 
components of the myelin sheath are rapidly degraded, so their presence within macrophages 
indicates an early lesion, while proteolipid protein (PLP) and MBP are degraded more slowly, 
indicating a later stage active lesion (Bruck et al., 1995; Van Der Valk and De Groot, 2000). 
Chronic inactive lesions are defined as hypocellular lesions with little infiltration, in which 
macrophages typically contain empty vacuoles or periodic acid-Schiff (PAS)-positive 
degradation products (Bruck et al., 1995; Trapp et al., 1998; Van Der Valk and De Groot, 
2000). Early remyelinating lesions are characterised by pronounced lymphocytic and 
macrophage infiltration and the presence of axons surrounded by thin myelin sheaths, while 
late remyelinated lesions (also known as shadow plaques) are associated with minimal 
macrophage infiltration, thin myelin sheaths around axons and astrogliosis (Bruck et al., 1995). 
1.2.3 Failure of repair and disease progression 
Evidence of remyelination at the edge of WMLs can be observed as the wrapping of naked 
axons in thin single, bi- or tri-lamellar sheaths of oligodendrocyte cytoplasmic processes using 
electron microscopy (Perier and Gregoire, 1965). Remyelination occurs as an early event in 
lesion formation and often occurs at the same time as demyelination (Prineas et al., 1984). 
Remyelinated lesions are frequently observed in early MS (Prineas et al., 1993a; Goldschmidt 
et al., 2009) but in approximately 20% of chronic lesions the average extent of remyelination is 
47%, suggesting that extensive remyelination of WM can occur even in progressive MS 
(Patrikios et al., 2006; Patani et al., 2007). However, over time remyelination becomes 
inadequate to prevent the accumulation of disability in the progressive stages of MS. The 
reasons behind the progressive reduction in remyelination efficiency are incompletely 
understood, and are likely to be numerous and varied between individuals (Franklin, 2002). 
Failure of remyelination results in chronically demyelinated lesions, in which naked axons are 
vulnerable to damage, leading to axonal/neuronal loss (Franklin et al., 2012). MRI visualisation 
of the neuron- and axon- specific marker N-acetylaspartate showed a correlation between 
axonal loss and expanded disability scale scores (EDSS) in RRMS patients, but not SPMS 
patients, suggesting that while axonal loss in WMLs contributes to disability in early MS, it 
does not fully account for the accumulation of disability in progressive MS. 
 
Chapter 1 – Introduction   27 
 
1.3 Grey matter pathology  
1.3.1 Cortical GM pathology in MS  
GMLs in MS have been reported since the disease was first described by Charcot in 1887, but 
GML prevalence has previously been underestimated partly due to the low sensitivity of 
conventional histological staining methods, including Luxol Fast Blue, to detect the most 
common type, which are superficially located cortical subpial GMLs (Bo et al., 2003l; Geurts et 
al., 2012; Popescu and Lucchinetti, 2012). Improved MRI imaging protocols have allowed 
increasing visualisation of GMLs and recent studies have reported finding GMLs in 51-73% of 
MS patients depending on the method of MRI scan used, and the MS type, with GMLs being 
more frequent in SPMS compared to RRMS (Calabrese et al., 2007; Crespy et al., 2011; Sethi 
et al., 2012). GMLs have also been observed in the absence of WMLs in pre-diagnosis 
patients, suggesting that GML formation can be an early event in the MS disease course 
(Calabrese and Gallo, 2009). 
Cortical GM pathology is now recognised to play a significant role in the progression of MS 
and is associated with both cognitive and motor disability (Fisniku et al., 2008; Calabrese et 
al., 2009). Cortical GML volume is predictive of subsequent EDSS accumulation and 
correlates more closely with the progression of disability than WML burden (Bo et al., 2003l; 
Fisniku et al., 2008; Calabrese et al., 2010). Further studies have demonstrated that the 
prevalence of GMLs increases in progressive MS, with intracortical lesions being detected in 
73% SPMS patients compared to 64% RRMS patients (Calabrese et al., 2007). The 
prominence and extent of GMLs is also observably increased in PPMS and SPMS compared 
to RRMS patients at autopsy (Kutzelnigg et al., 2005).  
The most simplified and widely used system of classification for cortical GMLs separates the 
different lesion types based on their location, being either leukocortical (overlapping GM and 
WM areas; Type I; Figure 1. 1), intracortical (GM only; Type II) or subpial (underlying the 
meninges; Type III) (Peterson et al., 2001). Subpial lesions exhibit the most extensive areas of 
cortical demyelination, often extending over multiple gyri, and are usually the most numerous 
lesion type, accounting for 50-70% of cortical lesions (Peterson et al., 2001; Bo et al., 2003l; 
Magliozzi et al., 2007).  
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Figure 1. 1 Classification of cortical grey matter lesions 
Immunohistochemistry for myelin oligodendrocyte glycoprotein (MOG) highlights myelin loss in MS 
lesions. Leukocortical (type I) lesions are located on the border between the grey matter (GM) and white 
matter (WM; A). Intracortical (type II) lesions are located entirely within the GM, often surrounding a 
blood vessel (B). Subpial (type III) lesions extend from the pial surface into underlying brain parenchyma 
(C). Arrows indicate the lesion edge in A, B and C. Subpial lesions may extend over serveral gyri, 
resulting in an almost complete loss of myelin in the affected GM (black arrows in D). Separate WM 
lesions may also be present (white arrow in D). Adapted from (Calabrese et al., 2015). 
Macrophage and lymphocytic infiltration of GMLs in progressive MS is markedly reduced 
compared to WMLs, and few lipid-laden phagocytic macrophages are observed in intracortical 
lesions (Bo et al., 2003a; Popescu and Lucchinetti, 2012). However it is still possible to stage 
GMLs in a similar manner to WMLs, by observation of the distribution and density of cells 
expressing major histocompatibility complex (MHC) class II molecules, the majority of which 
have a morphology indicative of activated microglia (Peterson et al., 2001; Bo et al., 2003a; 
Bogie et al., 2014). A clear border of MHC II+ cells was observed at the lesion edge of active 
GMLs, accompanied by increased density of these cells in the lesion core. A border was also 
observed for chronic active lesions, but was associated with decreased or normal density of 
MHC II+ cells in the core, compared to normal appearing grey matter (NAGM). No distinct 
borders were observed in chronic inactive GMLs, and the density of MHC II+ cells in the core 
was comparable to NAGM (Peterson et al., 2001). 
1.3.2 Pathogenesis of cortical GMLs  
Cortical GMLs are characterised by demyelination accompanied by a relative lack of 
perivascular cuffs, lymphocytic infiltration or inflammation within the tissue (Bo et al., 2003a). 
BBB disruption, associated with leakage of plasma proteins and tight junction alteration, is a 
common feature of WMLs but is largely absent in GMLs (Van Horssen et al., 2007). Activated 
microglia are observed to be the major inflammatory cell type within GMLs and their density is 
spatially and quantitatively associated with lymphocyte infiltration of the overlying meninges 
(Peterson et al., 2001; Howell et al., 2011). The number of CD3+ T cells and CD68+ 
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microglia/macrophages present in GMLs is significantly less than the number present in 
WMLs; 13 fold fewer CD3+ T cells and 6 fold fewer CD68+ microglia/macrophages were found 
in GMLs compared to WMLs (Peterson et al., 2001). The difference in cellular infiltration 
between GM and WM is most clearly observed in leukocortical (type I) GMLs, where increased 
numbers of CD3+ T cells were observed in the WM portion of the same lesion, compared to 
the GM portion (Bo et al., 2003a). CD8+ T cells are more prevalent than CD4+ in GML 
parenchyma, particularly at the leading edge of lesions, but a direct cytotoxic effect of these 
cells is thought unlikely to be a significant pathogenic mechanism owing to their low 
abundance (Bo et al., 2003a). CD20+ B cells were rarely observed in the parenchyma and 
were predominantly found within WMLs rather than GMLs.  
Leptomeningeal infiltrates have been suggested to be a source of cytotoxic factors that may 
contribute to oligodendrocyte loss and myelin damage, since subpial lesions were observed to 
extend to a relatively constant depth from the pial surface, indicative of diffusion of a toxic 
factor from the CSF compartment (Bo et al., 2003a). 
1.3.3 Meningeal inflammation contributes to cortical GM pathology 
The meninges consist of 3 membranes: the dura mater, the arachnoid and the pia mater. The 
dura mater forms a thick outer membrane which covers the brain and other meningeal layers, 
and supports the dural venous sinuses (Decimo et al., 2012). The arachnoid and pia mater are 
linked by arachnoid trabeculae, and together form the leptomeninges beneath the dura mater, 
enclosing the subarachnoid space and CSF within. The CSF and meninges provide physical 
protection by cushioning the brain within the skull. In addition, cells within the meninges and 
CSF also play a role in immunological protection of the CNS; the subarachnoid space is a 
major site of antigen presentation and immune cell reactivation in the CNS, and meningeal 
cells are capable of phagocytosis and secretion of cytokines and chemokines in response to 
pro-inflammatory or infectious stimulation (Wells et al., 2001; Wieseler-Frank et al., 2007; Fan 
et al., 2012). During development, the vascular system within the meninges extends into the 
cortex, through the glia limitans that covers the surface of the brain and is composed of a 
basement membrane and astrocyte end-feet (Bechmann et al., 2007). Each extending vessel 
tracks through the glia limitans to form the intracerebral vasculature, ensheathed in the 
meninges, which creates perivascular spaces filled with CSF (Decimo et al., 2012).  
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Diffuse infiltrations of inflammatory cells within the meninges have been observed in autopsy 
material from PPMS and SPMS cases and are particularly associated with extensive subpial 
GMLs (Guseo and Jellinger, 1975; Kutzelnigg et al., 2005; Howell et al., 2011; Choi et al., 
2012). In addition to diffuse meningeal infiltrates, the presence of organised ectopic lymphoid 
follicle-like structures resembling tertiary lymphoid organs (TLOs) has recently been described 
in a significant proportion (40-54%) of SPMS cases (Serafini et al., 2004; Magliozzi et al., 
2007; Magliozzi et al., 2010; Howell et al., 2011). An additional study of biopsy material from 
early MS cases showed the presence of substantial meningeal infiltrates, suggesting that the 
formation of TLOs may be an early event in MS pathology (Lucchinetti et al., 2011).  
TLO formation is predominantly observed in the meninges within deep sulci (rather than in the 
meninges overlying cortical gyri), in the temporal, parietal and frontal lobes, and particularly in 
the insula, and pre-central and cingulate gyri (Magliozzi et al., 2010; Howell et al., 2011). 
SPMS cases in which TLOs are observed have been termed lymphoid follicle positive 
(F+SPMS), compared to lymphoid follicle negative (F-SPMS) cases which lack these 
structures (Magliozzi et al., 2007). The presence of TLOs in F+SPMS cases is associated with 
increased severity of subpial cortical pathology, an earlier age of MS onset, first wheelchair 
use and death compared to F-SPMS (Howell et al., 2011). A significantly increased number of 
GMLs was observed in F+SPMS compared to F-SPMS cases, together with a corresponding 
increase in the extent of GM demyelination (Magliozzi et al., 2007). Type III subpial lesions 
were found to predominate in F+SPMS cases, accounting for 70% of the total GML burden, 
while no preferential distribution was observed in F-SPMS cases (Magliozzi et al., 2007). In 
addition, a gradient of neuronal loss was observed in F+SPMS cases, which was absent in F-
SPMS, suggesting that diffusible cytotoxic factors secreted by TLOs in the meninges may 
contribute to the increased neuronal loss observed in cortical layers I-V in F+SPMS compared 
to F-SPMS cases (Magliozzi et al., 2010).   
Meningeal TLOs consist of proliferating Ki67+ B-cells, plasma cells, follicular dendritic cells 
(FDCs), CD68+ macrophages, CD4+ and CD8+ T cells, and are suggested to contribute to 
underlying cortical GM pathology through expression of cytotoxic cytokines, or by facilitating 
the continued production of autoantibodies, which are thought to play a role in demyelination 
(Lucchinetti et al., 2000; Serafini et al., 2004). A reticulum of CD35+ and CXCL13+ cells 
surrounding proliferating B cells and plasma cells, indicative of the formation of germinal 
centres, was confirmed in all meningeal TLOs (Magliozzi et al., 2007).  
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Intrathecal antibody production is a commonly observed feature of MS, and there is evidence 
for clonal expansion of B cells within the CNS and affinity maturation of antibodies, a process 
normally restricted to germinal centres in lymphoid organs (Colombo et al., 2000; Corcione et 
al., 2004; Beltran et al., 2014). TLOs have therefore been suggested to be the site of 
intrathecal B cell maturation. Increased presence of neuronal antigens in the CSF may 
facilitate autoantibody production by locally activated B cells or by presentation of 
autoantigens to T cells (Serafini et al., 2004). TLOs may also act as a site of Epstein-Barr virus 
persistence and reactivation, resulting in CD8+ T cell mediated targeting of infected B 
lymphocytes which may cause bystander damage of the underlying cortex (Serafini et al., 
2007; Serafini et al., 2010), although the detection of EBV infected B cells within meningeal 
TLOs has proved controversial (Pender, 2009; Willis et al., 2009; Zivadinov et al., 2009). 
Evidence is accumulating that suggests that meningeal inflammation, and particularly the 
formation of meningeal TLOs, contribute to MS progression in a significant proportion of SPMS 
cases, indicating that TLO neogenesis may represent a novel therapeutic target for reducing 
the rate of progression. 
1.4 Immunopathogenesis of MS  
1.4.1 T cells 
MS pathology is suggested to be initiated by infiltration of the CNS by encephalitogenic T cells, 
followed by B cell recruitment and involvement. T helper cells (Th cells) are characterised by 
expression of CD4 molecules and are functionally distinct from cytotoxic T cells which express 
CD8 molecules. The association of MS with particular MHC II haplotypes suggests that 
antigen presentation to CD4+ T cells is a key event in pathogenesis (Gourraud et al., 2012). 
Polarisation of CD4+ Th cells into different functional subsets defined by the secretion of 
signature effector cytokines, following antigen recognition and activation of naïve T cells, is 
influenced by a number of factors, particularly the local cytokine environment (Dittel, 2008; 
Kaiko et al., 2008).  
Th type 1 (Th1) cells typically secrete pro-inflammatory cytokines (IFNγ, TNF and LTα) and 
are important for macrophage activation and cell-mediated immunity, while secretion of 
interleukin (IL)-4, and IL5 is characteristic of Th type 2 (Th2) cells, which are potent helpers of 
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the humoral response and antibody production by B cells (Dittel, 2008; Zhu et al., 2010). 
Historically, the Th1 subset has been thought to be predominantly responsible for pathology, 
since MS-like phenotypes can be induced in naïve mice following adoptive transfer of Th1 but 
not Th2 cells (Khoruts et al., 1995). Also, administration of IFNγ, a Th1 effector cytokine, to 
RRMS patients induced disease exacerbations (Panitch et al., 1987). However the focus on 
the role of the Th1 subset has been shown to be overly simplistic, since other subsets have 
been shown to contribute to pathogenesis in animal models of MS. Investigation into the role 
of the Th17 subset, characterised by the expression of IL17A and IL22, has shown that 
adoptive transfer of MOG-specific Th17 cells in naïve mice induces meningeal TLO formation, 
in addition to an MS-like phenotype (Peters et al., 2011). However, while CD4+ cells are a 
component of perivascular cuffs and have been isolated from MS lesions, they are 
outnumbered by CD8+ cells (Babbe et al., 2000; Skulina et al., 2004). Depletion of CD4+ T 
cells in MS patients also failed to produce an improvement in the number of lesions detected 
by MRI, suggesting that the view of CD4+ T cells as the main pathogenic protagonists in MS 
too narrow (Van Oosten et al., 1997). Further investigation has revealed the important 
contributions of cytotoxic T cells and B cells to MS pathology (Van Oosten et al., 1997; 
Archelos et al., 2000; Bar-Or et al., 2010; Mars et al., 2011).  
CD8+ cytotoxic T cells induce the death of cells expressing their cognate antigen on MHC I 
molecules through a variety of mechanisms, including release of lytic enzymes and Fas ligand-
receptor binding (Mars et al., 2011). CD8+ cells also secrete pro-inflammatory cytokines 
including IFNγ, TNF and LTα, and thereby recruit and activate macrophages and microglia. 
Interestingly, CD8+ T cells from SPMS patients show co-stimulation independent secretion of 
LTα compared to cells isolated from RRMS patients, which is postulated to be a critical stage 
in the progression of MS from the earlier RRMS stage to SPMS, due to the cytotoxic effect of 
secreted LTα (Buckle et al., 2003). Clonal expansions of CD8+ T cells have been observed in 
active lesions (Babbe et al., 2000), CSF (Jacobsen et al., 2002) and serum (Skulina et al., 
2004), and the number of CD8+ T cells correlates with a marker of axonal damage in MS 
lesions, suggestive of an active pathogenic role (Bitsch et al., 2000; Kuhlmann et al., 2002). 
1.4.2 B cells 
B cells form a critical component of the humoral immune response and may be activated in 
either a T cell dependent or independent manner. Naïve B cells which encounter their cognate 
antigen in the secondary lymphoid organs mature into memory B cells, which have undergone 
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somatic hypermutation and isotype class switch to increase the affinity of the antibodies they 
secrete on stimulation. Naïve and memory B cells both express MHC II molecules, enabling 
antigen presentation function to T cells, while memory B cells may terminally differentiate into 
plasma cells, enabling increased secretion of antibodies (Archelos et al., 2000).    
Increasing evidence suggests that B cells play a crucial and pathogenic role in MS, since CSF 
B cell counts correlate with cortical inflammation in RRMS and CIS patients detected by MRI 
(Kuenz et al., 2008), and the presence of meningeal aggregates of proliferating B cells in 
F+SPMS cases is associated with more severe pathology (Villar et al., 2003; Serafini et al., 
2004; Magliozzi et al., 2007). Expansion of B cell clones specific for myelin antigens has been 
observed in the CSF (Lovato et al., 2011), and the persistence of intrathecal autoantibodies is 
indicative of continual production, since the half-life of serum Ig is less than 3 weeks and is 
assumed to be similar for CSF (Archelos et al., 2000). Extensive investigation of Ig in serum 
and CSF from MS patients has revealed a range of autoantibody specificities, and no unifying 
autoantibody common to all MS cases has yet been identified (Moller et al., 1989; Reindl et al., 
1999; Archelos et al., 2000; Haase et al., 2001; Nylander and Hafler, 2012). This suggests that 
either a range of autoantigens may be important in MS pathogenesis, or that initial 
autoreactivity to a single antigen may be followed by epitope spreading to involve additional 
epitopes or antigens, as has been shown in animal models of MS (Tuohy et al., 1999; Miller et 
al., 2007; Kuerten et al., 2012). Prominent antibody deposition has been observed in a subset 
of active WMLs (Lucchinetti et al., 2000; Lassmann et al., 2001), and the presence of 
oligoclonal CSF bands is associated with conversion from RRMS to SPMS and a significantly 
increased EDSS score (Villar et al., 2003), indicating a role for autoantibodies in pathology and 
clinical progression (Archelos et al., 2000).  
Autoantibodies may opsonise myelin, resulting in macrophage-mediated demyelination, or 
may activate the complement cascade, leading to the formation of the membrane attack 
complex (MAC) and deposition of complement fragments and complexes on the myelin 
sheath. Complement fragments act as chemoattractants for macrophages and lymphocytes, 
resulting in release of cytokines, reactive oxygen species (ROS) and matrix 
metalloproteinases (MMPs), which causes local inflammation and break down of the BBB. 
Deposition of MAC (C5b-9) on the myelin sheath opens pores in the membrane, disrupting the 
ionic balance and facilitating a calcium influx that disrupts impulse propagation and activates 
myelin-integral proteases which degrade the myelin sheath (Hartung et al., 1995; Hartung and 
Rieckmann, 1997). The C9neo antigen signifies formation of the terminal lytic complement 
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complex and has been observed co-deposited with Ig in active lesions, in phagocytic 
macrophages and on oligodendrocytes (Storch et al., 1998a). Antibodies have also been 
detected between the clathrin-coated pits of phagocytic macrophages and myelin debris 
(Prineas and Graham, 1981).  
In addition to direct pathogenic effects such as autoantibody production, B cells may also play 
a significant role as APCs, by facilitating activation of T cells and their recruitment to the CNS. 
Depletion of B cells in the CSF by Rituximab treatment resulted in significant reduction of CSF 
T cells in RRMS patients (Genain et al., 1999; Cross et al., 2006) and T cell infiltration is 
blunted in B cell deficient mice during the onset of the in vivo model of MS, experimental 
autoimmune encephalomyelitis (EAE) (Pierson et al., 2013). B cells express MHC II and 
reactivate CD4+ T cells infiltrating the CNS, and may preferentially reactivate Th1 T cells 
(Pierson et al., 2013). A higher proportion of Th1 T cells in the CNS may result in increased 
levels of pro-inflammatory cytokines in the CSF and creation of an inflammatory milieu that is 
suggested to drive pathology in MS (Reynolds et al., 2011). B cells themselves may also 
contribute to this pro-inflammatory environment through secretion of pleiotropic cytokines 
including LTα and TNF (Bar-Or et al., 2010).  
Although autoantibodies and complement components cannot cross the BBB, activated T and 
B cells can extravasate across the intact BBB into the Virchow-Robin space. Here, 
presentation of autoantigen on MHC II molecules results in activation of B and T cells resulting 
in cytokine release and intrathecal production of autoantibodies, leading to a 
compartmentalisation of the immune response behind the BBB. Formation of TLOs may then 
result in sites of persistent autoantigen presentation, autoreactive cell activation and 
intrathecal autoantibody production.  
1.4.3 Microglia and macrophages  
Microglia are the most numerous cell of myeloid origin in the CNS, and are highly specialised 
to carry out a variety of diverse functions including neuroprotection and repair. However, they 
can also initiate neurotoxic responses, and are implicated in contributing to neurodegeneration 
(Correale, 2014). “Resting” microglia actively and continually survey the local environment, 
and have a ramified morphology, characterised by fine, highly branched and motile processes 
with a relatively small cell soma (Nimmerjahn et al., 2005). When activated, microglia adopt a 
more amoeboid morphology, typified by short, thickened processes with a more rounded cell 
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soma, and show increased proliferation, motility, expression of pro- and anti-inflammatory 
mediators and antigen presenting molecules (Bogie et al., 2014). In SPMS, microglial 
activation is not only associated with demyelination and lesions, but also with NAGM and 
NAWM, indicative of a global diffuse inflammatory response within the CNS (Kutzelnigg et al., 
2005). 
Although considerable infiltration of phagocytic macrophages is observed in newly formed 
GMLs in early MS (Lucchinetti et al., 2011; Popescu and Lucchinetti, 2012), few infiltrating 
macrophages are observed in GMLs from progressive cases (Bo et al., 2003a). Cells with the 
morphology of activated microglia are observed to account for over 90% of phagocytic cells in 
chronic active GMLs (Peterson et al., 2001). The role of microglia in GML formation and 
development is unclear, as many studies have focused on WMLs, and it is uncertain to what 
extent, if any, the pathogenesis of WMLs and GMLs differs. Phagocytosis of myelin by 
microglia is thought to be a key contributing process to demyelination. Evidence of several 
mechanisms of demyelination have been detected in active WMLs from biopsies and autopsy 
material from MS cases of short duration (Lucchinetti et al., 2000), but it is suggested that the 
dominant mechanism in established MS WMLs becomes antibody- and complement-mediated 
phagocytosis (Breij et al., 2008). Microglial expression of the complement receptor CR3 allows 
activation of the complement cascade and phagocytosis, following binding with complement 
components deposited on myelin sheaths (Smith, 2001). However, the role of complement in 
GML pathogenesis is controversial, since significant deposition of complement fragments was 
not observed in purely cortical lesions (Brink et al., 2005). Microglia are known to phagocytose 
myelin via expression of Fc receptors, the rate of which is increased in vitro by the addition of 
antibodies specific for myelin components, suggesting a dependence on autoantibodies in vivo 
(Smith, 2001). Activation of microglia by infiltrating autoreactive T cells has also been shown to 
increase phagocytosis of myelin by microglia (Nielsen et al., 2009). In addition, Fc receptor-
mediated phagocytosis leads to ROS production (Ueyama et al., 2004), resulting in the 
release of glutamate and excitotoxic damage, to which oligodendrocytes are highly susceptible 
(Mcdonald et al., 1998; Werner et al., 2001; Barger et al., 2007; Sierra et al., 2013). Secretion 
of cytokines and cytotoxic inflammatory mediators by activated microglia may also contribute 
to pathology and oligodendrocyte loss, since microglial activation by TNF in vitro induced 
production of nitric oxide, TNF and ROS (Kuno et al., 2005).  
In addition to possible roles in the pathogenesis of MS, microglia and macrophages are also 
important for regenerative processes, and microglial expression of neurotrophic factors may 
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contribute to neuroprotection (Batchelor et al., 1999). The varied functions and phenotypes of 
microglia and macrophages can be characterised by the M1 (pro-inflammatory) – M2 (anti-
inflammatory) paradigm, where the classical inflammatory functions, including secretion of pro-
inflammatory cytokines and antigen presentation, are associated with polarization to the M1 
phenotype, while the M2 phenotype is associated with regenerative functions and the 
secretion of anti-inflammatory cytokines and growth factors (Bogie et al., 2014). During 
remyelination, microglia and macrophages switch from the M1 to the M2 phenotype, which has 
been shown to drive oligodendrocyte differentiation and is crucial for efficient remyelination 
(Miron et al., 2013). In addition, microglia may promote remyelination through phagocytosis of 
cellular and myelin debris, which inhibit axonal regeneration and OPC maturation (Robinson 
and Miller, 1999; Wang et al., 2002; Kotter et al., 2006; Plemel et al., 2013).  
1.5 Tertiary lymphoid organ neogenesis 
TLOs develop during chronic inflammation and their neogenesis is thought to be a dynamic 
process, where increasing structural organisation of infiltrating immune cells appears to 
correlate with increasing cellular density of aggregates (Aloisi and Pujol-Borrell, 2006). TLO 
neogenesis has been reported in rheumatoid arthritis (Young et al., 1984; Schroder et al., 
1996), myasthenia gravis (Weiss et al., 2013), Sjogren’s syndrome (Stott et al., 1998) and 
atherosclerosis (Houtkamp et al., 2001) among other inflammatory conditions (Hautz et al., 
2014; Pei et al., 2014).  
The precise structure, cellular composition and frequency of TLOs vary depending on the 
disease state, anatomical location and degree of inflammation/infiltration (Takemura et al., 
2001; Chen et al., 2002; Aloisi and Pujol-Borrell, 2006). Most studies report the cellular 
composition of TLOs to be similar to that of secondary lymphoid organs (SLOs; e.g. lymph 
nodes; Figure 1. 2), including proliferating B cells, plasma cells, T cells, and FDCs 
(Salomonsson et al., 2003; Serafini et al., 2004; Motallebzadeh et al., 2011). Development of 
high endothelial venules (HEVs) has also been reported to be a feature of TLOs but was not 
detected in the follicle-like structures studied in the meninges of SPMS cases (Serafini et al., 
2004; Canete et al., 2007). TLOs differ structurally from SLOs, as they are directly exposed to 
antigens and lack the micro-architecture of connective tissue conduits that influences 
interactions between APCs and immune cells, which may result in promotion of abnormal 
activation of T and B cells and promotion of autoimmunity (Weyand et al., 2001).  
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The role of LTα in lymphoid organ development was first suggested following the observation 
that LTα-/- transgenic mice develop only rudimentary mesenteric lymph node-like structures 
and no other lymph nodes or Peyer’s patches, show impaired segregation of B and T cells 
within splenic white pulp and increased numbers of IgM+ lymphocytes in spleen and peripheral 
blood (De Togni et al., 1994; Banks et al., 1995). The presence of rudimentary mesenteric 
lymph nodes in some mutants supports suggestions that other factors are also involved in 
SLO initiation and development (Banks et al., 1995). In addition to signalling through TNFR1, 
LTα also binds to the herpes simplex virus entry mediator (HVEM) receptor, which allows 
signalling via the classical nuclear factor-kappa B (NFκB) pathway (Mauri et al., 1998). HVEM 
is expressed by resting T cells, NK cells, monocytes, immature dendritic cells (DCs) and 
endothelial cells, but this pathway is not thought to play a role in lymphoid organogenesis as 
HVEM-/- mice show no abnormalities in lymphoid anatomy (Mauri et al., 1998; Schneider et 
al., 2004; Mana et al., 2013). 
LTβ is membrane bound and non-functional unless complexed with LTα, as LTα1β2 
(predominant form) or LTα2β1 heterotrimers, which are expressed by activated lymphocytes 
and signal via the lymphotoxin-β receptor (LTβR) expressed by stromal cells (Sacca et al., 
1998; Gommerman and Browning, 2003). LTα2β1 is a minor form without a clear biological role 
that can also bind to TNFR1 and TNFR2, though the functional relevance of this is unclear 
(Schneider et al., 2004). Much attention has focussed on the action of the membrane bound 
LTα1β2 heterotrimer, as clustering of lymphoid tissue inducer (LTi) cells, which express LTα1β2, 
is a key initial stage in SLO development (Van De Pavert and Mebius, 2010). However, roles 
for soluble LTα in inflammation and TLO formation have been elucidated that demonstrate 
non-redundant functions for the LTα homotrimer which are independent of LTβ. 
The contribution of LTα to TLO neogenesis was suggested following investigation of mice 
transgenic for LTα under the rat insulin II promoter (RIPLT mice), which express soluble LTα in 
pancreatic islet cells, the proximal convoluted tubules of the kidney and in the skin (Picarella et 
al., 1992; Kratz et al., 1996). Ectopic expression of LTα at these sites results in formation of 
organised inflammatory infiltrates composed of CD4+ and CD8+ T cells, B220+ and IgM+ B 
cells, FDCs and macrophages, with compartmentalisation of B and T cell areas, which is 
suggested to be lymphoid organogenesis (Kratz et al., 1996). Formation of pancreatic TLOs 
and ectopic expression of LTα is not directly cytotoxic, since the pancreatic insulitis and 
inflammation observed in RIPLT mice does not develop into diabetes, indicating a lack of 
tissue destruction (Picarella et al., 1992). Similar inflammation induced in RIPTNF mice also 
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failed to elicit diabetes (Picarella et al., 1993), but concomitant expression of TNF with the 
costimulatory molecule B7-1 resulted in local destruction of pancreatic tissue and diabetes, 
suggesting that local activation of infiltrating autoreactive cells through APC function in the 
tissue is crucial to initiate autoimmune damage (Guerder et al., 1994). The authors suggested 
that chronic autoimmune responses may depend on priming of self-reactive T cells in lymphoid 
organs followed by a local capability to sustain the activation of these cells in the tissue of 
interest (Guerder et al., 1994). This suggests a prominent role of TLOs in maintaining chronic 
inflammation in autoimmune diseases, including MS, through increased efficiency of 
autoantigen presentation in the CNS. In addition, the underlying CNS GM may be more 
susceptible to damage from production of cytokines and chemokines produced by meningeal 
TLOs compared to pancreatic islet cells, since meningeal inflammation in MS is associated 
with increased GM pathology and neuronal death, while pancreatic inflammation does not 
result in the death of islet cells (Picarella et al., 1992; Magliozzi et al., 2007; Magliozzi et al., 
2010; Howell et al., 2011; Choi et al., 2012). 
The pro-inflammatory effects of ectopic LTα expression have been shown to be mediated 
entirely through TNF receptor 1 (TNFR1) via the soluble LTα homotrimer (Sacca et al., 1998). 
RIPLT mice lacking TNFR1 showed no inflammation in the kidney or pancreas and those 
heterozygous for the TNFR1 deletion showed markedly reduced inflammation at these sites, 
whereas RIPLT TNFR2-/- mice showed similar levels of inflammation to RIPLT wild-type mice. 
In addition, the pro-inflammatory effects of ectopic LTα expression are largely independent of 
LTβ, since inflammation develops in the kidneys and pancreatic islets of LTβ-/- RIPLT mice, 
although the proportions of naïve and memory B cells are altered, suggesting a role for 
membrane bound LTα1β2 in the recruitment of naïve B cells (Sacca et al., 1998). In the 
absence of LTβ, LTα stimulation of endothelial cells in vitro induces expression of the 
adhesion molecules VCAM, ICAM, E-selectin and MAdCAM, the T cell chemoattractants 
RANTES and CXCL10, and the monocyte chemoattractant MCP-1, thus suggesting a 
mechanism by which LTα may induce inflammation in vivo (Cuff et al., 1999).  
LTα has been implicated in the pathogenesis of MS since it was observed to potently induce 
apoptosis of oligodendrocytes in vitro (Selmaj et al., 1991c), and was found to be expressed 
by CD3+ lymphocytes and microglia at the lesion edge of acute and chronic active MS lesions 
(Selmaj et al., 1991b; Cannella et al., 1997; Raine et al., 1998). LTα has also been detected in 
MS CSF (Corcione et al., 2004). Increased LTα mRNA expression was observed in peripheral 
blood lymphocytes prior to relapse in RRMS, and expression was strongly upregulated by 
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stimulation with MBP in vitro, suggesting that LTα may play a role in the exacerbation of MS 
(Rieckmann et al., 1995; Navikas et al., 1996). LTα is primarily secreted by CD8+ T cells 
(Buckle et al., 2003), but also by CD4+ T helper 1 (Th1) cells (Cuff et al., 1998), natural killer 
(NK), and B cells. CD8+ T cells from SPMS show significantly increased LTα secretion 
following anti-CD3 monoclonal antibody stimulation (mimicking co-stimulation) compared to 
CD8+ T cells from healthy controls, and LTα secretion from SPMS CD8+ cells following T cell 
receptor cross-linking in the absence of co-stimulation may reflect a generalised dysregulated 
immune response that may be acquired as MS progresses (Buckle et al., 2003).  
Astrocytes have been observed to secrete LTα when stimulated in vitro, but data on astrocytic 
expression in vivo is limited to one study, which did not observe LTα expression in microglia 
(Lieberman et al., 1989; Plant et al., 2005). LTα has a mitogenic effect on astrocytes in vitro, 
which may contribute to astrogliosis in MS (Selmaj et al., 1990), and is suggested to 
orchestrate the immune response by recruiting and activating monocytes (Esparza et al., 
1987) and inducing production of other cytokines, including granulocyte-macrophage colony-
stimulating factor in vivo (Kaushansky et al., 1988). Interestingly, the gene for LTα has been 
linked to MS susceptibility; individuals homozygous for the TNF-β 2 allele were found to be 
twice as likely to develop MS compared to heterozygotes or individuals lacking the allele 
(Fernandes Filho et al., 2002). TNF-β 2 homozygotes had significantly increased LTα 
(Whichelow et al., 1996) and TNF concentrations compared to those lacking the allele (Pociot 
et al., 1993; Stuber et al., 1996; Kallaur et al., 2014).  
A role for LTα in the pathogenesis EAE has also been suggested following observations that 
treatment of recipient mice with anti-LT/TNF antibody reduces EAE severity following transfer 
of encephalitogenic T cells (Ruddle et al., 1990; Selmaj et al., 1995; Lock et al., 1999). In 
addition, LTα secretion in vitro correlates with the encephalitogenicity of MBP-specific T cell 
clones in vivo (Powell et al., 1990), and LTα mRNA expression increases in the spinal cord 
prior to the onset of EAE, suggesting a role in pathogenesis and EAE initiation (Issazadeh et 
al., 1996). TNFR1 has been shown to be crucial to mediate the demyelinating effects of TNF 
and LTα during EAE (Eugster et al., 1999). The increased resistance to EAE observed in LTα-
/- mice compared to LTβ-/- or wild-type littermates, suggests that soluble LTα alone has an 
important role in inflammation and EAE susceptibility (Suen et al., 1997), although 
contradictory findings were demonstrated by other studies (Frei et al., 1997; Sean Riminton et 
al., 1998). However, due to the abnormal development of SLOs in LTα-/- mice (De Togni et al., 
1994; Banks et al., 1995), the results of studies on EAE induction susceptibility in these 
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transgenic strains is controversial and does not necessarily exclude a role for LTα in EAE or 
MS, suggesting that further investigation of this cytokine is warranted (Steinman, 1997).  
1.5.2 CXCL13 
CXCL13 is a B cell chemoattractant that has been postulated to play a key role in initiating the 
development of SLOs, by inducing clustering of lymphoid tissue inducer (LTi) cells which 
subsequently recruit SLO components (Van De Pavert et al., 2009). Ectopic expression of 
CXCL13 by pancreatic islet cells in transgenic mice was sufficient to induce formation of 
inflammatory aggregates containing B and T cell areas, stromal cells and high endothelial 
venules (HEVs) but lacking functional GCs, suggesting that other factors including LTα are 
needed for complete TLO neogenesis (Luther et al., 2000a). 
Since CXCL13 is involved in B cell organisation and recruitment to SLOs, studies have 
investigated whether it plays a role in recruitment of B cells to the CNS during disease. The 
concentration of CXCL13 in the CSF is significantly increased in RRMS, PPMS and SPMS 
patients, and strongly correlates with B cell numbers in the CSF in RRMS (Sellebjerg et al., 
2009). The majority of B cells in the CSF expressed the CXCL13 receptor CXCR5, suggesting 
that CXCL13 may mediate B cell recruitment to the CNS in MS (Sorensen et al., 1999; 
Sellebjerg et al., 2009). Data from in vivo studies of EAE are less clear however, suggesting 
that CXCL13 is not required for the initial recruitment of B cells to the CNS during EAE, 
although disease severity is limited in CXCL13 deficient mice suggesting other effects of this 
chemokine in disease (Bagaeva et al., 2006; Rainey-Barger et al., 2011).  
Macrophages and dendritic cells have been reported to express CXCL13 under inflammatory 
conditions (Carlsen et al., 2004; Perrier et al., 2004), and infiltrating macrophages are 
suggested to be the source of CXCL13 in active lesions, where CXCL13 is observed to be 
expressed in scattered cells infiltrating actively demyelinating tissue and perivascular infiltrates 
(Krumbholz et al., 2006). In SPMS, CXCL13 concentration in the CSF was linked to the 
degree of inflammation and was observed to be very variable, with few SPMS cases showing 
considerable CXCL13 levels, while it was undetectable in the majority of controls. The authors 
suggested that in SPMS CXCL13 CSF concentration may be correlated with the presence of 
meningeal TLOs, but this has yet to be investigated (Krumbholz et al., 2006).  
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1.5.3 CCL21 
CCL21 is a chemokine that is constitutively expressed by HEVs and stromal cells in the T cell 
areas of SLOs, and binds to the CCR7 receptor. It plays a key role in trafficking of naïve T 
cells and dendritic cells (DCs), since mice lacking CCL21 expression in lymphoid organs show 
defects in T cell recruitment and positioning of DCs (Gunn et al., 1999; Chen et al., 2002; 
Aloisi and Pujol-Borrell, 2006). Ectopic expression of CCL21 induced TLO formation in the 
pancreas of transgenic mice, suggesting that it may play an important role in recruitment of 
immune cells to TLOs following their formation through the actions of other 
cytokines/chemokines such as CXCL13 and LTα (Chen et al., 2002). CCL21 concentration is 
elevated in MS CSF (Pashenkov et al., 2003) and it is expressed by endothelial cells in 
intrameningeal blood vessels in a mouse model of MS, suggesting a role in T cell and DC 
recruitment to the CNS in MS (Columba-Cabezas et al., 2003).  
1.6 EAE models of MS 
Post-mortem human tissue from the UK MS Tissue Bank (UKMSTB) is a valuable resource to 
study the composition and location of meningeal TLOs and GM pathology. However, only one 
time-point per case can be studied and tissue represents the accumulation of chronic disease, 
which limits the ability to study the early development of TLOs and their role in disease 
pathogenesis. Pre-mortem factors (including, hypoxia, duration of agonal state, acidosis and 
fever) and post-mortem factors (including post-mortem delay between death and tissue 
preservation, and cadaver temperature) may also introduce variability to the quality of post-
mortem human tissue. In vitro systems, while useful for dissecting molecular and cellular 
mechanisms of pathology, are unable to fully model interactions between the immune and 
central nervous systems, so investigation of TLO formation requires in vivo models.  
Much has been learned about MS pathology through analysis of various in vivo models. These 
include the study of toxin-induced pathology in cuprizone models, induction of pathology by 
Theiler’s murine encephalomyelitis virus and particularly the large and commonly used group 
of experimental autoimmune encephalomyelitis (EAE) models (Batoulis et al., 2011). EAE 
involves inducing an inflammatory demyelinating MS-like phenotype in genetically susceptible 
animals by active immunisation with a myelin component or by transfer of autoreactive 
lymphocytes. The clinical phenotype of EAE is determined by the method of immunisation, the 
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antigen used, and the species and genetic background of the host animal. The most 
commonly used species/strains are the SJL/J mouse, C57BL/6 mouse, dark agouti (DA) rat 
and Lewis rat. Induction of EAE requires emulsification of a myelin-specific antigen (commonly 
MOG or MBP) in complete or incomplete Freund’s adjuvant (CFA or IFA respectively) followed 
by injection of pertussis toxin as required depending on the strain/species used. The resulting 
clinical symptoms of EAE are typically ascending paralysis, beginning with tail tone loss 
followed by progressive paralysis of the hind- then fore- limbs and possible death depending 
on the severity and duration of symptoms. Relapsing-remitting or chronic disease may be 
induced depending on the antigens, immunisation protocol, species or antigen specificity of 
transferred autoreactive T cells used (Batoulis et al., 2011). Pathology primarily affects the 
spinal cord and cortical lesions are rarely observed (Sriram and Steiner, 2005). In addition to 
these models of induced EAE, spontaneous EAE can be studied in mice transgenic for 
autoreactive B and T cells (Krishnamoorthy et al., 2006).    
1.6.1 MOG-EAE in DA rats 
MOG is a 28kDa myelin component that is expressed on the outer lamellae of the myelin 
sheath, and is the only CNS restricted myelin antigen able to induce a T and B cell response in 
vivo. In spite of comprising only 2.5% of the myelin proteins, MOG is a potent encephalitogenic 
autoantigen for inducing EAE in a variety of species (Delarasse et al., 2013). Immunisation of 
experimental animals with a recombinant protein that corresponds to residues 1-125 that form 
the extracellular Ig-like domain of MOG, results in immunopathology that closely resembles 
that observed in MS, and reflects the full spectrum of MS pathology (Storch et al., 1998b). 
Other factors, including antigen dosage, adjuvant, the ability of autoantibodies to activate 
complement, and the genetic background of the animals, co-determine the degree of 
demyelination observed. Immunisation of female dark agouti (DA) rats with recombinant rat 
MOG results in chronic relapsing EAE, accompanied by T and B cell mediated pathology 
(Storch et al., 1998b; Storch et al., 2006). Meningeal and perivascular inflammation dominated 
by T cells and phagocytic macrophages was observed, together with antibody deposition on 
demyelinating sheaths and a relative sparing of axons, followed by formation of glial scars. 
Similar pathology can be elicited in this strain by immunisation with recombinant mouse MOG 
(rmMOG), where progressive axonal loss and correlates with irreversible neurological deficit in 
the chronic stages of relapsing-remitting EAE (Papadopoulos et al., 2006). 
Chapter 1 – Introduction   44 
 
1.6.2 Cortical pathology incidence in EAE 
The study of cortical lesions in vivo has been hampered by the predominant targeting of the 
spinal cord and lack of cortical pathology observed in the majority of EAE models. Cortical 
lesions have been observed with increased prevalence in some EAE models, including the 
MOG-immunised Lewis rat. Development of intracortical, leukocortical and subpial GMLs 
following MOG immunisation in this strain is dependent on MHC isotype and allele 
combination, and is only observed in LEW.1AR1 RT1r2 and LEW.1W RT1u rats (Storch et al., 
2006). In addition, SJL/J mice develop forebrain lesions following PLP immunisation 
(Rasmussen et al., 2007). MOG immunisation of marmoset monkeys has been shown to 
induce cortical GMLs reminiscent of MS pattern II lesions, with evidence of complement and 
antibody deposition, and may prove a useful model for dissecting pathological mechanisms 
underlying this type of MS lesion (Merkler et al., 2006a). However, these models are limited by 
the inter-individual variation in lesion location and type in rat models, and the ethical 
considerations of marmoset models, which reduce feasibility and highlight the requirement for 
a reproducible model of GML formation in rodents (Merkler et al., 2006a; Storch et al., 2006).  
Induction of highly reproducible and extensive demyelination is observed in mice following 
addition of the copper chelator cuprizone (bis-cyclohexanone oxaldihydrazone) to the diet. 
However, the rapidly reversible oligodendrocyte loss observed in this model contrasts to 
chronic SPMS pathology, and can be induced in RAG1-/- mice lacking B and T lymphocytes, 
suggesting that the role of meningeal lymphocytic infiltration proposed in SPMS is not 
reflected, thus limiting the relevance of this model (Matsushima and Morell, 2001). In addition, 
ethical considerations limit its use, since major systemic toxicity occurs following prolonged 
exposure to cuprizone (Matsushima and Morell, 2001).    
1.6.3 Targeted EAE 
Targeted EAE models induce subclinical EAE to prime autoreactive T and B cells, which are 
then recruited to the desired lesion site (e.g. the motor cortex or spinal cord) by stereotaxic 
injection of the pro-inflammatory cytokines TNF and IFNγ (Kerschensteiner et al., 2004; Sun et 
al., 2004; Merkler et al., 2006b). Extensive WM demyelination was observed in the dorsal 
funiculus of the spinal cord in MOG-immunised Lewis rats following intraspinal injection of TNF 
and IFNγ administered at 18-22 days post-immunisation (dpi), while GM involvement was 
limited (Kerschensteiner et al., 2004). Demyelinated WMLs were associated with development 
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of clinical EAE, prominent infiltration of foamy macrophages, microglial activation surrounding 
the lesion, acute axonal damage and limited CD3+ T cell infiltration. IFA-immunised control 
animals injected with TNF and IFNγ did not develop EAE or WMLs, and only limited 
inflammatory cellular infiltration was observed at the injection site. 
Intracortical injection of TNF and IFNγ into the motor cortex in MOG-immunised Lewis rats 
induced extensive demyelinated leukocortical, intracortical and subpial GMLs, which were 
maximal at 3 days post-injection and fully remyelinated by day 14 (Merkler et al., 2006b). At 
the peak of pathology, subpial GMLs accounted for 90% of the demyelinated area, and 
macrophages/microglia were observed to contain phagocytosed MBP fragments, suggesting a 
prominent role for these cells in pathogenesis and active demyelination in this model. In 
addition, deposition of antibody and complement fragments were observed in areas of active 
demyelination, as well as significantly increased infiltration of CD4+ and CD8+ T cells 
compared to IFA-immunised control animals receiving identical injections of TNF and IFNγ. 
The number of amyloid precursor protein (APP)+ axonal spheroids, indicative of axonal 
damage (Gentleman et al., 1993), was correlated with CD4+ T cell infiltration and the density 
of activated microglia/macrophages, although no reduction in axonal density was observed. In 
spite of the utility of the model in reproducing all GML types observed in MS (Peterson et al., 
2001), the lack of a permanent reduction of axonal density, together with the observation of full 
remyelination of demyelinated lesions within 14 days is in marked contrast to MS pathology 
and is unable to represent the chronicity of the disease. In addition, tissue trauma associated 
with the direct intracortical injection of cytokines introduces artefacts including BBB breakdown 
which are not features of GMLs in progressive MS. 
To avoid the tissue trauma associated with cortical injections, a novel model of subarachnoid 
injection of TNF & IFNγ into female DA rats at 18-22 dpi with rmMOG was developed by this 
laboratory, since the subarachnoid space is recognised to be an important site of chronic 
inflammation in MS that may contribute to GML pathogenesis (Magliozzi et al., 2007). 
Meningeal infiltration of CD79a+ B cells, CD4+ and CD8+ T cells was observed following 
cytokine injection in MOG-immunised rats, accompanied by extensive microglial/macrophage 
activation and subpial demyelination (Gardner et al., 2013). Demyelination was absent in IFA-
immunised control animals. The pattern of subpial demyelination and microglial activation 
observed in the subarachnoid injection model of targeted EAE was remarkably similar to 
pathology observed in F+SPMS cases, particularly the gradient of microglial activation that 
was greatest in the outer cortical layers closest to the meninges, and decreased in magnitude 
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with increasing distance from the pial surface (Magliozzi et al., 2010; Howell et al., 2011; 
Gardner et al., 2013). In addition, microglia with short, thickened processes indicating an 
activated morphology were observed in close association with myelin sheaths at the leading 
edge of GMLs, also reminiscent of SPMS pathology (Gardner et al., 2013). Demyelination was 
most extensive at 7 days post-subarachnoid injection and remyelination was complete within 
14 days. Thus the subarachnoid model of targeted EAE provides a highly useful model both 
for investigating the pathogenic mechanisms of GML formation, and elucidating the role of 
different cytokines in these processes in the context of sub-clinical EAE, but the validity of this 
model is limited, as previous targeted EAE models have been, by the lack of chronic 
pathology.   
1.7 Hypothesis 
Chronic meningeal inflammation and raised concentrations of pro-inflammatory cytokines in 
the CSF are postulated to result in the formation of meningeal TLOs found in a significant 
proportion of SPMS cases (F+SPMS), and to contribute significantly to subpial GML formation 
and disease progression (Magliozzi et al., 2007; Magliozzi et al., 2010; Howell et al., 2011). 
This thesis tests the hypothesis that cytokines and chemokines involved in lymphoid organ 
development are expressed in the meninges and CSF during chronic meningeal inflammation 
in SPMS. We also test the hypothesis that acutely and chronically increased concentrations of 
these molecules in the subarachnoid space of MOG-EAE rats will induce meningeal 
inflammation, microglial activation, subpial demyelination and formation of meningeal TLOs in 
vivo.  
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1.8 Aims 
We aimed to determine the expression of lymphoid cytokines and chemokines in the meninges 
and CSF in SPMS, and to develop an in vivo model of TLO development, and chronic 
meningeal inflammation and subpial demyelination which replicates the pathological features 
of SPMS, to study the effect of chronic meningeal inflammation on cortical GM pathology.  
The specific aims were to: 
• Determine the expression of the lymphoid cytokines and chemokines LTα, CXCL13 and 
CCL21 in the meninges of post-mortem control and SPMS tissue and CSF.  
• Express and purify recombinant mouse MOG (rmMOG), then determine a suitable dose to 
induce sub-clinical MOG-EAE in female DA rats  
• Determine the acute effects of subarachnoid injection of LTα and IFNγ on meningeal 
inflammation and cortical pathology, using an in vivo rat model. 
• Determine the chronic effects of raised levels of LTα in the subarachnoid space, using 
injection of a lentiviral vector expressing LTα.  
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2.1 Analysis of human tissue 
2.1.1 Case selection for cohorts 
Tissue was kindly provided by the UK Multiple Sclerosis Tissue Bank (Imperial College 
London, UK) which obtains tissue with fully informed consent through a prospective donor 
scheme, approved by the National Research Ethics Committee (reference 08/MRE09/31). 
Three cohorts of 8-10 cases each were chosen for investigation of meningeal inflammation in 
non-neurological controls, and F+SPMS and F-SPMS cases that had been previously 
characterised as containing TLOs or not respectively by histopathology ((Howell et al., 2011), 
Table 2. 1).  
2.1.2 Histological analysis of human meningeal tissue 
Histological methods were used to qualitatively assess meningeal tissue from all cases. 
Cortical brain tissue blocks of approximately 2cm3 (Figure 2. 1) were cut from coronal slices of 
fresh brain tissue during dissection, snap-frozen in isopentane (Sigma-Aldrich) on dry-ice and 
stored at -80oC by the UK MS Tissue Bank (Imperial College, London). Between 3 and 16 
cortical tissue blocks were selected per case (220 blocks in total), and 10μm sections were 
taken from each block at -20oC using a cryostat. Due to ethical considerations of the most 
efficient use of the available tissue, the time-intensive nature of the protocol and the time-
limited nature of the study, the analysis and dissection of human meningeal tissue (sections 
2.1.2 to 2.1.3.4) were carried out in collaboration with Dr. R. M. Schalks and took 3 months to 
complete.  
2.1.2.1 Haematoxylin and eosin staining 
Sections from all blocks were examined for the presence of meningeal infiltrates by staining 
with haematoxylin (Haemalum Mayer, TCS Biosciences, Buckinghamshire, UK) and eosin 
(H&E; Raymond A. Lamb Ltd. from Thermo Scientific). Immersion in haematoxylin for 2 
minutes was followed by de-staining in lukewarm water running tap water for 5 minutes, then 
immersion in eosin for a further 2 minutes. A further de-staining step for 5 minutes in water 
was followed by dehydration through graded ethanol. Sections were cleared in xylene and 
mounted in DPX (VWR International Ltd., UK).  
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Controls 
 
    
 
  
Case Sex 
Age at 
death 
(yrs) 
Disease 
duration 
(yrs) 
PMD 
(hrs) Cause of death 
C14 M 64 NA 18 Cardiac failure - myocardial infarction 
C28 F 60 NA 13 Ovarian cancer 
C45 M 77 NA 22 Cardio pulmonary degeneration, old age 
C48 M 68 NA 10 Metastatic colon cancer 
C51 M 68 NA 24 Ischaemic heart disease 
C54 M 66 NA 16 Pancreatic cancer 
PDC8 F 71 NA NA Myocardial infarction  
PDC22 M 75 NA NA Malignant squamous cell carcinoma of the lung 
Mean 
 
68.6 
 
17.2 
 
 
F-SPMS 
Case Sex 
Age at 
death 
(yrs) 
Disease 
duration 
(yrs) 
PMD 
(hrs) Cause of death 
MS296 M 59 39 22 Multiple Sclerosis 
MS301 F 62 20 16 Septicaemia, urinary tract infection, Hypokalaemia, multiple sclerosis 
MS304 M 52 23 13 Pulmonary embolism, metastatic colon carcinoma, Multiple sclerosis 
MS311 F 45 17 22 Pneumonia 
MS318 F 59 34 13 Multiple Sclerosis 
MS326 M 62 32 24 Multiple sclerosis, prostate cancer 
MS335 M 62 38 22 Recurrent aspiration pneumonia, multiple sclerosis, renal failure 
MS347 M 50 28 13 Metastatic pancreatic carcinoma 
MS364 F 56 34 14 Bronchopneumonia, multiple sclerosis 
MS376 F 58 21 19 Multiple Sclerosis 
Mean 
 
56.5 28.6 17.8 
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F+SPMS 
  
  
Case Sex 
Age at 
death 
(yrs) 
Disease 
duration 
(yrs) 
PMD 
(hrs) Cause of death 
MS289 M 45 18 9 Advanced Multiple Sclerosis 
MS317 F 48 30 21 Aspiration pneumonia due to Multiple Sclerosis 
MS330 F 59 40 21 Pneumonia, multiple sclerosis 
MS352 M 43 19 26 Bronchopneumonia, multiple sclerosis 
MS356 F 45 16 10 Multiple Sclerosis 
MS371 M 40 17 27 Bronchopneumonia 
MS377 F 50 NA 22 Aspiration pneumonia 
MS402 M 46 21 12 Multiple Sclerosis, bronchopneumonia 
MS407 F 44 30 22 Multiple sclerosis 
MS426 F 48 19 21 Septicaemia, pneumonia 
Mean 
 
46.8 23.3 19.1 
 
Table 2. 1 Cases selected for analysis of meningeal gene expression and histology.  
Details of the control cases, and MS cases previously characterised as either containing TLOs 
(F+SPMS) or not (F-SPMS) that were chosen for meningeal analysis. M = male; F = female; PMD = 
post-mortem delay; yrs = years; NA = information not available. 
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Figure 2. 1 Fresh coronal brain slice dissected into tissue blocks. 
Cortical blocks were chosen based on the presence of deep sulci (red boxed blocks) and included the 
insular, inferior frontal, cingulate, lateral and superior temporal sulci, as these areas have been 
previously shown to contain TLOs (Howell et al., 2011). 
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2.1.2.2 Immunohistochemistry 
Immunohistochemistry (IHC) was used to identify CD20+ B cells, the major cell type within 
meningeal TLOs (Table 2. 2). Following removal from -20oC storage, sections were rehydrated 
in phosphate buffered saline (PBS) containing 0.1% (v/v) Triton X-100 (PBST). Endogenous 
peroxidase activity was quenched by incubation with 0.3% H2O2 in 0.3% normal horse serum 
(NHS; Sigma-Aldrich) in PBST (10 minutes; Sigma-Aldrich). Sections were blocked with 5% 
(v/v) NHS in PBST (1 hour) prior to incubation with primary antibody (Table 2. 2) diluted in 1% 
NHS in PBST (overnight, 4oC). Sections were incubated with secondary biotinylated antibody 
(Vector Laboratories) diluted 1:500 in 1% NHS in PBST (1 hour), followed by incubation with 
streptavidin-biotin-peroxidase complex (1 hour; Vectastain Elite ABC kit, Vector Laboratories). 
Bound antibody was visualised using 3,3’-diaminobenzidine (DAB; Vector Laboratories), 
counterstained with haematoxylin and mounted as described above. PBST washes were 
carried out between pre-treatment, blocking and incubation steps, and all steps were 
performed at rtp unless otherwise stated. IHC for MOG and LTα was carried out used to 
visualise the myelin sheath (to identify areas of demyelination) and LTα expression 
respectively (Table 2. 2). For MOG IHC, an additional incubation in methanol (10 minutes, -
20oC) was included for antigen retrieval prior to quenching in 0.3% H2O2.  
2.1.3 Gene expression analysis of human meningeal tissue 
2.1.3.1 Tissue preparation 
A total mass of 100-250mg meningeal tissue per case was dissected from the snap-frozen 
blocks used for histological analysis, using a sterile scalpel sprayed with ethanol and RNase 
Zap prior to use (Life Technologies, Paisley, UK). Dissected tissue was collected into RNase-
free microfuge tubes (Life Technologies) on dry ice, then stored at -80oC until RNA extraction.  
2.1.3.2 RNA extraction  
Ribonucleic acid (RNA) was extracted from the dissected meningeal tissue samples using an 
RNeasy Lipid Tissue Mini Kit (Qiagen, Crawley, Sussex, UK) according to the manufacturer’s 
instructions. Samples of approximately 200mg dissected meninges were removed from 
storage at -80oC and placed on dry ice. Tissue was homogenised for 30 seconds in 2mls 
Qiazol lysis reagent (Qiagen), then left for 5 minutes at rtp. Following centrifugation to remove 
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cellular debris (12,000g, 5 minutes, 4oC), a volume of chloroform (Sigma-Aldrich Co. Ltd, 
Dorset, UK) equal to 20% of the total recovered supernatant was added, and the samples 
shaken vigorously for 15 seconds. After incubation at rtp for 3 minutes, samples were 
centrifuged (12,000g, 15 minutes, 4oC) and the aqueous layer carefully removed. An equal 
amount of 70% ethanol was added and the sample vortexed before being transferred to an 
RNeasy Lipid mini spin column (Qiagen). Centrifugation (8,000g, 15 seconds, rtp) was 
repeated until the whole sample was filtered through the membrane and all flow-through was 
discarded. The membrane was then washed by addition of ethanol-based buffers supplied by 
the manufacturer followed by centrifugation (8,000g, 15 seconds, rtp). An optional genomic 
deoxyribonucleic acid (gDNA) elimination step was included in the protocol to remove any 
DNA contamination; the membrane was incubated with DNase solution for 15 minutes at rtp, 
before washing with an ethanol-based buffer and centrifugation (8,000g, 15 seconds, rtp). 
Removal of excess wash buffer was achieved by centrifugation (10,000g, 1 minute, rtp) and 
RNA eluted by addition of RNase-free water (Sigma Aldrich, UK) and incubation (1 minute, 
rtp), followed by centrifugation (8,000g, 1 minute, rtp). Eluted RNA was stored at -80oC. 
2.1.3.3 Assessing RNA integrity and purity 
The concentration and purity of eluted RNA was determined by measuring the absorbance at 
260nm, using a Nanodrop ND1000 spectrophotometer (Thermoscientific, Wilmington, USA). 
The integrity of eluted RNA was determined using a 2100 Bioanalyser (Agilent Technologies, 
California, USA) with an RNA 6000 Nano kit (Agilent) according to the manufacturer’s 
instructions.  
2.1.3.4 Reverse Transcription  
Reverse transcription of 1µg RNA per case to complimentary (cDNA) was performed 
immediately after RNA extraction using a Quantitect Reverse Transcription Kit (Qiagen) 
according to the manufacturer’s instructions. All kit reagents were thawed on ice before 
incubation of RNA samples with gDNA wipeout buffer at 42oC for 2 minutes. Following the 
addition of the Quantiscript Reverse Transcriptase enzyme, RT buffer and primer mix, 
samples were incubated at 42oC for 15 minutes, then at 95oC for 3 minutes to inactivate the 
enzyme. RNA and complementary DNA (cDNA) stocks were stored at -80 and -20oC 
respectively. In addition, RNA samples from a random selection of cases from each cohort 
were subjected to the same reverse transcription protocol, but water was added in place of the 
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Quantiscript Reverse Transcriptase enzyme. These samples were used as No-RT controls in 
future qPCR experiments to ensure that RNA samples were not contaminated with gDNA.  
2.1.3.5 Quantitative Polymerase Chain Reaction (qPCR) 
Prime Time qPCR Assays (Integrated DNA Technologies, Iowa, USA) were used to quantify 
expression of genes of interest (GOI; LTα, CXCL13 and CCL21) relative to the expression of 
two housekeeping genes (HKG; glyceraldehydes-3-phosphate dehydrogenase, GAPDH and 
Xpnpep1), in the cDNA samples. Normalisation to the geometric mean of multiple reference 
genes is considered to be the most reliable method of normalisation (Vandesompele et al., 
2002). Xpnpep1 is a stable HKG in post-mortem CNS tissue, with no known associations with 
neuroinflammatory or degenerative pathology (Durrenberger et al., 2012). All reagents and 
cDNA samples were thawed on ice for 30 minutes prior to preparation of reaction volumes. 
Master mixes containing 1µl PrimeTimeqPCR Assay primer and probe mix, 10 µl Brilliant II 
QPCR Master Mix Low ROX (containing SureStart Taq DNA polymerase, GUAC nucleotides 
and a 30nm final concentration ROX reference dye; Agilent Technologies, USA) and 8µl 
RNase free water were added to each well of the qPCR plates, and made up to a final reaction 
volume of 20µl with 1µl (50ng) cDNA. qPCR was performed in triplicate for each case on a 
Stratagene MXP4000 system (Agilent Technologies, Stockport, UK), with MxPro 2007 
software and using the thermal profile outlined in Table 2. 3. 
Each of the 3 cohorts (non-neurological controls, F-SPMS and F+SPMS) were represented on 
each qPCR plate to avoid inter-plate differences affecting cohort results. An inter-plate 
calibrator sample was made up prior to commencing qPCR and was composed of cDNA from 
a selection of cases. This sample was run in triplicate on each qPCR plate with the GAPDH 
reference gene, and the threshold cycle (Ct) values compared between samples on different 
plates to detect any inter-plate differences in efficiency between runs.  
2.1.3.6 Analysis of qPCR data 
Ct values were obtained for each well at the manually defined threshold, which was constant 
for all assays, above the automatically generated baseline and within the lower one-third to 
one-half of the linear phase of the amplification plot. Raw Ct values were analysed using 
REST09 (relative expression software tool), which calculates fold changes in gene expression 
while accounting for differing primer efficiencies, allowing for more accurate analysis than the 
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ΔΔCt method (Pfaffl et al., 2002). The software allows comparison of two groups by 
performing a randomisation test, with no assumptions of data distribution. 2000 repeated 
random reallocations of HKG and GOI Ct values results in generation of apparent fold 
changes. Generation of a p value, when differences exist between the original data groups, is 
possible by determining the proportion of apparent fold changes generated by random 
reallocation that are as great as the fold change generated by the original data groups (Pfaffl 
et al., 2002).  
2.1.3.7 Confirming qPCR assay specificity 
Agarose gel electrophoresis was performed to confirm the specificity of the five qPCR assays. 
Briefly, the 20μl reactions remaining for each assay following qPCR of pooled cDNA samples 
from all cases were mixed with 4μl of loading buffer, loaded onto a 3% agarose gel with 
ethidium bromide and run in Tris-acetate-ethylenediaminetetraacetic acid (EDTA; Sigma-
Aldrich) at 90V for approximately 60 minutes until the bands of the DNA ladder were clearly 
separated (10bp DNA Ladder; Life Technologies). Ultraviolet illumination was used to visualise 
the bands, and the size of the amplicons expected for each assay were calculated using the 
given primer sequences and the gene sequences in the NCBI database (Table 2. 4). A single 
band per assay of the expected size was taken as confirmation of primer specificity.  
2.1.4 Quantification of LTα and CXCL13 levels in human CSF  
The concentration of LTα and CXCL13 in post-mortem samples of CSF was quantified using a 
range of enzyme linked immunosorbent assays (ELISAs; see Table 2. 5). CSF aliquots, frozen 
at -80oC at the time of tissue dissection, were obtained from the UK MS Tissue Bank. Cases 
were chosen based on CSF colour and post-mortem delay. Only clear or pale pink CSF was 
used to reduce contamination with peripheral blood. The post-mortem delays (PMDs) of all but 
2 of the selected cases were below 24 hours. The longest PMDs were 27 and 33 hours, and 
the cases were included due to the limited number of CSF samples available (Table 2. 6). 
A Duoset ELISA kit (R&D Systems) was used to quantify LTα, according to the manufacturer’s 
instructions, and CXCL13 was quantified using a Quantikine ELISA kit. All samples were run in 
duplicate. CSF samples were thawed on ice for 1 hour then centrifuged (1.2g, 4oC, 10 
minutes) and the supernatants removed. Aliquots were stored at -80oC until required then 
thawed on ice for 1 hour before use. Duoset plates were coated overnight at 4oC with 100µl 
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capture antibody for human LTα (hLTα). Quantikine plates were pre-coated with the capture 
antibody for human CXCL13 by the manufacturer. Assay diluent was added to the plates 
(100μl/well), followed by standard or sample (50μl/well; 2 hours, rtp). Plates were incubated 
with LTα- conjugate or CXCL13-conjugate detection antibody (200μl/well; 2 hours, rtp). 
Substrate solution was added (200μl/well; 30 minutes in the dark, rtp). Stop solution (50μl/well) 
was added and optical density of the wells was determined using a VersaMax ELISA 
Microplate reader and SoftMax Pro software (Molecular Devices, Berkshire, UK). Washes with 
Wash Buffer were performed between incubations.  
Following the LTα Duoset ELISA, an ELISA Ready-Set-Go! Kit (eBioscience) was used 
according to manufacturer’s instructions to analyse a larger number of samples. Briefly, a 96 
well plate was coated with capture antibody overnight (4oC), washed with PBS 0.05% Tween-
20 then blocked with assay diluent (1 hour, rtp). Standards (highest standard 1000pg/ml, 
lowest standard 8pg/ml, zero standard Assay Diluent) and undiluted CSF samples were run in 
triplicate and incubated overnight (4oC). Plates were incubated with detection antibody (1 hour, 
rtp), followed by avidin-HRP (30 minutes, rtp), then substrate solution (15 minutes, rtp). Stop 
solution (1M H2SO4) was added and the plate read at 450nm. Readings taken at 540nm were 
subtracted from readings taken at 450nm to correct for optical imperfections in the plate. 
These data were entered into a web-based software package (elisaanalysis.com; Elisakit.com 
Pty Ltd, Scoresby, Australia) to be analysed using the Four Parameter Logistic (4PL) nonlinear 
regression model, as recommended by the ELISA manufacturers. The software calculates the 
mean of triplicates, subtracts the mean of the zero standard and performs four parameter 
logistic regression to calculate LTα and CXCL13 concentrations in CSF samples from the 
standard curve. The background signal is defined as 3 standard deviations above the mean 
zero standard.  
2.1.5 Electrochemiluminescence (ECL) assay to quantify LTα levels 
LTα concentration in human CSF samples was also analysed using electrochemiluminescence 
(ECL) plates (Meso Scale Discovery, USA), which have increased sensitivity compared to 
conventional ELISAs, to determine if very low concentrations of cytokines and chemokines 
could be detected in post-mortem CSF. ECL reagents in the wells emit light when an electrical 
charge is applied to the base. As the input stimulation is electricity and the signal output is 
light, background signal is reduced. Multiple excitation cycles amplify the signal and improve 
sensitivity. CSF samples from 3 SPMS cases with severe meningeal inflammation and a 
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young age of death were also included in the analysis of LTα levels by ECL plate (Table 2. 7). 
These cases are suspected to be F+SPMS but require further characterisation.  
2.2 Expression and purification of recombinant mouse MOG 
To avoid unnecessary repetition of identical experimental groups and waste of animals, in 
accordance with the 3Rs principle, the production and in vivo titration of rmMOG batch pXVII 
(sections 2.2 and 2.3) were carried out in collaboration with Dr. R. M. Schalks. 
2.2.1 Expression vector 
Lysogeny broth (LB) agar plates containing 1ml/l of 100mg/ml ampicillin sodium salt stock 
solution (Sigma) and 35mg/ml alcoholic solution of chloramphenicol stock solution (Sigma) 
were streaked with glycerol stocks of E. coli cells transfected with the pRSET A expression 
vector containing cDNA coding for the N-terminal sequence (amino acids 1-118) of mouse 
MOG. Plates were incubated overnight at 37oC in a shaking incubator and six colonies were 
selected to be further cultured in LB.  
2.2.2 DNA gel and sequencing of rmMOG construct 
DNA (50µg) was eluted from samples of the selected colonies using a QIAprep Spin Miniprep 
kit according to the manufacturer’s instructions (Qiagen). The concentration of DNA eluted 
from each culture was determined by Nanodrop (Labtech International, UK). Agarose gel 
electrophoresis was performed to determine which cultures contained the rmMOG construct. 
Restriction digest reactions were performed using HindIII in NEBuffer2 (New England Biolabs 
Inc., USA) for 1 hour at 37oC, followed by addition of 0.5µl 1M NaCl and EcoR1 for a further 
hour, before heat inactivation (65oC, 20 minutes). 2µl DNA loading buffer was added to 
samples of cut and uncut DNA and made up to 10µl total volume with distilled water (dH2O), 
before running on a 1% agarose gel with ethidium bromide, in 0.5x Tris-borate-EDTA buffer, 
for 1 hour at 109V, until the Hyperladder 1 sample (Bioline, UK) was well separated. Bands 
were visualised by ultraviolet illumination (BioDoc-It Imaging System; UVP, Cambridgeshire, 
UK). Molecular sequencing was performed on 500ng DNA samples from each culture by The 
MRC Clinical Sciences Genomics laboratory to check for presence of the 6 residue histidine 
tag ligated to the rmMOG construct.  
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Antigen Cell specificity Species Dilution Source 
MOG Myelin / 
oligodendrocytes 
Mouse 1:50 Professor Reynolds’ Group, 
Imperial College London 
CD20 B cells Mouse 1:5 ScyTek, USA 
Human LTα Cells expressing 
LTα  
Goat 1:200 R&D Systems, UK 
Table 2. 2 Antibodies used for immunohistological analysis of human tissue 
 
Number of cycles Duration of cycles Temperature (oC) 
1 10 minutes 95 
50 
15 seconds 95 
45 seconds 60 
Table 2. 3 qPCR thermal profile used for analysis of human meningeal gene expression 
 
 
Gene Expected amplicon size (bp) 
LTα 48 
CXCL13 48 
CCL21 32 
Xpnpep1 39 
GAPDH 38 
Table 2. 4 Expected sizes of amplicons for qPCR primer assays on human meninges 
 
Analyte Kit name & Supplier Sensitivity 
(pg/ml) 
Control 
(n) 
F- 
SPMS 
(n) 
F+ 
SPMS 
(n) 
LTα  Duoset (R&D Systems) 31.25 3 5 4 
LTα  Ready-SET-Go! 
(eBioscience) 
8.00 5 8 8 
LTα  ECL plate (Meso Scale 
Discovery) 
0.14 6 11 12 
CXCL13  Quantikine (R&D 
Systems) 
7.80 10 15 15 
Table 2. 5 Summary of ELISAs used to analyse human cerebrospinal fluid  
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Controls 
Control 
Case 
Sex Age at 
death (yrs) 
Disease 
duration (yrs) 
PMD 
(hrs) 
Cause of death 
C5# F 95 NA 10 Bronchopneumonia 
C7 F 85 NA 9 Oesophageal carcinoma and  
possible liver metastases 
C8# F 93 NA 9 Bronchopneumonia 
C15 M 82 NA 21 Old age 
C302# M 75 NA 17 Aspiration pneumonia 
C411 M 54 NA 20 Metastatic lung cancer  
C442# F 67 NA 33 Acute arrhythmia 
C492# M 85 NA 23 Heart failure 
C501# M 32 NA 6 Haemangiopericytoma cancer 
metastasised to bones 
PDC32 F 91 NA NA Old age 
Mean M:F 
5:5 
75.9 NA 16.4  
 
Follicle negative 
F-SPMS 
Case 
Sex Age at 
death (yrs) 
Disease 
duration (yrs) 
PMD 
(hrs) 
Cause of death 
MS074# F 64 36 7 Gastrointestinal bleed, 
pneumonia 
MS091# M 81 26 17 MS 
MS125# F 76 31 13 MS 
MS1392# F 62 22 9 Bronchopneumonia, MS 
MS155 F 80 37 13 Small bowel obstruction, 
pleurisy, heart problem, MS 
ms158 F 79 18 5 Bronchopneumonia, MS 
MS1812# F 71 32 20 Pneumonia, MS 
MS288 F 83 27 12 Bronchopneumonia, MS 
MS2961# M 59 39 22 MS 
MS3041# M 52 23 13 Pulmonary embolism, metastatic 
colon carcinoma, MS 
MS3122# F 68 23 24 Urinary Sepsis, MS 
MS340# F 53 20 17 Sepsis, pneumonia, MS 
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F-SPMS 
Case 
Sex Age at 
death (yrs) 
Disease 
duration (yrs) 
PMD 
(hrs) 
Cause of death 
MS3442# F 57 15 14 Septicaemia, MS 
MS3471# M 50 28 13 Metastatic pancreatic carcinoma 
MS3642 F 56 34 14 Bronchopneumonia, MS 
MS369 F 67 22 19 Bronchopneumonia, MS 
Mean M:F 
4:12 
66.1 27.1 14.5  
 
Follicle positive 
F+SPMS 
Case 
Sex Age at 
death (yrs) 
Disease 
duration (yrs) 
PMD 
(hrs) 
Cause of death 
MS046 M 40 24 18 Dehydration, MS 
MS0792# F 49 24 7 Bronchopneumonia, MS 
MS154 F 34 11 12 Pneumonia 
MS1601# F 44 15 18 Aspiration pneumonia, MS 
MS176 M 37 27 12 Intestinal obstruction, MS 
MS2353 M 53 33 14 Septicaemia due to UTI, MS 
MS2862# M 45 16 7 MS 
MS3173 F 48 29 21 Aspiration pneumonia, MS 
MS336# F 57 27 24 Respiratory failure, MS 
MS356# F 45 16 10 MS 
MS361 F 60 34 10 MS, sigmoid colon cancer 
MS3711 M 40 17 27 Bronchopneumonia 
MS3771# F 50 NA 22 Aspiration pneumonia 
MS4021# M 46 21 12 MS, bronchopneumonia 
MS4071# F 44 19 22 Septicaemia, pneumonia 
MS4261 F 48 30 21 MS 
Mean M:F 
6:10 
46.3 22.9 16.1  
Table 2. 6 Cases used for analysis of CXCL13 and LTα levels in CSF by ELISA.  
All listed cases were analysed for CXCL13 by Duoset ELISA (R&D) except MS364, MS235 and MS317, 
for which CSF was not available. 1Cases also used for LTα eBioscience ELISA. 2Cases also used for 
LTα eBioscience and Duoset (R&D). 3Cases also used for LTα Duoset ELISA (R&D). #Cases also used 
for ECL plate analysis of LTα. PMD- post-mortem delay. 
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Suspected follicle positive 
Case Sex Age at 
death 
(yrs) 
Disease 
duration 
(yrs) 
PMD 
(hrs) 
Cause of death 
MS438 F 53 18 17 MS 
MS448 F 37 13 13 Pulmonary emboli 
MS473 F 39 13 9 Bronchopneumonia, MS 
Mean  43 14.7 13  
Table 2. 7 Extra cases suspected to be F+SPMS, for ELISA analysis of CSF. 
 
 
 
Figure 2. 2 Map of pRSET A vector with MOG sequence and polyhistidine tag (6xHis)  
2875bp + 359bp
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2.2.3 Expression and purification of rmMOG 
A single mini-prep culture containing the correct tag and construct was diluted 1:1000 in fresh 
super optimal broth and incubated in a shaking incubator overnight at 37oC. Expression of 
rmMOG was induced at the mid-logarithmic phase of growth (when the OD600 absorbance 
reading reached approximately 0.3), by addition of 1mM isopropyl β-D-1 thiogalactopyranoside 
(IPTG; 1mM; Sigma-Aldrich), which dis-inhibits the lac operon of the host cell chromosome 
and allows expression of T7 polymerase, and the subsequent expression of rmMOG under the 
PT7 promoter. Bacterial cells were harvested when the OD600 reached 0.8-1.2, by centrifugation 
at 1377g (10 minutes, 4oC). Cells were lysed using pH8 lysis buffer (10mM Tris-HCl, 50mM 
PO4, 8M urea, 100mM NaCl; Sigma-Aldrich) and cell debris was removed by repeated 
sonication and centrifugation cycles at 16,100g (25 minutes, 4oC). A Talon metal affinity resin 
(Clontech, Saint-Germain-en-Laye, France) was equilibrated by repeated cycles of adding 
lysis buffer, centrifuging, and discarding the supernatant. Protein-resin binding was achieved 
by addition of the resin to the rmMOG-containing supernatant, followed by agitation for 1 hour 
on a rotary shaker. Centrifugation at 700g for 15 minutes removed the excess protein 
supernatant, followed by washing with a volume of lysis buffer. The resin was loaded onto a 
gravity flow column and washed with lysis buffer, followed by wash buffer (pH7; 50mM PO4, 
300mM NaCl, 8M urea) until the UV spectrophotometer plotter reached baseline. Elution buffer 
(pH5.3; 50mM PO4, 300mM NaCl, 8M urea, 20mM MES [2-(N-morpholino)ethanesulfonic acid; 
Sigma-Aldrich]) was added and eluted protein was detected by measuring UV absorbance at 
280nm. Eluted protein was diluted in a volume of pH7.4 arginine (1M; Sigma-Aldrich) in PBS, 
added to dialysis tubing (SnakeSkin 3.5K MWCO; Pierce, Rockford, Illinois, USA) and dialysed 
against 3 volumes of pH7.4 dialysis buffer (1M arginine, 2mM reduced glutathione and 0.2mM 
oxidised glutathione in PBS; Sigma-Aldrich) at 4oC overnight, followed by concentration by 
centrifugation at 4000g at 4oC in15ml Amicon Ultra centrifugal filter tubes (Millipore, 
Hertfordshire, UK). The concentration of rmMOG was determined using a Nanodrop 
spectrophotometer (Labtech International, UK) at 280nm.  
2.2.4 SDS-PAGE and Western blot  
Sample buffer and reducing agent (Invitrogen) were added to 10µg rmMOG, made up to a 
total volume of 10µl with distilled water and heated at 70oC for 10 minutes. The sample was 
then loaded onto a 4-12% a Bis-Tris gradient gel (Life Technologies) together with protein 
molecular weight markers (SeeBlue Plus2 Pre-Stained Standard; Life Technologies) and 
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control samples of 2mg/ml BSA in PBS and another batch of rmMOG previously produced by 
this laboratory. The gel was run with MES running buffer and added NuPAGE antioxidant (Life 
Technologies) at ~200V for 45 minutes. Protein bands were detected by immersion in 
Coomassie brilliant blue (Sigma) followed by de-staining in ethanol (10% v/v; Sigma-Aldrich) 
and acetic acid (7.5% v/v; BDH Chemicals from VWR International Ltd, UK) to give a clear 
background. The monomer:dimer ratio of rmMOG was assessed by densitometry, using the 
Image Pro software line profile tool (Media Cybernetics), and taking the mean of 3 readings. A 
greater proportion of monomers within the rmMOG batch is thought to be more 
encephalitogenic (unpublished observations from this laboratory). 
Western blotting to detect mouse MOG protein was performed by semi-dry electrotransfer of 
protein bands at ~2V for 1 hour, from the SDS-PAGE gel (performed as described above) onto 
a 0.2µm nitrocellulose membrane (Life Technologies), which was pre-soaked in transfer buffer 
and placed under the gel between 2 pieces of filter paper. The membrane was washed in Tris-
buffered saline (pH7.4) with 0.1% Tween 20 (TBST; Sigma-Aldrich), before blocking non-
specific binding sites with 5% (w/v) semi skimmed dried milk powder (Marvel, Premier Foods, 
Hertfordshire, UK) in TBST for 1 hour under agitation. Following a 10 minute wash in TBST, 
the membrane was incubated under agitation with goat anti-mouse MOG antibody (R&D 
Systems, Oxfordshire, UK), diluted 1:10,000 in 2% (w/v) milk in TBST, for 1 hour. After 3 
consecutive 5 minute washes in TBST, the membrane was incubated with horseradish 
peroxidase conjugated donkey anti-goat IgG secondary antibody (R&D Systems) under 
agitation for 1 hour. Following a 30 minute TBST wash, protein bands were detected using 
electrochemiluminescence (ECL) Western Blotting Detection Reagent (Amersham, GE 
Healthcare Life Sciences, Buckinghamshire) and exposed on HyperECL film (Amersham) 
according to the manufacturer’s instructions.   
2.3 Induction of EAE in female DA rats 
2.3.1 Immunisation protocol 
All in vivo procedures were performed under UK Home Office project licence 70/7213. Female 
DA rats (Charles River, Germany), aged 8-12 weeks and weighing approximately 160g, were 
housed in individually ventilated cages in the animal facility at Imperial College London, under 
standard conditions, with standard chow and water available ad libitum, and a 12:12 hour 
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dark-light cycle. Animals were allowed to acclimatize for a period of 7 days prior to any 
regulated procedures being carried out, and those with clinical EAE were provided with wet 
mash.  
Immunisation was performed under general anaesthesia (2% isoflurane; Abbott Laboratories, 
Berkshire, UK and oxygen 2l/min). The dorsal aspect of the base of the tail was shaved and 
cleaned with povidone-iodine antiseptic (Videne; Ecolab, Yorkshire, UK), prior to intradermal 
injection. Rats were immunised with 2, 5 or 50µg recombinant mouse myelin oligodendrocyte 
glycoprotein (rmMOG; n=4-8 per group), diluted in PBS and emulsified in an equal volume of 
incomplete Freund’s adjuvant (IFA) to give a total injection volume of 100µl per rat. Control 
rats were immunised with PBS emulsified in an equal volume of IFA.  
2.3.2 Clinical evaluation of EAE 
All animals were weighed and clinically scored daily after immunisation. A modified scoring 
system based on a previous study was used to define the level of neurological deficit (Storch 
et al., 2006) (Table 2.1). A loss of 25% of the body mass of the animal (measured the day prior 
to deficit onset) for a period of 48 hours, or complete paralysis of both hind limbs for more than 
5 days without weight gain were the humane endpoints for the clinical evaluation of EAE, 
which necessitated culling and removal from the experiment, in compliance with Home Office 
regulations. 
2.3.3 Tissue preparation 
Rats received an overdose of sodium pentobarbital (200mg/ml Euthatal; Merial Animal Health, 
Essex, UK) by intraperitoneal (i.p.) injection at 28 days post-immunisation (dpi) or at 24 hours 
after the peak of neurological deficit. Following cessation of respiration, rats were perfused 
with 50mls PBS followed by 100mls 4% w/v paraformaldehyde (PFA; Sigma-Aldrich) in PBS 
via the left ventricle. Blood was collected from an incision in the right atrium and processed as 
described in 2.3.6. Brains and spinal cords were removed and post-fixed in 4% PFA (4 hours, 
rtp), prior to cryo-protection in 30% sucrose solution in PBS (48 hours or until equilibrated, 
4oC). Spinal cords were cut into 8 sections, (2 cervical, 4 thoracic, and 2 lumbar segments), 
mounted in optimal cutting temperature compound (OCT; Tissue-Tek; Sakura, The 
Netherlands) and frozen in isopentane on dry ice. 10µm coronal sections were cut using a 
cryostat (Leica, Wetzlar, Germany) and stored at -20oC.  
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2.3.4 Immunofluorescence  
Double-labelling immunofluorescence (IF) for MOG and ionized calcium binding adaptor 
molecule 1 (Iba1) identified areas of demyelination and macrophage/microglial activation in the 
CNS respectively. Exposure of the MOG antigen was performed by immersion in -20oC 
methanol (Sigma-Aldrich) for 6 minutes. Non-specific binding was blocked with 5% NHS in 
PBST (1 hour, 4oC), and sections were incubated with primary antibodies diluted in 1% NHS in 
PBST (overnight, 4oC; Table 2. 9). Incubation with horse anti-mouse biotinylated secondary 
antibody diluted 1:500 in 1% NHS in PBST (1 hour; Vector Laboratories, Cambridgeshire, UK), 
was followed by incubation with streptavidin-conjugated Alexa Fluor 488 secondary antibody 
(Alexa Fluor Dyes; Life Technologies) and goat anti-rabbit Alexa Fluor 546 both diluted 1:1000 
(1 hour, in the dark). After a 5 minute incubation with 4’,6-diamidino-2-phenylindole (DAPI; 
Sigma-Aldrich) to visualise nuclei, sections were mounted in Vectashield mounting medium 
(Vector Laboratories). PBST washes were performed after methanol immersion, and between 
all incubations, which were performed at rtp unless stated. 
Demyelination was confirmed by performing IF for myelin basic protein (MBP) using the same 
protocol as for MOG. Neuronal axons were visualised by IF, using an anti-neurofilament H 
(Nfil) antibody without antigen retrieval. To identify CD4+ and CD8+ T cells, sections were 
blocked with 5% NGS then incubated with CD4 primary antibody (overnight, 4oC; AbD 
Serotec, Kidlington, UK). CD4 antibody binding was detected using incubation with goat anti-
mouse IgG2a biotinylated secondary antibody (Life Technologies), diluted 1:500 in 1% NGS in 
PBST (1 hour), followed by incubation with streptavidin-conjugated Alexa Fluor 488 secondary 
antibody (Life Technologies) as above. Sections were then incubated with CD8 primary 
antibody (overnight, 4oC; AbD Serotec), and binding detected by incubation with goat anti-
mouse IgG1 Alexa Fluor 546 as above (Life Technologies). CD79a+ B cells were identified 
using the same protocol as for MOG, replacing methanol with heat mediated antigen retrieval 
in pH6 citrate buffer (0.1M citric acid, 0.1M sodium citrate; Sigma-Aldrich) heated to 90oC in a 
vegetable steamer. CD3+ T cells were identified by IHC performed as described in 2.1.2.2, 
using the CD3 primary antibody detailed in Table 2. 9, with the addition of heat mediated 
modified pH6.1 citrate buffer (Dako UK Ltd, Cambridgeshire, UK), in a steamer prior to 
immersion in 0.3% hydrogen peroxide. 
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Clinical 
Score Neurological Deficit 
0 No deficit 
0.25 Loss of tone of tail tip 
0.5 Loss of tone of half of tail 
1 Complete weakness of tail 
2 Partial weakness of one limb 
2.5 Complete weakness of one limb 
3 Partial weakness of both hind limbs 
3.5 Complete weakness of both hind limbs / weakness in limbs on one side 
4 Weakness of all limbs or complete weakness in limbs on one side 
5 Complete weakness of all limbs 
Table 2. 8 Scoring system used to assess neurological deficits daily. 
 
Antigen Cell specificity Species Dilution Source 
MOG Myelin / 
oligodendrocytes 
Mouse 1:50 Professor Reynolds’ 
Group, Imperial 
College London 
MBP Myelin / 
oligodendrocytes 
Rabbit 1:200 Dako, UK 
Nfil Neurofilament H Chicken 1:1000 Millipore, UK 
Iba1 Macrophages / microglia Rabbit 1:2000 Wako, Japan 
CD79a B cells Mouse 1:2000 Thermoscientific, UK 
CD3 T cells Mouse 1:500 BD Biosciences, UK 
CD4 CD4 T cells Mouse IgG2a 1:500 AbD Serotec 
CD8 CD8 T cells Mouse IgG1 1:500 AbD Serotec 
Table 2. 9 Primary antibodies used in IF and IHC protocols. 
 
Secondary 
antibody 
Serum dilution Antibody dilution Source 
Total IgG 1:4000 1:5000 Southern Biotech 
IgG1 1:1000 1:4000 AbD Serotec 
IgG2a 1:1000 1:4000 AbD Serotec 
Table 2. 10 Serum dilutions and secondary antibody details for anti-MOG ELISA  
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2.3.5 IF and IHC image capture and analysis  
High resolution tiled IF images of whole spinal cord sections were captured using a Nikon 
Eclipse 50i or 80i microscope (Nikon, Surrey, UK) with a QImaging QICAM digital camera 
(QImaging, Staffordshire, UK) and Image Pro Plus software (Media Cybernetics, 
Buckinghamshire, UK). Demyelinated areas were delineated and quantified using image-Pro 
Plus 7.0 software (Media Cybernetics, USA). The threshold function of ImageJ software (NIH, 
Maryland, USA) was used to calculate the area of Iba1 immunoreactivity (IR) per section, 
which was calculated as a fraction of the total area of each section. The 20x objective was 
used to manually quantify T and B cell parenchymal infiltration. Three adjacent sections per 
spinal cord segment were analysed per animal, and a mean calculated.  
2.3.6 ELISA analysis for peripheral anti-MOG antibodies 
Peripheral anti-MOG antibodies were detected in serum from blood samples taken at 14 and 
28 dpi. Animals were placed in a 28°C hot box for 10 minutes prior to restraint in a tube, with 
the tail placed in warm water (~40oC) for 2 minutes to aid vasodilation. A maximum of 250µl 
per blood sample was collected from the lateral tail vein into an Eppendorf tube containing 
10µl of 46mg/ml EDTA (final concentration of 2.3mg/ml to prevent clotting) using a 23G 
butterfly needle (Venofix; Medisave, Dorset, UK). Whole blood was centrifuged at 3700g for 10 
minutes, and the serum removed and stored at -20oC.  
Anti-MOG antibodies were detected by ELISA. Briefly, 96 well microplates (BD Biosciences) 
coated with 10µg/ml rmMOG (overnight, 4oC) were washed 5 times with PBST and blocked 
with 2% (w/v) bovine serum albumin (BSA) in PBS (1 hour, 37oC). Serum samples were 
diluted in 1%BSA/PBS (as detailed in Table 2. 10) and run in triplicate (2 hours, 37oC). Plates 
were incubated with goat anti-rat IgG-specific alkaline phosphatase-linked secondary 
antibodies (detailed in Table 2. 10) in 1% BSA/PBS (1 hour, 37oC). Bound antibody was 
detected using SIGMAFAST p-Nitrophenyl phosphate tablets (30 minutes, in the dark; Sigma-
Aldrich). Optical density was measured at 405nm using a VersaMax ELISA Microplate Reader 
with SoftMax Pro software. All incubations at 37oC were carried out under agitation, and PBST 
washes were performed between incubations. 
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2.4 Subarachnoid injections in vivo 
Following rmMOG immunisation to induce subclinical EAE, animals were neurologically scored 
daily (as described in 2.3.1 and 2.3.2), and culled if humane endpoints were reached (loss of 
25% of their body weight from the day prior to deficit onset, or hind-limb paralysis lasting more 
than 48 hours). Stereotaxic injections of cytokines or lentiviral (LV) vectors into the 
subarachnoid space were performed at 19-21 dpi, or at an equivalent time-point in age-
matched naïve control animals. The co-ordinates were determined from a rat brain atlas 
(Paxinos and Watson, 1998), and were 0.9mm caudal to bregma, on the midline, to a ventral 
depth of 2.4mm from the dura mater (Figure 2. 4), based on previous studies in this laboratory 
which targeted the motor cortex (Gardner et al., 2013). However, the ventral co-ordinate was 
reduced by 0.1mm from 2.5mm to avoid damaging the corpus callosum, as this was a 
frequently observed artefact in pilot studies.  
2.4.1 Cytokines  
To determine the acute effect of raised concentrations of cytokines in the subarachnoid space, 
stereotaxic injections of 1µl total volume of recombinant rat IFNγ (reconstituted in pH8 sodium 
phosphate [10mM; Sigma-Aldrich] and diluted in 0.1% (w/v) BSA in sterile PBS; Peprotech, 
New Jersey, USA) and recombinant human LTα (hLTα; reconstituted in 0.1% (w/v) BSA in 
sterile PBS; Peprotech) were performed. At the time of designing our experiments, 
recombinant rat and mouse LTα were prohibitively expensive and insufficiently concentrated 
respectively, so recombinant hLTα was used for all in vivo experiments. Sequence homology 
between human and rat LTα was calculated to be 73%, using the NCBI BLAST sequence 
analysis tool. The major receptor for LTα is TNFR1 (Sacca et al., 1998). Human LTα has been 
shown to bind mouse TNFR1 in vitro, and the sequence homology between rat and mouse 
TNFR1 is 82%, so it is likely that hLTα will bind to rat TNFR1 (Bossen et al., 2006). Since 
previous experiments have shown limited pathology following subarachnoid injection of TNF or 
IFNγ alone, but a significant synergistic effect when both are co-injected (Gardner et al., 
2013), we co-injected LTα+IFNγ. Given that LTα, like TNF, signals through TNFR1, and due to 
our consideration of the ethical use of animals, to reduce the number of animals required for 
our experiments, we did not investigate injection of LTα alone.  
Details of cytokine doses used for the dose response experiment are outlined in Table 2. 11. 
The chosen dose of 75ng IFNγ was used previously to induce acute cortical pathology when 
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co-injected with 1.25μg TNF (Gardner et al., 2013). The biological activities of recombinant 
hLTα and recombinant rat TNF were determined by the manufacturers using a standard 
cytotoxicity assay, which measured cytolysis of murine L929 cells in the presence of the 
metabolic inhibitor actinomycin-D, to give ED50 values that correspond to the concentration of 
cytokine required to result in 50% cell death. A higher ED50 concentration indicates lower 
biological activity. The ED50 for hLTα is 50pg/ml compared to 10-20pg/ml for rat TNF, 
suggesting that double the concentration of hLTα would be required to elicit a biological effect 
equivalent to 1.25μg TNF used in the previous study (Gardner et al., 2013). However, for the 
dose response experiment the highest LTα dose was limited to 1μg, since 1μg/μl was the 
highest concentration that could be reconstituted without encountering solubility problems, and 
the injection volume was limited to 1μl to enable comparison with the previous study (Gardner 
et al., 2013). This dose (1µg LTα + 75ng IFNγ) was also used for the subsequent time-course 
experiment (Table 2. 12).  
Monastral blue (Copper II phthalocyanine-tetrasulfonic acid tetrasodium salt; Sigma-Aldrich, 
Dorset, UK) was added to all subarachnoid injections as a tracer to determine the location of 
injections, as used by previous studies (Kerschensteiner et al., 2004; Merkler et al., 2006b; 
Rodriguez et al., 2014). Control animals were immunised with rmMOG and received an 
injection of sterile PBS with monastral blue (MOG PBS controls; n=5). A group of age-matched 
naïve rats, which received no immunisation or subarachnoid injections, provided an additional 
control (n=3). 
2.4.2 Lentiviral vectors 
To determine the chronic effects of raised concentrations of cytokines in the subarachnoid 
space, stereotaxic injection of lentiviral (LV) vectors expressing human LTα (LVLTα) or 
enhanced green fluorescent protein (LVGFP) was performed (Table 2. 13). A group of 3 naïve 
animals were injected with the LV vehicle TSSM alone (20mM Tromethamine, 100mM sodium 
chloride, 10mg/ml sucrose and 10mg/ml mannitol; all Sigma-Aldrich), and culled at 7 days 
post-injection. 
2.4.2.1 Lentiviral vector production 
LV vectors were kindly produced by Dr. Rachel James. A human immunodeficiency virus type 
1 (HIV-1) transfer plasmid (326-pRRL-sincppt-CMV-eGFP-WPRE genome plasmid) carrying 
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the full human cytomegalovirus promoter (CMV) promoter was used for lentiviral production. 
The human LTα cDNA sequence with Xba1 and Sal1 sequences added at 5’ and 3’ ends 
respectively was designed in house and produced by Invitrogen GeneArt based on accession 
sequence AB103618. Restriction digest using Xba1 and Sal1 was used to excise the LTα DNA 
fragment prior to purification by preparative agarose gel electrophoresis. The GFP fragment 
was excised from the transfer plasmid using restriction digest with Xba1 and Sal1, and the LTα 
DNA transgene fragment was ligated in-frame using the same restriction sites. Restriction 
digest using enzymes for the same restriction sites used for cloning confirmed that cloning was 
successful. Previous pilot studies in this laboratory suggested that the early CMV promoter in 
the transfer vector resulted in inconsistent long-term expression following injection into the 
subarachnoid space in vivo. This promoter was replaced with an enhanced CMV promoter 
cloned by RT-PCR and inserted into the transfer plasmid by restriction digest, to ensure stable 
long-term expression of the transgene in vivo over a period of months. 
To produce the LV vectors, calcium phosphate four plasmid co-transfection was carried out in 
293T cells, using 15μg of transfer vector with 15μg Gag-pol (pMD2-LgpRRE), 3μg Rev (pRSV-
Rev) packing plasmids and 5.1μg of the VSV-g envelope plasmid. The virus was concentrated 
by centrifugation overnight followed by ultracentrifugation, before resuspension in 100μl of 
TSSM. Biological titres for GFP expressing control vectors were determined by transducing 
293T cells in the presence of polybrene (8μg/ml) using serial dilutions and FACS analysis, and 
were between 1010-1011 TU/mL. qPCR using viral RNA was used to determine physical titres 
for all vectors, with typical yields between 1011-1012 genomic copies. Typical subarachnoid 
injections of 2μl volume contained 1x108-9 total genomic copies of viral RNA.  
LTα transgene expression was confirmed by transfection in 293T cells and primary meningeal 
cells, followed by detection of a single band by western blot, and immunohistochemistry. 
Levels of secreted LTα in transduced human embryonic kidney 293T (HEK) cells and primary 
meningeal cell culture supernatant were measured by ELISA. 
2.4.3 Stereotaxic surgery 
Rats were fully anaesthetised as described in 2.3.1, and the scalp was shaved and disinfected 
with Videne. Subcutaneous injections of 0.9% saline (Sigma-Aldrich) and 0.01mg/kg 
buprenorphine (Vetergesic; Alstoe Animal Health, North Yorkshire, UK) were administered to 
provide post-operative rehydration and analgesia at a dose that has been shown to have no 
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effect on inflammatory processes (Carrigan et al., 2004). Rats were positioned on the 
stereotaxic frame (Stoelting, Dublin, Ireland) under anaesthesia, and an incision made through 
the shaved site on the scalp to visualise bregma on the surface of the skull. A fine hole was 
drilled with a small power drill (RS Components, Northamptonshire, UK) at 0.9mm caudal to 
bregma, at the location of the motor cortex. The injection was made using a fine glass capillary 
mounted on the 26 gauge needle of a 10μl Hamilton syringe (Figure 2. 3; Hamilton, 
Graubünden, Switzerland). The needle was lowered to a depth of 2.3mm ventral to the dural 
membrane and the cytokines or lentiviral vectors were infused at a rate of 0.2µl/min using an 
automated infuser (Figure 2. 4; KD Scientific, USA). After 5 minutes had elapsed, to allow for 
diffusion of the injection solution away from the injection site, the needle was withdrawn and 
the incision closed using simple interrupted silk sutures (Mersilk; Covidien, Dublin, Ireland). 
Sutures were removed at 7-10 days post-surgery. All animals were monitored daily until the 
termination of the study, and recovery from surgery was uneventful in the majority of cases. 
Brains were removed and processed as described in 2.3.3. Consecutive 10µm sections were 
taken in the coronal plane throughout the brain, and analysis of immune cell infiltration and 
demyelination were carried out using IF, as described in 2.3.4 and 2.3.5. In addition, the 
expression of human LTα in animals injected with LVLTα was investigated using IF and the 
primary antibody detailed in Table 2.2. The IF protocol described in 2.3.4 was adapted for use 
with the goat anti-LTα primary antibody by using a horse anti-goat biotinylated secondary 
antibody (Vector Laboratories, Cambridgeshire, UK), followed by incubation with streptavidin-
conjugated Alexa Fluor 488 secondary antibody (Alexa Fluor Dyes; Life Technologies). 
2.4.4 Investigation of alternative injection sites  
To investigate alternative injection sites for subarachnoid injections, a small pilot study was 
conducted in naïve female DA rats weighing ~160g, acclimatised for 1 week prior to 
subarachnoid injection of Indian ink (Stevens, UK) diluted 1:50 in sterile filtered PBS (1µl total 
volume; n=3 per injection site). Injection sites were calculated to correspond to 5.8mm and 
7.2mm posterior to bregma in the Rat Brain Atlas (Paxinos and Watson, 1998). The difference 
in skull/brain size between the atlas (based on Sprague Dawley rats weighing 290g) and the 
160g female DA rats was taken into account. Stereotaxic measurement of the interaural-
bregma distance on the skulls of 2 female DA rats, of similar age and weight, was carried out 
during a parallel study and the mean percentage difference compared to the atlas was 
calculated to be -7%, so the injection co-ordinates were adjusted accordingly (Table 2. 14). 
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Indian ink was used as a tracer instead of monastral blue, due to being easier to visualise and 
more particulate, increasing the likelihood that it would remain in the vicinity of the injection 
site despite being injected into a greater volume of CSF. Brains were removed at 7 days post-
stereotaxic injection and processed as described in 2.3.3.  
2.4.5 Investigation of the position of the sagittal sinus 
A pilot study (n=5) was conducted in naïve female DA rats to determine the location and 
diameter of the superior sagittal sulcus. Rats were culled by an i.p. overdose of pentobarbital 
and 2 hours elapsed to allow blood to clot in the sagittal sinus, to aid visualisation of the 
vessel. Whole heads were removed and immersed intact in formalin for 6 days. The skull was 
carefully dissected post-fixation to keep the dura and sagittal sulcus intact, and the brain and 
attached dura were embedded in paraffin wax using an automated embedding machine. 
Microtome sections 10μm thick were analysed following H&E staining and mounting as 
previously described (see 2.1.2.1). 
2.5 Detection of viral transduction in vivo  
2.5.1 ELISA and ECL assay analysis of CSF  
CSF samples were withdrawn from the cisterna magna of rats under terminal anaesthesia. 
Rats were placed on a stereotaxic frame in the same position as described for stereotaxic 
injection of cytokines in section 2.4.3. The dorsal aspect of the neck and base of the skull was 
shaved and cleaned with 70% ethanol. A small incision through the skin and underlying 
muscle layer was made directly over the junction between the base of the skull and the first 
cervical vertebra. A 26G Hamilton syringe was inserted into the cisterna magna and up to 60μl 
CSF was withdrawn into RNase free tubes, snap frozen on dry ice and stored at -80oC.  
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 Figure 2. 3 Fine glass capillary for the stereotaxic injection of cytokines  
A fine glass capillary of approximately 30μm internal diameter at the tip (A) was mounted and sealed 
onto the metal tip (B) of a 10μl 26S Hamilton needle using nail varnish (C), and used for stereotaxic 
injection of cytokines into the subarachnoid space of female DA rats. 
 
 
Figure 2. 4 Stereotaxic co-ordinates of the subarachnoid space used for injections 
Cytokines LTα+IFNγ were injected into the subarachnoid space (circled in red) of female DA rats at -
0.9mm posterior from bregma, by insertion of a fine glass capillary through the sagittal sulcus (red 
dotted arrow; 0.0mm lateral co-ordinate) to a depth of 2.3mm ventral to the dural surface. Adapted from 
(Paxinos and Watson, 1998).   
A B C
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Immunisation Recombinant 
human LTα (µg) 
Recombinant 
rat IFNγ (ng) 
Time-point 
(days) 
Number of 
animals (n) 
IFA 0.5 75 7 6 
10µg rmMOG 0.5 75 7 6 
Naïve 1 75 7 5 
IFA 1 75 7 6 
10µg rmMOG 1 75 7 6 
Table 2. 11 Groups for the dose response experiment 
 
 
Immunisation Recombinant 
human LTα (µg) 
Recombinant 
rat IFNγ (ng) 
Time-point 
(days) 
Number of 
animals (n) 
5µg rmMOG 1 75 3 6 
5µg rmMOG 1 75 7 5 
5µg rmMOG 1 75 14 6 
5µg rmMOG 1 75 21 5 
Table 2. 12 Groups for the time-course experiment 
 
Immunisation Virus Injection 
volume 
(µl) 
Viral titre 
(copies/µl) 
Time-
point 
(days) 
Number 
of 
animals 
(n) 
Naïve LVGFP 1 2.2 x 106 7 4 
Naïve LVGFP 1 2.2 x 107 7 4 
Naïve LVGFP 1 2.2 x 106 28 4 
Naïve LVGFP 1 2.2 x 107 28 4 
Naïve LVLTα 2 1.76 x 109 7 4 
Naïve LVLTα 2 1.76 x 109 28 7* 
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Immunisation Virus Injection 
volume 
(µl) 
Viral titre 
(copies/µl) 
Time-
point 
(days) 
Number 
of 
animals 
(n) 
5µg rmMOG LVGFP 2 2.3 x 108 28 5 
5µg rmMOG LVLTα 2 1.76 x 109 28 3 
Naïve LVGFP 2 2.3 x 108 3 
months 
5 
5µg rmMOG LVGFP 2 2.3 x 108 3 
months 
5 
Naïve LVLTα 2 1.76 x 109 3 
months 
5 
5µg rmMOG LVLTα 2 1.76 x 109 3 
months 
8 
Table 2. 13 Experimental group details for all LV vector studies 
* = 2 animals were used to prepare fresh tissue lysates for western blot analysis.  
 
 
 
Atlas anterior-posterior 
co-ordinate (mm) 
Adjusted anterior-posterior 
co-ordinate (mm) 
Adjusted ventral 
co-ordinate 
(mm) 
-5.8 -5.4 -2.0 
-7.2 -6.7 -1.5 
Table 2. 14 Adjusted stereotaxic co-ordinates for alternative injection sites in DA 
females 
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Gene 
of 
interes
t 
Accession 
No. 
Forward Primer (5’-
3’) 
Reverse Primer (5’-
3’) 
Product 
size (bp) 
LTα #1 NM_080769.2 AGGGCCATTCCTAC
TCCCAT 
TCCTTGTAGCCCCG
GATACA 
117 
LTα #2 NM_080769.2 CTTCCAGGACAGCT
CACCAG 
GTCCGTGTTTGCTC
TCCAGA 
122 
LTα #3 NM_080769.2 ACTCTCTCCTGATC
CCCACC 
AGGAAAACAGCTGG
ACCTCG 
129 
CXCL1
3 
NM_00101749
6 
CCCTGCTTCTTCTA
CTGGCC 
GTCGAGCTCACCTT
GGAACA 
100 
HVEM NM_00101503
4 
GGGAGTTGCGATA
GTGGGAG 
CCTGATGGCGTCCT
CTTGTT 
127 
TNFR1 NM_013091 CCCCTGTTCGGAAA
T GGGAA 
TGAACTCCTTCCAG
C GTGTC 
120 
Table 2. 15 Primers used for SYBR green qPCR on samples from fixed rat tissue 
 
 
Antigen Species Dilution Source 
TNFR1 Mouse 1:200 Bio-Rad, UK 
Human LTα Goat 1:200 R&D Systems, UK 
Iba1 Rabbit 1:2000 Wako, Japan 
Cleaved caspase 3 Rabbit 1:500 Cell Signaling, USA 
Laminin Rabbit 1:500 Wako, Japan 
Table 2. 16 Antibodies used for immunofluorescence of cultured meningeal cells  
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2.5.2 ELISA analysis of fresh brain tissue lysates 
Brain tissue lysates were prepared using fresh brain tissue perfused with PBS alone. The 
brain was removed, placed into sterile PBS on ice and the injection site of LVLTα identified by 
the presence of monastral blue in the sagittal sulcus. The cortical tissue surrounding the 
injection site (for a distance of approximately 2mm on either side) was isolated from the rest of 
the brain using a sterile scalpel and a lysate of the tissue prepared. Further lysate samples 
were prepared from the remaining brain tissue and cerebellum. Lysates were prepared by 
manually homogenising the tissue with a pestle and mortar, followed by addition of four times 
the volume of RIPA buffer (Thermoscientific) to each sample and sonication on ice for 2 x 30 
seconds. Lysates were centrifuged (4oC, 16.1g, 15 minutes) and the supernatants were 
removed and stored at -80oC. A BCA assay (Thermoscientific) was performed according to the 
manufacturer’s instructions, to determine the protein concentration of the lysate samples. The 
concentration of hLTα in approximately 70µg lysate per sample was quantified by Duoset 
ELISA kit (R&D Systems) as described in 2.1.4.  
2.5.3 Analysis of gene expression in fixed brain tissue by PCR  
2.5.3.1 Reverse transcription of RNA from fixed rat brain tissue 
RNA was extracted from sections of fixed frozen rat brain to detect changes in rat gene 
expression. For each animal four 10μm sections of brain fixed in 4% PFA as previously 
described, mounted on glass slides and stored at -20oC, were scraped into RNase free tubes 
using a sterile scalpel treated with RNase Zap prior to use (Life Technologies). Following the 
RecoverAll Total Nuclei Acid Isolation protocol, 100μl digestion buffer was added to each 
sample and the samples incubated at 50oC for 15 minutes, then 80oC for 15 minutes. Isolation 
additive (120μl per sample) was added with 275μl 100% ethanol, followed by mixing by 
pipette. Each sample was transferred to a filter cartridge, centrifuged at 10,000g for 30 
seconds and the flow-through discarded. The cartridge was washed with 700μl Wash Buffer 1, 
the centrifugation step was repeated and the flow-through was discarded. 500μl Wash Buffer 
2/3 was added to the cartridge, the centrifugation step was repeated, the flow-through was 
discarded and the cartridge was centrifuged for a further 30 seconds to remove residual fluid. 
RNA was eluted by addition of 60μl elution solution to the cartridge membrane, incubation for 
1 minute at room temperature and centrifugation at 16,100g for 1 minute.  
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The concentration and purity of eluted RNA was determined by spectrophotometer 
(Nanodrop). RNA concentration was approximately 30ng/μl for all samples and purity was 
assessed by a 260/280 ratio of above 1.8. RNA integrity was determined by gel 
electrophoresis and samples gave clear bands with minimal smearing, indicating acceptable 
preservation of RNA integrity. A Precision DNase kit (PrimerDesign) was used according to 
manufacturer’s instructions on eluted RNA, prior to reverse transcription using a Nanoscript 2 
kit (PrimerDesign). Reverse transcription was carried out immediately following RNA 
extraction, using a combination of random nonamer primers and oligo-dT primers, which is 
recommended for RNA samples extracted from formalin fixed tissue. cDNA samples were 
stored at -20oC until use for qPCR. RNA samples were stored at -80oC. 
2.5.3.2 SYBR green primer design, validation and gel electrophoresis 
Primers for rat genes were designed using DNA dynamo software and are detailed in Table 2. 
15 (Bluetractor UK). Primers were designed to span exons, with products of 100-150bp. 
Primers were validated on a sample of cDNA from fixed rat tissue, and used at a concentration 
of 200nM per reaction with Brilliant III high Rox mastermix (Agilent). The dissociation curves 
showed one clear peak, indicating minimal primer dimer formation, with the exception of the 
first two sets of LTα primers listed in Table 2. 15, which were discarded in favour of the third 
LTα primer set (LTα #3, Table 2. 15). The correct size of primer products and the absence of 
significant primer dimer formation was verified by gel electrophoresis on a 2% agarose gel in 
TAE buffer, run at 70V for 60 minutes.  
2.5.3.3 SYBR green PCR 
A GeNorm kit (PrimerDesign) identified the YWHAZ and TOP1 HKGs as having the most 
stable expression in cDNA samples from fixed rat tissue compared to 4 other HKGs in the 
GeNorm panel, and determined that normalisation to two HKGs was optimal. qPCR was 
carried out using 25ng cDNA per reaction and performed in duplicate. The expected product 
size for each gene was confirmed following qPCR by gel electrophoresis. No template control 
reactions in which cDNA was omitted and replaced by nuclease-free water, were performed 
for each primer set. 
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2.5.3.4 PrimerDesign probe PCR 
A fluorescent probe was custom-made and validated by PrimerDesign to detect the codon-
optimised viral transcript of human LTα in cDNA samples from fixed rat tissue (Southampton, 
UK). PrimerDesign confirmed that the probe was specific for the codon-optimised sequence of 
the viral hLTα transcript and did not bind to the rat LTα cDNA transcript. Due to the limited 
volume of cDNA samples available, data was normalised to one HKG, β-actin, the expression 
of which has been shown previously to be relatively stable in the cDNA from fixed rat tissue. 
qPCR was performed on 25ng cDNA per reaction in duplicate, using Brilliant II master mix 
(Agilent). No template control reactions were included for both genes, in which cDNA was 
omitted.  
2.6 Primary meningeal cell culture 
2.6.1 Isolation of meningeal cells  
Meningeal cells were isolated from neonatal rat pups 2 days old. Intact brains were removed 
and the meninges were dissected away from the brain as a sheet using a sharp sterile needle 
under a dissecting microscope. Tissue dissociation to a single cell suspension was achieved 
by incubation for 20 minutes with Accutase (Life Technologies). Cells were centrifuged at 380g 
for 5 minutes and resuspended in 5mls Dulbecco’s modified Eagle media (DMEM: Sigma). 
Live cells were counted using the trypan blue exclusion method and transferred to T25 tissue 
culture flasks precoated with 10µg/ml poly-D-lysine (Sigma) at approximately 1x106 per flask 
and 1x106 cells/well. 
2.6.2 Passaging and purification of meningeal cells  
Meningeal cells were maintained at 37oC and 5% CO2 in DMEM-F12 (Sigma), supplemented 
with 10% fetal calf serum (Sigma), 6g/l glucose (Sigma), 2.4g/l sodium bicarbonate (Sigma), 
0.37g/l L-glutamine (Life Technologies), 100 U/ml penicillin (Life Technologies) and 100µg/ml 
streptomycin (Life Technologies). Media was part exchanged one day after dissection and 
then replaced with fresh media every other day until confluency (~2 weeks). Microglia and 
oligodendrocytes were removed from confluent cells by orbital shaking at 200rpm for 2 hours 
at 37oC. The remaining meningeal cell bed layer was incubated for 30 minutes in fresh media 
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and passaged using EDTA and 0.05% Trypsin for 30-60minutes. Secondary meningeal cells 
were centrifuged, counted and re-plated in 24 well plates at 1x105/well. 
2.6.3 Transduction of meningeal cells with LVGFP or LVLTα  
At 48 hours after passaging, secondary meningeal cells in 24 well plates were treated with 1% 
polybrene in 500µl of either plain media (controls) or LVLTα or LVGFP at a multiplicity of 
infection (MOI) of either 1000 or 2000. Cells were incubated at 37oC. Supernatant was 
removed at 3 time-points (72, 96 hours and 7 days) and the concentration of hLTα quantified 
using a Duoset ELISA kit (R&D Systems) as described in 2.1.4. There were three technical 
replicates/wells per condition. In addition, cells were plated in 6 well plates and transduced 
with polybrene and LVLTα (MOI 1000) or plain media (control) after 48 hours. Cells were 
harvested at 72 hours post transduction and the level of hLTα in the lysates was measured by 
Western Blot. 
2.6.4 Immunofluorescence of meningeal cells 
Secondary meningeal cells were plated onto plastic slides and transduced with MOI 1000 
LVLTα or medium (control). At 72 hours post-transduction, the medium was removed and the 
cells were fixed for 10 minutes in 4% PFA (rtp). After a wash step (3x2 minutes in PBST), cells 
were blocked with 5% NGS for 30 minutes. Cells were incubated with primary antibody in 1% 
NGS for 1 hour (rtp; Table 2. 16), then washed and incubated with Alexafluor secondary 
antibodies against the species of the primary antibody (1:1000 dilution in 1% NGS,1 hour, rtp). 
DAPI was used to stain nuclei (1:5000, 5 minutes, rtp) and the slides were mounted in 
Vectashield. Primary meningeal cells were also plated onto glass slides and analysed for 
expression of TNFR1 and LTα upon reaching confluency. 
2.7 Statistical analysis 
GraphPad Prism 4 (GraphPad Software California, USA) was used to construct all graphs and 
perform statistical analysis. All data are presented as the mean ± the standard error of the 
mean (SEM). A Kruskal-Wallis one-way analysis of variance (ANOVA) with Dunn’s multiple 
comparison post-hoc test was used to determine statistical significance between more than 2 
groups. A p value of <0.05 was considered significant.   
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3.1 Introduction 
3.1.1 Cortical grey matter pathology in MS 
The prevalence of GMLs in MS and their contribution to disease progression has been 
underestimated historically, in part due to the difficulty in detecting them using histological 
techniques (Peterson et al., 2001) or more recently MRI (Calabrese et al., 2007; Gilmore et al., 
2009). Chronic GML pathology is suggested to drive disease progression and result in the 
accumulation of irreversible disability which characterizes SPMS (Calabrese et al., 2010; 
Reynolds et al., 2011; Geurts et al., 2012), while a low burden of cortical pathology is 
associated with a more benign disease course (Calabrese et al., 2013). 
Cortical lesions in MS have been broadly classified into 3 types by location within the tissue, 
namely leukocortical (spanning the border between the grey and white matter), intracortical 
(GM involvement only), and subpial (adjacent to the pia mater) (Peterson et al., 2001). Subpial 
lesions are the most extensive and most numerous type, and have recently been shown to be 
associated with the presence of meningeal inflammation (Bo et al., 2003l; Magliozzi et al., 
2007; Magliozzi et al., 2010; Howell et al., 2011).  
3.1.2 Meningeal inflammation contributes to cortical GM pathology 
The observation of extensive subpial GMLs in SPMS cases with high levels of meningeal 
inflammation, coupled with the relative lack of inflammation associated with intracortical 
lesions (Bo et al., 2003a), suggests that soluble cytotoxic factors produced by cells in the 
meninges may contribute to GML pathogenesis (Kutzelnigg et al., 2005; Magliozzi et al., 2007; 
Magliozzi et al., 2010). Indeed, the extent of GML pathology, as well as the age of attainment 
of several clinical milestones, are significantly correlated with the degree of meningeal 
inflammation, implicating meningeal inflammation as a major driver of cortical GM pathology 
(Magliozzi et al., 2007; Magliozzi et al., 2010; Howell et al., 2011).  
The organization of meningeal inflammation into structures resembling ectopic lymphoid 
follicles in approximately 40% SPMS cases (termed follicle positive SPMS cases; F+SPMS) is 
associated with a more severe disease course compared to cases in which diffuse meningeal 
inflammation is observed (follicle negative cases; F-SPMS) (Magliozzi et al., 2007; Howell et 
al., 2011). These follicle-like structures have been shown to contain Ki67+ proliferating CD20+ 
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B cells, CD35+ follicular dendritic cells, IgG, A, or M+ plasma cells and CD3+T cells (Serafini 
et al., 2004; Magliozzi et al., 2007), and resemble tertiary lymphoid organs (TLOs), the 
formation of which has been described in several other chronic inflammatory diseases 
(Randen et al., 1995; Schroder et al., 1996; Stott et al., 1998; Houtkamp et al., 2001). The 
presence of meningeal TLOs is associated with a significant decrease in the age of attainment 
of several clinical markers of disease progression, including onset of disease, time from onset 
to progression, first wheelchair use and death (Magliozzi et al., 2007; Magliozzi et al., 2010; 
Howell et al., 2011). In line with increased disease severity, meningeal TLOs are associated 
with increased cortical pathology, including increased subpial demyelination and cortical 
atrophy, a gradient of neuronal loss that is greatest in cortical layers closest to the pial surface, 
and a gradient of increased microglial activation which parallels the gradient of neuronal loss 
(Magliozzi et al., 2010). While the diffuse meningeal inflammation observed in F-SPMS cases 
represents a source of soluble factors that may contribute to cortical damage, gradients in 
cortical pathology were not observed in F-SPMS cases (Magliozzi et al., 2010), suggesting 
that TLO formation represents the more extreme end of a spectrum of inflammation, and that 
organisation of meningeal inflammation into TLOs is important in contributing to damage of the 
underlying GM.  
3.1.3 TLO neogenesis in MS  
Given the association of TLOs with increased disease severity in SPMS, further research into 
TLO neogenesis in the meninges is warranted. The presence of TLOs has only been observed 
in SPMS cases (Serafini et al., 2004; Magliozzi et al., 2007). Due to a relative lack of autopsy 
material from RRMS cases it is unknown whether TLOs may form at an earlier disease stage, 
or represent a shift towards progressive disease (Serafini et al., 2004). However a study of 
cortical biopsies from early MS cases found meningeal aggregates of inflammatory cells 
adjacent to subpial GMLs, suggesting that significant meningeal inflammation may be present 
very early in the disease course (Lucchinetti et al., 2011). It remains to be seen whether these 
have the characteristics of TLOs. 
No evidence of TLO formation has been found in PPMS cases, although increased meningeal 
inflammation, including formation of dense infiltrates, has been shown to be associated with 
increased GML burden in PPMS, and GMLs were often situated in close proximity to foci of 
meningeal inflammation (Serafini et al., 2004; Magliozzi et al., 2007; Choi et al., 2012). The 
pathology described in PPMS cases was similar but less extensive than that described in 
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F+SPMS, suggesting that TLO formation may exacerbate the damage mediated by diffuse 
meningeal inflammation (Choi et al., 2012). 
3.1.4 LTα, CXCL13 and CCL21 in TLO neogenesis and MS 
TLO neogenesis is postulated to involve the same chemokines and cytokines as those 
required for secondary lymphoid organ (SLO) formation, and LTα, CXCL13 and CCL21 are 
implicated in both processes (Weyand et al., 2001; Aloisi and Pujol-Borrell, 2006; Van De 
Pavert and Mebius, 2010). TLOs develop at sites of ectopic LTα expression in transgenic mice 
which express the LTα gene under the rat insulin promoter (RIPLT), suggesting a key role of 
LTα in TLO neogenesis (Kratz et al., 1996; Sacca et al., 1998). LTα ectopic expression in vivo 
also induces expression of the B cell chemoattractant CXCL13 and the T cell chemoattractant 
CCL21 (Hjelmstrom et al., 2000). In vitro and in vivo, LTα induces upregulation of the adhesion 
molecules ICAM, VCAM and P- and E-selectin on endothelial cells, providing a mechanism by 
which LTα can induce inflammation (Cuff et al., 1998; Cuff et al., 1999). In MS, LTα is 
upregulated in demyelinated lesions suggesting a role in demyelination (Selmaj et al., 1991b; 
Lock et al., 1999), and has been shown to play a role in EAE (Powell et al., 1990; Ruddle et 
al., 1990; Issazadeh et al., 1996). 
CXCL13 plays a key role in the organisation of B cell follicles  in vivo, as mice lacking the 
CXCL13 receptor CXCR5 show significantly impaired migration of mature B cells to lymphoid 
follicles and lack functional germinal centres and splenic follicles (Forster et al., 1996). Ectopic 
expression of CXCL13 in transgenic mice results in aggregates of B and T cells, organised 
into separate zones, but lacking follicular dendritic cells or functional GCs (Luther et al., 
2000a). The observation of intrathecal Ig synthesis and the accumulation of clonal expansions 
of B cells in MS have led to increasing interest in CXCL13 as a B cell chemoattractant within 
the CNS. CXCL13 expression has been detected in B cell follicles in EAE (Columba-Cabezas 
et al., 2004; Bagaeva et al., 2006) and MS (Serafini et al., 2004; Magliozzi et al., 2007), and 
CXCL13 concentration in the CSF correlates with the presence of B cells, plasmablasts, T 
cells, and intrathecal Ig synthesis (Krumbholz et al., 2006).  
CCL21 is expressed by high endothelial venules (HEVs) and stromal and dendritic cells within 
T cell zones of lymphoid organs (Cyster, 1999). Mice deficient in CCL21 or its receptor CCR7 
show impaired trafficking of naïve T cells into lymph nodes across HEVs and disorganized T 
cell zones (Forster et al., 1999; Luther et al., 2000b). CCL21 has been implicated in the 
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migration of encephalitogenic T cells into the CNS in EAE, as its expression has been 
described in inflamed CNS venules (Alt et al., 2002) and lesions (Columba-Cabezas et al., 
2003; Bagaeva et al., 2006) in EAE.  
3.1.5 Aims  
These experiments aimed to determine the expression of LTα, CXCL13 and CCL21 in the 
meninges and CSF of control cases and SPMS cases that had been previously characterized 
as either having TLOs (F+SPMS) or lacking them (F-SPMS) using snap-frozen cortical tissue 
(8-10 cases per group). The specific aims of the study were: 
• To characterise meningeal inflammation in all cases by histological analysis 
• To quantify meningeal expression of LTα, CXCL13 and CCL21 by qPCR  
• To quantify LTα and CXCL13 CSF concentration by ELISA   
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3.2 Results  
3.2.1 Characterisation of human meningeal inflammation in SPMS 
3.2.1.1 Meningeal inflammation was present in SPMS cortical sections 
All cases in the 3 cohorts chosen for RNA analysis of the meninges were subjected to a 
qualitative assessment of meningeal preservation and the extent of meningeal infiltration, to 
confirm that sufficient meningeal tissue existed for subsequent RNA extraction from each 
case. Sections from 3 to 16 snap-frozen cortical tissue blocks per case were stained with 
haematoxylin and eosin (H&E). Each cortical tissue block from each case was given a 
qualitative rating of meningeal infiltration based on the observed density of cells in the 
meninges, as described in Howell et al., (2011) (Table 3. 1 and Figure 3. 1).  
No meningeal infiltration was observed in the non-neurological control cases (Figure 3. 1 A, B; 
Table 3. 2). Moderate, diffuse meningeal infiltration was observed at higher frequency in 
F+SPMS cases compared to F-SPMS cases (Figure 3. 1 C, D; Table 3. 2), while substantial, 
dense cellular infiltration of the meninges (Figure 3. 1 E) and tightly packed cellular aggregates 
(Figure 3. 1 arrow in F) were observed exclusively in F+SPMS cases (Figure 3. 1 E, F; Table 
3. 2), in keeping with findings by previous studies (Magliozzi et al., 2007; Howell et al., 2011). 
Cellular infiltration was most often observed in deep sulci. Preservation of the meninges varied 
between cortical tissue blocks sampled for each case but was generally well preserved in 
deep sulci. Further immunohistochemical (IHC) characterisation of meningeal infiltration was 
performed prior to dissection of meningeal tissue from sulci and overlying gyri for RNA 
extraction and analysis of chemokines/cytokine gene expression. 
3.2.1.2 CD20 positive cells were present in SPMS meninges 
IHC for CD20 was performed to identify B cells in adjacent tissue sections to those rated ++ by 
H&E analysis, and a selection of adjacent sections from F-SPMS and control cases. No 
CD20+ cells were observed in meninges from control cases (Figure 3. 2 A), while B cells were 
clearly present in F+SPMS meninges in varying numbers (Figure 3. 2 B). Large, densely 
packed cellular aggregates observed in the meninges of F+SPMS cases by H&E and rated ++ 
(Figure 3. 2 C) were shown to contain large clusters of B cells (Figure 3. 2 arrows in D), further 
examples of which are shown (Figure 3. 2 arrow in E, F). 
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Score Meningeal appearance 
0 Normal appearance. Little or no meningeal infiltration. 
+ 
Moderate, diffuse meningeal infiltration, and increased meningeal 
cellular density compared to score 0 meninges. 
++ 
Substantially increased meningeal cellular density and/or presence of 
densely packed cellular aggregates. 
Table 3. 1 Qualitative scoring system used to analyse meningeal appearance  
 
 
 
 Percentage of blocks in each 
score category 
 
Cohort 0 + ++ Total number of blocks 
Control 100 0 0 87 
F-SPMS 88 12 0 76 
F+SPMS 24 46 30 62 
Table 3. 2 Results of qualitative meningeal scoring of cases 
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 Figure 3. 1 Qualitative assessment of meningeal inflammation 
Meningeal infiltration was qualitatively assessed in all cases, using H&E stained sections from snap 
frozen cortical tissue blocks. Sections were scored based on the maximum density of meningeal 
infiltrates observed. No meningeal infiltration was observed in control blocks and all scored 0 (A, B). 
Moderate  meningeal infiltration was rated “+”, and  observed in F+ and F-SPMS cases as loosely 
packed cells and an increased meningeal cellular density compared to blocks rated “0” (C,D). 
Substantial meningeal infiltration where cellular density was markedly increased (E), or densely packed 
aggregates were observed (arrow in F), was rated “++”. Men = meninges, Ctx = cortex. Images are 
representative. Scale bars: A, B = 400µm; C-F = 200µm.  
A B
C D
E F
+ +
++ ++
0 0
Men Ctx Men Ctx
Men
Ctx
Men
Ctx
Men Ctx MenCtx
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 Figure 3. 2 CD20+ B cell rich meningeal aggregates were present in F+SPMS cases  
IHC for CD20 showed that B cells were not present in control case meninges (A), but identified variable 
numbers of B cells in F+SPMS meninges (B). H&E staining revealed a large, dense, cellular aggregate 
in an F+SPMS sulcus (C) and CD20 IHC on an adjacent section revealed a large cluster of CD20+ B 
cells within the aggregate (arrows in D). Other F+SPMS meningeal aggregates also contained B cell 
rich areas (arrow in E, F). Images are representative and D and F are magnifications of the boxed areas 
in C and E respectively. Scale bars: C = 500µm; E = 200μm; A, D, F = 100µm; B = 25μm. 
A B
C D
E F
H&E
CD20 Control case CD20 F+SPMS case
CD20
CD20CD20
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3.2.1.3 LTα is present in SPMS meninges 
IHC for LTα was performed on F+SPMS blocks previously shown by H&E to contain 
substantial meningeal infiltration, to determine if LTα is expressed in areas of diffuse infiltration 
or dense aggregates suspected to be TLOs. Non-specific IHC was absent from negative 
control slides lacking primary LTα antibody, while specific LTα IHC was observed lining 
intracortical vessels in some F+SPMS cases (Figure 3. 3 arrow in B). Both cellular and diffuse 
LTα IHC was observed in positive control spleen sections (Figure 3. 3 C). LTα IHC was absent 
from the meninges of control cases (Figure 3. 3 D), and the negative control F+SPMS slide 
(Figure 3. 3 E). An adjacent F+SPMS slide revealed diffuse LTα staining and low numbers of 
LTα+ cells evenly distributed within meningeal infiltrates (Figure 3. 3 arrows in F and J). Areas 
of diffuse meningeal infiltration in F+SPMS cases were weakly positive for LTα (Figure 3. 3 G). 
LTα+ cells were also observed adjacent to a dense meningeal aggregate (Figure 3. 3 black 
arrow in H, dense aggregate indicated by arrow in white). 
3.2.1.4 Presence of subpial demyelination in SPMS cases 
IHC for MOG as a marker of the myelin sheath was performed to identify areas of 
demyelination in SPMS and control cases in adjacent sections to those analysed for the 
presence of CD20+ B cells (Figure 3. 4). No demyelination was observed in any control cases 
(Figure 3. 4 A, B). Demyelinated areas were observed in all SPMS cases in both GM and WM, 
including extensive subpial GMLs, which could extend along the entire length of a sulcus 
(Figure 3. 4 arrow in C). Patchy MOG IHC was observed at the edges of lesions (Figure 3. 4 
arrows in D and E), which were sometimes observed adjacent to suspected TLOs in F+SPMS 
cases (Figure 3. 4 E and arrow in F), identified as tightly packed meningeal aggregates by 
haematoxylin counterstaining. 
3.2.2 qPCR analysis of human meningeal gene expression 
Tissue selection, meningeal dissection from the sulci and over the gyri of cortical tissue blocks, 
RNA extraction and qPCR were performed as described in Chapter 2.1.3. RNA expression of 
lymphoid cytokines and chemokines was determined by qPCR in the meninges of the cases 
selected and characterised by H&E and immunohistochemistry. PrimeTimeqPCR Assays 
(IDT) were used to determine the expression of the LTα, CXCL13 and CCL21 genes relative to 
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the geometric mean of the housekeeping genes GAPDH and Xpnpep1 in meningeal cDNA. 
Raw Ct values were analysed with REST09 software, described in 2.1.3.6 (Pfaffl et al., 2002). 
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 Figure 3. 3 Immunohistochemistry revealed LTα in the meninges of F+SPMS 
Negative control sections which lacked the primary anti-human LTα antibody were free from non-
specific staining (A, E), while LTα IHC was observed lining intracortical vessels in an adjacent F+SPMS 
section (arrow in B). Strong LTα IHC was observed in the positive control sections of human spleen (C). 
No positive LTα IHC was observed in the meninges of control cases (D) or in the  negative control slide 
(E) adjacent to the F+SPMS meninges in which LTα IHC was observed (arrows in F). Weak diffuse LTα 
staining was present in large areas of diffuse meningeal inflammation in F+SPMS (G). Cellular staining 
was observed in close proximity to a dense cellular aggregate (arrow in H, aggregate arrow in white) 
and more diffuse meningeal inflammation (arrow in J). Scale bars: A = 100μm, C, D = 50μm.  
A B C
D E F
G H J
Negative ctrl 
F+SPMS LTα F+SPMS
LTα F+SPMS
LTα F+SPMSLTα F+SPMSLTα F+SPMS
Negative ctrl 
F+SPMS
Spleen
Control case
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 Figure 3. 4 MOG immunohistochemistry showed areas of demyelination in SPMS  
Cortical tissue sections adjacent to those analysed by CD20 IHC were immunostained for MOG to 
visualise the myelin sheath. No loss of MOG IHC was observed in control cases (A, B). Areas of 
demyelination of variable size were observed in all SPMS cases, including extensive subpial areas 
extending the entire length of a sulcus in an F+SPMS case (arrow in C). MOG IHC revealed remaining 
myelin at the lesion edge (arrows in D and E) of subpial lesions, some of which were adjacent to large 
meningeal aggregates in F+SPMS (E, arrow in F). Images are representative and B and F are 
magnifications of the boxed areas in A and E respectively. Men = meninges, ctx = cortex. Scale bars: A, 
D, F = 100μm; B = 50μm; C = 1000μm, E = 200μm.    
A B
C D
E F
Control
F+SPMS
MenCtx Ctx
MenCtx Ctx
Men
Ctx
Ctx
F+SPMS
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3.2.2.1 RNA and cDNA quality 
RNA was extracted from between 100 and 250mg dissected meningeal tissue per case. RNA 
concentration as determined by measuring absorbance at 260nm using a spectrophotometer 
ranged between approximately 100 and 400 ng/µl. All samples were free from significant 
protein contamination, determined by the ratio of measurements at 260nm divided by 
measurements at 280nm, which were above the accepted 1.8 (Wilfinger et al., 1997; Fleige 
and Pfaffl, 2006). In addition, the majority of samples were free from significant 
phenol/guanidine contamination from the RNA extraction process, having 260/230nm ratios of 
approximately 2.0 or above (Krebs et al., 2009).   
Analysis of RNA samples using the Agilent 2100 Bioanalyzer indicated generally good integrity 
of RNA, with 70% of cases achieving a RIN of 5 or above, and a mean RIN of 5.2 for all cases. 
18S and 26S ribosomal RNA appeared as two clear peaks on the electropherograms (Figure 
3. 5 A), although traces of degraded RNA were also observed as earlier peaks. There was no 
significant correlation between RIN and PMD, age at death, cohort or gender (Figure 3. 5 B-E 
respectively). Following RNA extraction and confirmation of quality and concentration, 1µg 
RNA per case was reverse transcribed to complementary DNA (cDNA) and meningeal gene 
expression analysed by qPCR. 
No Ct values were obtained for the wells in which No-RT control samples were run, indicating 
an absence of gDNA contamination in cDNA from the randomly selected cases from each 
cohort. Specificity of primer assays was confirmed by visualisation of a single amplicon band 
of the expected size for each primer assay following agarose gel electrophoresis (Figure 3. 6 
A).   
3.2.2.2 LTα, CXCL13 and CCL21 expression is upregulated in SPMS meninges 
A significant 2-fold upregulation of LTα gene expression relative to non-neurological control 
cases was detected in F-SPMS (2.2 fold; p=0.028) and F+SPMS (2.1 fold; p=0.013) meninges 
(Figure 3. 6 B). There was no significant difference between LTα gene expression in F-SPMS 
compared to F+SPMS meninges. CXCL13 expression was highly significantly upregulated in 
F+SPMS meninges compared to control cases (11.7 fold; p=0.017) and F-SPMS (p=0.022; 
Figure 3. 6 B). There was no significant difference between F-SPMS and control CXCL13 
expression. CCL21 expression was also significantly upregulated in F+SPMS compared to F-
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SPMS (2.0 fold; p=0.036; Figure 3. 6 B). Since CCL21 expression was not significantly 
increased compared to the control group however, it was decided not to investigate this 
chemokine further in the current study.  
3.2.3 Quantification of proteins of interest in human CSF 
3.2.3.1 LTα was detected in F+SPMS CSF but undetectable in F-SPMS & control 
To investigate whether changes in gene expression in the meninges correlated with changes 
in protein levels in the CSF, ELISAs were performed to determine the concentration of 
CXCL13 and LTα in post-mortem CSF from control, F-SPMS and F+SPMS cases. Levels of 
LTα were measured in CSF samples using a Duoset ELISA kit (R&D Systems) and a Ready-
SET-Go! ELISA kit (eBioscience). A total number of n=5 control cases, n=9 F-SPMS and n=10 
F+SPMS cases were analysed. Absorbance readings at 450nm for all cases were not 
significantly raised above the blank reading, indicating that LTα levels were below the limit of 
detection (8pg/ml) in all CSF samples.  
CSF samples were also analysed using an ECL plate with increased sensitivity (0.14pg/ml; 
Meso Scale Discovery). A total of n=6 control cases, n=11 F-SPMS and n=9 F+SPMS CSF 
samples were analysed. In addition to these cases, CSF samples from 3 SPMS cases with a 
young age of death and severe meningeal inflammation were included, as these are 
suspected to be follicle positive. LTα was detectable in CSF samples from one F+SPMS case 
(MS402) and from one suspected F+SPMS case (MS448). LTα levels in these CSF samples 
were 0.6 and 0.3pg/ml respectively. Levels of LTα were below the limit of detection in all other 
cases. 
3.2.3.2 CXCL13 levels were significantly increased in F+SPMS CSF 
CXCL13 was detectable in 30% (3/10) control CSF samples (mean CXCL13 = 3.3pg/ml; range 
10.4-11.5pg/ml; Figure 3. 7 A). The mean CXCL13 concentration of the positive cases was 
11.0pg/ml. CXCL13 levels were detectable in 20% (3/15) F-SPMS CSF samples (mean 
CXCL13 = 3.2pg/ml; range 10.4-23.8pg/ml; Figure 3. 7 A). There was no significant difference 
between CXCL13 levels in F-SPMS CSF compared to control samples. The mean CXCL13 
concentration of the positive cases was 16.0pg/ml. 
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 Figure 3. 5 RNA quality  
Clear electropherogram peaks corresponding to 18S and 28S ribosomal RNA, and RNA integrity 
number (RIN) scores above 5 (A), indicated preservation of RNA integrity, which was not significantly 
altered by post-mortem delay or age at death (linear regression slopes were not significantly above or 
below zero; B,C). Cohort and gender also had no significant effect on RIN (mean ± SEM; Kruskal-Wallis 
with Dunn’s multiple comparisons post-test; D, E). 
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Figure 3. 6 qPCR primer specificity and meningeal relative gene expression ratios 
Single amplicon bands following agarose gel electrophoresis were observed to be the expected size 
compared to the DNA ladder in the lane on the far left (A; expected amplicon sizes for each assay in 
base pairs [bp] are written below the gel) confirming PCR primer assay specificity. Meningeal gene 
expression was quantified by qPCR and raw Ct values were analysed by REST09 software, with the p 
values of significant differences compared to control cases shown above each group. Upregulation of 
CXCL13 and CCL21 in F+SPMS compared to F-SPMS was also observed and is shown on the graph. 
Statistics: Pair Wise Fixed Reallocation Randomisation Test with 2000 iterations (Pfaffl et al., 2002), 
data is shown as the mean relative expression compared to the control group. n=8-10 per group.  
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Figure 3. 7 CSF concentration of CXCL13 in control, F- and F+SPMS cases by ELISA  
CXCL13 was significantly increased in F+SPMS compared to control (A, p=0.0475; Kruskal-Wallis with 
Dunn’s post-test) and F-SPMS (p=0.0103, presented as mean ± SEM) CSF samples. There was no 
significant correlation between CXCL13 and post-mortem delay (B; linear regression), disease duration 
(D), onset to progression (E) or progression to death (F). When the outlier MS402 was removed, 
CXCL13 was significantly increased in females (C; p=0.0203, unpaired T test). Increased CXCL13 
concentration correlated with a younger age at progression (G, p=0.0039 if MS402 was excluded) and 
first wheelchair (WC) use (H, p=0.0410), but not age at death (J). n=10 controls, n=15 F-SPMS, n=15 
F+SPMS.  
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In contrast, CXCL13 was detected in 71.4% (10/14) F+SPMS CSF samples (mean CXCL13 = 
22.37pg/ml; range 9.26-125pg/ml; Figure 3. 7 A). The mean concentration of CXCL13 in 
F+SPMS CSF samples was significantly increased compared to levels in control CSF samples 
(p=0.0475; Kruskal-Wallis with Dunn’s multiple comparisons test) and F-SPMS CSF 
(p=0.0103). The mean CXCL13 concentration of the positive cases was 31.3pg/ml. There was 
no significant correlation between CXCL13 concentration in CSF samples and post mortem 
delay (Figure 3. 7 B), suggesting that variable post-mortem delays up to 24 hours did not 
significantly affect the results. The outlier observed was identified as case number MS402, an 
F+SPMS case in which particularly fulminant meningeal infiltration has been observed. The 
CXCL13 CSF concentration for this case (125pg/ml) was comparable with the highest 
concentration recorded by a previous study of CSF from SPMS patients (approximately 
100pg/ml), indicating that while this case was an outlier in the current study, it may be 
reflective of the degree of meningeal infiltration observed and may not be an outlier if the 
sample size of F+SPMS cases were to be increased (Krumbholz et al., 2006).  
Removal of this case from the analysis of the F+SPMS cohort showed that the mean CXCL13 
CSF concentration of this group was still significantly increased compared to F-SPMS 
(p=0.0193, Kruskal-Wallis with Dunn’s multiple comparisons test). There was no significant 
effect of gender on CSF concentration of CXCL13, unless MS402 was removed, in which case 
CXCL13 was significantly increased in females (p=0.0203, unpaired T test; Figure 3. 7 C). 
There was no significant correlation between disease duration (Figure 3. 7 D), the time of 
disease onset to progression (Figure 3. 7 E), or the time from progression to death (Figure 3. 7 
F) regardless of the inclusion or exclusion of MS402. However, the age at progression 
approached significance (p=0.0501, linear regression correlation; Figure 3. 7 G) and was 
significant when MS402 was excluded (p=0.0039). In addition, the age at first wheelchair (WC) 
use correlated significantly with CXCL13 CSF concentration, with a younger age at first use 
associated with increased CXCL13 (p=0.0410 or p=0.0035 if MS402 was excluded, linear 
regression correlation; Figure 3. 7 H). The correlation between increased CXCL13 CSF 
concentration and a younger age at death also approached significance if MS402 was 
included (p=0.0635, linear regression correlation; Figure 3. 7 J).  
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3.3 Discussion 
In the current study we characterised meningeal infiltration and inflammation observed in F-
SPMS and F+SPMS cases and successfully demonstrated increased meningeal and CSF 
expression of LTα and CXCL13 in SPMS cases compared to controls. Our findings suggest 
that these lymphoid cytokines and chemokines may play a crucial role in TLO neogenesis in 
F+SPMS, which may be supported by the expression of CCL21.  
3.3.1 Meningeal inflammation in SPMS  
Characterisation of meningeal inflammation present in the SPMS cases used in the current 
study confirmed observations of previous studies. In the current study, cases were separated 
into F+SPMS or F-SPMS cohorts based on the observation of at least one TLO in each 
F+SPMS case, and no observation of any TLOs in either F-SPMS or control cases during prior 
characterisation of the cases (Magliozzi et al., 2007; Howell et al., 2011). Substantial, dense 
meningeal inflammation was restricted to F+SPMS cases, while diffuse inflammation was 
observed in both F-SPMS and F+SPMS cases, in keeping with findings by previous studies 
(Magliozzi et al., 2007). Meningeal inflammation was more often found in deep sulci than 
overlying the cortex, and dense cellular meningeal aggregates found in F+SPMS cases were 
B cell rich, also supporting previous data (Serafini et al., 2004; Magliozzi et al., 2007; Magliozzi 
et al., 2010; Howell et al., 2011). Deep sulci are postulated to favour the formation of a pro-
inflammatory niche for the formation of TLOs due to reduced CSF flow facilitating an increased 
local concentration of cytokines (Reynolds et al., 2011). Areas of subpial demyelination were 
observed both with and without large meningeal aggregates, although the most extensive 
demyelinated areas corresponded to cases with the most prominent meningeal inflammation, 
again supporting previous work and the hypothesis that exposure to an inflammatory milieu in 
the CSF may result in pathology of the underlying cortical GM (Magliozzi et al., 2007; 
Magliozzi et al., 2010; Howell et al., 2011; Reynolds et al., 2011). 
Although poor preservation of the meninges is a recognised problem that can hamper 
research (Aloisi et al., 2010), in the current study sufficient intact meningeal tissue was 
observed within cortical sulci and overlying gyri for all cases in each cohort, to enable 
subsequent meningeal dissection. Our use of snap frozen rather than paraffin-embedded 
tissue permitted RNA extraction and molecular analysis of chemokine and cytokine 
expression.  
Chapter 3 – Expression of lymphoid cytokines and chemokines in SPMS 102 
 
3.3.2 Meningeal and CSF expression of LTα in SPMS 
To our knowledge, the current study is the first to quantify human meningeal LTα, CXCL13 
and CCL21 gene expression. LTα gene expression is upregulated in SPMS meninges relative 
to control cases, suggesting that LTα may be an important contributor to meningeal 
inflammation in SPMS, and the underlying GM pathology with which meningeal inflammation is 
associated. Dysregulated, co-stimulation independent LTα secretion following CD3 stimulation 
of CD8+ T cells from SPMS compared to RRMS patients and control cases has been 
demonstrated, and it is suggested that alterations in LTα secretion may be a factor in 
conversion to progressive disease (Buckle et al., 2003). Unfortunately the sample size of 14 
SPMS patients studied by these authors was not large enough to determine if patients could 
be divided into higher and lower LTα-secreting groups so it is unknown whether differences in 
LTα-secretion might exist between F+ and F-SPMS, but the increased secretion observed in 
SPMS compared to control cases supports our finding of increased SPMS meningeal LTα 
expression in the current study.  
Interestingly, we found no significant difference between LTα mRNA expression in F+SPMS 
compared to F-SPMS meninges. This was surprising, given the known role of LTα in TLO 
neogenesis in other studies and diseases (Kratz et al., 1996; Sacca et al., 1998; Calmon-
Hamaty et al., 2011), and suggests perhaps that other chemokines may be required in concert 
with LTα to induce TLO formation in F+SPMS cases. However, LTα IHC was only observed in 
F+SPMS cases and appeared to be expressed by endothelial cells lining parenchymal 
vessels, in addition to cell-specific and more diffuse staining within areas of meningeal 
inflammation. This pattern of LTα IHC contrasts with that of a previous study, where LTα and 
CXCL13 were both observed to be expressed on the outer layers of post-capillary venules in a 
similar pattern to extracellular matrix expression, but not in endothelial cells (Corcione et al., 
2004). It is possible that the increased tissue preservation of paraffin-embedded tissue 
compared to the snap frozen tissue used in the current study allowed more accurate 
observation of IHC localisation (Corcione et al., 2004). These authors detected LTα and 
CXCL13 in ~50% of vessel walls in chronic active lesions, and expression was frequently but 
not exclusively associated with demyelination or inflammatory infiltrates. F+SPMS is 
characterised by increased GM pathology and meningeal inflammation compared to F-SPMS, 
so an increase in the number of meningeal LTα-secreting CD8+ T cells in F+SPMS might be 
expected to lead to an increase in CSF concentrations of LTα in F+ compared to F-SPMS. 
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This postulated increase in LTα CSF concentration in the F+SPMS cohort may not be 
reflected by the meningeal LTα gene expression observed in the current study, as meningeal 
tissue was dissected from areas overlying gyri and not exclusively from deep sulci in which 
substantial meningeal inflammation and TLOs are most often found in F+SPMS, due to the 
difficulty of accurate dissection of sufficient meningeal tissue from deep sulci.  
While LTα concentration in CSF samples analysed in the current study was below the limit of 
detection by conventional ELISAs, it was detected at sub-picogram/ml concentrations in the 
CSF from two particularly inflammatory F+SPMS cases using an ECL assay with greater 
sensitivity. This suggests that global CNS levels of LTα may be higher in F+SPMS compared 
to F-SPMS, but also that levels are either generally low or LTα degradation occurred post-
mortem. No other studies have been reported that investigate LTα in post-mortem CSF, and 
only one study to our knowledge has investigated secreted LTα concentration in CSF from 26 
MS patients (Corcione et al., 2004). The mean concentration reported by these authors was 
approximately 10pg/ml but no details of patients’ MS stage or disease course was given, so it 
is unknown whether this level is representative of SPMS cases.  
Quantification of LTα mRNA expression by CSF cells may also be used to give an indication of 
cytokine production in the CSF. Mononuclear cells expressing LTα mRNA were significantly 
enriched in the CSF compared to peripheral blood in MS patients, and compared to CSF in 
patients with other inflammatory neurological diseases (OIND) (Matusevicius et al., 1996). In 
addition, MBP-reactive LTα mRNA expressing cells were increased in MS patient CSF 
compared to OIND patients, particularly during relapse, suggestive of a pathogenic role 
(Matusevicius et al., 1996). Although mRNA expression data must be interpreted with caution, 
as post-transcriptional regulation of LTα mRNA translation or regulation of LTα secretion may 
cause discrepancies between mRNA expression and secretion, a positive correlation has been 
shown between TNF mRNA expression and secretion, suggesting that indications of increased 
LTα production in MS CSF provided by mRNA studies are likely to be correct (Rieckmann et 
al., 1995). Given these results, CSF concentrations of LTα in MS patients is expected to be 
increased compared to controls, and the paucity of data on LTα CSF concentration may be 
due to lack of investigation, or a relatively short half-life of LTα.  
To estimate LTα degradation in post-mortem CSF and determine if LTα concentrations in CSF 
from living SPMS patients may be considerably higher than those measured in the current 
study, we compared our data to that obtained for TNF, which is similar in structure to LTα and 
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estimated to have a similar instability index using the ExPASy online tool. The serum half-life 
of TNF in mice is less than 20 minutes (Ferraiolo et al., 1988), and while TNF concentrations 
of up to 70pg/ml have been reported in CSF from progressive MS patients, the highest 
concentrations of TNF in post-mortem CSF were approximately 4pg/ml in F+SPMS and only 
0.25pg/ml in F-SPMS (Gardner et al., 2013; Rossi et al., 2013). LTα may be expressed at 
lower concentrations than TNF since it was only detected at sub-picogram concentrations in 
F+SPMS cases in the current study, but together these data also suggest that the variable 
post-mortem delays of up to 24 hours are likely to have resulted in significant LTα protein 
degradation and contributed to the very low concentrations.  
Global increases of LTα throughout the CSF may contribute to CNS inflammation in SPMS 
through effects on BBB activation, increased expression of adhesion molecules and 
recruitment of immune cells to the CNS, since these effects have been observed in vitro (Cuff 
et al., 1998) and in vivo (Cuff et al., 1999). In addition, LTα may contribute to the general 
inflammatory milieu that is postulated to contribute to subpial demyelination since LTα has 
cytolytic functions and is toxic to oligodendrocytes (Selmaj et al., 1991c). However, significant 
increases in global CSF concentration, if present, are unlikely to be necessary for TLO 
formation. Since TLOs are often associated with deep sulci, it is postulated that meningeal 
inflammation within the relatively sheltered confines of a sulcus may lead to a local increase in 
CSF concentration of cytokines and cytotoxic factors, and result in damage of the adjacent 
GM, which may not be reflected by overall CSF concentrations (Serafini et al., 2007; Magliozzi 
et al., 2010; Howell et al., 2011).  
LTα and TNF promote FDC differentiation and maintain DC homeostasis (Matsumoto et al., 
1997), and these cell types are crucial for TLO maintenance by secreting homeostatic 
chemokines (including CXCL13 and CCL21), organising of TLO structure and cell positioning 
(Geurtsvankessel et al., 2009). FDCs within GCs are also required for B cell maturation, due to 
their role in antigen presentation, promotion of B cell proliferation and prevention of B cell 
apoptosis (Van Nierop and De Groot, 2002; Aloisi and Pujol-Borrell, 2006). The source of the 
FDCs observed in meningeal TLOs is unknown, but fibroblast-like synoviocytes have been 
suggested to undergo differentiation to become fully functional FDCs during rheumatoid 
arthritis (RA) (Lindhout et al., 1999; Kain and Owens, 2013). The chronic presence of LTα 
and/or TNF is suggested to drive local fibroblasts into converting to an FDC phenotype in RA 
and may occur in chronically inflamed meninges in F+SPMS (Van Nierop and De Groot, 2002; 
Gardner et al., 2013). B cells expressing LTα are capable of inducing FDC clusters and GC 
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formation in the absence of T cells, and are suggested to induce TLO formation during 
inflammation (Fu et al., 1998). In addition, macrophages have been shown to express high 
levels of LTα and induce formation of TLOs, and stromal cell expression of lymphoid 
chemokines via TNFR1 signalling in vivo (Guedj et al., 2013). We therefore suggest that 
substantial meningeal inflammation containing B, T cells and macrophages expressing LTα 
may reach a critical mass in sulci in F+SPMS, and result in FDC differentiation, clustering and 
expression of lymphoid chemokines including CXCL13 and CCL21, which may maintain the 
inflammatory response and result in TLO formation. In areas of diffuse inflammation, and in F-
SPMS, we suggest that the local concentrations of LTα, TNF and other pro-inflammatory 
cytokines may not reach a critical threshold required to drive TLO formation.  
Although there was no significant difference in meningeal expression of LTα between F-SPMS 
and F+SPMS cases in the current study, it is possible that a difference in the expression of 
other pro-inflammatory cytokines or receptors between these groups potentiates the effects of 
LTα and TNF in F+SPMS. IFNγ and TNF meningeal gene expression is significantly 
upregulated in F+SPMS compared to controls, while no significant difference in IFNγ gene 
expression was observed in F-SPMS (Gardner et al., 2013). TNF was also increased in the 
CSF in F+SPMS compared to F-SPMS and controls. The expression of TNFR1, through which 
LTα mediates inflammation (Sacca et al., 1998), is influenced by both TNF and IFNγ in vitro. 
Microglia, oligodendrocytes and astrocytes constitutively express TNFR1 mRNA, and 
expression increases following addition of IFNγ (Dopp et al., 1997). Interestingly, addition of 
TNF only increased TNFR1 expression in oligodendrocytes, suggesting that increased levels 
of TNF and IFNγ in F+SPMS compared to F-SPMS and controls, may influence receptor 
expression on glial cells and therefore determine the effect of meningeal inflammation, 
resulting in pathological differences between F-SPMS and F+SPMS.  
3.3.3 Meningeal and CSF expression of CXCL13 in SPMS  
The current study is the first, to our knowledge, to demonstrate a correlation between the 
presence of meningeal TLOs, and CXCL13 meningeal gene expression and concentration in 
post-mortem CSF, and confirms speculation of a link by previous studies (Krumbholz et al., 
2006). Our finding that CXCL13 gene expression was substantially upregulated in F+SPMS 
compared to F-SPMS cases and controls, and CSF concentration was increased in F+SPMS 
compared to F-SPMS, suggests that CXCL13 may play a significant role in meningeal TLO 
formation.  
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Although few studies have investigated CXCL13 concentration in SPMS CSF and none have 
investigated post-mortem CSF, our results support the many reports of increased CXCL13 in 
RRMS CSF and the correlation of CXCL13 concentration with markers of intrathecal B cell 
maturation and autoantibody production, which are suggested to occur in TLOs (Krumbholz et 
al., 2006; Kuenz et al., 2008; Sellebjerg et al., 2009; Villar et al., 2010). CXCL13 in RRMS 
CSF correlates with intrathecal Ig-production, and the presence of plasmablasts and B and T 
cells (Krumbholz et al., 2006) and with CSF leukocyte count in progressive MS (Sellebjerg et 
al., 2009). CXCL13 is known to play a key role in the organisation and recruitment of B cells to 
SLOs, and is thought to play a similar role in TLOs (Aloisi and Pujol-Borrell, 2006; Drayton et 
al., 2006), so the correlation found in the current study between the presence of meningeal 
TLOs and increased CXCL13 in the CSF agrees with previous data. The difference in 
structure and relative lack of organisation observed in TLOs compared to SLOs is suggested 
to contribute to autoimmunity by promoting the mishandling of autoantigens, resulting in the 
breaking of tolerance (Weyand et al., 2001). TLOs arise in areas close to autoantigen 
production, and are suggested to optimise autoimmune responses by production of 
increasingly specific autoantibodies through affinity maturation. In addition, TLOs are 
postulated to contribute to B cell (Pollinger et al., 2009; Cornaby et al., 2015) and T cell 
(Kuerten et al., 2012) epitope spreading, which is suggested to occur in MS, resulting in a 
range of intrathecal autoantibody specificities per patient (Quintana et al., 2012), and 
correlates with the development and progression of EAE (Yu et al., 1996; Pollinger et al., 
2009). We suggest that in F+SPMS cases the autoimmune response is optimised by the 
formation of TLOs, which may be initiated and maintained by LTα and CXCL13 among other 
cytokines and chemokines, resulting in increased pathology compared to F-SPMS cases. 
The significant increase in CXCL13 CSF concentration in females observed in the current 
study, when the outlier case was excluded from analysis, has not been previously reported. 
However, as with other autoimmune diseases (Selmi et al., 2012), MS affects approximately 
twice as many women as men, a fact that was reflected by our selection of cases for CSF 
samples in the current study, (males n=14, females n=24), suggesting that the correlation 
between gender and CXCL13 concentration may be influenced by the inherent sex bias in 
studying MS cases.  
Our findings of a correlation between CXCL13 and F+SPMS, as well as increased CXCL13 
correlating with a younger age at first wheelchair use, (and a younger age at progression when 
the outlier was removed) support the suggested role of CXCL13 in the exacerbation of 
Chapter 3 – Expression of lymphoid cytokines and chemokines in SPMS 107 
 
disease, since F+SPMS is associated with a more severe disease course compared to F-
SPMS (Magliozzi et al., 2007; Howell et al., 2011). The involvement of CXCL13 in relapses 
and intrathecal Ig production was suggested following observation of a significant increase in 
CXCL13 CSF concentration during relapse in patients with oligoclonal bands against myelin 
antigens in the CSF, compared to those without (Villar et al., 2010). Increased CXCL13 CSF 
concentration also correlates with measures of disease activity, including an increased number 
of gadolinium-enhancing MRI brain lesions in RRMS and CIS, increased relapse rate and 
EDSS score (Sellebjerg et al., 2009; Khademi et al., 2011). In addition, elevated CXCL13 
concentrations were associated with increased rate and speed of conversion from CIS to MS, 
leading the authors to suggest that CXCL13 could be used as a prognostic marker in the early 
stages of disease (Khademi et al., 2011). The findings of the current study also support reports 
of wide ranging CSF concentrations between SPMS cases. The authors of a previous study 
which quantified CXCL13 CSF concentration noted that SPMS cases could be roughly divided 
into two subsets, one with low or undetectable CXCL13 CSF concentrations and the other with 
high concentrations, which they speculated might be correlated with the presence of 
meningeal TLOs (Krumbholz et al., 2006). Our study confirms this speculation.  
The cellular source of CXCL13 was not identified in the current study. Large, dense meningeal 
aggregates were rarely found as mentioned previously, due to the relatively small study size 
and limited sampling. Little TLO tissue was available for CXCL13 IHC and optimisation of 
antibodies for use on snap frozen tissue proved extremely time-consuming. However, several 
other studies have been successful in demonstrating CXCL13 expression in cells thought to 
be FDCs within meningeal TLOs (Serafini et al., 2004; Magliozzi et al., 2007). DCs and 
macrophages are also known to express CXCL13 under inflammatory conditions (Carlsen et 
al., 2004; Perrier et al., 2004), and CXCL13+ cells have been described in the parenchyma 
and perivascular cuffs of active lesions (Krumbholz et al., 2006). Infiltrating macrophages have 
been suggested to be the source of CXCL13 in active lesions in acute inflammation, but 
meningeal TLOs may be the major source of CXCL13 in SPMS in chronic disease (Krumbholz 
et al., 2006). As discussed earlier, meningeal fibroblasts may be driven to differentiate into 
CXCL13-expressing FDCs by the high local concentrations of pro-inflammatory cytokines, 
including LTα and/or TNF, within sulci in F+SPMS. No data is available on whether meningeal 
cells themselves are capable of secreting CXCL13 without differentiation of fibroblasts into 
FDCs, although rat meningeal cultures have been observed to express high levels of CXCL13 
in vitro (unpublished observations from this laboratory). In addition, CXCL13 appears to be 
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expressed by meningeal cells adjacent to aggregates of immune cells and suspected TLOs in 
F+SPMS, associated with the concomitant expression of CXCR5 by astrocytes in the 
underlying GM (unpublished observations from this laboratory). This raises the intriguing 
possibility that the meninges themselves may be activated by infiltrating inflammatory cells and 
become a source of cytokines and chemokines, including TNF, which has been observed 
following inflammatory stimulation of fibroblasts in vitro (Wells et al., 2001; Barone et al., 2012; 
Fan et al., 2012), and would support observations from the current study that CXCL13 was 
highest in the F+SPMS cases associated with particularly prominent meningeal inflammation. 
Data from EAE studies found CXCL13 expression to be upregulated only in mice developing 
relapsing-remitting and chronic relapsing EAE, and not in mice with non-relapsing chronic EAE 
(Columba-Cabezas et al., 2004) also suggesting a role for CXCL13 in the exacerbation of 
CNS inflammation during relapse, as suggested by human studies. Depletion of CXCL13 in 
CXCL13-/- mice did not impact B cell accumulation in the CNS in EAE however, suggesting 
that CXCL13 plays a more important role in facilitating lymphocyte organisation and interaction 
within the CNS than recruiting lymphocytes from the periphery in this model (Bagaeva et al., 
2006; Rainey-Barger et al., 2011). Ectopic expression of CXCL13 induces formation of TLO-
like structures, but these lack germinal centres (Luther et al., 2000a), in contrast to ectopic 
expression of LTα (Kratz et al., 1996), suggesting that LTα may be more important for initiating 
fully functional TLO formation while CXCL13 may have other roles in the organisation of 
inflammation. Indeed, LTα has also been shown to induce ectopic expression of CCL21 and 
CXCL13 in vivo suggesting that it may be upstream of CXCL13 in the signaling cascade 
during TLO neogenesis (Hjelmstrom et al., 2000).  
Studies of other inflammatory diseases suggest that CCL21 expression is also important for 
TLO formation. CCL21 and CXCL13 expression correlates with autoantibody titres and the 
presence of TLOs in thyroid AI (Armengol et al., 2003), and mice deficient in the receptors of 
these chemokines (CXCR5 and CCR7 respectively) show severely impaired formation of 
TLOs and reduced cellular and humoral responses in an in vivo model of RA (Wengner et al., 
2007). Ectopic expression of CCL21 results in the formation of lymphocyte aggregates with 
FDCs, but since these structures lack functional GCs and often HEVs, they may not represent 
fully functional TLOs as demonstrated by ectopic LTα expression (Fan et al., 2000; Chen et 
al., 2002; Martin et al., 2004).  
Chapter 3 – Expression of lymphoid cytokines and chemokines in SPMS 109 
 
Our finding that CCL21 meningeal gene expression was increased in F+SPMS compared to F-
SPMS supports a role for CCL21 in TLO formation in MS. However the increase in CCL21 
expression was not statistically significant compared to control cases, and further study of a 
larger cohort is needed to confirm the reliability of these results. Although reports of CCL21 
expression in the meninges are lacking, CCL21 CSF concentration is elevated in MS 
(Pashenkov et al., 2003) and it is postulated to play a role in recruitment of T cells to the CNS 
during MS, since nearly all T cells in the CSF were shown to express the CCL21 receptor, 
CCR7 (Kivisakk et al., 2004). In addition, CCL21 gene expression is upregulated during 
chronic EAE and IHC showed that expression was confined to cerebral blood vessels 
(Columba-Cabezas et al., 2003), supporting a role in immune cell recruitment to the CNS. 
These findings contrast with those of a relatively small study in which CCL21 was 
undetectable by IHC in meningeal tissue from MS cases (Kivisakk et al., 2004; Serafini et al., 
2004). Since CCL21 is primarily expressed by HEVs and stromal cells in the T cell zones of 
SLOs, the lack of CCL21 expression in meningeal TLOs was suggested to be due to the 
apparent absence of HEV formation (Cyster, 1999; Luther et al., 2000b). Our results suggest 
that either HEVs are formed in F+SPMS and express CCL21, or support the findings of CCL21 
expression by endothelial cells in intrameningeal vessels during chronic EAE (Columba-
Cabezas et al., 2003). However, as CCL21 was not confirmed by the current study to be 
increased in SPMS compared to control cases, it was not investigated further by CSF or IHC 
analysis. 
3.4 Conclusions 
The current study has demonstrated that gene expression of LTα, CXCL13 and CCL21, which 
have previously been shown to play a role in SLO/TLO neogenesis, is upregulated in F+SPMS 
meningeal tissue compared to non-neurological control cases and may contribute to 
meningeal TLO neogenesis in F+SPMS. We conclude that since LTα gene expression was 
upregulated in both SPMS cohorts, it may play a broader role in meningeal inflammation in 
SPMS and is not limited to TLO induction in F+SPMS. We suggest that LTα may contribute to 
CNS inflammation through activation of the BBB and upregulation of adhesion molecules on 
endothelial cells of meningeal vessels, resulting in cellular recruitment to the meninges. LTα 
may be produced at additional CNS sites in F+SPMS, and the local concentration of pro-
inflammatory cytokines including LTα resulting from increased meningeal inflammation in 
F+SPMS cases compared to F-SPMS may induce TLO formation. We suggest that increased 
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local concentrations of LTα and other pro-inflammatory cytokines in sulci where TLOs are 
found, may drive FDC differentiation and TLO formation through expression of CXCL13 and 
CCL21, since these chemokines are only upregulated in F+SPMS. We also show that CXCL13 
CSF concentration is increased in F+SPMS compared to F-SPMS and controls, demonstrating 
a link between meningeal TLOs and this biomarker for the first time, and suggesting that 
CXCL13 could be used as a prognostic indicator of TLO formation and disease progression. 
Together these data show that cytokines and chemokines implicated in TLO neogenesis are 
expressed in F+SPMS, may contribute to meningeal TLO formation, and suggest a key role for 
LTα as an inducer of lymphoid chemokine expression in the meninges. Since the aim of this 
thesis is to investigate TLO neogenesis in MS, LTα was chosen for further investigation in 
vivo.   
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4.1 Introduction 
4.1.1 Myelin Oligodendrocyte Glycoprotein – structure and function 
In addition to the myelin proteins myelin basic protein (MBP) and proteolipid protein (PLP), 
myelin also contains a number of quantitatively minor glycoproteins including MOG (Johns and 
Bernard, 1999). MOG accounts for approximately 0.05-0.1% of the total myelin protein and is 
expressed on the extracellular surface of the myelin sheath by mature oligodendrocytes 
(Brunner et al., 1989; Scolding et al., 1989; Amiguet et al., 1992). Cloning studies showed 
mature MOG to be a highly conserved, 218 amino acid member of the immunoglobulin family, 
with approximately 90% homology between species (Gardinier et al., 1992; Pham-Dinh et al., 
1993; Johns and Bernard, 1999). MOG has been shown to form dimers and trimers following 
extraction from several species, purification and Western blotting (Slavin et al., 1997), with a 
monomer mass of approximately 28kDa (Amiguet et al., 1992). 
The precise function of MOG has yet to be elucidated. The binding of anti-MOG antibodies to 
MOG on cultured oligodendrocytes results in loss of microtubules within membrane sheets, 
suggesting a role in cytoskeleton regulation possibly during the compaction of myelin (Dyer 
and Matthieu, 1994). MOG is also thought to play a role in adherence between adjacent 
myelinated axons to form bundles (Burger et al., 1993), although as yet no ligand for MOG has 
been identified to support this suggestion. The extracellular location of the Ig-like domain in the 
proposed model of MOG membrane topology suggests a role in facilitating myelin-immune 
system interactions (Kroepfl et al., 1996). Indeed, native MOG and the purified extracellular Ig-
like domain have both been shown to activate complement in a dose-dependent manner by 
binding the C1q component (Johns and Bernard, 1997). The majority of research into the role 
of MOG in MS has focused on the suggestion that MOG functions as an autoantigen, since 
MOG is a CNS-specific antigen, in keeping with the restriction of MS lesions within the CNS, 
and is accessible for immune system recognition due to expression on the myelin surface, 
making it a key autoantigen candidate. 
4.1.2 Role of MOG as an autoantigen in MS 
Interest in MOG as an autoantigen arose when it was identified as the major antigenic target in 
autoantibody-mediated demyelination in EAE (Lebar et al., 1986) and anti-MOG antibody titres 
were shown to correlate with the demyelinating activity of serum from EAE guinea pigs 
Chapter 4 – Characterisation of acute subarachnoid targeted EAE 113 
 
(Linington and Lassmann, 1987). Subsequently it has been shown that the extracellular Ig-like 
domain of MOG elicits both production of demyelinating autoantibodies and encephalitogenic 
T cell responses (Linington et al., 1993; Genain and Hauser, 1996). The extensive 
demyelinating pathology induced by the interaction of these responses in EAE models 
(Linington and Lassmann, 1987; Genain et al., 1995; Storch et al., 1998b) reflects pathology 
observed in subsets of MS lesions (Storch et al., 1998a; Genain et al., 1999; Lucchinetti et al., 
2000). 
Proliferation of peripheral blood T lymphocytes in response to in vitro stimulation with MOG 
was more frequently observed in MS patients compared to stimulation with other myelin 
antigens, including MBP and PLP, suggesting that at least in a proportion of MS patients MOG 
may be the dominant autoantigen (Kerlero De Rosbo et al., 1993). MOG autoantibodies are 
present at higher titres in MS CSF compared to serum, suggesting intrathecal production, and 
were found more frequently and at higher titres in MS compared to CSF from patients with 
other neurological diseases (Xiao et al., 1991). This data is supported by the finding that MOG 
reactive T and B cells are enriched in the CSF of MS patients compared to peripheral blood, 
and are increased in number compared to other neurological diseases (OND) control patients 
(Sun et al., 1991). MOG autoantibodies have also been observed to induce relapses and 
demyelination in EAE (Schluesener et al., 1987), and were found bound to damaged myelin in 
acute MS lesions (Genain et al., 1999). In addition, MOG autoantibodies have been found to 
be substantially increased in IgG purified from SPMS CNS lesions compared to IgG from 
control CNS tissue, and SPMS CSF and serum, suggesting a pathogenic role for the 
accumulation of MOG autoantibodies in MS lesions (O'connor et al., 2005). 
However, the pathogenic role of MOG autoantibodies in MS is controversial. A study of 
epitope specificity of MOG autoantibodies isolated from MS patients suggested that specificity 
was heterogeneous and that not all MOG autoantibodies are capable of binding to native MOG 
expressed on cultured cells in vitro, suggesting that autoantibody mediated demyelination may 
be restricted to a subset of MS patients (Haase et al., 2001). In addition, MOG autoantibodies 
are not present in all MS patients and the percentage of seropositive patients varies between 
studies (38%-54%) (Lindert et al., 1999; Reindl et al., 1999). MOG autoantibodies have been 
found in a significant proportion of patients with other inflammatory neurological diseases 
(OIND; 53%) and healthy controls (22%), although antibody responses in OIND patients were 
observed to be transient, while MOG autoantibody titres persist from the early stages of MS 
into progressive disease (Lindert et al., 1999; Reindl et al., 1999). Given the range of 
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autoantibody specificities found in MS patients (Moller et al., 1989; Reindl et al., 1999; Haase 
et al., 2001) it is possible that MS pathology arises from a range of autoantigens, or that 
epitope spreading occurs to involve more than one epitope or antigen as has been shown in 
EAE (Tuohy et al., 1999; Miller et al., 2007; Kuerten et al., 2012). 
The ability of MOG autoantibodies to induce demyelination in rats following passive transfer of 
encephalitogenic T cells is related to their ability to fix complement (Piddlesden et al., 1993). In 
MS the C9 antigen is co-deposited with immunoglobulins in active WMLs, and in phagocytic 
macrophages with myelin degradation products (Storch et al., 1998a). However, formation of 
the membrane attack complex (MAC) is not required for antibody-mediated demyelination in 
EAE, suggesting that other pathways including antibody dependent cell-mediated cytotoxicity 
may also contribute to demyelination (Piddlesden et al., 1991). Since antibodies have been 
detected between the clathrin-coated pits of phagocytic macrophages and myelin debris, and 
Fc receptor knockout mice are protected against demyelination in EAE, opsonisation of myelin 
and subsequent phagocytosis of myelin may represent a major effector mechanism (Prineas 
and Graham, 1981; Abdul-Majid et al., 2002). Opsonisation of myelin by macrophages in vitro 
is dependent on the epitope and isotype of the antibody and greatest with anti-MOG 
antibodies, suggesting a role for MOG autoantibodies in myelin destruction in vivo (Van Der 
Goes et al., 1999). In addition, phagocytosis of myelin by macrophages results in increased 
production of TNF and NO which may contribute further to demyelination via the antibody 
dependent cell-mediated cytotoxicity response (Van Der Laan et al., 1996).  
4.1.3 MOG-induced EAE as a model of MS 
Experimental autoimmune encephalomyelitis (EAE) is the most widely used group of animal 
models of MS, and involves inducing an inflammatory demyelinating MS-like disease 
phenotype in genetically susceptible animals by active immunisation with a myelin protein and 
an inflammatory adjuvant. By varying the species, strain, adjuvant, antigen, and concentration 
used, it is possible to mimic a range of MS-like pathologies and clinical courses. MOG is the 
only currently known CNS restricted antigen to induce both demyelinating autoantibodies and 
encephalitogenic T cell responses (Storch et al., 1998b; Iglesias et al., 2001), and 
immunisation of several species with MOG induces EAE with a similar range of pathology to, 
and more accurate reflection of, that observed in MS (Lucchinetti et al., 2000). 
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Different mechanisms of demyelination have been observed in MOG-EAE depending on the 
genetic background of the host and properties of the autoantigen. Immunisation with MOG 
peptides compared to the full extracellular Ig-like domain gives rise to different pathology, 
thought to be due to differential antigen processing favouring T or B cell dominated responses. 
The role of B cells in MOG-EAE has been questioned since B cell deficient mice develop EAE 
if immunised with the 35-55 amino acid MOG peptide (Hjelmstrom et al., 1998). However, a B 
cell response is required for EAE induction following immunisation with MOG protein (Lyons et 
al., 1999). Further studies have shown that demyelination following immunisation of mice with 
MOG35-55 peptide is critically dependent on TNFR1 function (Eugster et al., 1999; Probert et al., 
2000). However, MOG35-55 peptide immunisation induces a T cell dominated response in mice, 
and therefore does not reproduce the full range of responses observed in MS (Dang et al., 
2015). In contrast, demyelination in MOG-EAE induced in rats and marmosets is antibody- and 
complement-dependent, with demyelination being associated with antibody titres and their 
ability to fix complement (Linington and Lassmann, 1987; Piddlesden et al., 1993; Adelmann et 
al., 1995; Genain et al., 1995; Storch et al., 1998b; Iglesias et al., 2001). Integration of the B 
and T cell response is thought to be important for the development of CNS pathology, since 
disruption of the BBB by encephalitogenic T cells has been suggested to be crucial to mediate 
autoantibody entry to the CNS and subsequent demyelination in MS (Reindl et al., 1999) and 
EAE (Litzenburger et al., 1998). In addition, pathology in these models links the innate and 
adaptive immune responses, since re-activation of pathogenic T cells in the CNS induces 
expression of monocyte chemoattractants, leading to microglial/macrophage activation and 
inflammation (Kawakami et al., 2004).  
4.1.4 MOG-EAE and in the DA rat 
The pathology and clinical course of MS can be replicated in vivo through immunisation of 
female DA rats with soluble recombinant MOG emulsified in IFA (Storch et al., 1998b; 
Lucchinetti et al., 2000). The clinical course of EAE elicited depends on the dose of MOG, with 
50μg eliciting a chronic progressive course, in contrast to a relapsing-remitting course elicited 
by immunisation with 200μg (Papadopoulos et al., 2006). The formulation of MOG also 
influences the clinical and pathological features of EAE, since precipitated MOG emulsified in 
CFA induced a high incidence of neuromyelitis optica (NMO), and increased cortical and 
spinal demyelination, while soluble MOG was observed to result in aggressive and often lethal 
disease, characterised by prominent inflammation but limited demyelination. The substitution 
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of CFA for IFA substantially increased demyelination when using soluble MOG (Storch et al., 
1998b). In addition, a higher incidence of NMO was observed in female compared to male DA 
rats, suggesting that gender also influences the pathology of MOG-EAE (Storch et al., 1998b).  
Immunisation of female DA rats with 75μg of soluble extracellular Ig-like domain of 
recombinant MOG emulsified in IFA has been shown to result in 100% incidence of clinical 
EAE, characterised by demyelinating pathology in 97.5% of animals, with lesions located 
predominantly in the spinal cord and optic nerves (Storch et al., 1998b). Lesions were also 
observed in the cerebellum and brainstem, but were absent from the cortex. Axonal loss was a 
feature of all demyelinated lesions, compared to NAWM, and correlates with EAE severity, 
indicating that axonal loss is a major determinant of permanent disability, as has been 
suggested in MS (Storch et al., 1998b; Papadopoulos et al., 2006; Reynolds et al., 2011). Ig 
and complement deposition along degenerating myelin sheaths at the lesion edge was also 
observed, accompanied by macrophages in which Ig, complement fragments and myelin 
degradation products were present, reminiscent of type II WMLs that have been observed in 
MS (Storch et al., 1998b). MOG-EAE in the DA rat is suggested to involve both T and B cell 
mediated pathology, making it a useful model to replicate many of the pathological features of 
MS.  
4.1.5 MOG-EAE and in vivo models of focal cortical lesions 
As with the majority of rodent EAE models, cortical GM lesions are scarce or absent (Storch et 
al., 1998b; Storch et al., 2006). It has previously been shown that focal cortical lesions can be 
induced in vivo, by immunising rats with a sub-clinical dose of MOG to induce comparable 
production of anti-MOG antibodies as animals with clinical EAE, and prime anti-MOG specific 
T and B cells, without eliciting full clinical symptoms of EAE and with minimal CNS 
inflammation and no demyelination. Subclinical EAE conditions the immune system to 
recognise the myelin sheath as foreign upon further stimulation. The “primed” immune system 
can then be stimulated focally by injection of cytokines into the CNS location of interest, 
resulting in the formation of targeted demyelinated lesions (Kerschensteiner et al., 2004; 
Merkler et al., 2006b). This model has been successfully used to induce lesions in the spinal 
cord and motor cortex by stereotaxic injection of TNF and IFNγ (Kerschensteiner et al., 2004; 
Merkler et al., 2006b). To avoid tissue trauma artefacts associated with intracortical injections 
and to study the role of chronic meningeal inflammation in GML pathogenesis, this laboratory 
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developed a novel model involving subarachnoid injection of TNF and IFNγ in female DA rats 
with rmMOG-induced subclinical EAE (Gardner et al., 2013).   
 
4.1.6 Aims of the study 
The aim of these experiments was to determine a suitable dose of rmMOG with which to 
immunise female DA rats in order to elicit production of sufficiently pathogenic antibodies, 
without inducing the full clinical symptoms of EAE. In addition, we aimed to optimise the 
subarachnoid injection model used previously (Gardner et al., 2013). To achieve this aim the 
following experiments were performed: 
• Expression, isolation and purification of rmMOG 
• Determination of a suitable dose of rmMOG to elicit subclinical EAE 
• Characterisation of pathology induced by rmMOG immunisation 
• Optimisation of the subarachnoid injection model 
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4.2 Results 
4.2.1 Expression and isolation of rmMOG 
The N-terminal sequence (amino acids 1-118) of mouse MOG was expressed using E.coli 
glycerol stocks transformed with the pRSET A expression vector (rmMOG). The presence of 
the rmMOG-coding DNA insert within the vector in the colony chosen to express rmMOG was 
confirmed by DNA gel electrophoresis. Visualisation of bands of the expected size in the 
EcoR1 and HindIII cut lane confirmed the presence of the cut vector (2.875kb) and the excised 
rmMOG-coding DNA insert (359bp; Figure 4. 1 A). The supercoiled vector (3.234kb) in the 
uncut lane migrated through the gel faster than the cut vector fragment in the EcoR1 and 
HindIII lane, as expected for supercoiled DNA. DNA sequencing was carried out to ensure that 
the rmMOG insert also contained the sequence for the 6 residue histidine tag, which allowed 
subsequent purification of the expressed protein by metal affinity chromatography.  
The concentration of rmMOG produced by the current study (batch pXVII) was determined by 
NanoDrop spectrophotometer to be 2.46mg/ml. SDS-PAGE followed by a Coomassie stain 
showed bands of monomer at ~20kDa in both the pXVII lanes and the pXV lanes (a control 
rmMOG batch produced previously; Figure 4. 1 B). Monomer:dimer ratios were calculated to 
be 8.7:1 for pXVII and 12.0:1 for pXV, using densitometry on the Coomassie stained bands to 
avoid the confounding factors associated with quantification of proteins by Western blot 
(including efficiency of protein transfer and unequal binding affinities of the antibody for 
monomers, dimers and trimers). A high monomer content is thought to be more 
encephalitogenic (unpublished observations from this laboratory). 
Western blot confirmed the identity of rmMOG as MOG, with bands of the expected sizes 
corresponding to monomers (~20kDa), dimers (~40kD) and trimers (~60kD) observed in both 
the pXVII and control pXV batch produced previously (Figure 4. 1 B). A band at 14kDa was 
also observed in both batches by Coomassie staining and Western blot. 
Chapter 4 – Characterisation of acute subarachnoid targeted EAE 119 
 
4.2.2 In vivo titration of rmMOG and induction of EAE 
4.2.2.1 Immunisation with 2μg or 5μg rmMOG pXVII was asymptomatic 
Female DA rats were immunised with 2µg, 5µg (all groups n=4) or 50µg (n=8) pXVII rmMOG 
emulsified in an equal volume of incomplete Freund’s adjuvant (IFA). Control tissue and serum 
samples from animals immunised with IFA and PBS (IFA controls; n=3) were taken from a 
previous study to reduce animal numbers required for the current study, in line with the 3Rs 
principle.  
Animals immunised with 2µg or 5µg pXVII rmMOG were asymptomatic, culled at 28 dpi and 
given a score of 0, according to the scoring table (Figure 4. 1 C). Clinical EAE was induced in 
all of the 8 rats immunised with 50μg rmMOG, and was observed to be monophasic in the 4 
animals culled post-recovery at 28 days post immunisation (dpi; referred to as the 50μg recov 
group), with the disease peak followed by remission and a reduction in clinical score (Figure 4. 
1 C). The remaining 4 animals immunised with 50μg were culled 24 hours after peak 
neurological deficit had been reached (referred to as the 50μg peak group). The mean day of 
onset of clinical symptoms for both 50μg groups was 16 dpi (mean 16.25 dpi, range 13-19 dpi; 
Figure 4. 1 C), and symptoms followed an ascending course, typically starting with loss of tail 
tone followed by progressive weakness of the hind limbs. Two rats immunised with 50µg 
developed atypical symptoms, including ataxia and involuntary rotation, so were culled due to 
humane endpoints being reached. They were given a score of 5 for the remainder of the study 
and were excluded from all further analysis.  
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Figure 4. 1 Expression and isolation of rmMOG and in vivo titration in female DA rats 
DNA gel electrophoresis confirmed the presence of the excised 359kb rmMOG-coding DNA insert and 
the 2875kb vector following digest by EcoRI and HindIII restriction enzymes of DNA isolated from E.coli 
colonies (A). The uncut lane shows the supercoiled uncut vector. Bands of monomer were observed at 
~20kDCoomassie stain and Western blot, with 3 clear bands visible by Western blot corresponding to 
trimeric, dimeric and monomeric formations of the expected sizes (B). In vivo titration in female DA rats 
resulted in clinical EAE only in rats immunised with 50μg rmMOG (n=8), which was assessed according 
to a scoring system (C). Rats immunised with 2 or 5μg rmMOG were asymptomatic (n=4 per group). 
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Figure 4. 2 DA rats immunised with 2 or 5µg pXVII rmMOG were asymptomatic  
Female DA rats were immunised with 2, 5 or 50µg pXVII rmMOG emulsified in an equal volume of 
incomplete Freund’s adjuvant (IFA). IF for MOG as a marker of the myelin sheath and Iba1 for 
microglia/macrophages in spinal cord sections from control rats immunised with IFA + PBS did not 
reveal any observable loss of myelin or microglial activation (A, B). Spinal cords from rats immunised 
with 5μg rmMOG were indistinguishable from IFA control rats C, D). Demyelinated lesions (loss of MOG 
IF) and microglial activation (increased Iba1 IF) were observed in 50µg rmMOG immunised animals 
culled at 24 hours post-peak of neurological deficit (E, F). Images are representative and images on the 
right are magnifications of the boxed areas in the images on the left. Scale bars: A, C, E = 500µm; B, D, 
F = 100µm. n=3-6. 
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4.2.2.2 No demyelination or microglial activation in asymptomatic rats 
Immunofluorescence (IF) for MOG revealed no loss of myelin sheaths in IFA controls (Figure 
4. 2 A, B) or animals immunised with 2μg or 5μg rmMOG (Figure 4. 2 C, D). Iba1 IF revealed 
ramified microglia with small cell bodies and many fine, branching processes in IFA controls 
and the 2μg and 5μg groups, indicating a lack of microglial activation.  
Immunisation with 50µg rmMOG pXVII resulted in significant WM spinal cord demyelination in 
75% of rats culled at 24 hours post-peak of neurological deficit, observed as a loss of MOG IF 
(Figure 4. 2 E, F). The most extensive areas of demyelination were observed in the lower 
thoracic and lumbar sections (Figure 4. 3 A, B), in the lateral funiculus, particularly in the 
anterior and posterior spinocerebellar tracts and bordering the anterior and lateral 
spinothalamic tracts. Demyelination was also observed in the cuneate and gracile fasciculi of 
the dorsal funiculus. Spinal cord GM demyelination was not observed. No demyelination was 
observed in 50μg rats culled at 28 dpi, which was likely due to full remyelination between the 
peak of clinical symptoms (between 16 and 18 dpi) and termination of the study at 28 dpi, by 
which time all animals were in remission.  
Demyelinated lesions were accompanied by high numbers of activated microglia with rounded 
cell bodies and short, thickened processes, visualised by Iba1 IF (Figure 4. 2 F). A statistically 
significant increase in Iba1 immunoreactivity (IR) was observed in the spinal cords of all 50µg 
rmMOG immunised animals compared to asymptomatic 2µg and 5µg rmMOG immunised 
animals, indicating an increase in microglial/macrophage activation and density in rats with 
clinical EAE, in spite of the absence of demyelination in 50μg rats culled at 28dpi (Figure 4. 3 
C, D). Microglial/macrophage activation was most extensive in the lumbar region, as for 
demyelination in the 50μg animals culled at peak symptoms (Figure 4. 3 C).  
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Figure 4. 3 Quantification of spinal cord demyelination and microglial activation in EAE 
Demyelination was observed as a loss of MOG IF exclusively in spinal sections from rats immunised 
with 50μg rmMOG culled at 24 hours post-peak of neurological deficit (50 peak group), and was most 
extensive in the lower thoracic segments (A, B). No demyelination was observed in 50μg rats culled at 
28 dpi during recovery from monophasic EAE (50 recov group). Microglial activation observed by Iba1 
IF was significantly increased in all rats immunised with 50μg rmMOG compared to IFA-immunised rats, 
and was observed throughout the length of the spinal cord (C, D). No significant difference in microglial 
activation was observed between asymptomatic animals immunised with 5 or 2μg rmMOG and control 
animals immunised with IFA alone. Data is presented as mean ± SEM. Statistics: Kruskal-Wallis with 
Dunn’s multiple comparisons test; * = p≤0.05, ** = p≤0.01 vs. IFA. n=3 for IFA group, n=4 for remaining 
groups.   
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4.2.2.3 Absence of B or T cell spinal cord infiltration in asymptomatic rats 
Numbers of CD79a+ B cells (Figure 4. 4 A) and CD3+ T cells (Figure 4. 4 B) infiltrating the 
parenchyma were quantified in all segments of the spinal cord, using IF and IHC respectively. 
Positive cells observed in the meninges were excluded due to variation in the preservation of 
the meninges between sections. B cells were not observed in the spinal cord parenchyma in 
IFA control rats, and were rarely observed in animals from the 2, 5, or 50μg recov groups and 
culled at 28 dpi, mostly in the lower thoracic and lumbar segments (Figure 4. 4 C, E). There 
was a significant increase in B cell number in animals with clinical EAE in the 50μg peak group 
(Figure 4. 4 C, E).  
Minimal T cell infiltration was observed in the parenchyma of asymptomatic rats immunised 
with 2 or 5µg rmMOG, and there was no significant difference in the number of T cells/mm2 
between these groups (Figure 4. 4 D, F). A significant increase in T cell infiltration was 
observed in the 50µg recov group compared to IFA control rats, and a further significant 
increase was observed in the 50μg peak group culled with clinical EAE (Figure 4. 4 D, F).  
4.2.2.4 Anti-MOG antibody response in asymptomatic rats 
Titres of anti-MOG antibodies were quantified by ELISA in serum from peripheral blood 
samples taken at 14 and 28 dpi (Figure 4. 5). At 14 dpi, only IgG1 levels were significantly 
increased in animals immunised with 50μg rmMOG compared to naïve and IFA-immunised 
control rats (Figure 4. 5 C), while levels of total IgG (Figure 4. 5 A) and IgG2a (Figure 4. 5 E) 
were not significantly different from levels in the IFA or naïve groups. At termination of the 
study (28 dpi), titres of total IgG (Figure 4. 5 B), IgG1 (Figure 4. 5 D) and IgG2a (Figure 4. 5 F) 
were all significantly increased in the 50μg rmMOG-immunised group compared to naïve and 
IFA controls. There was no significant difference between titres in asymptomatic rats 
immunised with 2 or 5μg rmMOG compared to rats with symptomatic EAE immunised with 
50μg, although levels of IgG1 were observed to be low in asymptomatic rats at both time-
points (Figure 4. 5 C, D). No change in total IgG and IgG2a titres was observed from 14 dpi to 
28 dpi in asymptomatic rats.  
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Figure 4. 4 Quantification of B and T cell spinal cord infiltration in EAE 
B and T lymphocytes infiltrating the spinal cord were identified by CD79a IF (A) and CD3 IHC (B) 
respectively. T  and B cell infiltration was significantly increased in rats immunised with 50μg rmMOG 
culled at 24 hours post peak of neurological deficit (50μg peak group; C and D respectively), and was 
observed throughout the length of the spinal cord (E, F). Significantly increased T cell infiltration was 
also observed in rats post-EAE recovery (50μg recov group) compared to control animals immunised 
with IFA alone (D). No significant difference in T and B cell infiltration was observed between 
asymptomatic animals immunised with 5 or 2μg rmMOG and IFA alone. Data is presented as mean ± 
SEM. Statistics: Kruskal-Wallis with Dunn’s multiple comparisons test; * = p≤0.05, ** = p≤0.01 vs. IFA; # 
= p≤0.05, ## = p≤0.01 vs. 5μg group). n=3 for IFA group, n=4 for remaining groups.  
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4.2.3 Titration of rmMOG with subarachnoid cytokine injections  
A pilot study was conducted to determine the effect of subarachnoid injection of 1.25μg TNF + 
75ng IFNγ in female DA rats immunised 20-22 days previously with 5 or 10μg pXVII rmMOG, 
or 5 or 10μg pXIIIa rmMOG (5μg pXVII group n=3, all other groups n=4). The pXIIIa rmMOG 
batch was produced previously and used to develop the subarachnoid injection model 
(Gardner et al., 2013). 
All rats immunised with 5 or 10µg pXVII were asymptomatic. Incidence of clinical EAE was 
100% in rats immunised with 5 or 10µg pXIIIa. Stereotaxic injection of cytokines into the 
subarachnoid space was carried out at 20-22 dpi. Animals with a score of >3 (clinical 
symptoms more severe than hind-limb weakness) on the day of stereotaxic injection were 
culled due to attainment of humane endpoints and did not receive cytokine injections. Two 
animals from each of the 5 and 10µg pXIIIa groups were culled prior to surgery, and the brains 
and spinal cords were harvested for analysis by MOG and Iba1 IF. No cortical demyelination 
was observed in these animals, and cortical MOG and Iba1 IF were indistinguishable from 
naïve no-surgery control animals.  
4.2.3.1 Cortical demyelination in pXIIIa rats post-cytokine injection 
Stereotaxic injection of 1.25µg TNF and 75ng IFNγ into the subarachnoid space at 20-22 dpi 
did not result in any quantifiable loss of MOG IF in rats immunised with 5 or 10µg pXVII in 
cortical sections taken at the injection site (sections containing the greatest observable 
quantity of monastral blue tracer; Figure 4. 6 A). Meningeal inflammation was observed as an 
increase in cellular infiltration of the subarachnoid space, the majority of which were observed 
to be Iba1+ cells. Microglial activation was observed to be limited to areas immediately 
surrounding the subarachnoid space. No pathology was observed in the spinal cord.  
In contrast, cortical demyelination was observed in 1/2 and 2/2 rats immunised with 5µg or 
10µg pXIIIa respectively following subarachnoid injection of cytokines (Figure 4. 6 B and C 
respectively). Loss of subpial MOG IF was accompanied by increased numbers of microglia 
with an activated morphology, including large rounded cell somas and short, thickened 
processes (Figure 4. 6 D). Cortical demyelination was subtle and less extensive in the 5μg 
immunised group (Figure 4. 6 B) and observably more extensive in rats immunised with 10μg 
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rmMOG (Figure 4. 6 D). For this reason, immunisation for subsequent studies used 10μg 
pXIIIa rmMOG.  
4.2.4 Peripheral anti-MOG antibody response in asymptomatic rats  
Following the observation of a discrepancy between the cortical pathology induced by identical 
subarachnoid injection of cytokines in rats immunised with pXVII compared to pXIIIa rmMOG 
batches, antibody responses to immunisation with both batches were investigated. Peripheral 
anti-MOG immunoglobulin (IgG) levels were determined by ELISA using serum from blood 
samples taken at 14 dpi (Figure 4. 7 A, C, E) and at termination of the study (28 dpi; Figure 4. 
7 B, D, F). Data was compared to serum samples from IFA control rats from a previous study.  
Immunisation with 50µg pXIIIa induced a significant increase in anti-MOG IgG1 levels 
compared to the IFA control group at both time-points (Figure 4. 7 A, B). A non-significant 
trend towards increased levels of IgG1 following immunisation with 50μg pXVII was observed. 
There was no significant difference between IgG1 levels in rats immunised with 5µg or 10µg of 
pXIIIa or 5μg pXVII compared to rats immunised with 50µg of either rmMOG batch at either 
time-point. However, a non-significant trend towards decreased IgG1 levels in rats immunised 
with 5μg pXVII compared to the 5μg pXIIIa group was observed at both time-points.  
IgG2a levels were significantly increased following immunisation with 50μg pXIIIa and pXVII at 
14 dpi (Figure 4. 7 C) and at 28 dpi in the 50μg pXIIIa group (Figure 4. 7 D) compared to the 
IFA control group. There was no significant difference between IgG2a levels in rats immunised 
with 5µg or 10µg of pXIIIa or 5μg pXVII compared to the 50μg groups at either time-point, and 
a non-significant trend towards increased IgG2a levels post-rmMOG immunisation was 
observed in all rmMOG groups compared to the IFA control group. 
A significant increase in total IgG levels was detected in rats following immunisation with 50μg 
pXIIIa at 14 dpi (Figure 4. 7 E) and 10μg pXIIIa at 28 dpi (Figure 4. 7 F). Total IgG levels were 
not significantly different in rats immunised with 5μg or 10μg pXIIIa at 14 dpi (Figure 4. 7 E) or 
5μg pXVII at both time-points (Figure 4. 7 E, F) compared to the 50μg groups. A non-
significant trend towards increased total IgG was observed in all rmMOG-immunised groups 
compared to IFA control rats. 
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Figure 4. 6 Difference in targeted EAE after immunisation with pXVII or pXIIIa rmMOG 
Rats received a subarachnoid injection of TNF + IFNγ at 20-22 dpi with 5μg pXVII rmMOG (A), and 5μg 
(B) or 10μg pXIIIa rmMOG (C, D). Cortical MOG IF was intact in all pXVII immunised rats (A) but subpial 
demyelination was observed surrounding the sagittal sulcus in 5 and 10μg pXIIIa rmMOG-immunised 
rats (arrows in B, and C). Iba1 IF revealed microglial activation in areas of subpial demyelination (D). 
Images are representative and image D is a magnification of the boxed area in image C. Scale bars: A, 
B, C = 200µm D = 50µm. n=2-4 per group. 
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 Figure 4. 7 Asymptomatic rmMOG rats had a peripheral anti-MOG antibody response  
ELISA analysis of serum samples collected at 14 days post immunisation (dpi) and at termination of the 
study (28 dpi) from rats immunised with 5, 10 or 50µg pXIIIa, or 5 or 50µg pXVII rmMOG revealed an 
increase in peripheral anti-MOG IgG in all rmMOG-immunised groups compared to IFA-immunised 
control animals at the 14 dpi and terminal time-points (Fig 3.4 A, C) which just failed to reach 
significance. There was no significant difference in anti-MOG antibody levels between rats immunised 
with 5µg or 10µg rmMOG compared to those immunised with 50µg rmMOG at either time-point (A, B, 
C). Data is presented as the mean ± SEM. Statistics: Kruskal-Wallis test with Dunn’s comparison post-
test, *: p<0.05; **: p<0.01; ***: p<0.001. n = 2-4 per group.  
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4.2.5 Pilot study to determine the injection site for optimal accuracy  
The current model of subarachnoid injection of cytokines at 0.9mm posterior to bregma results 
in accurate injection placement in ~60-75% of animals, cortical damage and 
inaccurate/intracortical injection occur in ~40-25%. A small pilot study was conducted to 
investigate alternative injection sites to increase the accuracy of injections, refine the model, 
and reduce the number of animals required per study. Naïve female DA rats received a 
stereotaxic injection (1μl total volume) of sterile filtered PBS with Indian ink tracer (Stevens, 
UK; n=3 per injection site), to investigate the effect of different anatomical sites on the spread 
of tracer and to determine any improvement in injection accuracy. The sagittal sulcus between 
the hemispheres widens towards the junction of the cortices with the cerebellum. The two 
injection sites chosen were calculated to correspond to 5.8mm and 7.2mm posterior to bregma 
in the Rat Brain Atlas (Paxinos and Wilson), on the midline but closer to lambda, where the 
corpus callosum no longer holds the hemispheres together in tight proximity, allowing the 
sagittal sulcus to widen and providing a larger space through which to access the 
subarachnoid space. Injection coordinates were adjusted to account for the lower weights of 
female DA rats compared to the standard rat atlas so injection sites were -5.4 and -6.7mm 
from bregma. All injections were accurate into the sagittal sulcus, as no ink was observed in 
cortical tissue or underlying structures. Small traces of ink were observed in 1/3 rats at -5.4mm 
(Figure 4. 8 A, C), and 1/3 rats at -6.7mm (Figure 4. 8 B, D) indicating that injection of ink into 
the CSF was successful. However, no tracer was found in the remaining rats in either group, 
suggesting that the majority of tracer does not remain in the local vicinity of the injection site at 
these alternative sites.  
A further small pilot study was conducted to refine the model by improving injection accuracy, 
to reduce the number of animals required per study. This study aimed to determine the 
location of the superior sagittal sinus, and ascertain whether a space exists around the vessel 
that cytokines could be injected into without damage to the vessel or cortex, to remove the 
necessity of inserting the glass capillary between the cortices to reach the subarachnoid 
space, which risks damage to the adjacent GM. However, the superior sagittal sinus was 
found to occupy almost all of the available subdural space at the dorsal surface of the sagittal 
sulcus, leaving no room for the accurate injection of cytokines without risking damage to the 
sinus or adjacent cortex (Figure 4. 8 E).  
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Figure 4. 8 Injection of tracer at alternative injection sites and characterisation of sinus 
PBS with Indian ink tracer was injected into the subarachnoid space at -5.4mm (A, C) or -6.7mm (B, D) 
from bregma in naïve rats. Traces of ink were observed in the meninges at both sites at 7 days post-
injection (C, D). The sagittal sinus was visualised at the dorsal aspect of the sagittal sulcus in naïve rats, 
fitting into the subdural space between the cerebral hemispheres (E). Scale bars: A, B = 500μm, C-E 
200μm. n=3-5 per group.    
A B
C
D
E
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4.2.6 Characterisation of subarachnoid injections 
The effect of injection of PBS with monastral blue tracer was determined in rmMOG-
immunised rats at -0.9mm from bregma. Upon removal of the brain following accurate 
subarachnoid injection, monastral blue tracer was clearly observed in the meninges beneath 
the dura, in line with the sagittal sulcus (Figure 4. 9 A). Tracer particles were observed to 
spread from the olfactory bulbs to the cerebellum but the majority of monastral blue beneath 
the dura was observed over a distance of approximately 3mm. Monastral blue tracer was also 
observed to extend laterally from the midline over the dorsal surface of the cortex, to an 
approximate distance of 500μm from the midline (Figure 4. 9 arrows in A).  
Particles of monastral blue were clearly visible in the subarachnoid space and sagittal sulcus 
following accurate subarachnoid injection (Figure 4. 9 B), and were observed to spread from 
the base of the sulcus at the border with the corpus callosum to the dorsal surface of the 
cortex under the SSS.  
Inaccurate placement of subarachnoid injections resulted in intracortical injections, where 
monastral blue tracer was clearly observed in the cortex adjacent to the sagittal sulcus and 
subarachnoid space (Figure 4. 9 C). In the majority of cases, intracortical injections were less 
than 100μm from the subarachnoid space (Figure 4. 9 D). Localised tissue damage was 
observed along the needle track (Figure 4. 9 E), accompanied by microglial activation 
indicated by Iba1 IF visualisation of many microglia with short, thickened processes and a 
rounded cell soma surrounding the needle track (Figure 4. 9 F). The spread of monastral blue 
tracer within the subarachnoid space was observed to be less extensive following intracortical 
compared to subarachnoid injections. 
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Figure 4. 9 Characterisation of subarachnoid and intracortical injections using tracer 
PBS with monastral blue tracer was injected into the subarachnoid space at -0.9mm from bregma in 
rmMOG-immunised rats, then visualised at 7 days post-injection under the dura (A) and sagittal sulcus 
and subarachnoid space (B). Inaccurate placement of injections resulted in observation of tracer in the 
adjacent cortex (C, D). The needle track was clearly visible in rats with intracortical injections and 
associated with interrupted MOG IF (E) and microglial activation indicated by increased Iba1 IF (F). 
Scale bars: A = 500μm, B, C = 200μm. n=5 per group.    
A B C
D E F
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4. 3 Discussion 
4.3.1 Induction of EAE, clinical course and pathology 
The extracellular Ig-like domain of mouse MOG was successfully purified and induced EAE in 
vivo. Our finding that immunisation of female DA rats with 50μg rmMOG in IFA resulted in 
monophasic EAE followed by remission (defined as a clinical score reduction of 2 which is 
maintained for 2 days (Weissert et al., 1998)) in animals not culled at the peak of neurological 
deficit, contrasts with a previous study, which demonstrated development of chronic 
progressive EAE (Papadopoulos et al., 2006). Another study described induction of EAE with 
a variable disease course following an identical immunisation protocol to that used in the 
current study (Zeis et al., 2008), and it is suspected that the difference in clinical course 
following similar immunisation protocol may arise from inter-batch variation in monomer:dimer 
ratios, which, although not reported in the literature, have been observed by this laboratory to 
influence the course of EAE (unpublished observations from this laboratory). However, the n 
number of animals in the current study was relatively small to detect differences clinical course 
compared to the previous studies with larger n numbers, and it is unknown whether the rats 
culled at the peak of clinical symptoms may have developed progressive EAE if observed for a 
longer period of time. In addition, both previous studies used animals supplied by Harlan 
Laboratories, but animals used in the current study were supplied by Charles River 
Laboratories due to a viral outbreak at Harlan, and minor differences between the colonies 
may account for the difference in clinical courses.  
In the current study, spinal cord WMLs were associated with infiltrating T cells, and high 
numbers of activated microglia/macrophages, replicating features of WMLs observed in MS 
(Lucchinetti et al., 2000) and confirming findings from previous studies of MOG-induced EAE 
in DA rats (Storch et al., 1998b; Papadopoulos et al., 2006; Schreiner et al., 2009). The 
location of WMLs in the current study, often in the dorsal and lateral funiculi, was in keeping 
with the development of the motor deficits observed, since corticospinal tract damage elicited 
by targeted EAE is associated with motor impairments, assessed by grid walk, open field 
locomotion and clinical scoring (Kerschensteiner et al., 2004). The lack of quantifiable 
demyelination observed in the spinal cord of diseased animals culled at 28 dpi, rather than at 
the peak of neurological deficit, could be due to rapid remyelination, which has been shown to 
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occur 5-10 days after disease onset and could have been complete before termination of the 
study (Papadopoulos et al., 2006).  
4.3.2 Induction of sub-clinical EAE 
Reproduction of the targeted EAE models requires induction of subclinical EAE, which is 
characterised by a lack of neurological deficit, CNS inflammation, demyelination and leukocyte 
infiltration. The presence of an anti-MOG antibody response which is not significantly different 
from that observed in diseased rats indicates that the immunisation has resulted in 
autoreactive priming of the immune system, which is necessary for lesion induction following 
administration of a targeted stimulus to the CNS. The absence of CNS inflammation, infiltration 
and demyelinated lesions in subclinical EAE is important to eliminate confounding variables, in 
order to be able to attribute pathology observed following targeted stimulation to the stimulus, 
and not to the essentially random formation of EAE lesions in the CNS following immunisation.  
Although asymptomatic animals immunised with 2 or 5μg pXVII rmMOG lacked significant T 
cell infiltration into the spinal cord, peripheral blood anti-MOG antibody titres confirmed that an 
immune response was mounted. No demyelination and no significant activation of microglia or 
infiltration of macrophages were observed following immunisation with 2 or 5μg, confirming 
that subclinical EAE induces minimal CNS inflammation (Kerschensteiner et al., 2004; Merkler 
et al., 2006b; Gardner et al., 2013). At 21 dpi, antibody levels in rats immunised with 5µg were 
not significantly different from diseased animals, so the 5µg dose of pXVII was chosen for 
subsequent immunisations to induce subclinical EAE.   
4.3.3 Difference in targeted cortical demyelination with pXVII vs. pXIIIa 
In the current study differences existed in susceptibility to induction of cortical pathology 
between animals immunised with different batches of rmMOG. The absence of cortical 
pathology in this strain following induction of MOG-EAE supports previous findings (Storch et 
al., 2006). Interestingly, animals immunised with pXVII rmMOG did not develop cortical 
demyelination following subarachnoid injection of TNF and IFNγ, in contrast to subpial GMLs 
accompanied by microglial activation found in 3 of 4 animals pXIIIa-immunised rats. Since 
demyelination has been shown to be dependent on auto-antibodies in rat MOG-EAE 
(Linington and Lassmann, 1987; Piddlesden et al., 1993; Adelmann et al., 1995; Genain et al., 
1995; Storch et al., 1998b; Iglesias et al., 2001), a further ELISA was performed to measure 
different antibody isotypes in peripheral blood from rats immunised with both rmMOG batches.  
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All groups had comparable levels of IgG2a, suggested to be a more pathogenic isotype than 
IgG1 due to the increased efficiency of complement fixation observed with IgG2a (Piddlesden 
et al., 1993). However IgG1 levels were observably reduced in rats immunised with 5μg pXVII 
compared to pXIIIa-immunised rats. Variation in demyelinating ability has been observed 
previously within the IgG1 isotype, which is suggested to be due to differences in affinities for 
MOG or the ability to bind macrophage Fc receptors (Piddlesden et al., 1993). The formation 
of WMLs in the spinal cord indicates that demyelinating antibodies are produced in response 
to immunisation with 50µg pXVII, but it is possible that immunisation with 5μg pXVII may have 
resulted in production of insufficient levels of pathogenic antibodies with a sufficient affinity to 
initiate demyelination following CNS entry during targeted EAE (Piddlesden et al., 1993). 
Production of antibodies with an insufficient affinity for MOG would decrease the persistence 
of antibody deposition on the myelin sheath and the duration of complement fixation and 
macrophage activation, and might not reach the threshold required for initiation of 
demyelination. Alternatively, it is possible that antibodies produced in response to 
immunisation with pXVII recognised a greater proportion of linear MOG epitopes, which have 
been shown not to directly participate in demyelination, compared to pathogenic 
conformational-dependent epitopes (Haase et al., 2001). Although the same isolation and 
purification protocol was followed in the production of both rmMOG batches, differences in the 
proportion of linear to conformational rmMOG species may have arisen between batches. 
Immunisation with bacterially expressed recombinant MOG is recognised to result in a 
complex anti-MOG antibody response, characterised by recognition of both linear and 
conformational epitopes (Adelmann et al., 1995; Litzenburger et al., 1998; Brehm et al., 1999; 
Iglesias et al., 2001). The use of urea in isolation protocols is suggested to denature and 
linearise the protein, resulting in differential processing of recombinant versus native proteins 
following immunisation in vivo (Iglesias et al., 2001). Measurement of IgG levels by ELISA 
does not necessarily indicate the presence of a demyelinating antibody response since 
ELISAs recognise antibodies specific for incorrectly folded and denatured MOG. Differences in 
linear versus conformational epitope specificities between animals immunised with different 
rmMOG batches in the current study would therefore not be detected and could explain the 
difference in pathology observed following subarachnoid injection of cytokines.  
Fluorescent activated cell sorter (FACS) assays using cells transfected to express MOG can 
be used to confirm whether anti-MOG antibodies will recognise MOG expressed by cells in the 
CNS in vivo (Brehm et al., 1999; Haase et al., 2001), thus giving a better indication of 
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pathogenicity than ELISAs, but these assays are limited by the high variability of cell lines in 
use, highlighting the need for an ELISA which provides only correctly folded MOG as an 
antigen. A tetramer radioimmunoassay, where 4 MOG extracellular domains were 
tetramerised and used to detect antibodies via immunoprecipitation, was also found to be 
more specific than ELISA for detecting pathogenic anti-MOG antibodies. This was due to the 
increased avidity of the antigen and the more specific identification of antibodies against 
conformational, correctly folded MOG protein, as the MOG tetramer does not bind antibodies 
specific for linear MOG epitopes (O'connor et al., 2007).  
Following the observation of subpial pathology in all 10μg pXIIIa rmMOG-immunised animals 
following cytokine injection, and no apparent difference in EAE incidence between the 5 or 
10μg pXIIIa groups, it was concluded that 10μg pXIIIa was the optimum immunisation dose for 
use in further targeted EAE studies. No cortical demyelination or microglial activation was 
observed in animals at the peak of neurological deficit in either the 5 or 10μg pXIIIa groups, 
suggesting that in spite of spinal EAE pathology, cortical pathology following cytokine injection 
can still be reliably attributed to the effects of the injected cytokines. Changes in cortical 
NAGM gene expression have been observed in chronic EAE following immunisation with 50μg 
recombinant rat MOG in the absence of observable cortical pathology, in line with NAGM 
observations from MS studies (Dutta et al., 2006; Zeis et al., 2008). However these gene 
expression changes were not observed in animals with a variable EAE course similar to that of 
rats immunised with 5 or 10μg pXIIIa described in the current study, suggesting that chronic 
disease may be required to induce gene expression changes in cortical NAGM tissue distant 
from spinal lesion sites. Therefore, the 10μg pXIIIa rmMOG dose was used in future studies of 
the targeted EAE model to determine the effect of subarachnoid injection of LTα. 
4.3.4 Alternative injection sites are less relevant to F+SPMS pathology 
Injections into the subarachnoid space at both alternative injection sites closer to lambda were 
achieved with 100% accuracy, but ink was only observed in 33% of animals suggesting that 
the volume of CSF and possibly flow rate are too great at these sites to allow a concentrated 
local increase in cytokines as is suggested to occur in sulci in SPMS. Therefore, the current 
model of subarachnoid injection deep into the sagittal sulcus provides a more relevant model 
for studying the effect of cytokine production by the meninges/TLOs in a confined space 
similar to that found in the sulci of MS brains, where inflammation is suggested to be confined 
and local production of inflammatory mediators may result in relatively high localised 
Chapter 4 – Characterisation of acute subarachnoid targeted EAE 139 
 
concentrations and associated pathology of underlying grey matter (Magliozzi et al., 2007; 
Magliozzi et al., 2010; Howell et al., 2011).  
The superior sagittal sinus was observed to fill almost all of the available subdural space at the 
dorsal aspect of the sagittal sulcus between the 2 cerebral hemispheres, and it was concluded 
that no suitable space exists around the vessel into which cytokines could be injected without 
damage to the vessel or surrounding cortex. Together these pilot studies therefore confirm the 
subarachnoid injection model as the most relevant for future studies into meningeal 
inflammation and pathology of the underlying GM, in spite of the difficulty of accurate injection 
placement into the subarachnoid space. The dimensions and anatomical position of the 
superior sagittal sinus has been imaged in Sprague-Dawley (SD) rats, but had not previously 
been characterised in DA rats to our knowledge (Szabo, 1995; Stolz et al., 2011). The 
anatomy of the sinus in DA rats appears to be identical to that described in SD rats. The 
current study highlights the remarkable ability of this vessel to repair following presumed 
insertion of the glass capillary through the sinus during subarachnoid injection, since no 
animals were lost due to cranial bleeding during stereotaxic surgery for the whole duration of 
the project, and control animals that were operated on but only received PBS injections had no 
cortical pathology (Gardner et al., 2013). 
4.3.5 Accuracy and distribution of subarachnoid injections  
Accurate model reproduction of targeted EAE following subarachnoid injection requires that 
the surgical procedure of cytokine injection causes little or no damage to the BBB, or the 
cingulate cortex and corpus callosum surrounding the injection site, in order to be able to 
attribute any subsequent pathology to the cytokines injected, rather than to the injection 
procedure. BBB preservation increases the relevancy of the model to pathology observed in 
MS cortical GMLs, which lack significant BBB disruption (Van Horssen et al., 2007).  
Monastral blue tracer was confirmed to be a useful marker of the accuracy of subarachnoid 
injection placement, following the observation of monastral blue in the sagittal sulcus and its 
absence from the adjacent cortex, while substantial amounts of tracer in the cortex indicated 
inaccurate (intracortical) injections. Observation of the tracer beneath the dural membrane, 
which was removed during tissue processing, demonstrated the remarkable spread of injected 
material in anterior-posterior and lateral directions from the midline. Tracer studies in rats 
suggest that CSF flows in an anterior direction within the subarachnoid space towards the 
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cribriform plate and into the nasal lymphatics (Zhang et al., 1992). In the current study, 
monastral blue particles were observed to extend from the cerebellum to the olfactory bulbs 
but tracer appeared to be more dense in the anterior sections compared to the posterior 
sections at the same distance from the injection site, suggesting that diffusion of the injected 
cytokines occurred in both directions along the subarachnoid space, but was also influenced 
by the anterior direction of CSF flow. As expected, the distribution of tracer along the 
subarachnoid space appeared to be more limited following intracortical compared to 
subarachnoid injections, due to the confinement of tracer within the cortical tissue. The 
observation of substantial lateral spread of the tracer supports previous studies in which GMLs 
have been observed located on the dorsal aspect of the cortex in addition to the GMLs lining 
the sagittal sulcus following injection of pro-inflammatory cytokines, suggesting that diffusion of 
cytokines in a similar distribution pattern to that observed in the current study contributes to 
the pattern of GML formation (Gardner et al., 2013).  
Although the glass capillaries used in the current study have a much reduced external 
diameter (~50µm) compared to the cited cortical injury model implements (123µm - 2mm), 
BBB disruption and microglial activation along the needle tract is inevitable following an 
intracortical injection. Indeed, microglial activation and limited demyelination was observed 
along the needle tract in rmMOG-immunised rats following intracortical injection of PBS in the 
current and previous studies (Merkler et al., 2006b; Gardner et al., 2013). In addition the more 
limited distribution of tracer along the subarachnoid space following intracortical injections may 
influence the distribution of GMLs due to altered patterns of diffusion of cytokines, planned for 
use in future studies. Given the wide ranging effects on the innate and adaptive immune 
responses which can be initiated by cortical injury and intracortical injections, animals in which 
the injection site was found to be intracortical rather than within the subarachnoid space were 
excluded from further analysis in the current and future studies.  
Accurate subarachnoid placement of injections was hampered by the high degree of variation 
in the coronal and sagittal sutures on the skull, resulting in difficulty in precisely locating the 
midline. In the current study, intracortical injections were observed within 30μm of 
subarachnoid space, highlighting the requirement for a high degree of precision and an 
estimated tolerance of less than 10μm either side of the midline. Despite these factors, 
accurate subarachnoid injections were achieved in the majority of animals. The information 
yielded from these animals retains relevancy to the pathogenesis of MS, and future studies will 
be performed to determine the effect of raised concentrations of cytokines within the CSF and 
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specifically within a deep sulcus, with little damage to surrounding structures and preservation 
of the BBB (Gardner et al., 2013).   
4.4 Conclusions 
RmMOG batch pXVII was successfully expressed, isolated and purified from genetically 
modified E.coli. When titrated in vivo against a previous batch, pXIIIa, differences in cortical 
GM demyelinating pathology were observed following subarachnoid injection of pro-
inflammatory cytokines to induce targeted EAE, which are suggested to be due to differences 
in epitope specificity and pathogenicity of anti-MOG antibodies between immunisation groups. 
We conclude that rmMOG batch pXIIIa is most suitable for subsequent immunisations. In 
addition, we confirmed that the sagittal sinus fills the majority of the subdural space at the 
dorsal surface of the sagittal sulcus and does not represent an alternative injection site, while 
the other sites investigated did not accurately model the enclosed space found in deep sulci 
where TLOs are most frequently observed in MS. We therefore conclude that injecting 
cytokines into the subarachnoid space at the location of the motor cortex (-0.9mm from 
bregma) is the most relevant model for further investigation of cytokines involved in TLO 
formation and the effect of meningeal inflammation on the underlying GM in vivo. In future 
studies, animals will be excluded from analysis if the injection is intracortical, due to the 
confounding variables of tissue trauma and the associated microglial activation induced by 
inaccurate needle placement.   
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5.1 Introduction 
5.1.1 The subarachnoid space and CSF in MS 
The subarachnoid space plays an important role in the pathogenesis of MS. Plasma cells are 
observed to chronically persist in the subarachnoid space, and intrathecal synthesis of 
antibodies is such a commonly observed phenomenon that the presence of oligoclonal bands 
in the CSF but not in serum is used as a diagnostic criteria for MS, found in 88% of MS 
patients (Frischer et al., 2009; Dobson et al., 2013). The subarachnoid space is also involved 
in immune surveillance of the CNS and contains large numbers of MHC II+ dendritic cells and 
macrophages surrounding meningeal vessels, which function as antigen presenting cells 
(APCs) to immune cells entering the CNS (Mcmenamin, 1999; Bartholomaus et al., 2009; 
Kivisakk et al., 2009). Activated meningeal vessels are thought to be the major route of entry 
for autoreactive T cells into the brain during EAE, and reactivation of these cells occurs within 
the subarachnoid space (Bartholomaus et al., 2009; Ransohoff, 2009). In addition, 
accumulation and proliferation of CD4+ Th1/Th17 cells in the subarachnoid space and their 
interaction with APCs, is observed early in EAE prior to the onset of clinical symptoms, 
suggesting a key role for the subarachnoid space in the initiation of EAE (Kivisakk et al., 
2009). 
CSF is secreted by choroid plexus cells in the lateral, third and fourth ventricles, and flows out 
into the subarachnoid space (Abbott, 2004). Arachnoid granulations act as valves and 
maintain CSF at a constant pressure by facilitating drainage of excess CSF into cerebral veins 
when CSF pressure exceeds venous pressure. In addition, CSF drainage occurs via 
perivascular spaces alongside large blood vessels and cranial nerves, and drains into the 
lymphatic system on exiting the CNS (Nagra et al., 2006; Iliff et al., 2012). The CSF is 
separated from the blood by 3 barriers - the BBB (formed by endothelial cells), the choroid 
plexus epithelium (Blood-CSF-Barrier), and the arachnoid epithelium between the blood and 
CSF within the subarachnoid space. CSF within the subarachnoid space is separated from the 
underlying cortical GM by the pial membrane, which is a 1-2 cells thick layer of squamous 
epithelial cells joined by gap junctions, allowing significant exchange of substances between 
the two compartments (Abbott, 2004; Adeeb et al., 2013). The pia mater overlies the multi-
layered and less permeable glia limitans, composed of astrocytic elements (Johanson et al., 
2005; Adeeb et al., 2013). 
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Studies using tracer injected into the CSF have shown that substances within the CSF and the 
interstitial fluid that bathes the parenchymal brain tissue can be exchanged across the pial 
surface as well as via the ependyma lining the ventricles (Iliff et al., 2012). Intracortically 
injected tracers have been shown to enter the CSF via perivascular spaces by crossing the 
leptomeningeal sheath surrounding the subarachnoid perivascular space (Abbott, 2004). 
These studies support the hypothesis that soluble cytotoxic factors within the CSF or produced 
by inflammation in the meninges overlying the GM may diffuse through the pia mater and drive 
GM pathology (Magliozzi et al., 2010; Howell et al., 2011; Reynolds et al., 2011). In addition, it 
is possible that factors produced by activated glial cells within the cortex may drain into the 
CSF and contribute to/influence meningeal inflammation and GM pathology.  
5.1.2 Meningeal inflammation  
The hypothesis that factors in the CSF may drive cortical pathology in MS is supported by the 
lack of immune cell infiltration into GMLs and independence from WML pathology, and the 
prevalence of subpial GMLs adjacent to the CSF compartment (Peterson et al., 2001; Bo et 
al., 2003l; Magliozzi et al., 2007). The correlation between demyelination observed in the 
cerebellum and forebrain was also suggested to support the hypothesis of the presence of a 
common factor involved in widespread GML pathology in CSF (Kutzelnigg et al., 2007).  
Compartmentalisation of inflammation within the subarachnoid space has been suggested to 
create a niche for the development of an inflammatory milieu within the CSF (Meinl et al., 
2008; Reynolds et al., 2011). Diffuse inflammatory infiltrates are commonly observed within 
the meninges in both PPMS and SPMS cases, composed largely of T and B cells and 
macrophages (Kutzelnigg et al., 2005; Kooi et al., 2009; Howell et al., 2011; Choi et al., 2012). 
Severity of diffuse inflammation is significantly associated with GM demyelination and the 
number of parenchymal CD68+ microglia, suggesting that meningeal inflammation may 
contribute to both demyelination and microglial activation (Howell et al., 2011). This view is 
supported by the finding that meningeal infiltration of T cells is significantly correlated with 
microglial expression of other markers of activation, including MHC, CD68 and inducible nitric 
oxide synthase (Dal Bianco et al., 2008). 
In addition to diffuse meningeal inflammation, the formation of B cell follicle-like structures has 
been described in MS. These structures were defined as containing Ki67+ CD20+ proliferating 
B cells, Ig+ plasma cells, T cells and CD35+/CXCL13+ follicular dendritic cells (Serafini et al., 
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2004; Magliozzi et al., 2007; Howell et al., 2011). These structures are indicated to function as 
ectopic lymphoid follicles or tertiary lymphoid organs (TLOs) that have been found to develop 
in other chronic inflammatory diseases (Randen et al., 1995; Schroder et al., 1996; Stott et al., 
1998; Houtkamp et al., 2001). The presence of meningeal TLOs is correlated with a younger 
age at wheelchair use, disease onset and death (Serafini et al., 2004; Magliozzi et al., 2007; 
Magliozzi et al., 2010; Howell et al., 2011). A gradient of neuronal loss was also observed in 
the motor cortex of SPMS cases with TLOs (F+SPMS) compared to those without (F-SPMS), 
which was most prominent in layer I beneath the pia mater and extended through cortical 
layers III-V. Increasing neuronal loss was accompanied by increasing microglial activation 
(Magliozzi et al., 2010). TLOs are suggested to facilitate the continued local production of 
autoantibodies within the CNS, which are thought to play a key role in demyelination (Archelos 
et al., 2000; Lucchinetti et al., 2000; Serafini et al., 2004; Sadaba et al., 2012).  
Pro-inflammatory cytokine and chemoattractant release from reactivated lymphocytes may 
contribute to the inflammatory milieu in the CSF and influence lymphocyte recruitment from the 
periphery through activation of the BBB. Together these data suggest that severe meningeal 
inflammation and TLO neogenesis result in increased damage to the underlying cortical tissue, 
leading to the accumulation of disability and disease progression. This is hypothesised to be 
due to increased production of soluble cytotoxic factors which diffuse from the meningeal 
compartment and CSF to drive GML pathology (Magliozzi et al., 2010). Meningeal TLO 
neogenesis may therefore represent an important therapeutic target, warranting further 
investigation in vivo. 
5.1.3 Tertiary lymphoid organ neogenesis and LTα 
The role of LTα in TLO neogenesis was demonstrated by studies using transgenic mice which 
ectopically express soluble LTα under the control of the rat insulin II promoter (RIPLT mice) in 
the pancreas, skin and kidney (Picarella et al., 1993; Kratz et al., 1996). Ectopic expression of 
LTα in pancreatic islet cells resulted in formation of organised inflammatory infiltrates 
composed of CD4+ and CD8+ T cells, B220+ and IgM+ B cells and macrophages, which was 
suggested to be lymphoid organogenesis (Picarella et al., 1992; Kratz et al., 1996). Infiltration 
of islets occurred with increasing frequency as animals aged, with more infiltrated islets being 
observed in 5 month compared to 1 month mice, and persisted up to 1 year (Picarella et al., 
1992). RIPLT mice lacking TNFR1 showed no inflammation in the pancreas, indicating that the 
inflammation / lymphoid organogenesis observed in RIPLT mice is dependent on TNFR1 
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signalling via LTα, and independent of LTβ, as LTα1β cannot bind TNFR1 (Sacca et al., 1998). 
In addition, almost identical inflammation was observed in RIPLT.LTβ-/- transgenic mice which 
have a genetic deletion of LTβ, confirming that the inflammation observed in RIPLT mice is 
due to LTα acting through TNFR1 and is independent of LTβ (Sacca et al., 1998). 
The mechanism for the role of LTα in leukocyte recruitment to sites of inflammation was 
indicated after LTα was found to potently activate endothelial cells and increased adhesion of 
lymphocytes in vitro, an effect that was augmented by the addition of IFNγ (Pober et al., 1987; 
Cavender et al., 1989). Murine LTα in the absence of LTα1β2 induces expression of VCAM, 
ICAM, E-selectin, MAdCAM, RANTES, MCP-1 and CXCL10 in murine endothelial cells in vitro 
(Cuff et al., 1998). RANTES, MCP-1 and CXCL10 all act as T cell chemoattractants, while 
MCP-1 attracts monocytes. The induction of these molecules on endothelial cells is consistent 
with the large proportion of mononuclear cells that were observed to infiltrate into tissue 
ectopically expressing high concentrations of LTα. 
Human LTα potently induces apoptosis of oligodendrocytes in vitro, and is expressed by CD3+ 
T cells and microglia at the edge of both acute and chronic active MS lesions (Selmaj et al., 
1991b; Selmaj et al., 1991c; Lock et al., 1999). LTα also shows mitogenic properties when 
applied to astrocytes in vitro, suggesting a role in glial scar formation in MS (Selmaj et al., 
1990). LTα production by MBP-specific T cells was found to correlate with encephalogenicity 
in vivo, and treatment of mice with a neutralising antibody specific for LTα and TNF prevented 
adoptive transfer of EAE, suggesting a role for LTα and TNF in EAE pathogenesis (Powell et 
al., 1990; Ruddle et al., 1990). Data from studies inducing EAE in mice with genetic deletions 
of LT has yielded more conflicting results about the role of LTα in EAE, likely due to the 
abnormal lymphoid organ development observed in these mice. LTα-/- mice are resistant to 
EAE while LTβ-/- mice can develop EAE suggesting that LTα alone plays an important role in 
inflammation and EAE susceptibility (Suen et al., 1997), although other studies contradict 
these findings (Frei et al., 1997; Sean Riminton et al., 1998).  
The suggested roles of LTα in inflammation, lymphoid organogenesis, EAE and MS indicate 
that LTα is a key target for MS research. Further study is warranted to determine the role of 
LTα in meningeal inflammation and cortical pathology in MS, using an in vivo model of 
meningeal inflammation in the context of EAE. 
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5.1.4 IFNγ 
IFNγ is a pleiotropic cytokine that has been implicated in MS since a clinical trial was shown to 
increase the severity and number of relapses in RRMS patients following administration of 
recombinant-IFNγ, which corresponded to an increase in circulating blood monocytes 
expressing MHC II (Panitch et al., 1987). It was subsequently discovered using a whole-blood 
mitogen assay that increased secretion of IFNγ precedes relapses by up to 2 weeks, with 
benign cases being associated with a rapid disappearance of the increased IFNγ production, 
while persisting increases were associated with exacerbations of disease (Beck et al., 1988).  
In human MS autopsy tissue, IFNγ is found at the leading edge of chronic active lesions, 
together with apoptotic oligodendrocytes, and recombinant rat IFNγ has been shown to induce 
apoptosis of rat oligodendrocytes in vitro (Vartanian et al., 1995).  
IFNγ is primarily secreted by Th1 CD4+ and CD8+ cytotoxic T cells, although B cells, NK cells 
and APCs are also capable of secreting IFNγ (Schroder et al., 2004). As well as stimulating 
microglia and macrophages to secrete TNF, IFNγ has roles in inflammation and the infiltration 
of leukocytes, regulation of T cell apoptosis, promotion of APC maturation and macrophage 
activation, and influences Ig production and class switching in B cells (Boehm et al., 1997; 
Schroder et al., 2004; Welser-Alves and Milner, 2013). IFNγ causes upregulation of MHC II 
expression on microglia, which was observed in previous studies to be particularly strong in 
EAE lesion sites, suggesting a role in antigen presentation to CD4+ T cells (Steiniger and Van 
Der Meide, 1988; Vass and Lassmann, 1990). In addition, IFNγ may increase oligodendrocyte 
susceptibility to cytotoxic CD8+ T cell-mediated death, TNF-induced apoptosis and FasL-
mediated cell death by enhancing cell surface expression of MHC I molecules, TNFR1 and 
Fas (Dopp et al., 1997; Buntinx et al., 2004).  
5.1.5 In vivo models of cortical pathology 
EAE pathology in most rodent models is focussed on the spinal cord and often acute in nature, 
making these models unsatisfactory for the study of chronic and cortical pathology, both of 
which are key characteristics of MS (Sriram and Steiner, 2005). Cortical lesions are observed 
in marmosets following rmMOG immunisation, but the husbandry requirements of this species 
render it unsuitable for widespread study of cortical lesion pathogenesis (Merkler et al., 
2006c). Cortical pathology is rarely observed in the majority of rodent EAE models in the 
absence of an inflammatory stimulus directed to the brain (Merkler et al., 2006b; Gardner et 
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al., 2013). Subarachnoid injection of the pro-inflammatory cytokines TNF and IFNγ has 
recently been shown to result in subpial GMLs and microglial activation in female DA rats that 
were immunised 21 days previously with a subclinical dose of recombinant mouse MOG 
(rmMOG), sufficient to elicit an anti-MOG antibody response but not to induce clinical EAE 
(Gardner et al., 2013). GM pathology was accompanied by meningeal infiltrates comprised of 
CD4+ and CD8+ T cells, B cells and macrophages, which was maximal at 1 day post-cytokine 
injection (Gardner et al., 2013). Subpial demyelination was most extensive at 7 days post-
cytokine injection and was repaired by 14 days.  
5.1.6 Aims  
The aim of the current study was to determine the acute effects of raised concentrations of 
LTα and IFNγ in the CSF on the underlying meninges and cortex. To achieve this aim, we 
adapted the in vivo model developed by Gardner et al. (2013), which involved injection of pro-
inflammatory cytokines into the subarachnoid space of female DA rats pre-immunised with a 
subclinical dose of rmMOG. For the current study the following experiments were carried out: 
• A dose response experiment to determine the acute effect of subarachnoid injection of 0.5µg 
(recombinant human) LTα versus 1µg LTα, both co-injected with 75ng (recombinant rat) IFNγ. 
Effects were examined at 7 days post-subarachnoid injection in both rmMOG-immunised and 
control rats immunised with IFA alone. 
• A time course experiment to examine the dynamics of the effects arising from injection of the 
optimal dose of LTα+IFNγ (as determined by the dose response experiment), in rmMOG-
immunised rats at 3, 7, 14 and 21 days post-subarachnoid injection.  
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5.2 Results 
5.2.1 Dose response experiment 
Female DA rats immunised with 10μg pXIIIa rmMOG in IFA received a stereotaxic injection 
into the subarachnoid space of 0.5µg recombinant human LTα (LTα) + 75ng recombinant rat 
IFNγ (IFNγ) or 1μg LTα + 75ng IFNγ at 20-22 days post immunisation (Figure 5. 1). Control 
groups were immunised with IFA + PBS, or were age-matched naïve rats, and received an 
identical subarachnoid injection of cytokines. An additional control group was immunised with 
rmMOG and received a subarachnoid injection of PBS with MB tracer (MOG PBS controls). All 
animals were culled at 7 days post subarachnoid injection. All groups were compared to age-
matched naïve rats that received no subarachnoid injection and no immunisation (naïve rats). 
5.2.1.1 Incidence of arthritis in IFA control rats 
Female DA rats immunised with IFA only + PBS (IFA controls) developed transient arthritis in 
their hind limbs. Overall incidence was 92% (11/12), with 58% developing arthritis prior to 
subarachnoid injection of LTα+IFNγ and 33% developing arthritis following subarachnoid 
injections. All affected rats were treated with analgesic drugs and given soft nesting materials. 
Daily subcutaneous injections of 5mg/kg carprofen (Rimadyl; Zoetis, New Jersey, USA), 
combined with 0.01-0.05mg/kg buprenorphine (Vetergesic; Alstoe Animal Health) were 
administered up to a maximum continuous period of 72 hours. A 72 hour washout period prior 
to subarachnoid injections was observed, when no drugs were administered. Following 
surgery, 0.01mg/kg buprenorphine was used as an analgesic up to every 12 hours as required 
until the experimental endpoint at 7 days post-subarachnoid injection.   
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5.2.1.2 Incidence of clinical EAE in rmMOG rats was higher than expected 
Female DA rats immunised with 10μg pXIIIa rmMOG + IFA (rmMOG-immunised rats) 
developed clinical EAE with an incidence of 67% (8/12). Animals with complete hind-limb 
weakness (clinical score of 3.5) prior to subarachnoid injection were culled due to reaching the 
humane endpoint for the study (42%, 5/12). No cortical demyelination was observed in 
rmMOG-immunised rats culled at peak symptoms. Ambulatory animals with mild, partial hind-
limb weakness, loss of tail tone, or with subclinical EAE (score 3 or below) at 21 days post 
immunisation (dpi) received subarachnoid injections (58%, 7/12). Of the 7 rats that received 
subarachnoid injections, at the time of surgery 4 rats had subclinical EAE (score 0), 2 rats 
were recovering from a relapse (had progressively improving neurological scores) and 1 rat 
had tail tone weakness that progressed to a relapse (peak score 3) following subarachnoid 
injection.   
5.2.1.3 Accuracy of subarachnoid injections of LTα+IFNγ  
The accurate placement of cytokine injections was determined by visualisation of monastral 
blue tracer in the subarachnoid space, by light microscopy of sectioned brain tissue. The 
injection site was taken to be the section containing the maximum observed amount of 
monastral blue tracer. Accurate injection of cytokines into the subarachnoid space with 
minimal disruption to the adjacent cortex was achieved in 63% of rats (12/19).  
Monastral blue tracer was observed in the adjacent cingulate cortex on either side of the 
subarachnoid space in the remaining 7 animals. These rats were excluded from further 
analysis, due to the confounding effects of tissue trauma and microglial activation associated 
with cortical injection (see chapter 4, Figure 4. 9 and section 4.2.7). Excluding animals with 
cortical injections inevitably reduced the n numbers of groups but the resulting data was felt to 
be more accurate, as we wished to study the effects of raised cytokine concentrations within 
the CSF on cortical pathology without interference from other factors including surgical trauma. 
Following animal exclusions due to EAE and accuracy of subarachnoid injections, n=3 per 
group was achieved and used for subsequent analysis.   
5.2.1.4 Subpial demyelination and meningeal inflammation  
Immunofluorescence (IF) for MOG and Iba1 was performed to identify areas of demyelination 
and microglial activation respectively in coronal brain sections from each animal. Sections in 
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which monastral blue tracer was at maximum density within the subarachnoid space were 
taken to be the injection site in each animal and were chosen for IF analysis. The formation of 
dense cellular infiltrates indicated by large numbers of DAPI+ nuclei in the subarachnoid space 
and sagittal sulcus was observed in IFA control rats at 7 days post-subarachnoid injection with 
0.5µg or 1µg LTα+IFNγ (Figure 5. 2 A, B). Limited microglial activation was observed by Iba1 
IF surrounding the sagittal sulcus, but IF for MOG did not reveal any areas of quantifiable 
demyelination.  
Formation of dense cellular infiltrates was also observed in the subarachnoid space and 
sagittal sulcus of rmMOG-immunised rats at 7 days post-subarachnoid injection with 0.5µg or 
1µg LTα+IFNγ (Figure 5. 2 C, D, E). In addition, subpial demyelinated cortical lesions were 
observed as a loss of MOG IF in the grey matter (GM) of the cingulate cortex surrounding the 
subarachnoid space and sagittal sulcus in all rmMOG-immunised rats (Figure 5. 2 arrows in C, 
and also present in D).  
There was no observable demyelination or microglial activation within the corpus callosum 
(Figure 5. 2 C, D). GM demyelination was observed in both hemispheres and typically 
extended from the GM of the cingulate cortex overlying the corpus callosum to the dorsal 
surface of the primary and secondary motor cortices. The density of DAPI+ nuclei within the 
GM was used to define the cortical layers. Layers II-III were observable as a band of nuclei 
present at high density, situated ventral to an area of nuclei at low density beneath the 
meninges that was defined as layer I. Subpial demyelination in rmMOG-immunised rats 
following injection of 0.5µg or 1µg LTα+IFNγ extended through layers I-III into layer IV but did 
not extend into layer V. The pattern of demyelination observed within these subpial lesions 
was reminiscent of type III lesions described in MS cortical GM pathology (Peterson et al., 
2001).  
Subpial demyelination was accompanied by microglial activation, observed as an increase in 
numbers of microglia with shortened processes and more amoeboid morphology, identified by 
Iba1 IF (Figure 5. 2 D inset), that was particularly apparent in demyelinated cortical areas 
lacking MOG IF (Figure 5. 2 C, D, E). Intracortical perivascular demyelination, accompanied by 
microglial activation, was also observed in one animal that was reminiscent of type II lesions 
described in MS (Figure 5. 2 D arrows). No subpial demyelination was observed in naïve rats 
following injection of 1µg LTα+IFNγ (Figure 5. 2 F, G), although microglial activation was 
observed surrounding dense cellular infiltrates in the subarachnoid space (Figure 5. 2 G). One 
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intracortical lesion was observed in one animal at the injection site accompanied by microglial 
activation, in spite of the presence of monastral blue exclusively within the subarachnoid 
space and in the absence of any observable subpial demyelination. A small area of subpial 
demyelination was observed in one rmMOG-immunised rat receiving a subarachnoid injection 
of PBS 0.1%BSA (PBS control rats; Figure 5. 2 H, J). Microglial activation was not observed 
(Figure 5. 2 J). Demyelination was limited to the first cortical layer and did not extend more 
than approximately 80µm into the cortex. No demyelination or microglial activation was 
observed in any other animals within the group. No meningeal infiltration or formation of 
cellular infiltrates was observed in any MOG PBS animals.  
Areas of subpial demyelination were quantified in all animals at the injection site (-0.9mm from 
bregma) and at 400µm anterior and posterior to the injection site (+400µm and -400µm 
respectively) to determine the extent of cortical pathology (Figure 5. 3). No areas of 
demyelination were observed at +/-400µm from the injection site or at the injection site in IFA 
control rats, but the data is omitted from the graph for clarity (Figure 5. 3). The mean area of 
demyelination quantified at 400µm anterior to the injection site in rmMOG-immunised rats that 
received 0.5µg LTα+IFNγ was significantly increased above IFA control rats that received the 
same dose, in which no demyelination was observed (p=0.0352, Kruskal-Wallis with Dunn’s 
multiple comparisons post-test; Figure 5. 3). Subpial demyelination was present at 400µm 
anterior and posterior to the injection site in all rmMOG-immunised rats following injection of 
0.5µg LTα+IFNγ, and extended laterally up to 3.07mm from the sagittal sulcus to cover a total 
distance of up to 5.7mm over the dorsal cortical surface. Subpial demyelination was present at 
400µm anterior to and at the injection site in all rmMOG-immunised rats following 1µg 
LTα+IFNγ, and at 400µm posterior to the injection site in 2/3 animals. The observed trend for 
smaller areas of demyelination in the higher LTα dose group was not statistically significant 
(Figure 5. 3). For rmMOG-immunised cytokine-injected rats, up to approximately 50% of the 
cortical surface, including adjacent to the sagittal sulcus, was demyelinated at the level of the 
injection site. 
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 Figure 5. 2 Demyelination occurs only in MOG-DA rats following injection of LTα+IFNγ 
Demyelination and microglial activation were visualised at 7 days post-cytokine injection using IF for 
MOG and Iba1 respectively. No loss of MOG IF was observed  in IFA-immunised rats at 7 days after low 
(A) and high (B) dose cytokine injection, although DAPI+ cellular infiltrates were observed in the 
subarachnoid space in both dose groups. Loss of MOG IF, indicating demyelination, was observed in 
rmMOG-immunised rats after low (C) and high (D) dose cytokine injection, accompanied by 
subarachnoid infiltrates (E) and increased microglial activation (inset E). No loss of MOG IF was 
observed in naïve rats after the high dose injection, although subarachnoid infiltrates were observed (F, 
G). Very limited demyelination was observed in one rmMOG-immunised rat following injection of PBS 
0.1% BSA (H, J), but this was not observed in any other animals in the group. Scale bars: D = 500µm, 
E, G, J = 100µm. n=3 per group. 
rmMOG 0.5μg  LTα + 75ng IFNγ
IFA 0.5μg LTα + 75ng IFNγ
DAPI
Iba-1
MOG
IFA 1μg LTα + 75ng IFNγ
rmMOG 1μg LTα + 75ng IFNγ
A B
DC
Dii
rmMOG PBS
F GE
Naive 
LTα
+IFNγ
H J
rmMOG 1μg LTα + 75ng IFNγ rmMOG PBS
Naive LTα +IFNγ
Chapter 5 – Acute injection of LTα & IFNγ  155 
 
  
Figure 5. 3 Quantification of subpial demyelination following cytokine injection  
Areas of subpial demyelination (visualised by an absence of MOG IF) were quantified 7 days after 
injection of cytokines at 0 µm from the injection site, and at +400µm (anterior) and -400µm (posterior) 
from the injection site. Demyelination extended at least 400µm anterior and posterior from the injection 
site following injection of the low and high doses of cytokines, and was similar in extent at the 400µm 
anterior and posterior sites compared to the injection site. Data is presented as the mean ± SEM. 
Statistics: Kruskal-Wallis with Dunn’s multiple comparisons post-test.* = p=0.0352 vs. IFA / 0.5µg 
LTα+IFNγ in which no demyelination was observed. n=3 per group. 
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5.2.1.5 Loss of MBP in GMLs but no observable loss of axonal neurofilaments 
Loss of myelin was confirmed by IF for myelin basic protein (MBP), which appeared to be 
identical to MOG IF for all groups, with no loss observed in subpial areas in naïve no-surgery 
(Figure 5. 4 A) or rmMOG-immunised PBS injected (Figure 5. 4 B) control rats, or IFA-
immunised cytokine injected rats (Figure 5. 4 C), and MBP loss only observed in rmMOG-
immunised rats following cytokines (Figure 5. 4 D).  
IF for axonal neurofilaments (Nfil) and MOG revealed no observable loss of axons compared 
to naïve no-surgery control rats (Figure 5. 5 A-C) in rmMOG-immunised PBS-injected rats 
(Figure 5. 5 D-F), IFA-immunised cytokine-injected rats (Figure 5. 5 G-J), or in demyelinated 
lesions observed in rmMOG-immunised rats following cytokine injection (Figure 5. 5 K-M). 
Small numbers of demyelinated axons were observed in the corpus callosum closest to the 
subarachnoid space (Figure 5. 5 arrows in K). 
5.2.1.6 Observation of channels in infiltrates following injection of LTα+IFNγ  
The subarachnoid infiltrates formed following injection of LTα+IFNγ were observed to contain 
many channels of variable diameter, which were particularly obvious in the largest infiltrates 
(Figure 5. 2 E, Figure 5. 5 K). These channels ranged in size from approximately 10-150µm in 
diameter, and often took up a large proportion of the subarachnoid space. The diameter of 
individual channels was observed to change over a distance of approximately 400µm, but was 
consistent between adjacent sections, causing minimal variation to cell counts within infiltrates 
in the same animal.  
The number of channels per infiltrate was not quantified since it was too difficult to accurately 
quantify the number of channels/meningeal blood vessels present in the subarachnoid space 
in control animals which lacked infiltrates, so it was unfortunately not possible to determine 
whether the observed channels in infiltrates were newly formed, additional structures, or were 
simply more visible due to the presence of infiltrating cells. However, LTα has been shown to 
play a role in lymphangiogenesis, suggesting that these vessels may represent newly formed 
lymphatic channels (Mounzer et al., 2010). HEV formation has also been shown at sites of 
ectopic LTα expression so some of the smaller channels might be HEVs (Kratz et al., 1996). 
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 Figure 5. 4 Loss of MBP confirms loss of the myelin sheath in subpial GMLs 
MBP IF was observed to be identical to MOG IF in all groups. No loss of MBP in the cortex adjacent to 
the sagittal sulcus was observed in naïve no-surgery control rats (A), rmMOG-immunised rats following 
PBS injection (B), or IFA-immunised rats following cytokine injection. Loss of MBP IF in the cortex 
adjacent to the injection site confirmed loss of myelin in subpial areas in rmMOG-immunised rats 
following cytokine injection (D), and corresponded to the same areas in which loss of MOG IF was 
observed in adjacent sections. Sparse MBP IF was observed at the edge of subpial lesions (arrow in D). 
Scale bar: A = 50μm. n=3 per group.  
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Figure 5. 5 No observable loss of axonal neurofilaments in subpial GMLs 
Heavy neurofilaments in neuronal axons were identified by Nfil IF, with MOG IF as a marker for myelin 
in naïve no-surgery control rats (A-C). No loss of MOG or Nfil IF was observed in rmMOG-immunised 
rats following subarachnoid injection of PBS (D-F), or in IFA-immunised rats following LTα+IFNγ (G-H). 
Substantial loss of MOG in subpial areas in rmMOG-immunised rats following LTα+IFNγ (K-L) was not 
accompanied by any observable loss of Nfil IF (K-M). Scale bars: A = 250μm; B, C = 50µm. n=3 per 
group.  
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 5.2.1.7 Injection of LTα+IFNγ results in formation of B cell infiltrates 
Formation of dense cellular infiltrates in the subarachnoid space was observed 7 days after 
injection of 0.5µg or 1µg LTα+IFNγ in 100% of naïve animals (3/3), 50% of IFA control animals 
(3/6) and in 84% of rmMOG-immunised animals (5/6). Diffuse meningeal inflammation was 
observed in the remaining 50% of IFA controls (3/6) at this time-point.  
IF for the rat B cell marker CD79a revealed focal B cell-rich areas within all large infiltrates 
(Figure 5. 6. A, B). B cells within infiltrates were quantified in 3 adjacent tissue sections and 
the mean number per infiltrate was calculated. B cells were the most numerous cell type in all 
infiltrates, although this was a non-significant trend. A range of sizes of infiltrates was 
observed in animals that received 0.5µg LTα+IFNγ (Figure 5. 6 A-C). Although there was no 
clear dose response in B cell numbers between groups receiving 0.5µg or 1μg LTα+IFNγ, and 
B cell numbers quantified within groups were variable, a non-significant trend was observed 
towards increased B cell infiltration following injection of 1μg LTα+IFNγ in naïve (mean = 
423.80 ± 200.00 SEM) and rmMOG-immunised rats (mean = 402.00 ± 143.30; Figure 5. 6 D, 
E) compared to the lower dose groups (IFA 0.5μg LTα+IFNγ mean = 142.10 ± 69.97; MOG 
0.5μg LTα+IFNγ mean = 78.00 ± 36.72; Figure 5. 6 A-C, E).  
The relatively low number of infiltrating B cells in the IFA group following injection of 1μg 
LTα+IFNγ was completely unexpected (mean = 32.17 ± 17.75), since the batches of cytokines 
used for the IFA-immunised groups were the same ones used for the rmMOG-immunised 
groups. However, the amount of monastral blue tracer observed in 2 of the 3 IFA-immunised 
rats following injection of 1μg LTα+IFNγ was reduced compared to the remaining animal in the 
group and appeared to correlate with the decreased B cell counts in these 2 animals, 
suggesting a partial needle blockage during stereotaxic surgery. 
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 Figure 5. 6 CD79a+ B cells cluster in the subarachnoid space following LTα+IFNγ 
CD79a+ IF revealed distinct, densely packed, focal clusters of B cells within larger DAPI+ cellular 
infiltrates in the subarachnoid space of IFA- and rmMOG-immunised rats at 7 days after injection with 
the low (A,B,C) and high (D) dose of cytokines. Quantification of B cells in 3 adjacent sections per 
animal revealed non-significant trends towards increased B cell infiltration of the subarachnoid space 
following injection of the high dose (E). Scale bars: A, C, D, E = 100µm, B = 20µm. n=3 per group. 
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5.2.1.8 T cell areas within infiltrates 
CD4+ and CD8+ T cells, identified by IF, infiltrated the subarachnoid space following injection 
of 0.5µg or 1µg LTα+IFNγ (Figure 5. 7 A & C, and B & D respectively). T cells were quantified 
in the sagittal sulcus in three adjacent sections per animal and the mean of each cell type was 
calculated (Figure 5. 8 A, B). CD4+ cells were significantly increased in naïve rats following 
subarachnoid injection of 1µg LTα+IFNγ (mean = 131.30 ± 12.54; p=0.0333, Kruskal-Wallis 
with Dunn’s multiple comparisons post-test; Figure 5. 8 A), compared to naïve no-surgery 
control animals (mean = 2.11 ± 0.29). There were no statistically significant differences 
between CD4+ T cell numbers quantified in other groups, although a non-significant trend 
towards increased CD4+ numbers was observed in IFA-immunised rats following injection with 
0.5µg LTα+IFNγ (mean = 128.90 ± 79.72).  
There was a significant increase in CD8+ T cells in naïve rats following injection with 1µg 
LTα+IFNγ (mean = 223.10 ± 33.47; p=0.0187; Figure 5. 8 B) compared to the naïve no-
surgery control group. Non-significant trends towards increased CD8+ T cell numbers in the 
IFA-immunised 0.5µg LTα+IFNγ-injected group (mean = 98.89 ± 66.42), and rmMOG-
immunised rats following injection of 1µg LTα+IFNγ (mean = 52.78 ± 39.16) were also 
observed. Proportions of CD4+ and CD8+ T cells compared to CD79a+ B cells varied between 
groups, although CD79a+ B cells were the most numerous cell type in all groups (Figure 5. 8 
C). CD79a+ B cells were found in the greatest numbers in naïve and rmMOG-immunised rats 
following injection of 1µg LTα+IFNγ, compared to other cell types across the groups, although 
this difference was not statistically significant (Figure 5. 8 C). 
5.2.1.9 Organisation of T and B cell areas within infiltrates 
Basic organisation of infiltrates was observed following IF for CD4 and CD8 T cell markers on 
adjacent sections to those on which IF for the CD79a marker was performed. Segregation of T 
cells and B cells to different areas within infiltrates was particularly apparent in the densest 
infiltrates (Figure 5. 9 A-C). CD79a+ B cells were observed to cluster around the outer edge of 
cellular infiltrates, while CD4+ and CD8+ T cells were found in more central positions within 
infiltrates (Figure 5. 9 B and C respectively). A small number of B cells infiltrated the cingulate 
cortex parenchyma adjacent to the infiltrate, to a distance of less than 50µm lateral from the 
sagittal sulcus (Figure 5. 9 arrows in B), although the majority were confined to the sulcus. In 
contrast, CD4+ and CD8+ T cells did not infiltrate the parenchyma (Figure 5. 9 C).  
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 Figure 5. 7 Meningeal infiltration of CD4+ and CD8+ T cells following LTα+IFNγ  
CD4 and CD8 IF revealed variable numbers of T cells within the dense cellular subarachnoid infiltrates 
observed in IFA-(A, B) and rmMOG-immunised (C, D) rats following injection of the low (A, C) and high 
dose (B, D) of cytokines. T cells appeared to be scattered loosely throughout infiltrates, with no 
observable organisation, but were generally absent from areas in which B cell clusters had been 
observed in adjacent sections. Images are representative and inset images are magnifications of the 
boxed areas in images on the left. Scale bars: A- D = 500µm, inset scale bars = 100µm. n=3 per group. 
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 Figure 5. 8 Quantification of immune cell infiltration to the subarachnoid space  
CD79a+ B cells and CD4+ (A) and CD8+ (B) T cells were identified by IF and quantified within the 
subarachnoid space in 3 adjacent sections per animal. CD79a+ B cells were the most numerous cell 
type in all groups although this was not significant (C). Data is presented as the mean ± SEM. Statistics: 
Kruskal-Wallis with Dunn’s multiple comparisons post-test. * = p=0.0333 (CD4) or p=0.0187 (CD8) vs. 
naïve no-surgery control rats which did not receive cytokines. n=3 per group. 
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5.2.2 Time course experiment  
Following the dose response experiment, a time course experiment was carried out to 
determine the dynamics of pathology arising from injection of 1µg LTα+IFNγ in rmMOG-
immunised rats. Despite the lack of a clear dose response, the higher concentration of 1µg 
LTα+IFNγ was chosen for further studies, as the largest B cell infiltrates were observed in 
rmMOG-immunised rats at this dose. Rats received a subarachnoid injection of 1µg LTα+IFNγ 
at 20-22 days post-immunisation (dpi) with rmMOG and were culled at 3, 7, 14, or 21 days 
post subarachnoid injection (Figure 5. 10). 
5.2.2.1 Reduction of incidence of clinical EAE in rmMOG-immunised rats 
For this study female DA rats were immunised with 5µg rmMOG rather than the 10µg used 
previously. This was in order to reduce the number of animals that developed clinical EAE. 
The 5µg rmMOG dose has been previously shown to elicit an anti-MOG antibody response 
that is not significantly lower than animals immunised with 50µg rmMOG which develop clinical 
EAE (Gardner et al, 2013).  
Incidence of clinical EAE was reduced to 41% of rats (9/22) by immunisation with 5µg rmMOG 
(compared to 67% incidence following immunisation with 10µg rmMOG in the dose response 
experiment). Two rats (9%) developed clinical EAE and were culled prior to surgery due to 
having clinical symptoms which exceeded the inclusion criteria for stereotaxic surgery (score 
>3). All remaining rats underwent subarachnoid injection of cytokines. Five rats (23%) 
developed EAE prior to surgery but recovered following stereotaxic injection of cytokines and 
were subclinical at the cull date. Two rats (9%) developed clinical EAE following stereotaxic 
surgery and were culled at score >3.   
5.2.2.2 Accuracy of subarachnoid injections 
Accurate placement of subarachnoid injections was achieved in 50% of rats (10/20). An 
increase in the variation of animal weights contributed to decreased accuracy of injections in 
this experiment. As discussed previously, the accuracy of injections was limited by the 
anatomical variation in the coronal and sagittal sutures on the skull which was increased by 
the variation in body weight, hampering the precise localisation of the midline. As with the 
previous experiment, tissue was excluded from further analysis if monastral blue tracer was 
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observed in the cingulate cortex either side of the sagittal sulcus, although this exclusion 
criteria resulted in lower n numbers. 
5.2.2.3 Subpial demyelination is maximal at 7 days post-injection 
Subpial demyelination accompanied by microglial activation was observed at the injection site 
in 67% of MOG immunised rats (n=3) at 3 days post-subarachnoid injection of 1µg LTα+IFNγ 
(Figure 5. 11 arrows in A and B). MOG+ debris was observed in the extracellular spaces in 
lesions, but was very rarely observed in Iba1+ cells, although numerous activated microglia 
with short, thickened process were observed in demyelinated areas and at the lesion edge in 
close contact with MOG+ axons. Demyelination was also observed in 100% of rats at 7 and 14 
days post-injection (n=3 and n=2 respectively; Figure 5. 11 arrows in C-D, and E-F 
respectively). Areas of demyelination were more extensive at the 3 and 7 day time-points 
compared to those observed at day 14, and no quantifiable demyelination was observed at the 
21 day time-point (n=2; Figure 5. 11 G, H), indicating that remyelination was ongoing at the 14 
day time-point and complete by day 21. At the 14 day time-point, areas of subpial 
demyelination were small and located on the dorsal cortex and adjacent to the sagittal sulcus, 
in a similar pattern to that observed at the earlier time-points but less extensive, forming small, 
isolated lesions (Figure 5. 11 upper arrow in E) rather than a continuous ribbon of subpial 
demyelination. In some subpial areas at day 14 myelin was present but observably less dense 
compared to animals at day 21 or naïve no surgery control animals, and still accompanied by 
microglial activation (Figure 5. 11 lower arrow E and arrow in F), while in other areas 
remyelination appeared to be complete and indistinguishable from animals at day 21. Small 
numbers of MOG+ cell bodies were also observed in and adjacent to demyelinated subpial 
areas at day 14, indicative of ongoing remyelination. 
The area of subpial demyelination was quantified at the injection site, and at 400µm anterior 
(+) and posterior (-) to the injection site, and was found to be present at the anterior and 
posterior sites in 67% of rats (n=3) at 3 days, 100% of rats at 7 days and 50% of rats at 14 
days. Subpial demyelination was maximal at 7 days post-subarachnoid injection and was 
significantly increased above IFA controls at the injection site (p=0.0419, Kruskal-Wallis with 
Dunn’s multiple comparisons post-test; Figure 5. 12). Demyelination at all time-points was 
most extensive at the injection site, and the extent of demyelination at the anterior and 
posterior sites was greatest at 7 days post-injection compared to other time-points, although 
these trends were not statistically significant (Figure 5. 12). 
Chapter 5 – Acute injection of LTα & IFNγ  167 
 
 Figure 5. 11 Demyelination at 3, 7 and 14 days post-injection with 1µg LTα+IFNγ  
Iba1 and MOG IF revealed microglial activation and demyelination respectively in rmMOG-immunised 
rats culled at 3 (A-B), 7 (C-D) and 14 (E-F) days post-cytokine injection but remyelination was complete 
by 21 days (G-H). Demyelination was limited at 14 days compared to earlier time-points but was present 
in small subpial areas (top arrow in E). In other subpial areas at day 14 myelin was present but 
observably reduced in density and accompanied by microglial activation (lower arrow in E and arrow in 
F) compared to animals at day 21 (H). Images are representative and images on the right are 
magnifications of the boxed areas in images on the left. Scale bars: A, C, E, G = 500µm, B, D, F, H = 
100µm. n=2-3 per group. 
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 Figure 5. 12 Time-course of subpial demyelination at 3, 7, 14 and 21 days. 
Areas of subpial demyelination were quantified at 0 µm (at the injection site), and at +400µm (anterior) 
and -400µm (posterior) from the injection site. Demyelination was maximal at the injection site at 7 days 
post-subarachnoid injection of cytokines. Data is presented as the mean ± SEM. Statistics: Kruskal-
Wallis with Dunn’s multiple comparisons post-test. * = p=0.0419 vs. IFA LTα+IFNγ at 7 days in which no 
demyelination was observed. n=2-3 per group. 
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5.2.2.4 Infiltration of B cells is maximal at 7 days post LTα+IFNγ 
Immunofluorescence for CD79a on sections adjacent to the injection site revealed infiltration of 
CD79a+ B cells into the subarachnoid space to form large cellular infiltrates at 3, 7 and 14 
days post-subarachnoid injection with 1µg LTα+IFNγ (Figure 5. 13 A, B, C). Relatively small 
numbers of B cells appeared to be scattered throughout the large cellular infiltrates observed 
at the 3 day time-point (mean = 64.11 ± 22.08 SEM; Figure 5. 13 A; Figure 5. 14). They were 
also observed forming small clusters at the outer edges of the subarachnoid space, close to 
the edge of the cortex, but did not appear to penetrate into the parenchyma (Figure 5. 13 A 
inset).  
Infiltration of CD79a+ B cells was maximal at 7 days post-injection compared to other time-
points, although this trend was not significant (mean = 305.30 ± 136.70; Figure 5. 14). B cells 
were observed in large numbers, organised into dense clusters within the subarachnoid space 
and sagittal sulcus (Figure 5. 13 B). Interestingly, the overall size of the infiltrates at 7 days 
(indicated by the number of DAPI+ nuclei and the width of the subarachnoid space) was 
observed to be slightly smaller compared to infiltrates observed at the 3 day time-point in spite 
of the marked increase in the number of B cells.  
The numbers of CD79a+ B cells decreased sharply by 14 days post-injection and varied 
markedly between animals (mean = 56.00 ± 53.33; Figure 5. 14). A dense cluster of B cells 
was observed surrounding a possible vessel within the sagittal sulcus at this time-point (Figure 
5. 13 C). CD79a+ B cells were present in very small numbers or completely absent from the 
subarachnoid space by the 21 day time-point (mean = 10.00 ± 1.67; Figure 5. 13 D; Figure 5. 
14). 
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 Figure 5. 13 Meningeal infiltration of B cells following cytokine injection  
CD79a+ IF revealed low numbers of CD79a+ B cells scattered loosely throughout infiltrates in the 
subarachnoid space at 3 days post-injection, particularly close to the cortical parenchyma (arrows in A), 
forming small clusters (inset A). B cell infiltration was maximal at day 7 (B) when multiple dense clusters 
were observed in discrete areas of the cellular infiltrates within the sagittal sulcus (arrows in B and B 
inset). CD79a+ clusters were reduced in size at day 14 (C) and limited numbers or no B cells were 
observed at day 21. Scale bars: B = 100µm, inset = 20µm. n=2-3 per group. 
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 Figure 5. 14 CD79a+ B cell infiltration was maximal at 7 days post-cytokine injection  
CD79a+ B cells were identified by IF and quantified in 3 sections per animal adjacent to the injection 
site. No B cells were observed in naïve no-surgery control rats or in rmMOG-immunised rats following 
subarachnoid injection of PBS. B cells were observed to infiltrate the subarachnoid space following 
injection of 1µg LTα + 75ng IFNγ in rmMOG-immunised rats, and numbers were maximal at 7 days 
post-cytokine injection. n=2-3 per group. 
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5.2.2.5 CD4+ and CD8+ T cells are present at all time-points 
CD4+ and CD8+ T cells were scattered throughout the subarachnoid space at all time-points 
(Figure 5. 15 A, B, C, D). Infiltration of CD8+ T cells into the subarachnoid space was maximal 
at the 3 day time-point, and cells were observed throughout the large cellular infiltrates with no 
observable organisation (Figure 5. 15 A). The mean number of CD8+ cells was significantly 
increased in rmMOG-immunised rats at 3 days post-cytokine injection (mean = 71.44 ±3 6.95; 
p=0.0165; Figure 5. 15 F) compared to naïve no-surgery control rats. CD4+ T cells were also 
present throughout the infiltrates and numbers appeared to be increased in rmMOG-
immunised rats after cytokine injection compared to control groups, although this trend was 
not significant (Figure 5. 15 E). 
The number of infiltrating CD4+ T cells was maximal at 7 days post-subarachnoid injection 
although this was not significant compared to the other time-points (mean = 53.56 ± 14.39; 
Figure 5. 15 B). In contrast, the number of CD8+ T cells approximately halved at 7 days, 
compared to the 3 day time-point (Figure 5. 15 B, F). Limited organisation of immune cell 
types within the subarachnoid space and sagittal sulcus was observed at the 7 day time-point, 
as T cells were observed in areas from which B cells were absent, and vice versa (Figure 5. 
15 B).  
CD4+ T cell numbers were observed to decline at days 14 and 21 post-injection compared to 
the observed peak at the 7 day time-point, and cell numbers at day 21 were similar to those at 
day 3, although this reduction was not statistically significant (Figure 5. 15 C, D, E). The 
numbers of infiltrating CD8+ T cells was decreased at the 14 and 21 day time-points compared 
to the peak at day 3, although the difference was not significant (Figure 5. 15 C, D, F).  
A non-significant trend towards increased lymphocyte infiltration following injection of LTα and 
IFNγ was observed at all time-points (Figure 5. 16). Proportions of B and T cells were 
approximately equivalent at the 3 day time-point. B cells were observed to increase to give an 
approximate 5:1 ratio compared to T cells at the 7 day time-point. The ratio decreased at 14 
days and B cells were virtually absent at 21 days, in contrast to CD4 T cells which were 
present in similar numbers from day 3 to day 21.  
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 Figure 5. 15 Diffuse infiltration of CD4+ and CD8+ T cells post-LTα+IFNγ 
IF for CD4 and CD8 revealed infiltration of T cells into the subarachnoid space in rmMOG-immunised 
rats at 3 (A), 7 (B), 14 (C) and 21 (D) days after injection with 1µg LTα + 75ng IFNγ. Few T cells were 
observed in naïve rats, or rmMOG-immunised rats that received PBS 0.1%BSA (MOG PBS). T cells 
were diffusely scattered within subarachnoid infiltrates and were absent from CD79a+ B cell areas 
identified in adjacent sections. Little variation in CD4+ T cell infiltration was observed between day 3 
and day 21 (E), but CD8+ T cell numbers were significantly increased compared to naïve rats at 3 days 
post-cytokine injection (F). Data is presented as the mean ± SEM. Statistics: Kruskal-Wallis with Dunn’s 
multiple comparisons post-test. * = p=0.0165 vs. naïve no-surgery control group. Scale bar: B = 100μm. 
n = 2-3 per group. 
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Figure 5. 16 Time course of immune cell infiltration after injection of cytokines  
IF revealed few CD4+ and CD8+ T cells, and no CD79a+ B cells, in the subarachnoid space of naïve 
no-surgery control rats (Naïve), and rmMOG-immunised rats 7 days post-subarachnoid injection with 
PBS (MOG PBS). Increased subarachnoid infiltration was observed in rmMOG-immunised rats at 3, 7, 
14 and 21 days after subarachnoid injection with 1µg LTα + 75ng IFNγ. CD8+ T cell numbers were 
significantly increased compared to naïve rats at 3 days post-cytokine injection (p=0.0165). Data is 
presented as the mean ± SEM. Statistics: Kruskal-Wallis with Dunn’s multiple comparisons post-test. 
n=2-3 per group. 
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5.3 Discussion 
The current study was designed to test the hypothesis that raised concentrations of the pro-
inflammatory cytokines LTα and IFNγ in the CSF can result in pathology of the underlying 
cortical GM (Reynolds et al., 2011). To this end, we adapted a targeted EAE model that has 
been used previously to investigate the effect of raised concentrations of TNF and IFNγ in the 
CSF within the subarachnoid space (Gardner et al., 2013).  
5.3.1 Subpial demyelination following injection of LTα+IFNγ   
The pattern of subpial demyelination observed in rmMOG-immunised rats following 
subarachnoid injection of LTα and IFNγ was consistent with that observed in previous studies 
in vivo, and confirms that cytokines within the CSF can induce subpial demyelination in the 
underlying cortical GM, but only in the presence of an anti-MOG immune response (Merkler et 
al., 2006b; Magliozzi et al., 2007; Magliozzi et al., 2010; Reynolds et al., 2011; Gardner et al., 
2013). Demyelination was observed exclusively in rmMOG-immunised rats injected with 
cytokines and was entirely absent in IFA-immunised control rats which received identical 
cytokine injections, in keeping with other studies (Kerschensteiner et al., 2004; Merkler et al., 
2006b; Gardner et al., 2013; Rodriguez et al., 2014). This suggests that demyelination was not 
due to direct acute cytokine cytotoxicity to oligodendrocytes, but required the development of a 
specific anti-myelin autoimmune response, and was dependent on immune cell priming 
against a component of the myelin sheath in the periphery. LTα and IFNγ both induce 
apoptosis in oligodendrocytes in vitro, although the data for IFNγ cytotoxicity is conflicting 
(Selmaj et al., 1991a; Selmaj et al., 1991c; Mclaurin et al., 1995; Vartanian et al., 1995). The 
lack of direct cytokine cytotoxicity observed in the current may result from differences in 
cytokine concentrations used in vitro, compared to the concentrations that diffuse through the 
pial surface to reach cortical oligodendrocytes in vivo. In addition, cytokine concentrations are 
assumed to decrease locally in this acute in vivo model, as the injected cytokines diffuse from 
the injection site and are subject to CSF flow within the subarachnoid space.  
Interestingly, although subpial demyelination was absent in IFA-immunised rats following 
cytokine injection, microglial activation was observed, limited to the GM immediately 
surrounding the sagittal sulcus. This indicates that an anti-MOG immune response is not 
required for limited microglial activation in these animals, and suggests a direct effect of 
cytokine injection. However, a pre-existing anti-MOG response, and/or the demyelination 
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resulting from cytokine injection in rmMOG-immunised rats, appears to potentiate this effect, 
since much more extensive microglial activation was observed throughout the GMLs in the 
rmMOG-immunised group.  
The subpial lesions observed in the current study were reminiscent of type III lesions 
described in MS, being of a remarkably consistent depth relative to the pial surface and 
extending only through cortical layers I-IV, leaving layer V intact (Peterson et al., 2001). No 
quantifiable demyelination or microglial activation was observed in the corpus callosum, 
although a very limited number of demyelinated axons (constituting an area too small to be 
quantified) were observed in the outermost part of this structure, closest to the subarachnoid 
space, suggesting that demyelination does occur but not to the same extent as in the adjacent 
GM. Possibly the density of the corpus callosum may prevent sufficient diffusion of 
demyelinating factors from the CSF into this structure in this model of acute inflammation, but 
it remains to be seen if more chronic inflammation would induce quantifiable demyelination or 
microglial activation.  
Intracortical perivascular lesions deep within the cortex, associated with local demyelination 
and extensive microglial activation, were observed in one animal 7 days after injection of the 
high cytokine dose. These lesions featured many Iba1+ cells with short, thickened processes, 
suggestive of local activation of surrounding microglia rather than infiltrating monocytes 
forming perivascular cuffs. Tracer studies suggest that penetration of solutes from the 
subarachnoid CSF into the cortical parenchyma depends largely on molecular weight (Iliff et 
al., 2012). Albumin with a molecular weight of 66kDa (similar to 55.8kDa homotrimeric LTα) is 
able to cross the pia mater and move between the perivascular spaces and the subarachnoid 
space (Ichimura et al., 1991). Therefore cytokines injected into the subarachnoid space might 
also diffuse into the perivascular spaces, resulting in local activation of microglia and providing 
a possible mechanism for formation of subpial and perivascular lesions as seen in the current 
and previous studies (Merkler et al., 2006b).  
5.3.2 Remyelination and lack of neuronal loss  
Subpial demyelination observed in rmMOG-immunised rats in the current study at 7 days after 
injection of LTα and IFNγ was extensive, but no quantifiable demyelination was observed at 
day 21, suggesting that remyelination occurred. Evidence of remyelination in a targeted EAE 
model was shown in a previous study using electron microscopy to determine the ratio of axon 
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to fibre diameter (g-ratio). The g-ratio of myelinated fibres close to the injection site was 
significantly increased at 14 days post-intracortical cytokine injection compared to non-injected 
controls indicating reduced thickness of the myelin sheath, which is suggestive of 
remyelination (Merkler et al., 2006b).  
Since remyelination has been previously studied in targeted cortical lesion models it was 
therefore not the focus of the current study, but the time-course of remyelination, which was 
observed by us to be complete within 21 days post-cytokine injection, is in keeping with 
previous findings (Merkler et al., 2006b; Gardner et al., 2013; Rodriguez et al., 2014). The 
capacity of the cortex for repeated remyelination within a maximum of 3 weeks following 
experimental demyelination was demonstrated by repeated intracortical injection of TNF and 
IFNγ, which did not result in chronic demyelination or loss of Olig2+ OPCs even after 4 cycles 
of demyelination and remyelination (Rodriguez et al., 2014). The lack of attenuation in 
remyelination capacity is at odds with the eventual failure of remyelination observed in MS 
(Franklin, 2002), and may be due to the acute nature of the demyelinating stimulus in vivo ; the 
21 day interval may have allowed time for the dissipation of pro-inflammatory cytokines and 
the resolution of inflammation, as was also observed in the current study, in contrast to the 
chronic meningeal inflammation suggested to occur in SPMS.  
Our finding that axonal density was not observably altered between GMLs in rmMOG-
immunised rats following cytokine injection, and NAGM in IFA-immunised rats, is consistent 
with the lack of significant neuronal loss induced by cytokine injection in previous studies 
(Merkler et al., 2006b; Gardner et al., 2013). This contrasts to findings in SPMS, where severe 
meningeal inflammation is associated with a gradient of neuronal loss, which is most 
pronounced in the cortical layers closest to the meninges (Magliozzi et al., 2010). We suggest 
that the lack of resemblance to chronic demyelination in SPMS in these models is due to lack 
of a sustained inflammatory milieu within the CSF that has been postulated to drive GM 
pathology in SPMS.  
5.3.3 Possible mechanisms of demyelination 
5.3.3.1 Humoral immunity and B cells  
Previous experiments have studied the mechanisms of demyelination following injection of 
TNF and IFNγ in rmMOG-immunised rats in more detail than was feasible in the current study 
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(Merkler et al., 2006b; Gardner et al., 2013). However B cell numbers peaked at 7 days post-
cytokine injection in the current study, in line with the maximum extent of demyelination in 
rmMOG-immunised rats, indicating a role in the pathogenesis of GMLs in this model, as has 
been suggested in MS (Archelos et al., 2000; Bar-Or et al., 2010; Reynolds et al., 2011). 
These cells were observed to form tight clusters, in contrast to their more scattered 
appearance at the 3 day time-point, possibly indicating progressive organization of these cells 
within the infiltrates. B cells were the most numerous cell type in meningeal infiltrates, in 
keeping with the B cell rich nature of TLOs observed in F+SPMS (Serafini et al., 2004; 
Magliozzi et al., 2007), and in contrast to the previous study when relatively few B cells were 
observed, suggesting that LTα has different effects on immune cell recruitment to the CNS 
compared to TNF (Gardner et al., 2013). This view is supported by the finding that infiltrates 
formed in the kidneys of RIPLT mice (which ectopically express LTα in the proximal 
convoluted kidney tubules) consist of B and T cells in a 3:1 ratio (Kratz et al., 1996; Sacca et 
al., 1998), while B cells constitute less than 50% of the infiltrates formed in RIPTNF mice 
(Picarella et al., 1993). In the current study the proportions of B cells compared to T cells 
varied between groups and time-points, and no clear overall trend in proportions was 
observed.  
The lack of demyelination observed in IFA-immunised and naïve animals following LTα and 
IFNγ injection, in spite of the presence of meningeal infiltrates within the subarachnoid space, 
suggests that demyelination in this model requires priming of the immune response in the 
periphery, and the development of a humoral response. Antibody- and complement-mediated 
mechanisms of demyelination are implicated in the pathogenesis of MS and EAE. Deposition 
of complement components and immunoglobulin (Ig) on myelin sheaths in MS lesions has 
been described (Storch et al., 1998a; Archelos et al., 2000; Lucchinetti et al., 2000; Sadaba et 
al., 2012), although the role of complement in GMLs is controversial, as it has been noted to 
be less frequently observed in cortical GMLs compared to WMLs (Brink et al., 2005). 
Deposition of Ig and complement component 9 (C9) has also been observed on degenerating 
myelin sheaths and macrophages in active spinal cord lesions in MOG-EAE DA rats (Storch et 
al., 1998b). C9 and Ig were observed, albeit transiently, deposited on myelin sheaths at the 
leading edge of GMLs in targeted EAE models (Merkler et al., 2006b; Gardner et al., 2013), 
suggesting that this mechanism may contribute to the demyelination observed in the current 
study.  
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B cells have also been suggested to play a role in the pathogenesis of MS through abnormal 
secretion of cytokines. B cells can secrete IFNγ (Harris et al., 2005), and B cells isolated from 
RRMS patients exhibit abnormal and exaggerated secretion of LTα and TNF in response to 
activation in the presence of IFNγ, when compared to B cells from healthy controls (Bar-Or et 
al., 2010). Interestingly, B cell secretion of LTα is crucial for formation of germinal centres 
(GCs) and FDC clusters in the spleen (Fu et al., 1998), suggesting that B cell clusters could 
promote formation of GCs within the meninges, as have been observed in F+SPMS cases 
(Serafini et al., 2004; Magliozzi et al., 2007; Howell et al., 2011). Unfortunately, lack of a 
suitable antibody compatible with rat tissue for IF labeling of FDCs, and lack of time to 
investigate other markers of GCs (e.g. plasmablasts/plasma cells), precluded further 
characterization of the subarachnoid infiltrates in the current study to determine if they 
represent TLOs with functional GCs. 
The effect of B cell-secreted LTα and TNF on the activation and proliferation of pro-
inflammatory T cells may play a crucial role in TLOs, or in lesions, where the presence of Th1 
cytokines including IFNγ may result in increased LTα production by B cells which may 
potentiate T cell-mediated inflammation and tissue damage by increasing T cell proliferation 
and production of Th1 and Th17 cytokines. This may also lead to formation of a positive 
feedback loop, where IFNγ produced by T cells may alter B cell secretion of cytokines 
following activation, which increases proliferation and IFNγ production by T cells (Harris et al., 
2005). In rmMOG-immunised rats, autoreactive B and T cells within meningeal infiltrates may 
secrete different molecules to cells in infiltrates in IFA-immunised rats, which may underlie the 
presence of demyelination only in rmMOG-immunised rats despite infiltrate formation in IFA-
immunised groups.  
In addition, the ability of B cells to function as antigen presenting cells (APCs) and activate T 
cells (Constant et al., 1995; Rodriguez-Pinto and Moreno, 2005) is suggested to be an 
important mechanism of B cell contribution to disease activity in MS, since depletion of B cells 
in RRMS decreases CD4+ and CD8+ T cell proliferation in the periphery and T cell numbers in 
the CSF (Bar-Or et al., 2010). Infiltrates of B cells in rmMOG-immunised rats may therefore 
contribute to demyelination by activating MOG-primed T cells, while no such activation would 
occur in IFA-immunised rats, perhaps explaining the lack of demyelination in IFA-immunised 
rats despite infiltrate formation.  
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5.3.3.2 T cells  
Consistent with previous studies, injection of pro-inflammatory cytokines induced infiltration of 
both CD4+ and CD8+ T cells to the subarachnoid space and meninges, with minimal 
infiltration of subpial GMLs (Gardner et al., 2013) in keeping with studies on MS tissue 
(Peterson et al., 2001; Frischer et al., 2009; Magliozzi et al., 2010).  
T cell activation by B cells is sufficient for the induction of EAE, in the absence of autoantibody 
production (Jagessar et al., 2012; Molnarfi et al., 2013). Although T cells were not observed 
infiltrating the parenchyma in the current study, suggesting that direct T cell involvement in 
demyelination is not a feature of this model, production of soluble factors by reactivated MOG-
primed T cells may contribute to the increased activation of microglia and demyelination 
observed in rmMOG-immunised compared to IFA-immunised rats following cytokine injection. 
This suggestion is supported by the spatial and quantitative association of meningeal T cells 
with the extent of subpial demyelination in MOG-EAE marmosets, accompanied by little T cell 
cortical infiltration, suggesting that the pathogenic effect of these cells may be due to cytokine 
secretion rather than direct cytotoxicity (Lovett-Racke et al., 2011; Kramann et al., 2014). Both 
T cell types are capable of secreting pro-inflammatory cytokines, including IFNγ and LTα 
(Sonobe et al., 2007; Dittel, 2008; Zhu et al., 2010). Furthermore, it has been shown that 
reactivation of autoreactive CD4+ T cells by APCs surrounding meningeal vessels results in a 
strong upregulation of IFNγ expression, together with other chemokines and matrix 
metalloproteinases, facilitating increased meningeal infiltration (Bartholomaus et al., 2009; 
Kivisakk et al., 2009). In the current study however, meningeal infiltrates were not significantly 
increased in rmMOG-immunised animals, suggesting that although cytokine secretion by 
autoreactive T cells may contribute to microglial activation and demyelination, it does not 
appear to significantly increase meningeal infiltration in this model.   
5.3.3.3 Microglia/macrophages 
In the current study macrophages were not quantified in the subarachnoid infiltrates, but were 
observed using Iba1 IF surrounding the injected monastral blue tracer and diffusely scattered 
within the infiltrates. The majority of cells within the infiltrates that were not T or B cells were 
observed to be Iba1+ cells. The proportion of macrophages to T and B cells was observed to 
be highest at day 3 after cytokine injection, in keeping with the observations of previous 
studies (Merkler et al., 2006b; Gardner et al., 2013).  
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Following injection of LTα and IFNγ activated microglia retaining short, thickened processes 
were observed throughout all subpial GMLs in rmMOG-immunised rats, suggesting local 
proliferation and a role in GML pathogenesis in this model. Microglial activation following 
cytokine injection is consistent with previous studies that demonstrated highly activated 
microglia in close proximity to myelin sheaths in the GM, and at the leading edge of lesions 
(Merkler et al., 2006b; Gardner et al., 2013). Localisation of microglia at the leading edge of 
lesions was not observed to the same extent in the current study, with pronounced microglial 
activation being observed more evenly throughout GML areas than has been previously 
reported (Gardner et al., 2013). Consistent with the observations of the current study, CD68+ 
and MHC II+ activated microglia have also been described within GMLs in MS and also in 
NAGM, and activation of microglia is associated with overlying meningeal inflammation 
(Peterson et al., 2001; Kutzelnigg et al., 2005; Magliozzi et al., 2007; Magliozzi et al., 2010; 
Howell et al., 2011).  
Secretion of pro-inflammatory cytokines by microglia may contribute to the inflammatory milieu 
of the CNS and lead to oligodendrocyte death via indirect cytotoxicity. Microglia are a source 
of LTα, and it is suggested that Th1 cytokines within the CNS could induce local secretion of 
LTα, leading to death of the surrounding oligodendrocytes (Cannella et al., 1997; Lisak et al., 
2006). Stimulation of microglia with IFNγ results in upregulation of constitutive expression of 
TNFR1 and TNFR2 (Dopp et al., 1997). IFNγ also causes upregulation of TNF expression by 
microglia, which is suggested to induce formation of a positive feedback system, where 
microglial TNF acts in an autocrine manner to further increase TNF production, providing a 
possible mechanism for long-term chronic activation (Kuno et al., 2005; Welser-Alves and 
Milner, 2013). TNF stimulation of microglia was also shown to increase expression of other 
pro-inflammatory products of microglial activation, including IL-6, NO and ROS (Kuno et al., 
2005). In addition, TNF is known to upregulate TNFR1 expression only on oligodendrocytes 
and is directly cytotoxic, and so TNF expressed by microglia may contribute to cell death and 
demyelination in this model (Selmaj et al., 1991c; Dopp et al., 1997).  
In the current study microglial activation was observed to be most extensive in rmMOG-
immunised rats at 7 days following cytokine injection, coinciding with the peak of 
demyelination, although microglial activation was also observed surrounding the subarachnoid 
space in IFA rats (Gardner et al., 2013). This suggests that activation of microglia by injection 
of cytokines was not sufficient to elicit demyelination in IFA animals and that an anti-myelin 
humoral response or the presence of activated MOG-specific immune cells was required. It 
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also suggests that in MOG immunised animals, further microglial activation occurred, possibly 
due to production of cytokines by reactivated immune cells within the subarachnoid infiltrates.  
5.3.4 Role of LTα in infiltrate formation  
The presence of large, partially organised infiltrates of B and T cells within the subarachnoid 
space following injection of LTα and IFNγ in both IFA- and rmMOG-immunised rats in the 
current study resembled the severe meningeal inflammation observed in F+SPMS cases. The 
presence of organised infiltrates of immune cells resembling ectopic lymphoid follicles within 
the meninges of F+SPMS cases is associated with increased severity of MS, including a 
younger age at disease onset and death, more extensive cortical GMLs and increased 
microglial activation compared to F-SPMS cases lacking these structures (Serafini et al., 2004; 
Magliozzi et al., 2007; Magliozzi et al., 2010; Howell et al., 2011). The predominance of 
subpial lesions (resembling type III) observed in the current study is also supported by findings 
from SPMS tissue, where approximately 70% of GMLs found in F+SPMS cases in one study 
were type III, representing a 5.3 fold increase, compared to F-SPMS cases which showed no 
predominance of lesion type (Magliozzi et al., 2007). 
The formation of dense subarachnoid infiltrates following injection of LTα and IFNγ is in 
keeping with studies of ectopic LTα expression (Kratz et al., 1996; Sacca et al., 1998). 
Although organisation of B and T cell areas was less apparent in the current study compared 
to the ectopic expression studies (Kratz et al., 1996), B cells were observed to infiltrate and 
form dense clusters in different areas to those occupied by CD4+ and CD8+ T cells. The lack 
of distinct organisation in the current study may be due to the movement of CSF within the 
subarachnoid space. The kidney parenchyma, in which infiltrates formed in the ectopic 
expression studies, may have supported increased cell type segregation and infiltrate 
structure. 
The large infiltrates observed in the current study are in contrast to the relatively limited diffuse 
meningeal inflammation observed following TNF and IFNγ (Gardner et al., 2013). Infiltrate 
formation following cytokine injection in IFA-immunised and naïve rats suggests that the 
recruitment of cells to the CNS in this model does not require an autoimmune response and is 
entirely dependent on the action of LTα and IFNγ on the BBB and blood-CSF barrier. IFNγ 
secreted at the site of inflammation results in dilation of local blood vessels, upregulation of 
chemokines and adhesion molecules, and diapedesis of leukocytes across the endothelium 
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(Hou et al., 1994; Schroder et al., 2004), while LTα induces increased expression of VCAM-1, 
ICAM, MAdCAM and E-selectin in mouse endothelial cells in vitro (Cuff et al., 1998; Weiser et 
al., 2007). A recent study showed no difference between the cellular signalling, or ability to 
induce apoptosis or necroptosis, following binding of LTα or TNF to TNFR1, and concluded 
that differences in the effects of the ligands may be due to differential regulation and 
expression, LTα signalling through its alternative receptor HVEM, or formation of heterotrimers 
with LTβ. However, IFNγ has been shown to have a significant synergistic effect when 
combined with LTα on the expression of a range of adhesion molecules expressed by 
transformed mouse brain endothelial cells in vitro (Weiser et al., 2007). This synergy was not 
observed with TNF and IFNγ, thus providing a possible explanation for the increased 
infiltration of cells to the subarachnoid space following injection of LTα compared to TNF with 
IFNγ (Weiser et al., 2007). 
A striking feature of the large infiltrates formed following LTα and IFNγ injection were the many 
channels of variable diameter within infiltrates, some of which appeared to be large dilated 
vessels similar to those described by Perros et al., (2012) in pulmonary TLOs. Formation of 
lymphatic vessels has been described in TLOs formed at sites of ectopic LTα expression 
(Mounzer et al., 2010). Ectopic expression of LTα has also been shown previously to induce 
the expression of adhesion molecules associated with HEVs, including MAdCAM-1 and PNAd 
in vivo (Kratz et al., 1996; Drayton et al., 2003) and angiogenesis of HEVs has been 
suggested to occur at sites of ectopic LTα expression (Kratz et al., 1996). Unfortunately the 
MAdCAM-1 and PNAd antibodies for high endothelial venules proved impossible to optimise 
for use on the fixed frozen rat tissue available in the current study.  
Together our data suggests that infiltrate formation in itself is not pathogenic in this acute 
model, unless the infiltrating cells are primed to be autoreactive to MOG by peripheral MOG-
immunisation. It remains to be seen whether chronic infiltrate formation in IFA-immunised or 
naïve animals might result in demyelination through non-specific effects of a pro-inflammatory 
environment in the CSF on the underlying GM. In the following chapter we investigated the 
use of lentiviral vectors to induce chronic inflammation in this model to attempt to answer this 
question.    
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5.4 Conclusions 
The current study shows that injection of LTα and IFNγ into the subarachnoid space of female 
DA rats previously immunised with rmMOG is sufficient to induce formation of large meningeal 
infiltrates, accompanied by microglial activation and demyelination in the underlying GM. The 
pathology observed following cytokine injection, including immune cell infiltration, formation of 
B cell infiltrates in the meninges, and demyelination, is consistent with pathology described 
previously in MS subpial GMLs. We conclude that the model is a useful tool for further 
research into pathogenic mechanisms involved in cortical demyelination driven by meningeal 
inflammation, as is postulated to occur in SPMS. Cortical pathology was shown to resolve 
within 21 days in the current study, prompting investigation of alternative methods of inducing 
chronic meningeal inflammation, to increase the relevancy of this model to the pathology 
observed in human SPMS. In the following chapter, we will investigate subarachnoid injection 
of a lentiviral vector expressing LTα to induce chronic meningeal inflammation.  
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6.1 Introduction 
6.1.1 Chronic meningeal inflammation and demyelination in SPMS  
Progressive MS is characterised by increased cortical GM pathology, which includes 
widespread cortical demyelination, axonal degeneration, neuronal and glial cell loss and a 
reduction in synaptic density, and is thought to be a major driver of the accumulation of 
disability (Peterson et al., 2001; Kutzelnigg et al., 2005; Wegner et al., 2006; Magliozzi et al., 
2007; Magliozzi et al., 2010). Subpial demyelinated lesions account for up to 70% of GMLs 
and may extend over multiple gyri (Peterson et al., 2001; Bo et al., 2003l). In approximately 
40% SPMS cases (termed F+SPMS), subpial demyelination is associated with significant 
neuronal loss in cortical layers I-IV and the presence of organised inflammatory infiltrates in 
the meninges, suggested to be TLOs (Magliozzi et al., 2007; Magliozzi et al., 2010; Howell et 
al., 2011). The correlation between neuronal loss, organisation of meningeal inflammation and 
accumulating disability suggests that chronic GM pathology in SPMS contributes to increasing 
cognitive, sensory and motor decline during progressive disease. 
Evidence of remyelination has been demonstrated in approximately 80% of WMLs from early 
MS cases, but is observed significantly less often in WMLs from chronic MS cases, with a 
corresponding increase in the number of completely demyelinated chronic MS lesions (40%) 
compared to early MS (Goldschmidt et al., 2009). Remyelination was observed in 95% of 
GMLs in chronic MS cases and was more extensive in GMLs compared to WMLs, indicating a 
high propensity of cortical tissue for remyelination (Albert et al., 2007). The increased capacity 
for remyelination in the cortex compared to WMLs has been suggested to be due to a lack of 
reduction in progenitor cell density GMLs in contrast to chronic WMLs, reduced astrogliosis 
and lower expression of extracellular matrix molecules which inhibit oligodendrocyte precursor 
cell (OPC) differentiation (Chang et al., 2012). However, chronic demyelinated cortical lesions 
accumulate over time and are characteristic hallmarks of progressive MS, indicating that 
remyelination eventually fails (Kutzelnigg et al., 2005). The failure of this repair process is 
suggested to be due to a failure of OPC differentiation and maturation, resulting in chronic 
demyelination, rather than due to a lack of progenitors (Franklin, 2002; Franklin and Ffrench-
Constant, 2008), since OPCs are still present in chronic MS lesions, but fewer differentiating 
OPCs are observed compared to early MS lesions (Reynolds et al., 2002; Kuhlmann et al., 
2008).  
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6.1.2 Targeted EAE models lack chronic cortical pathology 
EAE models fail to accurately model the chronic cortical pathology observed in SPMS. In the 
previous chapter and in previous studies, subarachnoid injection of cytokines induced subpial 
demyelination which was fully remyelinated within 3 weeks, in line with the resolution of 
demyelinating pathology observed in other studies (Penderis et al., 2003; Merkler et al., 
2006b; Gardner et al., 2013). Repeated intracortical administration of pro-inflammatory 
cytokines or injection of ethidium bromide over the brainstem also failed to elicit chronic 
demyelination (Penderis et al., 2003; Rodriguez et al., 2014). The lack of neuronal loss and 
absence of a significant reduction in oligodendrocyte precursor numbers observed in these 
models are in contrast to the chronic pathology observed in SPMS and more representative of 
early MS (Merkler et al., 2006b; Gardner et al., 2013; Rodriguez et al., 2014). In the current 
study we aimed to evaluate the use of lentiviral vectors expressing LTα to induce chronic 
meningeal inflammation and determine if the chronic presence of pro-inflammatory cytokines 
in the subarachnoid space would induce chronic demyelination. 
6.1.3 Lentiviral vectors 
The use of lentiviral (LV) vectors for therapy and research has received interest due to their 
low immunogenicity, ability to transduce both dividing and non-dividing cells, and to result in 
long term stable expression of the gene of interest due to insertion into the host genome 
(Naldini et al., 1996; Jakobsson and Lundberg, 2006; Segura et al., 2013). LVs are spherical 
particles between 80-120nm in diameter, composed of 2 single strands of RNA 7-12 kb in 
length. The LV genome is organised around the gag, pol and env genes, which encode the 
capsid/core proteins, viral replication enzymes and viral envelope glycoproteins respectively, 
in addition to accessory and regulatory genes and elements important for gene integration and 
expression (Tiscornia et al., 2006; Segura et al., 2013).  
The majority of LV vectors are modified, replication deficient forms of the human 
immunodeficiency virus (HIV) (Sakuma et al., 2012). Modification to ensure replication 
deficiency of LV vectors relies on removal of unnecessary viral genes, and on the separation 
of the cis-acting sequences that are complexed with the transgene and facilitate RNA 
production, from the trans-acting sequences that are required for viral infection and integration 
and packaging (Naldini et al., 1996; Tiscornia et al., 2006). To achieve this separation, third 
generation LV vectors consist of four plasmids, one containing the cis-acting sequences and 
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the transgene, and the other three containing the Gag-Pol, Rev (encodes a regulatory protein) 
and VSV-G trans-acting factors (Tiscornia et al., 2006). HIV virion entry to host cells is 
mediated by binding of the gp120 subunit of the gp160 envelope protein to the CD4 receptor 
expressed on T cells, monocytes, macrophages (Redel et al., 2010) and dendritic cells (Keele 
et al., 2008), which induces a conformational change resulting in membrane fusion of the host 
cell with the virion. Following cell entry and uncoating of viral proteins, the viral genome is 
released into the cytoplasm, reverse transcribed into double-stranded DNA, imported to the 
host nucleus and integrated into the host genome by viral integrase enzymes (Sakuma et al., 
2012).  
LV vectors can be targeted to transduce particular cell types by replacing the native gp160 
envelope protein with alternative viral envelope proteins, a process known as pseudotyping. 
The G protein of vesicular stomatitis virus (VSV-G) is most commonly used and results in 
highly efficient transduction of a broad range of cell types in vitro and in vivo, although the 
receptor remains to be identified (Akkina et al., 1996; Jakobsson et al., 2003; Coil and Miller, 
2004). The use of VSV-G as an envelope protein also improves viral stability, allowing higher 
titres to be achieved during production compared to other envelope genes (Sena-Esteves et 
al., 2004).  
6.1.3.1 Use of lentiviral vectors for transgene expression within the CNS 
Stable transgene expression for up to 6 months has been demonstrated following injection of 
an HIV LV vector pseudotyped with VSV-G into the striatum of Fischer rats in vivo (Blomer et 
al., 1997). Although several studies have observed that neurons are the predominant cell type 
transduced when using VSV-G pseudotyped vectors (Naldini et al., 1996; Blomer et al., 1997), 
it has subsequently been shown that both glial and neuronal populations are transduced 
(Jakobsson et al., 2003). Importantly, injection of LV vectors into the striatum of rats did not 
result in a quantifiable innate or cellular immune response (Abordo-Adesida et al., 2005). 
Transduction of the pia mater, leptomeningeal cells and cells lining the Virchow-Robin spaces 
has been achieved in vivo following intrathecal injection of LV vectors into the spinal canal in 
neonatal mice, in the absence of inflammation or immune cell infiltration (Fedorova et al., 
2006). Interestingly these authors also demonstrated that in addition to secretion of the 
transgene product into the CSF, it was also detected at relatively high levels in the serum 
suggesting that soluble factors secreted by cells in the meninges can enter the systemic 
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circulation, possibly via the arachnoid granulations (Fedorova et al., 2006). Meningeal cells 
were also readily transduced following treatment with LV vector in vitro, and transduction of 
astrocytes, neurons, microglia, macrophages and oligodendrocyte precursors was observed in 
vivo (Hendriks et al., 2007). To the best of our knowledge, no studies have yet reported the 
effect of subarachnoid injection of LV vectors, although experiments within this laboratory have 
demonstrated meningeal transduction with an LV vector carrying the transgene for enhanced 
green fluorescent protein (GFP) at 90 days post-subarachnoid injection.   
6.1.4 Aims 
The current study aims to reproduce the key pathological features of SPMS in an animal 
model, including chronic meningeal inflammation, demyelination and microglial activation. The 
in vivo model of cortical pathology driven by the injection of pro-inflammatory cytokines into the 
subarachnoid space in DA rats, which was previously shown to induce acute meningeal 
inflammation and demyelination, was further developed in the current study by injecting 
lentiviral vectors expressing either enhanced green fluorescent protein (LVGFP) or human LTα 
(LVLTα). It is hypothesised that injection of the lentiviral vectors will result in transduction of 
meningeal cells and the long-term expression of LTα or GFP. The chronic expression and 
presence of LTα within the meninges is hypothesised to lead to chronic meningeal 
inflammation, microglial activation and demyelination. Through developing this animal model, 
we also aim to evaluate the use of lentiviral vectors expressing genes of interest to induce the 
chronic elevation of pro-inflammatory cytokines within the CSF. 
The specific aims were: 
• To characterise viral transduction following subarachnoid injection of LVGFP in naïve rats. 
• To determine the effect of LVLTα injection in naïve rats up to 90 days.  
• To determine the effect of a pre-existing anti-MOG response on LVGFP / LVLTα injection in 
rmMOG-immunised rats up to 90 days. 
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6.2 Results 
6.2.1 Lentiviral characterisation in vitro 
Primary rat meningeal cells were isolated from two day old pups, cultured and characterised in 
vitro. Expression of TNFR1 was not clearly observed by IF (Figure 6. 1 A). Iba1 expression 
was present in approximately 20% of cells, indicating the presence of macrophages in the 
cultures (Figure 6. 1 A). Approximately 98% of cells expressed laminin (Figure 6. 1 B). 
Meningeal cells were transduced with LVGFP at MOI 1000 and approximately 95% of cells 
expressed GFP at 72 hours post-transduction (Figure 6. 1 C, D). Control meningeal cells 
treated with plain media did not express LTα (Figure 6. 1 E), while approximately 95% of 
meningeal cells expressed LTα at 72 hours post-transduction with LVLTα at MOI 1000 (Figure 
6. 1 F). Expression of LTα post-LVLTα transduction was observed to be cytoplasmic. Very few 
apoptotic cells (approximately <1%) were observed following LVLTα transduction or treatment 
with plain media, as determined by IF for cleaved caspase 3 (Figure 6. 1 G). 
 
Secretion of LTα by HEK cells was determined by ELISA using supernatant collected at 24 
hours (Figure 6. 1 H) and 48 hours (Figure 6. 1 J) post-transduction with LVLTα MOI 5, 10, 20, 
35 or 50. A dose-dependent increase in the concentration of LTα in supernatant following 
LVLTα transduction was observed at both time-points (Figure 6. 1 H, J). The concentration of 
LTα was significantly higher in supernatant from cells transduced with MOI 35 (p=0.0422, 
Kruskal-Wallis) and MOI 50 (p=0.0059) at both time-points compared to control cells (treated 
with plain media) and those transduced with LV-GFP (Figure 6. 1 H, J). Expression of LTα was 
approximately 10 fold higher at 48 hours post-transduction compared to the 24 hour time-point 
(Figure 6. 1 J). 
 
Secretion of LTα by passaged rat meningeal cells was determined by ELISA using 
supernatant collected at 72 and 96 hours and 7 days post-transduction with LVLTα MOI 1000 
or 2000 (Figure 6. 1 K). The concentration of LTα was significantly increased at 7 days post-
transduction with LVLTα MOI 2000 (p=0.0053, Kruskal-Wallis) compared to control cells 
(treated with plain media) and those transduced with LV-GFP (Figure 6. 1 K). A western blot 
was performed to detect β-actin and LTα in cell lysates of secondary rat meningeal cells 
harvested at 72 hours after treatment with LVGFP or LVLTα MOI 1000. Two bands were 
observed, at 42 and 22kDa corresponding to β-actin and LTα respectively (Figure 6. 1 L). 
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 Figure 6. 1 Characterisation of rat meningeal cell cultures and lentiviral vectors in vitro  
TNFR1 IF was not observed (A), but ~20% cells expressed Iba1 (A) and ~98% expressed laminin (B). 
Cells were transduced with lentiviral vectors (LVs) expressing enhanced GFP (LVGFP; C, D) or human 
LTα (LVLTα; F), or plain media (control; E). Transduction efficiency for both LVs was ~98% at 1000 MOI 
72 hours post-transduction, while apoptotic cells were rare (F). LTα expression by human embryonic 
kidney 293T (HEK) cells at 24 (H) or 48 hours (J) after transduction with 5, 10, 20, 35 or 50 MOI was 
determined by ELISA. LTα supernatant concentration was significantly increased following transduction 
with 35 and 50 MOI LVLTα  compared to control cells (medium only) and LVGFP (p=0.0422 and 
p=0.0059 respectively, Kruskal-Wallis with Dunn’s post-test). LTα supernatant concentration was 
significantly increased at 7 days post-transduction of meningeal cells with 2000 MOI LVLTα compared 
to control or LVGFP (p=0.0053; K). A western blot of meningeal cell lysates at 72 hours post-LVGFP or 
LVLTα transduction showed a ~42 kDa band corresponding to β-actin in all lanes (L) and a ~22kDa 
band corresponding to human LTα  post-LVLTα. 
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6.2.2 Characterisation of viral transduction in naïve rats using LVGFP  
6.2.2.1 Meningeal GFP expression was not accompanied by demyelination   
To characterise viral transduction following injection of an LV vector into the subarachnoid 
space in vivo, naïve rats received 1µl LVGFP at a lower (106 GC/μl) or higher titre (107 GC/μl) 
into the subarachnoid space and were culled at 7 or 28 days post-injection (Figure 6. 2).  
The majority of GFP+ cells observed at 7 days post-LVGFP had a rounded morphology, 
lacking cellular processes, and were located in the subarachnoid space and sagittal sulcus, 
lining the adjacent cortices (new figure 6.3 A, B). In addition, GFP+ long, branched processes 
were observed in the cortex adjacent to the subarachnoid space, suggestive of astrocyte end-
feet transduction (new figure 6.3 C, D).  
MOG IF in the cortex and corpus callosum adjacent to the injection site appeared comparable 
with that previously observed in naïve no-surgery control rats, indicating that no quantifiable 
demyelination resulted from injection of either titre of LVGFP at the 7 (Figure 6. 4 A-D) or 28 
(Figure 6. 4 E-H) day time-points. In addition to GFP+ cells observed in the sagittal sulcus 
(Figure 6. 4 B, D), GFP expression was also observed infrequently in perivascular cells 
surrounding intracortical vessels close to the sagittal sulcus, which had a flattened morphology 
(Figure 6. 4 F), and in cortical cells with a morphology suggestive of neuronal transduction 
(Figure 6. 4 H).  
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Figure 6. 3 Morphology of LVGFP transduced cells at 7 days post-injection in naïve rats 
A variety of GFP+ cell morphologies was observed following subarachnoid injection of LVGFP in naïve 
rats. The majority of GFP+ cells were confined within the subarachnoid space (SAS; A, B) in line with 
the meninges, and typically had a rounded morphology devoid of processes. GFP+ cells with branched 
processes and the appearance of astrocyte end-feet were also observed lining the edge of the cortex 
(ctx) adjacent to the SAS (C, D). Scale bars: A = 100μm. n=3.    
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6.2.2.2 Co-localisation of GFP expression   
The accuracy of co-localisation was hampered by the intensity of the GFP expression by 
positive cells, and the wavelength of enhanced GFP, which overlapped with the red 
fluorescent channel and resulted in some GFP signal being observed in both channels. 
However the earlier observation of GFP+ branched processes of a small proportion of the 
GFP+ cells, and their position at the edge of the cortical parenchyma adjacent to the sagittal 
sulcus, indicated that small numbers of astrocyte end-feet lining the sagittal sulcus were 
transduced, which was confirmed by limited co-localisation of GFP with GFAP IF (Figure 6. 5 
A, arrows in C). An increased proportion (~75%) of GFP positive cells confined within the 
subarachnoid space and sagittal sulcus, in line with the meninges, were observed to co-
localise with Iba1 IF, indicating significant transduction of meningeal macrophages (Figure 6. 5 
B and D). A limited area of increased Iba1 IF, and the presence of small numbers of microglia 
with shortened processes and a more rounded morphology indicative of activation, was 
observed in the cortex immediately adjacent to the area of meningeal GFP expression (Figure 
6. 5 arrow in B and arrows in D). However no activated microglia were observed throughout 
the rest of the cortex, where Iba1 IF was comparable to that of naïve no-surgery control rats 
and rmMOG-immunised rats injected with PBS, suggesting that injection with LVGFP does not 
induce significant cortical microglial activation. 
6.2.2.3 Intracortical GFP expression   
Inaccurate injection placement resulting in intracortical injection of LVGFP demonstrated the 
efficacy of viral transduction when confined within the tissue, compared to injection into the 
subarachnoid space (Figure 6. 6). Increased numbers of GFP+ cells per section examined 
were observed following intracortical injection compared to subarachnoid injection, which was 
particularly clear at the 7 day time-point (Figure 6. 6 A, B). GFP positive cells within the cortex 
were observed to be less numerous at 28 days (Figure 6. 6 C, D) compared to at 7 days, but 
confirmed the conclusions from analysis of the subarachnoid injected rats that GFP expression 
is present at the 28 day time-point. However, since the majority of GFP positive cells were 
confined to the cortex at 28 days post-intracortical injection, with little or no observable viral 
transduction of cells within the sagittal sulcus or lining the cortices at this time-point (Figure 6. 
6 C, D), it was also concluded that subarachnoid injection results in more efficient and 
widespread transduction of cells within the meninges and sagittal sulcus, and thus is the most 
suitable method for further studies investigating the effect of LV meningeal transduction.  
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 Figure 6. 5 Co-localisation of GFP with astrocyte end-feet and microglia/macrophages 
Minimal co-localisation of GFP expression with GFAP (A, arrows in C) was observed, indicating limited 
viral transduction of astrocytes, with the majority of GFP+ cells located in the sagittal sulcus. Limited 
microglial activation was observed in the cortex adjacent to the sagittal sulcus (arrows in B and D) and 
Iba1 IF co-localised with ~75% GFP+ cells lining the cortex (D), indicating transduction of macrophages. 
Images are representative. C and D are magnifications of A and B respectively. Scale bars: A = 500μm, 
C = 100μm. n=3 per group. 
 
DC
DAPI
GFP
GFAP
A
DAPI
GFP
Iba-1
B
Chapter 6 – Chronic targeted EAE  198 
 
 Figure 6. 6 Intracortical injection of LVGFP demonstrated viral transduction efficacy  
GFP+ cells were observed to be more numerous per section examined following intracortical injection of 
LVGFP compared to subarachnoid injection at 7 (A, B) and 28 (C, D) days post-injection. GFP 
expression was observably stronger at 7 days (A) but still present at 28 days (C, D) post-injection. Little 
transduction of meningeal cells was observed following intracortical injection. Images are representative 
and B, D are magnifications of A, C. Scale bars: A, C = 500μm, B, D = 100μm. n=3 per group. 
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6.2.3 Evaluation of viral transduction with LVLTα in naïve rats  
6.2.3.1 Formation of infiltrates without demyelination at 7 days post-LVLTα  
To determine whether injection of an LV vector expressing human LTα could induce pathology 
similar to acute injection of the recombinant protein, naïve rats received a subarachnoid 
injection of LVLTα and were culled after 7 days (Figure 6. 2). A total volume of 2μl per rat 
LVLTα was injected to achieve the highest possible number of viral copies within the 
subarachnoid space and increase the likelihood of sufficient transduction of meningeal cells. 
The results were compared to tissue from naïve female DA rats injected with the viral vector 
vehicle (TSSM) alone and culled after 7 days. No loss of MOG IF or activated microglia were 
observed in the cortex adjacent to the injection site in TSSM control rats, and no cellular 
infiltration of the subarachnoid space was observed (Figure 6. 7 A, B). Tissue from these 
animals appeared to be identical to naïve no-surgery control rats.  
The formation of dense cellular infiltrates in the subarachnoid space was observed at 7 days 
following injection of LVLTα, indicated by the presence of large numbers of DAPI+ nuclei 
(Figure 6. 7 C). Iba1 IF was increased compared to TSSM control animals in the subarachnoid 
space and adjacent cortex, suggesting macrophage infiltration and microglial activation 
respectively (Figure 6. 7 C, D). MOG IF was clearly still present although it appeared to be 
slightly reduced in density compared to TSSM control animals. It is possible that this effect 
may be due to the increased activation/presence of microglia within the cortex (Figure 6. 7 
arrows in D), accounting for more space and displacing myelinated axons, compared to TSSM 
controls. The slight reduction in MOG IF density was impossible to quantify, as the difference 
was too subtle to be able to delineate the areas affected, so this tissue was not quantified or 
considered to be demyelinated.     
Consistent with observations in the previous chapter following injection of LTα+IFNγ (see 
section 5.2.1.6), infiltrates observed following LVLTα contained striking numbers of channels 
of variable diameter (Figure 6. 7 arrows in C). The number and appearance of these channels 
was similar following LTα+IFNγ and LVLTα, suggesting that exogenous IFNγ is not required 
for their formation. As suggested previously, these channels may represent the formation of 
lymphatic vessels or HEVs associated with LTα expression (Kratz et al., 1996; Mounzer et al., 
2010). 
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 Figure 6. 7 Acute injection of LVLTα induces infiltrate formation at 7 days post-injection 
MOG IF revealed no observable alteration in myelin at 7 days post-injection of TSSM (LV vehicle alone; 
A, B). No microglial activation was observed by Iba1 IF in TSSM-injected rats (B). Substantial DAPI+ 
cellular infiltrates, containing large numbers of channels of variable diameter (arrows in C), filled the 
subarachnoid space and sagittal sulcus at the injection site at 7 days post-LVLTα (C). Infiltrates were 
accompanied by an increase in subpial microglial activation observed by Iba1 (arrows in D), but no 
quantifiable loss of MOG IF. Images are representative and images on the right are magnifications of 
the boxed areas in images on the left. Scale bars: A, C = 250µm; B, D = 25µm. n=3 per group.   
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6.2.3.2 Subarachnoid infiltration of B and T cells at 7 days post-LVLTα  
CD79a+ B cells, CD4+ or CD8+ T cells and Ki67+ proliferating cells were identified by IF in 
sections adjacent to the injection site. Quantification of cells in 3 adjacent sections per animal 
showed that numbers of B, T and proliferating cells in TSSM injected animals were not 
significantly different to naïve no-surgery control animals. No B cells were observed in any 
sections in TSSM injected animals (Figure 6. 8 A, C). CD4+ and CD8+ T cells, and Ki67+ 
cells, were infrequently observed (mean CD4 = 0.56 ± 0.29 SEM, mean CD8 = 1.00 ± 0.51) 
and were often absent entirely from sections (Figure 6. 8 B, D).  
Infiltrates were B cell rich at 7 days post-LVLTα; B cells accounted for the majority of cells in 
the subarachnoid space and were significantly increased compared to the TSSM group 
(p=0.0402, Kruskal-Wallis with Dunn’s post-test). CD79a+ B cells were present in 
approximately 4-10 fold higher numbers (mean = 446.67 ± 101.8; Figure 6. 8 E) compared to 
CD8+ and CD4+ T cells, and were located in loose clusters often close to the cortical 
parenchyma, as well as scattered throughout the infiltrate. 16% of B cells were CD79a+Ki67+ 
proliferating cells (mean = 71.67 ± 20.39; Figure 6. 8 arrows in G). CD79a+ B cells were also 
observed to infiltrate the parenchyma immediately surrounding the subarachnoid space (mean 
= 69.89 ± 31.83; Figure 6. 8 arrows in E), of which 2.7% were CD79a+Ki67+ double positive. 
Very few CD79a+ cells were observed in the corpus callosum (mean = 0.89 ± 0.89). Single 
positive Ki67+ proliferating cells which were not B cells were also observed in the 
subarachnoid space (mean = 47.89 ± 3.35).  
CD8+ T cells were also a prominent feature of subarachnoid infiltrates (mean = 101.89 ± 
45.36; Figure 6. 8 F, H), while CD4+ T cells were less numerous but were significantly 
increased compared to the TSSM group (p=0.0391, mean = 31.00 ± 8.14). There was no 
observable organisation of CD4 and CD8 T cells within infiltrates, or infiltration of the 
parenchyma or corpus callosum.  
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 Figure 6. 9 Quantification of immune cell infiltration at 7 days post- injection 
Immune cell infiltration was quantified in the subarachnoid space, excluding any parenchymal infiltration, 
using IF markers to identify CD4+ (A) or CD8+ (B) T cells and CD79a+ B cells (C) at 7 days post-
injection of TSSM, LVGFP (106 or 107 GC/µl titre) or LVLTα (109 GC/µl titre). CD4+ T cells (A) and 
CD79a+ B cells (C) were significantly increased following LVLTα compared to TSSM injection 
(p=0.0391 and 0.0402 respectively, Kruskal-Wallis with Dunn’s post-test). Infiltration of CD79a+ and 
CD4+ cells was low in LVGFP and TSSM groups (D), but a non-significant increase in CD8+ T cells was 
observed in the higher GFP titre group (B and D).   
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6.2.3.3 Meningeal expression of human LTα at 7 and 28 days post-LVLTα  
Expression of human LTα was detected in all 3 experimental animals at 7 days post-injection 
of LVLTα using IF (Figure 6. 10 A-C). Due to the diffuse nature of the IF signal, the 
morphology of LTα+ cells was difficult to determine, but the majority were located in the 
sagittal sulcus lining the subarachnoid space (Figure 6. 10 D-F). A small proportion of LTα+ 
cells appeared to have branched processes extending into the cortical parenchyma, 
suggestive of astrocyte end-feet transduction (Figure 6. 10 upper arrow in D, and arrow in E), 
while others lining the cortices had a more flattened, spindle shaped morphology indicative of 
meningeal fibroblasts (Figure 6. 10 arrows in F). LTα+ cells with a rounded morphology lacking 
processes and located within infiltrates were also observed (Figure 6. 10 lower arrow in D). In 
all rats at the 7 day time-point, the substantial size of the DAPI+ subarachnoid infiltrates was 
remarkably uniform. Infiltrate size was reduced at the 28 day time-point, although LTα+ cells 
were observed in all 3 rats along the ventral-dorsal length of the sagittal sulcus (Figure 6. 11 
arrows in A and B, C) and appeared more numerous compared to the 7 day time-point (Figure 
6. 11 D-F). Few LTα+ cells at 28 days post-LVLTα were observed to have a morphology or 
location suggestive of transduced astrocytes, with the majority of LTα+ cells being located in 
the sagittal sulcus within the smaller infiltrates (Figure 6. 11 arrows in D and E), and lining the 
cortices (Figure 6. 11 arrow in F). Small clusters of LTα+ cells were observed lining the 
cortices and in the subarachnoid space, indicating local reproduction of transduced cells at this 
time-point suggestive of meningeal macrophages/fibroblasts. 
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 Figure 6. 10 Expression of human LTα in naïve rats at 7 days post-LVLTα injection 
Substantial DAPI+ cellular infiltrates were observed in the subarachnoid space and sagittal sulcus of all 
3 naïve rats in the experimental group at 7 days post-LVLTα injection (A-C). Infiltrates were interspersed 
with many channels of variable size. Human LTα expression was identified by IF in cells within the 
sagittal sulcus and lining the cortices in all rats (D-F). A small proportion of LTα+ cells had branched 
processes suggestive of transduced astrocytes (upper arrow in D and arrow in E), while others had a 
flattened morphology indicating transduced meningeal fibroblasts (arrows in F) or were rounded single 
cells (lower arrow in D). Lower images are magnifications of the boxed areas in images above. Scale 
bars: A-C = 500µm, D-F = 100µm.  
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 Figure 6. 11 Meningeal expression of human LTα in naïve rats at 28 days post-LVLTα 
Expression of human LTα was confirmed in cells in the subarachnoid space in all 3 naïve rats in the 
experimental group at 28 days post-LVLTα injection using IF (A-C). Expression was accompanied by 
cellular infiltration of the subarachnoid space indicated by DAPI+ nuclei. LTα+ cells were observed 
within subarachnoid infiltrates (arrows in D and E), and lining the cortices (arrow in E). Scale bars: A-C 
= 500µm, D-F = 100µm 
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6.2.4 Evaluation of viral transduction at 28 days in rmMOG rats 
6.2.4.1 Demyelination in rmMOG-immunised rats at 28 days post-LVLTα 
Following confirmation of the efficacy of LVLTα injection to induce meningeal infiltrate 
formation in naïve rats at 7 and 28 days, a subsequent experiment was carried out to examine 
the effect of LVLTα injection in rmMOG-immunised animals at 28 and 90 days post-injection 
(Figure 6. 12). MOG IF revealed no observable loss of myelin in naïve rats at 28 days post-
LVLTα injection (Figure 6. 13 A, F) or in rmMOG-immunised rats at 28 days post-LVGFP 
injection (Figure 6. 13 B, C, G). Cortical MOG IF in these animals was comparable to that seen 
previously in TSSM control animals, and was intact in the subpial GM (Figure 6. 13 arrow in 
B). GFP expression was limited to a few cells per section located in the sagittal sulcus (Figure 
6. 13 C, G). Substantial areas of subpial demyelination were observed as a loss of MOG IF in 
cortical layers I-IV, which extended from the GM just dorsal to the corpus callosum, up to the 
dorsal surface of the cortex, and also extended laterally for an distance of approximately 
1.5mm either side of the midline, at 28 days post-LVLTα injection in rmMOG-immunised rats 
(Figure 6. 13 arrows in D, E, H). Demyelinated subpial lesions accounted for up to 
approximately 40% of the cortex at the level of the injection site. MOG+ cell bodies were 
present in the GM close to the lesion border, indicative of remyelinating oligodendrocytes. 
Only sparse remnants of myelin were present in subpial areas bordering the subarachnoid 
space and sagittal sulcus (Figure 6. 13 H). There was a non-significant trend towards 
increased size of demyelinated areas quantified at the injection site and at 800μm and 400μm 
anterior to the injection site, compared to the posterior sites (Figure 6. 13 J).  
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 Figure 6. 13 Demyelination at 28 days post LVLTα injection in rmMOG-immunised rats 
No loss of MOG IF was observed in naïve rats at 28 days post-LVLTα (A, F), or in rmMOG-immunised 
rats post-LVGFP (arrow in B, C, G). Loss of MOG IF indicated demyelination in subpial areas 
surrounding the sagittal sulcus in rmMOG-immunised rats post-LVLTα (arrows in D, E, H). GFP+ cells 
were observed in the meninges, adjacent to normal-appearing cortical MOG IF (G). Only sparse MOG 
IF was present in subpial areas in rmMOG-immunised rats following LVLTα (H). Quantification of 
demyelinated areas revealed no significant differences but areas were observed to be larger at sites 
anterior to the injection site. Images C and E are magnifications of the boxed areas in B and D 
respectively. F, G and H are magnifications of the boxed areas in A, C and E respectively. Scale bars: 
A, C, E = 100µm; B, D = 500µm; F = 25μm. n=3 per group. 
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6.2.4.2 Microglial activation in rmMOG-immunised rats 28 days post-LVLTα 
Iba1 IF showed very limited microglial activation adjacent to the sagittal sulcus in rmMOG-
immunised rats at 28 days post-LVGFP (Figure 6. 14 A). Microglia in the cortex and corpus 
callosum had a resting/ramified morphology with thin processes and Iba1 IF overall was 
comparable with naïve TSSM injected animals seen previously (Figure 6. 14 B, C).  
Widespread prominent activation of cortical microglia was observed in rmMOG-immunised rats 
following LVLTα injection, extending deep into the cortex to include all layers (Figure 6. 14 D). 
Areas of particularly prominent activation, containing many microglia with a rounded 
morphology and short, thick processes were found in the cortex and corpus callosum (Figure 
6. 14 E, F) and corresponded to areas of reduced MOG IF, indicating an association with 
demyelination (Figure 6. 14 highlighted areas in cortex and corpus callosum in H). No 
demyelination was observed in rmMOG-immunised rats following LVGFP injection, indicated 
by intact MOG IF (Figure 6. 14, arrows in G), in contrast to the substantial areas of subpial 
demyelination following LVLTα, (Figure 6. 14, largest area highlighted in H). 
6.2.4.3 Meningeal B and T cell infiltration at 28 days post-LVLTα 
CD79a+ B cell meningeal infiltration was observed in all groups at 28 days post-LV injections 
(Figure 6. 15). B cells were observed to be scattered throughout the subarachnoid space and 
sagittal sulcus in naïve rats following injection of LVGFP (mean = 80.06 ± 19.75; Figure 6. 15 
A, C) and LVLTα (mean = 78.11 ± 20.40; Figure 6. 15 B, D). Little co-localisation of Ki67 with 
CD79a was observed in naïve LVLTα rats, suggesting that there were few dividing B cells 
present. B cells were also observed in rmMOG-immunised rats following injection of LVGFP 
(mean = 45.67 ± 19.02; Figure 6. 15 E, G) or LVLTα (mean = 49.67 ± 31.44; Figure 6. 15 F, 
H). Small dense clusters of B cells were observed in the meninges of one rmMOG-immunised 
LVLTα rat but little co-localisation of Ki67 with CD79a suggested that the majority of these 
cells were not dividing (Figure 6. 15 H). B cells were more evenly scattered in the remaining 
animals in the group. A small number of plasma cells were observed in the subarachnoid 
space and included in the B cell count, since they were CD79a+ cells, but also had high non-
specific binding for other antibodies suggestive of antibody production. Numbers ranged from 
~2-6 per section. 
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 Figure 6. 14 Microglial activation in rmMOG-immunised rats at 28 days post-LVLTα 
Iba1 IF revealed limited microglial activation immediately surrounding the sagittal sulcus and 
subarachnoid space in rmMOG-immunised rats at 28 days post-LVGFP injection (A). No activation of 
microglia was observed in the corpus callosum (B) or cortex (C) and density of Iba1+ cells appeared 
comparable to TSSM controls. Prominent microglial activation occurred throughout the corpus callosum 
(D, E) and cortex (F) following LVLTα injection in rmMOG-immunised rats – activated microglia with a 
rounded morphology with shortened processes were numerous (E, F). Intact subpial myelin in layers I-III 
shown by MOG IF (G arrows) was observed 28 days after LVGFP injection. Loss of MOG IF in the 
corresponding area was observed in rmMOG-immunised rats following LVLTα (highlighted areas H). 
Areas with reduced MOG IF in the cortex and corpus callosum (highlighted areas in H) corresponded to 
areas of prominent microglial activation (D, E, F). Images on the right are magnifications of the boxed 
areas in images on the left. Scale bars: A, D, G, H = 500µm; B, C, E, F = 100µm. n=3 per group. 
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CD4+ and CD8+ T cells were identified by IF and also observed to infiltrate the meninges in all 
groups at 28 days post-LV injection (Figure 6. 16). Fewer CD4+ cells were observed in naïve 
animals following LVGFP (mean = 16.89 ± 10.62; Figure 6. 16 A, D) compared to CD8+ cells 
(mean = 46.83 ± 6.26; Figure 6. 16 B, E). In spite of the apparent increased cellular infiltration 
of the subarachnoid space in naïve animals following LVLTα injection, few of these cells were 
identified as T cells of either type (Figure 6. 16 C, F). In rmMOG-immunised animals CD4+ 
cells were observably more numerous following injection of LVGFP (mean = 44.00 ± 3.51; 
Figure 6. 16 G, K) and LVLTα (mean = 51.33 ± 10.48; Figure 6. 16 J, M) compared to the 
corresponding naïve groups. Infiltration of CD8+ cells in rmMOG-immunised rats appeared 
similar following LVGFP (mean = 32.22 ± 1.60; Figure 6. 16 H, L) and LVLTα (mean = 21.67 ± 
6.57; Figure 6. 16 J, M). The majority of cells unaccounted for by T and B cell IF were found to 
be Iba1+ macrophages when adjacent sections were analysed. 
Quantification of immune cell types identified by IF corroborated observations of CD4+ T cell 
infiltration by revealing a non-significant trend towards increased infiltration in rmMOG-
immunised rats compared to naïve groups (Figure 6. 17 A). There was no significant 
difference in CD4+ cell infiltration between LVGFP or LVLTα injected groups. Significantly 
fewer CD8+ cells were observed in naïve rats following LVLTα injection compared to the naïve 
LVGFP group (Figure 6. 17 B; p=0.0279 Kruskal-Wallis with Dunn’s post-test), but there was 
no significant difference in CD8+ numbers between the rmMOG-immunised groups following 
LVGFP or LVLTα (Figure 6. 17 B). Numbers of CD79a+ B cells were also not significantly 
different between the groups (Figure 6. 17 C). When viewed as one graph, the proportions of 
infiltrating cell types appear to be more even in rmMOG-immunised animals compared to 
naïve animals, lacking a trend towards increased B cells which is seen in naïve animals 
(Figure 6. 17 D). The LVLTα groups appear to be strikingly similar to the correspondingly 
immunised LVGFP groups, suggesting that LVLTα had no significant impact on recruitment of 
CD79a+, CD4+ or CD8+ cells compared to LVGFP at this time-point (Figure 6. 17 D). The 
number of infiltrating B cells was markedly reduced (by approximately 4 fold) in animals at 28 
days post-LVLTα compared to the 7 day time-point, so although B cells were still the most 
numerous cell type in all infiltrates, only the naïve infiltrates were considered B cell rich, since 
T cells were present in similar numbers to B cells in the rmMOG-immunised groups. 
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 Figure 6. 15 Formation of CD79a+ B cell clusters at 28 days post-LVLTα 
CD79a+ B cells were identified in the subarachnoid space in naïve (A, C) and rmMOG-immunised (E, 
G) rats at 28 days post LVGFP injection using IF. Increased numbers of CD79a+ and Ki67+ cells were 
observed in naïve (B, D) and rmMOG-immunised (F, H) rats post-LVLTα. Little Ki67 IF co-localisation 
with CD79a IF was observed in LVLTα-injected rats (D, H). Images are representative and images on 
the right are magnifications of the boxed areas in images on the left. Scale bars: A-C, G-J = 250µm, D-
F, K-M = 25µm. n=3 per group.  
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 Figure 6. 16 Meningeal CD4+ and CD8+ T cell infiltration at 28 days post LV injection 
CD4+ (A, D) and CD8+ (B, E) T cells were identified by IF infiltrating the subarachnoid space in naïve 
rats at 28 days post-LVGFP. GFP+ meningeal cells were present in small numbers and entirely absent 
from some sections. CD4+ (G, K) and CD8+ (H, L) cells were observed in rmMOG-immunised rats post-
LVGFP. CD4+ and CD8+ cells were present within infiltrates of variable size in naïve (C, F) and 
rmMOG-immunised (J, M) rats following LVLTα. Images are representative and images on the right are 
magnifications of the boxed areas in images on the left. Scale bars: A-C, G-J = 250µm, D-F, K-M = 
25µm. n=3 per group. 
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 Figure 6. 17 Quantification of immune cell infiltration at 28 days post-LV injection 
Immunofluorescence (IF) was used to identify CD4+ (A) or CD8+ (B) T cells, and CD79+ B cells (C) in 
naïve and rmMOG-immunised rats at 28 days post-injection with LVGFP or LVLTα. Quantification of 
cells in the subarachnoid space and sagittal sulcus in did not reveal any statistically significant 
differences in CD4+ or CD79a+ cell numbers between groups, although there was a non-significant 
trend towards increased CD4+ cells in rmMOG-immunised animals (A). There was a significant 
decrease in CD8+ T cell number in naïve LVLTα-injected rats compared to the naïve LVGFP-injected 
group (p=0.0279; Kruskal-Wallis with Dunn’s post-test; B). There was a non-significant trend towards 
increased B cells in naïve rats compared to rmMOG-immunised rats (D). Data is represented as the 
mean ± SEM. n=3 per group. 
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6.2.4.4 Quantification of human LTα in brain tissue at 28 days post-LVLTα 
Following the observation of no significant differences in immune cell infiltration of the 
meninges between LVGFP- and LVLTα-injected groups at the 28 day time-point, we sought to 
confirm that injection of LVLTα resulted in production of LTα in vivo at this time-point. The 
brain of a naïve rat perfused with PBS at 28 days post-LVLTα injection was removed and 
lysates from 3 brain regions were prepared. The injection site was identified by visualisation of 
monastral blue tracer in the sagittal sulcus, isolated from the rest of the brain and a lysate 
prepared. Lysates using the remaining brain tissue and cerebellum were also prepared and 
the concentration of human LTα in all lysates was quantified using a Duoset ELISA kit (R&D 
Systems). Identical lysates were prepared using a sham injection control brain. The 
concentration of LTα in the injection site lysate from the LVLTα-injected rat was 4.45ng/ml and 
undetectable in the sham (Figure 6. 18 A). LTα was undetectable in the whole brain lysates 
from both animals suggesting that the majority of expression of LTα was concentrated in the 
tissue immediately surrounding the injection site (Figure 6. 18 A). A reading just above the limit 
of detection (0.33ng/ml) was obtained from the sham cerebellar lysate, suggesting that the 
ELISA kit minimally cross-reacts with another rat antigen. 
6.2.4.5 Quantification of human LTα in the CSF at 28 days post-LVLTα 
The concentration of human LTα was quantified in CSF samples taken from naïve rats at 7 
and 28 days post-LVLTα using a Duoset ELISA kit (R&D Systems; Figure 6. 18 B). LTα 
expression was confirmed by IF in all naïve rats at both time-points, but was only above the 
limit of detection in CSF from 1 naïve rat at 7 days (2179pg/ml, group mean 726.4pg/ml) and 1 
naïve rat at 28 days (101pg/ml, group mean 14.4pg/ml; Figure 6. 18 B). At the time of analysis, 
no naïve no-surgery control rat CSF was available, but samples were subsequently obtained, 
analysed using an ECL assay with a sensitivity of 0.14pg/ml, and were below the limit of 
detection (Figure 6. 18 C). LTα concentration was above the limit of detection in CSF from all 3 
rmMOG-immunised rats at 28 days post-LVLTα, and was undetectable in CSF from rmMOG-
immunised PBS-injected or LVGFP-injected control rats. The mean LTα concentration of the 
rmMOG-immunised LVLTα rats (295.4pg/ml) was significantly elevated above the control 
groups, and ranged between 849.3 and 1.7pg/ml. Interestingly, the animal with the greatest 
total area of demyelination also had the highest CSF LTα concentration, while the animal with 
the lowest concentration had no observable demyelination, but due to the small sample size it 
was impossible to carry out a statistical correlation.  
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 Figure 6. 18 Quantification of human LTα in CSF and brain at 7 and 28 days post-LVLTα 
The concentration of human LTα was quantified in fresh brain lysates prepared from the isolated 
injection site, remaining brain tissue (whole brain) and cerebellums of a naïve sham- and a naïve 
LVLTα-injected rat at 28 days post-injection (A) by ELISA. LTα concentration was highest in the 
injection site lysate of the LVLTα-injected rat. No LTα was detected in the whole brain and minimal 
cross-reactivity with rat antigens was observed in the sham cerebellum lysate. LTα concentration was 
detected in CSF samples from naïve rats at 7 and 28 days post-LVLTα by ELISA and is represented as 
the mean ± SEM (B). CSF samples from rmMOG-immunised rats contained significantly increased 
concentrations of LTα at 28 days post-LVLTα compared to rmMOG-immunised LVGFP rats (p=0.0086) 
and naïve no-surgery control rats and rmMOG-immunised PBS-injected rats at 7 days (p=0.0261; 
represented as the mean ± SEM; C). Statistics: Kruskal-Wallis with Dunn’s post-test. B and C: n=3-6 per 
group.    
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6.2.5 Evaluation of viral transduction at 90 days post-injection 
6.2.5.1 Demyelination in rmMOG-immunised rats at 90 days post-LVLTα 
Following the observation of widespread cortical microglial activation and subpial 
demyelination at 28 days post- LVLTα injection in rmMOG-immunised rats, a further study was 
designed to determine the effect of LVLTα injection at 90 days. No quantifiable loss of MOG IF 
was observed in naïve rats at 90 days post-LVGFP or LVLTα injection, indicating that 
demyelination was not present in either group at this time-point (Figure 6. 19 A-F). GFP 
expression was limited to very few meningeal cells per section (Figure 6. 19 B, C). Infiltrate 
formation in the subarachnoid space and sagittal sulcus was observed following injection of 
LVLTα in naïve rats (Figure 6. 19 D, E, F) but not following LVGFP injection in either rmMOG-
immunised (Figure 6. 19 G, H, J) or naïve rats. No quantifiable loss of MOG IF was observed 
in rmMOG-immunised rats after LVGFP. Loss of MOG IF was observed in 67% (4/6) of 
rmMOG-immunised rats at 90 days post-LVLTα injection, in subpial cortical areas and the 
corpus callosum surrounding the subarachnoid space (Figure 6. 19 K, L, M). Quantification of 
demyelinated areas revealed a non-significant trend towards an increase in the area of 
demyelination at 800μm anterior to the injection site, compared to the posterior site (Figure 6. 
20). MBP IF appeared identical to MOG IF in rmMOG-immunised LVLTα animals at 90 days, 
confirming that the loss of MOG IF observed in this group reflects loss of the myelin sheath in 
the areas of subpial demyelination, rather than loss of MOG without demyelination. 
Visualisation of axonal neurofilaments using Nfil IF together with MOG IF for myelin revealed 
no observable differences between naïve no-surgery control animals (Figure 6. 21 A-C), 
rmMOG-immunised rats which received a subarachnoid injection of PBS (Figure 6. 21 D-F) 
and rmMOG-immunised rats at 90 days post-LVGFP injection (Figure 6. 21 G-J). Subpial 
demyelination was clearly observed as a lack of in rmMOG-immunised LVLTα-injected rats at 
90 days (Figure 6. 21 K-L) but Nfil IF appeared indistinguishable from that of the rmMOG-
immunised LVGFP or other control groups throughout the cortex close to the injection site, 
including within demyelinated subpial GMLs (Figure 6. 21 M), and obvious axonal loss was not 
associated with demyelination in the model at this time-point.  
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 Figure 6. 19 Subpial demyelination in rmMOG-immunised rats at 90 days post-LVLTα 
MOG IF in naïve rats at 90 days post-injection of LVGFP (A-C) or LVLTα (D-F) was comparable to naïve 
no-surgery control rats. Formation of DAPI+ infiltrates in the subarachnoid space was observed 
following LVLTα (E). No quantifiable loss of MOG IF was observed in rmMOG LVGFP rats (G-J). Very 
few GFP+ meningeal cells were observed per section (B, H). Loss of MOG IF indicated subpial 
demyelination surrounding the sagittal sulcus and subarachnoid space in rmMOG LVLTα rats (subpial 
area above the dotted line in K-M). Images B, E, H, and L are magnifications of the boxed areas in A, D, 
G, and K respectively, and C, F, J and M are magnifications of the boxed areas in B, E, H, and L 
respectively. Scale bars: A, D, G, K = 500µm; B, E, H, L = 200µm; C, F, J, M = 25μm. n=3-6 per group. 
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Figure 6. 20 Quantification of demyelinated areas at 90 days post-LVLTα injection 
Areas of subpial demyelination (visualised by an absence of MOG immunofluorescence) were quantified 
at 90 days after injection of LVGFP or LVLTα in naïve and rmMOG-immunised rats, at 0 µm from the 
injection site, and at +800µm (anterior) and -800µm (posterior) from the injection site. Demyelination 
extended at least 800µm anterior and posterior from the injection site following LVLTα-injection in 
rmMOG-immunised rats. There was a non-significant trend towards increased area of demyelination at 
the 800µm anterior site compared to the injection and posterior sites. Data is presented as the mean ± 
SEM. Statistics: Kruskal-Wallis with Dunn’s multiple comparisons post-test. n=3-6 per group. 
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Figure 6. 21 Demyelination was not accompanied by observable axonal loss at 90 days 
IF for MOG and neurofilament (Nfil) revealed myelin and axons respectively in naïve no-surgery control 
animals (A, B, C) and no observable loss of either was observed in rmMOG-immunised rats following 
subarachnoid injection of PBS (D, E, F) or LVGFP (G, H, J). Prominent subpial demyelination (loss of 
MOG IF) was observed at 90 days post-LVLTα in rmMOG-immunised rats (K, L) without observable loss 
of axons or neurofilament IF (M). Images B, E, H, and L are magnifications of the boxed areas in A, D, 
G, and K respectively, and C, F, J and M have the green channel removed to reveal Nfil IF alone in the 
red channel. Scale bars: A = 200µm; B-C = 25μm. n=3-6 per group. 
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6.2.5.2 Microglial activation & macrophage infiltration post-LVLTα  
Iba1 IF revealed limited macrophage infiltration of the subarachnoid space, and local activation 
of microglia limited to the cortex immediately adjacent to the subarachnoid space and sagittal 
sulcus at the injection site at 90 days post-LVGFP in naïve rats (Figure 6. 22 A, B). No 
activation of microglia was observed in the corpus callosum or deep cortical layers IV-VI and the 
density of Iba1+ cells appeared comparable to TSSM controls (Figure 6. 22 C). Increased 
macrophage infiltration of the subarachnoid space was observed following LVLTα injection in 
naïve rats, accompanied by more widespread activation of microglia than seen following 
LVGFP, which extended through to cortical layers IV-V but was absent from the corpus 
callosum (Figure 6. 22 D-F). Very limited macrophage infiltration of the subarachnoid space was 
observed in rmMOG-immunised rats following LVGFP, accompanied by limited activation of 
microglia only in the subpial cortical layers I-III immediately surrounding the sagittal sulcus 
(Figure 6. 22 G-J). Strikingly widespread and prominent microglial activation was observed 
throughout cortical layers I-VI and in the corpus callosum in rmMOG-immunised rats at 90 days 
post-LVLTα, accompanied by substantial macrophage infiltration of the subarachnoid space 
(Figure 6. 22 K-M). Microglial activation was particularly evident in the subpial cortical areas 
bordering the sagittal sulcus and subarachnoid space (Figure 6. 22 K, L). In all groups, Iba1+ 
macrophages were observed to account for the majority of cells present in the subarachnoid 
space at this time-point.  
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Figure 6. 22 Widespread cortical microglial activation at 90 days post-LVLTα 
Iba1 IF revealed limited macrophage infiltration of the subarachnoid space (A, B) and very little 
microglial activation surrounding the sagittal sulcus (C) in naïve LVGFP rats. Prominent microglial 
activation occurred throughout the cortex (D, F) in naïve LVLTα rats, accompanied by macrophage 
infiltration of the subarachnoid space (E). Limited macrophage infiltration of the subarachnoid space (G, 
H) and little microglial activation immediately surrounding the sagittal sulcus in the corpus callosum or 
cortex (G-J) was observed in rmMOG-immunised LVGFP rats. Widespread microglial activation in the 
cortex and corpus callosum was observed in rmMOG LVLTα rats (K-M) accompanied by macrophage 
infiltration of the subarachnoid space (L). Images B, E, H, and L are magnifications of the boxed areas 
in A, D, G, and K respectively, and C, F, J and M are magnifications of the boxed areas in B, E, H, and L 
respectively. Scale bars: A, D, G, K = 500µm; B, E, H, L = 200µm; C, F, J, M = 25μm. n=3-6 per group. 
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6.2.5.3 Meningeal infiltration of B and T cells at 90 days 
Little infiltration of CD79a+ B cells was observed at 90 days post-LVGFP in either naïve (mean 
= 31.33 ± 3.50; Figure 6. 23 A, D) or rmMOG-immunised rats (mean = 13.67 ± 3.98; Figure 6. 
23 G, K). Very few Ki67+ cells were observed in the subarachnoid space or subpial cortex of 
these groups (Figure 6. 23 B, E and H, L respectively). Increased B cell infiltration was 
observed in naïve rats following LVLTα injection, although CD79a+ cells did not form the 
majority of cells in the infiltrates (mean = 75.67 ± 34.55; Figure 6. 23 C, F). Clusters of 
CD79a+ cells formed in the subarachnoid space but there was little co-localisation with Ki67 
IF, suggesting that dividing cells were not B cells (Figure 6. 23 F). Although subarachnoid 
infiltrate size was observably increased in rmMOG-immunised rats following LVLTα injection 
compared to the rmMOG-immunised LVGFP group, the majority of cells were not CD79a+ or 
Ki67+ (mean = 39.50 ± 13.39; Figure 6. 23 J, M). Small numbers of plasma cells were also 
observed in the subarachnoid space and included in the B cell count, ranging from ~2-6 cells 
per section, as for the day 28 time-point.  
CD4 and CD8 IF revealed meningeal infiltration of both T cell types at 90 days post-LVGFP 
injection in naïve (mean CD4 = 44.44 ± 11.0 5, mean CD8 = 70.89 ± 15.04; Figure 6. 24 A, D 
and B, E respectively) and rmMOG-immunised rats (mean CD4 = 11.44 ± 6.09, mean CD8 = 
19.11 ± 8.31; Figure 6. 24 G, K, and H, L, respectively). T cell infiltration was also observed 
following LVLTα injection in naïve (mean CD4 = 8.77 ± 2.86, mean CD8 = 40.45 ± 19.01; 
Figure 6. 24 C, F) and rmMOG-immunised rats (mean CD4 = 18.95 ± 4.62, mean CD8 = 24.50 
± 9.21; Figure 6. 24 J, M).  
CD4+ and CD8+ cells accounted for a relatively small proportion of the total cells within 
subarachnoid infiltrates, so despite formation of larger infiltrates following LVLTα but not 
LVGFP injection, there were no statistically significant differences in the numbers of infiltrating 
CD4+ (Figure 6. 25 A), CD8+ (Figure 6. 25 B), or CD79a+ cells (Figure 6. 25 C) between 
groups. There was a trend towards increased B cell infiltration in naïve and rmMOG-
immunised rats following LVLTα-injection compared to LVGFP but this was not significant, and 
no other infiltrates were considered to be B cell rich (Figure 6. 25 D). The majority of the 
remaining cells unaccounted for by T or B cell markers in the larger infiltrates observed 
following LVLTα injection were found to be Iba1+ macrophages, when adjacent sections were 
analysed by Iba1 IF, and constituted a large proportion of the infiltrates observed in naïve and 
rmMOG-immunised rats at 90 days post-LVLTα. 
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 Figure 6. 25 Quantification of meningeal inflammation at 90 days post-LV injection 
CD4+ (A) or CD8+ (B) T cells, and CD79+ B cells (C) were identified by IF in naïve and rmMOG-
immunised rats at 90 days post-injection with LVGFP or LVLTα. Quantification of cells in the 
subarachnoid space and sagittal sulcus in 3 adjacent sections per animal did not reveal any statistically 
significant differences, although there was a non-significant trend towards increased B cell numbers in 
LVLTα-injected animals (C, D). 
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6.2.5.4 Quantification of human LTα in CSF at 90 days post-LVLTα  
Samples of CSF were taken from naïve or rmMOG-immunised rats at 90 days post LVGFP or 
LVLTα and the concentration of human LTα analysed using an ECL assay (MSD). Limited 
non-specific background signal was observed, as CSF from LVGFP-injected animals gave 
readings below 2.1pg/ml (Figure 6. 26). LTα concentration in the CSF was detectable in 
(10/11) naïve and rmMOG-immunised rats at 90 days post-LVLTα (Figure 6. 26). In the 6 
rmMOG-immunised rats, LTα concentration ranged from 11-736.4pg/ml (group mean 313.5 ± 
132.2pg/ml). In naïve rats, LTα was above the LVGFP background signal level in (3/5) rats 
following LVLTα-injection, and ranged from 27.1-136.4pg/ml (group mean 75.29 ± 
32.21pg/ml). As for the 28 day time-point, the rmMOG-immunised rat with the largest total 
area of demyelination was found to have the highest concentration of LTα in the CSF, and the 
2 lowest concentrations were from the 2 animals in which no demyelination was observed.  
6.2.5.5 Quantification of human LTα and CXCL3 mRNA at 90 days post-LVLTα  
Quantitative PCR was performed on mRNA extracted from whole brain fixed tissue sections to 
verify transgene expression of human LTα in rmMOG LVLTα rats at 90 days, determine LTα 
receptor expression of TNFR1 and HVEM, and determine CXCL13 expression since ectopic 
LTα expression has been shown to induce expression of lymphoid chemokines in other in vivo 
models. RNA was extracted from rmMOG-immunised LVGFP or LVLTα rats at 90 days post-
injection and compared to naïve rats which received no immunisation or subarachnoid 
injection. A 62.8 fold increase in LTα mRNA (p=0.0209; Figure 6. 27 A) and a 23.9 fold 
increase in CXCL13 mRNA (p=0.0487; Figure 6. 27 B) were detected in rmMOG-immunised 
rats at 90 days post-LVLTα compared to naïve no-surgery control rats. No significant 
differences were detected between the naïve no-surgery control group and the rmMOG-
immunised LVGFP-injected group. There was no significant difference in the expression of rat 
LTα, TNFR1 or HVEM between groups.  
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 Figure 6. 26 Quantification of human LTα in CSF at 90 days post-LVLTα 
The concentration of human LTα in CSF samples from naïve and rmMOG-immunised rats at 90 days 
post-injection with LVGFP or LVLTα was quantified by ECL assay. There was a non-significant increase 
in LTα concentration in naïve rat CSF post-LVLTα compared to naïve LVGFP-injected rats. LTα was 
significantly increased in rmMOG-immunised LVLTα-injected rats compared to the rmMOG-immunised 
LVGFP group (p=0.0185 Kruskal-Wallis with Dunn’s post-test). 
 
Figure 6. 27 hLTα and CXCL13 mRNA in rmMOG-immunised rats at 90 days post-LVLTα 
Gene expression changes were detected using RT-PCR on fixed brain tissue from rmMOG-immunised 
LVGFP- and LVLTα-injected rats and naïve no-surgery controls. Human LTα (A)  and rat CXCL13 (B) 
mRNA were significantly increased in rmMOG-immunised rats at 90 days post LVLTα compared to 
naïve controls (p=0.0209 and p=0.0487 respectively, T test). There was no significant difference 
between the naïve controls and rmMOG-immunised LVGFP-injected group.  
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6.3 Discussion 
In this chapter, we sought to reproduce the key pathological features of SPMS in an animal 
model, including chronic meningeal inflammation, microglial activation and cortical 
demyelination. During the process of model development, we also evaluated the feasibility and 
efficacy of using LV vectors to induce chronic meningeal inflammation in the in vivo model 
used in the previous chapter. To this end, we determined the effects of injection of LV vectors 
expressing GFP or human LTα into the subarachnoid space in naïve and rmMOG-immunised 
rats, to test the hypothesis that chronically raised CSF concentrations of LTα can result in 
pathology of the underlying cortical GM. 
6.3.1 Characterisation of viral transduction in vitro  
Our findings support previous studies suggesting that LV vectors based on modified HIV-1 
represent a promising tool for long-term stable transduction of a range of cell types within the 
CNS (Blomer et al., 1997; Jakobsson et al., 2003; Fedorova et al., 2006). The high 
transduction efficiencies achieved with LVGFP and LVLTα in rat meningeal cells in vitro, lack 
of significant cell death and secretion of relatively high concentrations of LTα up to 7 days 
post-transduction suggested that transduction of meningeal cells in vivo by subarachnoid 
injection of LVLTα was feasible, and could lead to increased concentrations of LTα in the CSF, 
depending on the number of cells transduced. The expression of laminin by the majority of 
meningeal cells in vitro suggests that fibroblasts predominated, although a proportion of 
macrophages/microglia were also observed, as expected in meningeal cultures (Rutka et al., 
1986; Montagnani et al., 2000; Russi and Brown, 2014). Characterisation of rat meningeal 
cells in vitro revealed a lack of observable expression of TNFR1, suggesting that these cells 
are unable to respond to LTα in vitro, and may explain the lack of toxicity and apoptosis 
observed in the presence of relatively high LTα concentrations in the supernatant. Low 
constitutive expression of TNFR1 by ex vivo meninges has been reported, suggesting that it 
may be down-regulated in culture and that meningeal cells may respond to LTα in vivo 
(Nadeau and Rivest, 1999). Activation of meningeal fibroblasts with TNF in vitro results in 
decreased neuronal survival in co-cultures, suggesting that meningeal cells are capable of 
responding to TNF and of inducing damage to the underlying GM when activated by 
inflammatory infiltrates (Skaper et al., 1995).  
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6.3.2 LVGFP injection does not induce pathology  
Meningeal expression of GFP up to 90 days post-injection was achieved in naïve and rmMOG-
immunised animals in the absence of demyelination, significant microglial activation or 
meningeal inflammation. Subarachnoid injection of LV vectors is therefore an effective method 
of inducing stable transduction of cells lining the sagittal sulcus, with minimal activation of the 
innate or adaptive immune systems, and provides an ideal in vivo model in which to determine 
the effects of increased expression of cytokines in the meninges. The finding that LVGFP 
injection and subsequent GFP expression was not directly cytotoxic, and the minimal cellular 
infiltration of the subarachnoid space observed in the current study suggest that LVGFP does 
not induce significant stimulation of the immune system, consistent with previous studies 
(Abordo-Adesida et al., 2005). The majority of GFP expression was limited to pial cells and 
cells within the confines of the sagittal sulcus with a rounded morphology, some of which were 
Iba1+, suggesting that a significant proportion of transduced cells were meningeal 
macrophages and fibroblasts. These observations suggest that the pia mater was largely 
intact following subarachnoid injection, and prevented significant viral vector access to 
parenchymal cells, in keeping with observations following intrathecal viral vector injection in a 
previous study (Fedorova et al., 2006). However, limited transduction of astrocyte end feet 
was also observed, perhaps due to minor disruption of the pia mater at the injection site in 
some animals, which supports previous observations that VSV-G pseudo-typed viruses 
transduce a variety of cell types (Jakobsson et al., 2003). The apparent reduction in GFP 
expression observed at 28 days post-injection compared to 7 days may be due to down-
regulation of the CMV promoter, which has been suggested to occur in previous studies 
(Norrman et al., 2010), and may have occurred to a limited extent in the current study, in spite 
of the use of the full CMV promoter to enhance transduction and promote long-term 
expression. However, GFP expression at 90 days appeared to be similar to that observed at 
28 days, confirming that stable-expression was achieved in spite of some reduction compared 
to the 7 day time-point, leading us to conclude that subarachnoid injection of LVs is an 
effective method to induce long-term expression of molecules of interest in cells lining the 
subarachnoid space.  
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6.3.3 Meningeal inflammation following LVLTα  
6.3.3.1 LTα expression and creation of a pro-inflammatory CSF environment 
In MS it is suggested that the chronic presence of inflammatory cytokines in the CSF 
contributes to GM pathology and disease progression (Reynolds et al., 2011). The formation of 
very large infiltrates only following LVLTα and not LVGFP at 7 days post-injection suggests 
that production of LTα was sufficient to induce meningeal inflammation. Although the LTα CSF 
concentration was only above the limit of detection by ELISA in one animal at 7 days post-
LVLTα, we suggest that the local concentration achieved in the confines of the sulcus was 
sufficient to induce pathology. This data supports our suggestion in chapter 3 that global CSF 
LTα concentration may not reflect local LTα CSF concentrations in deep sulci where TLOs are 
found in human tissue.  
Expression of LTα appeared to be stable between 28 and 90 days post-LVLTα, since the CSF 
concentrations of each group were consistent at both time-points. However, LTα CSF 
concentration was markedly increased (although not always significant) in rmMOG-immunised 
compared to naïve rats at both time-points. LTα mRNA expression increases in cells isolated 
from rat CSF prior to the onset of EAE, and peaks in line with the peak of neurological deficit 
(Diab et al., 1997). However, in the current study LTα was undetectable in rmMOG-immunised 
rats following PBS or LVGFP injection, suggesting that the effect is dependent on LVLTα 
injection. LTα is a known astrocytic mitogen but would be expected to induce similar 
proliferation effects in both immunisation groups (Selmaj et al., 1990). Increased proliferation 
of transduced cells in rmMOG-immunised rats seems unlikely, since there was no observable 
difference in the size of the infiltrates observed in rmMOG-immunised and naïve rats at both 
time-points. We therefore suggest that the difference in LTα CSF concentration may be due to 
transduction of cells previously activated by rmMOG immunisation, or stimulation of 
transduced cells by factors expressed by MOG-reactive cells, resulting in increased secretion 
of LTα per transduced cell. Expression of retrovirus transgenes has been shown to be 
increased in highly activated T cells, suggesting a possible reason for the increase in LTα in 
rmMOG-immunised compared to naïve rats following LVLTα (Quinn et al., 1998). This would, 
to a certain extent, replicate the increased LTα secretion observed in CD8+ T cells from SPMS 
patients compared to controls (Buckle et al., 2003). However, the small n numbers of the 
current study should be taken into account when interpreting these results, particularly in light 
of the variability of concentrations of LTα in the CSF.  
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6.3.3.2 Comparison of MS TLOs to meningeal inflammation in the rat 
Meningeal TLOs in F+SPMS have been described to contain proliferating B cells, T cells, 
plasma cells and FDCs, and express CXCL13 and CCL21 (Serafini et al., 2004; Magliozzi et 
al., 2007; Howell et al., 2011). Early infiltrates observed at 7 days post-LVLTα in the current 
study are reminiscent of meningeal TLOs in F+SPMS, with several of the same components, 
and demonstrate that expression of LTα alone in the subarachnoid space is sufficient to 
induce immune cell infiltration. These infiltrates were also very B cell rich, in keeping with 
TLOs described in F+SPMS. In addition, B and T cells were observed in all infiltrates in all 
LVLTα-injected groups at all time-points, to some extent reproducing the chronic nature of 
meningeal inflammation of F+SPMS, within the limits of an in vivo model (Serafini et al., 2004; 
Howell et al., 2011). However, the composition of the infiltrates changed over time. Numbers 
of CD4+ and CD8+ T cells remained fairly consistent across time-points for all groups but a 
dramatic reduction in the number of CD79a+ B cells and proliferating B cells was observed to 
occur by 28 and 90 days compared to the large numbers present at 7 days post-LVLTα.  
Proliferating B cells were observed to make up ~16% of infiltrating B cells at 7 days post-
LVLTα and were scattered throughout infiltrates in a manner that was also observed in 
F+SPMS throughout the meninges (Magliozzi et al., 2007; Magliozzi et al., 2010). However, 
these cells were very rarely observed at the chronic time-points, and the more organised 
groups of proliferating B cells representing meningeal TLOs characteristic of F+SPMS were 
not observed. This suggests that if B cell germinal centres (GCs) were formed in the infiltrates 
at the 7 day time-point, they were not sustained. B cell infiltration and proliferation in this 
model appears to be an acute and self-resolving response to LTα, suggesting that other 
factors may be required for TLO organisation and maintenance.  
In contrast to the transient nature of B cell infiltration, macrophage infiltration was a prominent 
and persistent feature in LVLTα- but not LVGFP-injected groups. Macrophages were observed 
to constitute part of the large infiltrates of T and B cells formed at 7 days post-LVLTα, and 
accounted for the majority of cells in infiltrates at the 90 day time-point, since the observable 
size difference in infiltrates between LVLTα and LVGFP injected groups was not reflected by 
the numbers of T and B cells, which were similar between groups. Interestingly, macrophage 
infiltration appeared to be more prominent at the 90 day time-point compared to at 28 days, 
which may be due to ongoing demyelination. The chronic presence of LTα in the CSF may 
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increase meningeal inflammation over time, although in this model it is not sufficient to 
maintain chronic B cell rich TLOs.  
Interestingly, although B cell infiltration and proliferation was not maintained, other possible 
features indicative of TLO neogenesis were observed in our model. A previous study found 
that TLOs containing GCs were associated with the presence of high endothelial venules 
(HEVs) and “loose dilated” lymphatic vessels, and an increase in CXCL13 mRNA expression 
(Perros et al., 2012). Consistent with observations from the previous chapter, the presence of 
many channels of variable diameter was observed within the large infiltrates observed at 7 
days post-LVLTα, some of which resembled the “loose dilated” lymphatic vessels described by 
Perros et al., (2012). Others were smaller in diameter and may represent formation of HEVs. 
However, as mentioned in the previous chapter it was not possible to confirm the identity of 
these structures due to a lack of suitable IF or IHC markers for the tissue available. 
We also demonstrated that chronic expression of LTα in the subarachnoid space leads to 
upregulation of CXCL13 mRNA expression in whole brain samples, indicative of TLO 
formation and consistent with previous findings following ectopic expression of LTα 
(Hjelmstrom et al., 2000; Perros et al., 2012). In chapter 3 we suggested that chronic presence 
of LTα in the meninges could lead to induction of CXCL13 and CCL21 expression in F+SPMS, 
possibly by driving meningeal fibroblast differentiation into FDCs, resulting in the formation of 
TLOs. Unfortunately as mentioned in the previous chapter, a suitable FDC marker was 
unavailable during the current study, but the increase in CXCL13 mRNA expression following 
LVLTα injection in rmMOG-immunised animals at 90 days post-injection suggests that FDCs 
might be present in the subarachnoid infiltrates observed in this group.  
CXCL13 is known to organise and recruit B cells to SLOs and is postulated to play a similar 
role in TLOs and the CNS in MS, since the CSF concentration of CXCL13 is significantly 
elevated in RRMS, PPMS and SPMS patients, and is significantly correlated with numbers of 
B cells, plasma blasts and T cells in RRMS (Krumbholz et al., 2006; Sellebjerg et al., 2009). 
However, B cell recruitment to the CNS was not significantly impaired in CXCL13-/- mice 
during EAE, although disease was less severe, suggesting that other factors may be more 
important in attracting B cells to the CNS (Bagaeva et al., 2006). These results support the 
findings of the current study, where no significant difference in B or T cell number was 
observed between the rmMOG-immunised LVLTα- and LVGFP-injected groups at 90 days, 
despite the significant increase in CXCL13 mRNA in tissue from LVLTα-injected animals. 
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However, it is possible that although CXCL13 mRNA expression was elevated in the tissue, 
this did not result in a sufficient increase in CSF concentration to impact B and T cell numbers 
in the CSF. Unfortunately insufficient rat CSF was available to quantify CXCL13 concentration.  
We suggest that in the current study the upregulation of endogenous rat CXCL13 mRNA in 
rmMOG-immunised LVLTα rats was due to the increased subarachnoid infiltration of 
macrophages compared to the LVGFP group, since these cells are known to express CXCL13 
under inflammatory conditions (Carlsen et al., 2004). The observed increase in microglial 
activation may also contribute to the increase in CXCL13 mRNA, as a previous study showed 
an increase in LTα and CXCL13 gene expression in cultured rat glial cells following incubation 
with cytokines including TNF and IFNγ, suggesting that activated glial cells may contribute to 
the inflammatory milieu in the CSF through secretion of pro-inflammatory cytokines and 
chemokines (Lisak et al., 2006; Lisak et al., 2012).  
6.3.4 Widespread microglial activation post-LVLTα 
The current study demonstrates that chronic expression of LTα in the subarachnoid space is 
sufficient to induce fulminant microglial activation in the underlying GM, and provides strong 
supporting evidence for the hypothesis that pro-inflammatory cytokines in the CSF may drive 
cortical pathology, as well as achieving our aim of reproducing a key feature of SPMS GMLs in 
vivo. The observed increase in microglial activation surrounding the subarachnoid infiltrates in 
both naïve and rmMOG-immunised rats following LVLTα, which was not apparent following 
LVGFP or TSSM injection, indicates that LTα, or a soluble factor produced by the infiltrates, 
diffused through the pial membrane to activate microglia in the superficial cortical layers. Since 
microglial activation was maintained up to 90 days, while lymphocytic infiltration of the 
meninges was comparable between LVGFP and LVLTα groups at this time-point, we suggest 
that the difference in microglial activation in the current model was due to chronic LTα 
expression, or to a soluble factor expressed by macrophages observed in the subarachnoid 
space in LVLTα animals that were significantly more numerous than in LVGFP animals. The 
activation of cortical microglia by pro-inflammatory cytokines in the subarachnoid space is in 
keeping with findings from MS cortical tissue, and in vivo data from the previous chapter and 
previous studies using other pro-inflammatory cytokines (Kutzelnigg et al., 2005; Magliozzi et 
al., 2010; Howell et al., 2011; Reynolds et al., 2011; Lassmann et al., 2012; Gardner et al., 
2013).  
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The diffuse microglial activation in NAGM observed in naïve LVLTα-injected rats is highly 
reminiscent of NAGM in F+SPMS cases, supporting the suggestion that cortical microglial 
activation in F+SPMS is driven by meningeal inflammation (Magliozzi et al., 2010; Howell et 
al., 2011). Since the CSF concentration of LTα was relatively high and appeared to correlate 
with the extent of microglial activation at 28 and 90 days post-LVLTα, it is possible that LTα in 
the CSF in perivascular spaces gained access to microglia located deep in the cortex via this 
route. This suggestion is supported by a recent study, which showed that tracers of a similar 
molecular weight to LTα injected into the CSF entered cortical tissue via a para-arterial route 
approximately 40 minutes after injection (Iliff et al., 2012). However, F+SPMS is characterised 
by a gradient of microglial activation, with the greatest activation observed in layers closest to 
the pial surface suggesting that the greatest effect of pro-inflammatory mediators in the CSF 
occurs at the pial surface and not in perivascular regions (Magliozzi et al., 2010). We therefore 
suggest that chronic activation of microglia close to the pial surface may result in activation of 
neighbouring microglia located in the deeper cortical layers, leading in time to widespread 
activation as observed in the current study.  
In MS GMLs, activated microglia are the major inflammatory component (Peterson et al., 
2001; Bo et al., 2003a), but it is currently unknown whether microglial activation is a cause or 
consequence of demyelination. In the current study, widespread activation of microglia 
occurred in naïve LVLTα-injected animals in the absence of demyelination, suggesting that in 
this model, activation is not a consequence of demyelination and is insufficient to cause myelin 
damage in the absence of an anti-MOG immune response. This suggestion is supported by 
the observation that widespread microglial activation is also a feature of Alzheimer’s disease 
(AD), and occurs in the absence of demyelination (Dal Bianco et al., 2008). In contrast to AD, 
in MS microglial activation is thought to be primarily driven by a specific adaptive immune 
response, as activated microglia are correlated quantitatively and spatially to the extent of 
immune cell infiltration in the meninges in MS but not in AD (Bo et al., 2003a; Dal Bianco et al., 
2008; Magliozzi et al., 2010; Howell et al., 2011). This suggestion is supported by our 
observations of increased microglial activation in rmMOG-immunised compared to naïve 
LVLTα animals, and suggests that microglial activation by a pro-inflammatory CSF 
environment may be potentiated by an existing anti-MOG response. Whether this increase in 
microglial activation in rmMOG-immunised LVLTα animals reflects a contribution of microglia 
to the demyelination observed, or bystander activation of microglia as a result of the 
demyelination that occurs due to other processes was beyond the scope of our study.  
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6.3.5 Demyelination and the requirement for an anti-MOG response  
The lack of quantifiable demyelination observed in naïve rats at 90 days post-LVLTα is in 
keeping with data from the previous chapter, in which significant demyelination was only 
observed in rmMOG-immunised cytokine-injected rats. This clearly suggests that the presence 
of microglial activation, meningeal inflammation, and increased CSF LTα are not sufficient to 
induce demyelination in this model, and that a pre-existing anti-MOG response is required. 
Microglial activation was particularly prominent in rmMOG-immunised LVLTα rats at the 
chronic time-points in areas corresponding to the areas of demyelination, suggesting that 
microglia may contribute to demyelination in this model. The requirement for an anti-MOG 
response for demyelination to occur suggests that the microglial activation response may differ 
depending on prior immunisation (e.g. activated microglia release different effector molecules 
in rmMOG-immunised compared to naïve LVLTα rats), or that autoantibodies contribute to 
microglial-mediated demyelination in this model. A qualitative difference in the expression of 
cytokines and other soluble factors by autoreactive immune cell infiltrates in rmMOG-
immunised LVLTα rats, combined with the presence of increased LTα in the CSF which is 
necessary for microglial activation in this model, may result in altered activation of microglia. 
Altered microglial activation may lead to expression of toxic factors, including nitric oxide 
synthase and TNF as occurs in F+SPMS (Magliozzi et al., 2010), and demyelination in the 
rmMOG-immunised LVLTα group. 
Microglia were activated in all LVLTα groups, but it is possible that activated microglia in naïve 
rats were unable to initiate phagocytosis of MOG and demyelination due to a lack of 
autoantibodies. Among other mechanisms, autoantibodies can induce demyelination via 
stimulation of macrophages/microglia to release of inflammatory mediators by binding Fc 
receptors, or though opsonisation of myelin inducing phagocytosis by macrophages/microglia 
(Archelos et al., 2000). B cell numbers were comparable in rmMOG-immunised LVGFP and 
LVLTα groups at the chronic time-points, suggesting that LTα and/or a pro-inflammatory CSF 
environment is also required for any autoantibody production to result in demyelination, since 
no demyelination was observed in rmMOG-immunised LVGFP animals. Possibly chronic 
activation of microglia by LTα in the CSF is required for the subarachnoid production of 
autoantibodies to result in demyelination in rmMOG-immunised LVLTα rats. Autoantibodies 
may also induce demyelination through activation of complement, and immunoglobulin and 
complement fragment deposition have been observed on myelin sheaths at the lesion edge in 
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targeted EAE following subarachnoid and intracortical injection of TNF and IFNγ (Merkler et 
al., 2006b; Gardner et al., 2013), suggesting that humoral mechanisms may contribute to 
demyelination in these models and in the current study. While autoantibodies have been 
shown to play a role in demyelination in EAE (Linington and Lassmann, 1987; Linington et al., 
1988; Linington et al., 1992; Storch et al., 1998b; Storch et al., 2006), their contribution to the 
pathogenesis of GMLs in MS is less clear. Autoantibodies specific for a range of myelin 
antigens have been isolated from WMLs (Genain et al., 1999; Raine et al., 1999; O'connor et 
al., 2005), and antibody-mediated complement activation has been observed in a subset of 
MS lesions (Lucchinetti et al., 2000). However, deposition of complement has not been 
observed in cortical GMLs (Brink et al., 2005), although this may be because these lesions 
were not studied during the acute phase, when lymphocytic infiltration is prominent 
(Lucchinetti et al., 2011), or due to the transient nature of complement deposition which has 
been observed in rat cortical GMLs (Merkler et al., 2006b).  
The concentration of human LTα in the CSF appeared to correlate with the extent of 
demyelination in rmMOG-immunised LVLTα animals, but a directly demyelinating effect of LTα 
seems unlikely as demyelination was not observed in naïve LVLTα-injected rats, in spite of 
microglial activation in naïve animals suggestive of diffusion of a soluble activating factor from 
the CSF into the GM and corpus callosum. This again highlights the requirement for an anti-
MOG response. Although LTα has been shown to be toxic to neurons and oligodendrocytes in 
vitro, it is possible that endogenous TNFR1 expression in rat brain parenchyma in vivo is 
insufficient to mediate the directly cytotoxic effects of LTα. The presence of a milieu of other 
cytokines would more accurately reflect the CSF environment in MS. IFNγ gene expression is 
known to be upregulated in the meninges in F+SPMS compared to F-SPMS cases, and also 
induces upregulation of TNFR1 expression on oligodendrocytes, microglia and astrocytes, 
suggesting that addition of chronically elevated IFNγ in the CSF in this model might potentiate 
the effect of LTα, leading to increased pathology and possibly direct cytotoxicity of 
oligodendrocytes (Dopp et al., 1997; Buntinx et al., 2004). To exclude the possibility that the 
lack of demyelination in naïve LVLTα rats was due to a difference in the endogenous 
expression of receptors for LTα, we determined the expression of HVEM and TNFR1. 
Expression of these receptors was not significantly different between rmMOG-immunised rats 
at 90 days post-LVLTα or LVGFP and naïve no-surgery control rats, indicating that rmMOG 
immunisation, injection of LV vectors and/or the presence of meningeal inflammation did not 
induce up- or down-regulation of endogenous receptor expression at this time-point.  
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Unfortunately time constraints prevented quantification of subpial neuronal numbers during the 
current study, although analysis of neurofilament IF revealed no observable loss of axons in 
GMLs in rmMOG-immunised rats at 90 days post-LVLTα. Acute subarachnoid injection of 
cytokines was also insufficient to cause significant neuronal loss in a previous study (Gardner 
et al., 2013), or observable axonal loss in the previous chapter, in contrast to SPMS where 
severe meningeal inflammation has been shown to be associated with a gradient of neuronal 
loss, which is most pronounced in the cortical layers closest to the meninges (Magliozzi et al., 
2010). Replication of this important feature of SPMS thus remains to be determined in our 
chronic in vivo model. 
6.3.6 Cycles of remyelination, or chronic demyelination? 
The substantial areas of subpial demyelination that were observed in rmMOG-immunised rats 
at 28 and 90 days post-LVLTα, in contrast to the complete remyelination of GMLs observed to 
occur within 21 days of cytokine injection in the previous chapter and in other targeted EAE 
models (Merkler et al., 2006b; Gardner et al., 2013; Rodriguez et al., 2014), may represent 
chronic demyelination due to a failure of remyelination, or cycles of demyelination interspersed 
with intervening remyelination. The fact that demyelination was not observed in every rmMOG-
immunised animal following LVLTα at these time-points suggests that remyelination may occur 
between cycles of demyelination. In addition, the presence of MOG+ cell bodies in the GM 
close to the lesion edge in rmMOG-immunised LVLTα rats at 28 days suggested that 
remyelination was occurring at this time-point. Remyelination following cuprizone-induced 
demyelination is unaffected in LTα-/- mice, suggesting that LTα does not play a direct role in 
remyelination unlike TNF, but no studies to our knowledge have examined the effects of over-
expression of LTα in the CSF on demyelination or remyelination (Plant et al., 2005). Repeated 
cycles of demyelination may reduce the efficiency of remyelination (Johnson and Ludwin, 
1981; Prineas et al., 1993b), although this was not observed in GM following 4 cycles of 
targeted EAE (Rodriguez et al., 2014).  
Demyelination may be an early event, induced by factors produced by the large immune cell 
infiltrates observed at 7 days post-LVLTα, which persists until 90 days post-LVLTα due to a 
failure of remyelination. In MS it is suggested that chronically demyelinated lesions may occur 
if remyelination is incomplete when the inflammatory response subsides, since remyelination 
efficiency is positively correlated with inflammation (Raine and Wu, 1993; Franklin, 2002; 
Foote and Blakemore, 2005). Subarachnoid immune cell infiltrates of varying size were 
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present at 90 days post-LVLTα injection in rmMOG-immunised rats, as well as marked 
microglial activation, suggesting that an inflammatory response was ongoing at this time-point, 
which might be expected to promote remyelination. LTα is toxic to oligodendrocytes in vitro 
and might be expected to directly contribute to oligodendrocyte death and remyelination 
failure, but as discussed earlier, the lack of demyelination in naïve animals following LVLTα 
injection argues against a directly cytotoxic effect in this model (Selmaj et al., 1991c). It is 
possible that the chronic presence of LTα in the CSF, or other factors produced in response to 
LTα (e.g. by activated microglia), may inhibit OPC recruitment, proliferation, migration and/or 
differentiation into mature oligodendrocytes, although to our knowledge this has yet to be 
investigated in vitro or in vivo. Whilst our chronic model of targeted EAE successfully induced 
GMLs up to 90 days post-injection, the dynamics of this pathology remain to be determined, 
since unfortunately the time constraints of the current study did not allow quantification of 
oligodendrocytes and OPCs. Investigation of remyelination using electron microscopy to 
determine the g-ratios of myelinated axons was also beyond the scope of the current study.  
6.4 Conclusions  
In the current study we developed a novel model of chronic GM pathology driven by chronic 
presence of LTα in the CSF, following injection of LVLTα into rmMOG-immunised rats. The 
resulting pathology was characterised by meningeal inflammation, chronic demyelination and 
widespread microglial activation, and was reminiscent of SPMS. In addition to GM pathology, 
microglial activation and demyelination of the corpus callosum were also observed, 
demonstrating increasing involvement of this WM structure. Demyelination was dependent on 
the chronic presence of LTα / a pro-inflammatory CSF environment, and a pre-existing anti-
MOG response, since widespread microglial activation in naïve animals did not result in 
demyelination. Initial meningeal inflammation was characterised by B cell rich infiltrates, in 
keeping with TLOs observed in F+SPMS, while macrophages predominated at the chronic 
time-points. Although formation of channels resembling HEVs and lymphatic vessels, together 
with an increase in CXCL13 mRNA expression, were features of TLO formation that were 
observed in our model, the dissipation of lymphocytic meningeal infiltration suggests that other 
cytokines may be required to induce TLOs with GCs. 
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7.1 Meningeal inflammation and cytokine expression in SPMS 
A number of studies carried out in this laboratory and others have highlighted an important role 
for meningeal inflammation in MS pathology. The work presented in this thesis is the first to 
demonstrate meningeal and CSF expression of lymphoid cytokines and chemokines, which 
has not previously been reported in human meninges or in post-mortem CSF. Our finding that 
LTα meningeal gene expression is increased in SPMS compared to control cases supports a 
role for this cytokine in meningeal inflammation, which may include, but is not limited to, TLO 
neogenesis. Our data indicates that significant degradation of LTα in the CSF occurs post-
mortem, suggesting that LTα may be present in a higher proportion of cases than identified by 
our work. Further investigation of LTα concentrations in CSF from SPMS patients using 
sensitive ECL assays could clarify this point. However, an increase in global CSF 
concentration may not be necessary for LTα to significantly contribute to meningeal 
inflammation or TLO neogenesis in deep sulci, since the reduced CSF flow in these areas is 
postulated to allow a local increase in cytokine concentration within the sulcus which may not 
be reflected by global concentrations (Magliozzi et al., 2007; Howell et al., 2011).  
Our finding of B cell rich meningeal infiltrates in F+SPMS cases, which were frequently 
associated with extensive subpial GMLs, supports previous findings (Serafini et al., 2004; 
Magliozzi et al., 2007; Magliozzi et al., 2010; Howell et al., 2011), and is in keeping with the 
hypothesis that cytotoxic factors diffuse from areas of meningeal inflammation into the 
underlying GM and contribute to GML pathogenesis and disease progression. We suggest that 
in F+SPMS with prominent meningeal inflammation, LTα expressed by infiltrating cells in the 
meninges (suggested to be B cells (Fu et al., 1998) and/or macrophages (Guedj et al., 2013)) 
within sulci may induce a sufficient increase in the local LTα concentration to result in 
fibroblast differentiation into FDCs, and induction of lymphoid chemokines, including CXCL13 
and CCL21 as is suggested to occur in RA (Lindhout et al., 1999; Van Nierop and De Groot, 
2002; Geurtsvankessel et al., 2009; Kain and Owens, 2013). In F-SPMS, meningeal 
inflammation may contribute to GM damage through the production of LTα, but local 
concentrations within sulci may be insufficient to induce fibroblast differentiation and drive TLO 
formation due to the more diffuse and less fulminant nature of meningeal infiltration observed 
in F-SPMS compared to F+SPMS cases.  
The most striking finding of our investigation into meningeal gene expression was the 
substantial increase in CXCL13 meningeal gene expression observed only in F+SPMS cases. 
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Our subsequent finding that CXCL13 CSF concentration is also significantly increased only in 
F+SPMS cases supports the suggestion that this chemokine is important for, or is a marker of, 
TLO neogenesis, in keeping with previous studies (Zheng et al., 2005). We confirmed the wide 
variation in CXCL13 concentration in CSF from SPMS patients, that has been previously 
reported to result in a subset of patients with high CXCL3 concentrations and another with low 
or undetectable CXCL13 (Krumbholz et al., 2006). Our data supports the previous speculation 
that increased CXCL13 in the CSF may indicate the presence of TLOs, and that these subsets 
may represent F+SPMS and F-SPMS groups respectively (Krumbholz et al., 2006). The 
significant correlation between increased CXCL13 and a younger age of first wheelchair use 
shown by our data, and correlations approaching significance between increased CXCL13 and 
a younger age at progression and death, also support previous work (Sellebjerg et al., 2009; 
Khademi et al., 2011). We suggest that this data supports the use of CXCL13 CSF 
concentration as a promising prognostic marker of meningeal inflammation and possible TLO 
formation in SPMS, prompting earlier therapeutic interventions designed to limit meningeal 
infiltration as far as possible in MS patients with increased concentrations.  
The main limitation of our study of meningeal gene expression was that it was limited in size 
due to the intensity of effort (and time) required to dissect sufficient meningeal tissue from 
each case; up to 16 blocks per case were sampled in the current study compared to up to 30 
per case in a previous study (Howell et al., 2011). In addition, TLOs are found most often in 
deep sulci, where meningeal tissue is well preserved but difficult to manually dissect for RNA 
extraction. Collection of sufficient meningeal tissue required including meninges overlying gyri, 
which may have minimized the inclusion of TLOs from deep sulci in F+SPMS, reducing any 
differences in gene expression between the F-SPMS and F+SPMS groups.  
7.2 Acute and chronic animal models of cortical pathology 
The increasing evidence of the contribution of cortical GMLs to the accumulation of disability 
and clinical progression of MS (Bo et al., 2003l; Fisniku et al., 2008; Calabrese et al., 2009; 
Calabrese et al., 2010; Geurts et al., 2012) has prompted the development of several in vivo 
models of targeted EAE (Merkler et al., 2006b; Merkler et al., 2006c; Gardner et al., 2013). 
Subarachnoid injection of cytokines in a previously reported model of targeted EAE has 
proved a useful model to determine the effects of acutely raising the CSF concentration of pro-
inflammatory cytokines, and supports the hypothesis that a pro-inflammatory cytokine milieu in 
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the CSF can induce subpial GMLs in the presence of an anti-MOG immune response 
(Gardner et al., 2013). However, in vivo models using cytokine injection are limited by the 
acute and resolving nature of the cortical pathology induced. Development of a model of 
chronic cortical pathology, which can be induced in a targeted manner in a defined anatomical 
location, in a manner in keeping with postulated pathogenic mechanisms in MS, is important 
not only to allow investigation of GML pathogenesis and their role in clinical progression, but 
also to identify novel therapeutic targets and determine the effects of new therapies.  
The work presented in this thesis reproduced the model of subarachnoid injection of cytokines 
to investigate the acute effects of injection of LTα with IFNγ in comparison to the effect of TNF 
with IFNγ reported by a previous study (Gardner et al., 2013), since LTα, like TNF, is a ligand 
for TNFR1 and TNFR2 but has additional roles in lymphoid organogenesis and TLO 
neogenesis, and is therefore of interest in TLO formation in F+SPMS cases. LTα, like TNF, 
has also been shown to be directly toxic to oligodendrocytes (Selmaj et al., 1991c), but unlike 
TNF it does not stimulate cell survival signalling when interacting with the TNFR2 receptor. In 
addition, we developed a novel chronic model of cortical pathology driven by meningeal 
inflammation and a pro-inflammatory CSF environment, using injection of a lentiviral vector 
expressing LTα. To our knowledge, this is the only targeted EAE model that has demonstrated 
GML pathology at long time-points, in this case 90 days post-injection. Several key features of 
pathology were observed to arise in both the acute and chronic models. The implications of 
the findings from both models are discussed below and summarised in Figure 7.1. 
7.2.1 An anti-MOG response is required for demyelination in vivo 
We have demonstrated that acutely raising the concentration of LTα and IFNγ in the CSF 
through subarachnoid injection, elicits acute and severe meningeal inflammation regardless of 
prior priming of the immune system, but that subpial demyelination requires a pre-existing 
autoimmune anti-MOG response, in keeping with previous studies of TNF and IFNγ injection 
(Merkler et al., 2006b; Gardner et al., 2013). Similar subpial GMLs were observed in rmMOG-
immunised rats at 28 and 90 days after injection with LVLTα and reproduced key pathological 
characteristics of cortical type III lesions observed in MS, including microglial activation and 
minimal lymphocytic infiltration (Peterson et al., 2001; Bo et al., 2003a; Howell et al., 2011).  
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alone. Chronic elevated CSF concentration of LTα following LVLTα injection is not sufficient to 
induce GMLs at 28 or 90 days unless present in the context of an existing anti-MOG response, 
since no demyelinated lesions were observed in naïve animals following LVLTα. The 
requirement for an anti-MOG response suggests that autoantibodies and complement may 
play a role in the pathogenesis of demyelination in our model, although the evidence of 
complement-mediated demyelination in GMLs in MS is lacking (Brink et al., 2005), and this is 
discussed further in 7.2.3. It is also possible that the requirement for an anti-MOG response to 
induce demyelination in our models is due to a requirement for autoreactive T and B cells and 
the cytokine milieu they release when reactivated in the subarachnoid space, which may also 
be the case in MS. 
Naïve animals were observed to have lower LTα CSF concentrations at the 28 and 90 day 
time-points compared to rmMOG-immunised rats post-LVLTα, suggesting that perhaps there 
is an LTα concentration threshold that needs to be reached in order to result in cytotoxic levels 
that induce demyelination. A complex milieu of cytokines is suggested to contribute to GML 
pathogenesis in MS however, and it may be that the addition of other cytokines, including IFNγ 
which is upregulated in F+SPMS meninges and is known to upregulate TNFR1, may induce 
demyelination in the absence of an anti-MOG response. It is also possible that if more chronic 
time-points were studied (up to 12 months for example), the chronic presence of LTα in the 
CSF might eventually result in demyelination in naïve animals, and that an anti-MOG response 
may simply increase the speed and severity of GML pathology in this model. Although not 
sufficient, LTα is necessary for GML pathogenesis in this model since GMLs were not 
observed in rmMOG-immunised rats following LVGFP or PBS injections. In addition, without 
the chronic expression of LTα by LVLTα transduced cells, inflammation and demyelination 
resolves within 14-21 days, in line with the decrease in meningeal infiltration observed 
following the acute injection of cytokines and in keeping with previous studies (Merkler et al., 
2006b; Gardner et al., 2013). Thus GML development and maintenance requires chronic 
meningeal expression of LTα and an anti-MOG response.  
Interestingly, in spite of the observation of GMLs at 90 days post LVLTα, no apparent 
reduction of axonal neurofilaments was observed, consistent with observations of GMLs 
following acute injection of LTα and IFNγ, but further work is required to confirm if subtle 
changes in axonal integrity and density, and neuronal numbers, and are present that were not 
detectable by observation. Neuronal loss was not a feature of GMLs following acute 
subarachnoid injection of cytokines in a previous study (Gardner et al., 2013), but it is 
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expected that the chronic presence of LTα in the CSF might induce neuronal loss as observed 
in GMLs in MS (Wegner et al., 2006; Magliozzi et al., 2010; Reynolds et al., 2011). Neuronal 
loss is particularly pronounced in F+SPMS cases, where a gradient of loss is observed that is 
greatest in the most superficial cortical layers closest to the meninges, again supporting the 
hypothesis of diffusion of a toxic factor from the CSF/meningeal compartment (Magliozzi et al., 
2010). Further work, including neuronal quantification using the NeuN, neurofilament-H (Nfil) 
and amyloid precursor protein (APP) IF markers, will be carried out in cortical layers I-V to 
determine if a gradient of neuronal loss exists, as might be expected given the findings from 
F+SPMS cases. It is possible however, that the 90 day time-point is not sufficient for chronic 
meningeal inflammation to induce axonal damage or loss, and that a more chronic time-point 
may be required to induce this pathology. 
The chronic model developed by our work is promising as it appears to reproduce chronic 
cortical demyelination in contrast to the acute in vivo models studied previously in which 
remyelination is complete within 21 days after cytokine injection (Merkler et al., 2006b; 
Gardner et al., 2013). The observation of subpial lesions at 90 days after LVLTα suggests 
either a failure of remyelination, or a cycle of remyelination and demyelination which has been 
captured at one time-point. Further work to determine which of these scenarios is true would 
require high quality MRI of GMLs over multiple time-points, or multiple groups of animals at 
intervening time-points, or investigation of g-ratios to identify areas of remyelination. Detailed 
quantification of Olig2+ oligodendrocytes and NG2+ OPCs might also indicate if/why 
remyelination has failed, or is ongoing in the tissue.  
7.2.2 Microglial activation and the role of microglia in demyelination 
Subpial lesions in both models were associated with prominent microglial activation consistent 
with findings in SPMS and previous in vivo studies (Peterson et al., 2001; Merkler et al., 
2006b; Magliozzi et al., 2010; Howell et al., 2011; Gardner et al., 2013). Limited microglial 
activation was observed in naïve and IFA-immunised rats following acute injection of LTα and 
IFNγ, confined to the subpial edge of the cortical GM immediately surrounding the sagittal 
sulcus at the injection site, and which did not extend beyond cortical layer II. In contrast, there 
was widespread and prominent microglial activation throughout the cortex in naïve animals at 
90 days post-LVLTα. This demonstrates clearly that chronic meningeal expression of a pro-
inflammatory cytokine can induce activation of microglia throughout the cortex regardless of 
prior immunisation, thus supporting our hypothesis that chronically raised cytokines in the CSF 
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may induce cortical pathology, and reproducing a key feature of SPMS (Magliozzi et al., 2010; 
Howell et al., 2011). In addition to the raised CSF concentration of LTα, it is expected that a 
complex cytokine milieu is released by the substantial meningeal infiltrates of macrophages, T 
and B cells that are observed following LVLTα injection. We suggest that widespread 
microglial activation is induced either through diffusion of LTα and/or the cytokine milieu into 
the parenchyma via the CSF in the perivascular spaces that run throughout the cortex, or 
through activation of microglia closest to the pial layer and subarachnoid space, which in turn 
activate surrounding microglia deeper within the cortex.  
Meningeal cells are capable of secreting cytokines in response to an inflammatory stimulus 
and can activate glial cells in vitro, suggesting that LTα in the CSF may exert indirect effects 
on glia through activation of the meninges (Wu et al., 2005; Fan et al., 2012). In MS, the 
meninges are likely to be exposed to a more complex pro-inflammatory milieu in the CSF over 
a much greater period of time, leading to long-term activation of meningeal cells, which may 
contribute to the effects of inflammatory meningeal infiltrates through cytokine production, 
activation of glial cells and damage of the underlying GM.  
While microglial activation was substantially increased in naïve animals at 90 days post-LVLTα 
compared to post-LVGFP, activation appeared to be further enhanced in rmMOG-immunised 
LVLTα animals, suggesting an additional effect of rmMOG immunisation on microglial 
activation. As in SPMS, it is currently unknown whether this a cause or effect of the 
demyelinating pathology that was also observed in these animals. Interestingly, rat CSF 
concentrations of human LTα were higher in rmMOG-immunised rats at 28 and 90 days post-
LVLTα compared to naïve LVLTα animals, providing a possible explanation for the apparent 
increase in microglial activation in the rmMOG-immunised group. We suggest that the 
increased concentration of LTα is due to increased activation of transduced cells in the 
meninges, due to factors secreted by infiltrating reactivated autoreactive lymphocytes and 
macrophages in rmMOG-immunised compared to naïve animals (Quinn et al., 1998).  
Since microglial activation was observed in naïve animals at 90 days post-LVLTα in the 
absence of cortical demyelination, we suggest that microglia are not pathogenic to myelin and 
oligodendrocytes in the absence of an anti-MOG response in this chronic model. However, 
infiltration of autoreactive cells to a pro-inflammatory CSF environment may induce production 
of cytokines and a combination of activating factors that induces a pathogenic microglial 
phenotype, resulting in contribution to demyelination. Previous studies have shown phagocytic 
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microglia in close proximity to degenerating myelin sheaths supporting our suggestion of a 
pathogenic role for microglia in the context of an anti-MOG response (Gardner et al., 2013). 
The presence of IFNγ, for example, has been shown to induce a switch in phenotype in 
microglia in response to the same stimulus (Bsibsi et al., 2014) and to induce microglial 
production of nitric oxide in vitro (Meda et al., 1995). IFNγ has been shown to be upregulated 
in F+SPMS meninges, and possibly increased secretion of this cytokine by reactivated 
autoreactive T cells in infiltrates could alter the microglial phenotype (Gardner et al., 2013). In 
addition, autoantibodies may enhance microglial phagocytosis of myelin when an anti-MOG 
response is present.  
7.2.3 Infiltrates and demyelination 
Subpial lesions in both models were associated with meningeal inflammation, consistent with 
findings in SPMS (Magliozzi et al., 2007; Magliozzi et al., 2010; Howell et al., 2011) and in 
marmoset EAE (Kramann et al., 2014). Interestingly, the formation of substantial immune cell 
infiltrates in the meninges at 7 days after injection of LTα and IFNγ or LVLTα was observed 
regardless of prior immunisation, with no obvious difference in size or immune cell proportions 
between immunisation groups. This demonstrates that meningeal infiltration can occur 
regardless of immune cell specificity in response to CNS inflammation, and illustrates the 
action of LTα and/or IFNγ on activating meningeal vessels to facilitate immune cell infiltration. 
This also suggests that the formation of meningeal immune cell infiltrates is not simply a 
consequence of demyelination in the GM. 
The lack of demyelination observed in naïve and IFA-immunised groups in spite of infiltrate 
formation suggests that the effect of infiltrates of similar size, appearance and composition 
depends on the presence or absence of autoreactive, MOG-specific immune cells. We 
suggest that an anti-MOG response is required for the development of autoreactive T and B 
cells and APCs, and that the reactivation of these autoreactive lymphocytes within the CNS in 
rmMOG-immunised animals contributes significantly to demyelination. Indeed, reactivation of 
T cells specific for ovalbumin (OVA) by OVA-presenting APCs in the subarachnoid space, 
results in substantial release of cytotoxic factors including IFNγ and leads to mild EAE 
symptoms, demonstrating that T cell activation status rather than specificity is crucial in 
mediating pathology following CNS infiltration (Bartholomaus et al., 2009).  
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In addition, studies of ectopic expression of LTα have demonstrated that immune cell 
infiltration and formation of TLOs is insufficient to result in local tissue destruction, which 
requires concomitant ectopic expression of a co-stimulatory molecule, suggesting that local 
activation of infiltrating autoreactive cells through APC function in the tissue is crucial to initiate 
and sustain a chronic autoimmune response (Picarella et al., 1992; Guerder et al., 1994). The 
absence of demyelination in naïve and IFA-immunised animals may therefore be due to a lack 
of autoreactive APCs within meningeal infiltrates necessary to provide co-stimulation to the 
autoreactive cells which are present in the normal physiological repertoire. In contrast, 
peripherally primed anti-MOG APCs in subarachnoid infiltrates in rmMOG-immunised rats may 
reactivate autoreactive cells, which would also be present at much higher frequencies 
compared to IFA-immunised rats, resulting in demyelination. 
Our finding that B cells were typically the most numerous cell type in all infiltrates following an 
increase of LTα in the CSF suggests that these cells may play a significant role in pathology, 
as is suggested in MS (Genain et al., 1999; Archelos et al., 2000; Cross et al., 2006; Bar-Or et 
al., 2010). In F+SPMS cases, the development of TLOs may maintain and enhance the 
autoimmune response partly by facilitating the continued production of autoantibodies, which 
are thought to contribute to demyelination in a subset of MS lesions (Storch et al., 1998a; 
Archelos et al., 2000; Lucchinetti et al., 2000; Lassmann et al., 2001; Serafini et al., 2004) and 
in EAE models (Storch et al., 1998b). F+SPMS cases may represent a subset of cases in 
which the immune response is antigen specific, and we suggest that the increased pathology 
observed in F+SPMS cases may be due to increased pathogenicity of intrathecal antibodies, 
resulting from enhanced affinity maturation in TLOs compared to F-SPMS. Predominantly 
antigen-experienced memory B cells, primed in the periphery, infiltrate the CNS in MS and 
then undergo intrathecal affinity maturation (Lu and Robinson, 2014; Palanichamy et al., 2014; 
Stern et al., 2014), and we suggest that the same may occur in our models. Autoantibody and 
complement fragment deposition was observed on myelin sheaths at the lesion edge of 
subpial GMLs following subarachnoid and intracortical injection of TNF with IFNγ in rmMOG-
immunised rats, suggesting that this mechanism may contribute to demyelination after 
increasing LTα and/or IFNγ in the CSF (Merkler et al., 2006b; Gardner et al., 2013). Although 
both previous studies suggest that antibody deposition is a transient effect, this may also be 
the case in MS, since a relative lack of complement deposition has been observed in GMLs 
(Brink et al., 2005). Further work to establish the presence and specificity of intrathecal 
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antibodies in our models might elucidate the role played by autoantibodies in these 
experimental systems. 
Autoreactive B cells may also act as APCs to autoreactive T cells (Rodriguez-Pinto and 
Moreno, 2005), and are important for T cell activation, cytokine expression and cell recruitment 
(Pierson et al., 2013), independent of autoantibody expression (Jagessar et al., 2012). In 
F+SPMS, TLOs may enhance the efficiency of reactivation of infiltrating autoreactive 
lymphocytes, and result in altered cytokine secretion by infiltrating cells exposed to a more 
inflammatory CSF environment compared to F-SPMS cases lacking TLO. Indeed, B cells from 
RRMS patients exhibit abnormal and exaggerated secretion of LTα and TNF, and induce 
increased T cell proliferation, in response to activation in the context of IFNγ, compared to B 
cells isolated from healthy controls (Bar-Or et al., 2010), suggesting that a pro-inflammatory 
CSF environment in MS may potentiate meningeal inflammation.   
Peripheral immunisation with other CNS antigens likely to be presented by meningeal APCs 
may elucidate the role of an existing autoreactive response in contributing to demyelination 
observed in this model. In addition, the contribution of lymphocyte infiltration of the 
subarachnoid space to subpial demyelination observed in the model could be investigated by 
prophylactic treatment with Natalizumab, a monoclonal antibody specific for the α1β4 integrin 
expressed on circulating T cells, which enables tethering to endothelial cells via VCAM-1, a 
crucial step in CNS infiltration (Ransohoff and Engelhardt, 2012). Blocking this interaction has 
been shown to improve EAE course and reduce T cell infiltration (Yednock et al., 1992; Kent et 
al., 1995). It would also help to elucidate the mechanisms behind the increased microglial 
activation observed in rmMOG-immunised animals following LVLTα at the most chronic time-
point, since mediators from reactivated autoreactive cells are suggested to induce increased 
microglial activation compared to naïve animals. 
7.2.4 A complex cytokine milieu may be required for TLO maintenance 
The severe meningeal inflammation observed following acute subarachnoid injection of LTα 
and IFNγ resolved within 21 days, and B cell division was only observed at early time-points in 
the chronic model but not at later time-points, suggesting that these subarachnoid infiltrates 
were not self-sustaining, long-lasting TLOs, complete with fully functional germinal centres 
capable of generating pathogenic autoantibodies, as have been described in other 
inflammatory conditions (Randen et al., 1995; Schroder et al., 1996; Stott et al., 1998; 
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Houtkamp et al., 2001). Possibly TLOs are cleared by the macrophages observed at the later 
time-points in our models, but may be prevented from being cleared in human SPMS and 
other diseases. Or they may also be dynamic structures in SPMS, but this will remain 
unknown until we are able to image TLOs in patients.  
Other lymphoid cytokines may be required in addition to LTα with or without IFNγ to induce 
and maintain TLOs, including CXCL13 and CCL21. Our data has shown that CXCL13 is 
associated with the presence of TLOs, and supports further investigation into its potential use 
as a biomarker for severe meningeal inflammation, as previously suggested (Khademi et al., 
2011). We suggest that proactive treatment with therapies designed to reduce meningeal 
infiltration (e.g. Natalizumab) may prevent formation of TLOs, and at the least reduce the 
damage to GM caused by meningeal inflammation, which ultimately contributes to irreversible 
disability. CXCL13 and CCL21 expression can be induced by ectopic expression of LTα in 
vivo, via TNFR1 signalling (Hjelmstrom et al., 2000). Interestingly however, TLOs were not 
maintained in the chronic model, in spite of upregulation of CXCL13 at 90 days post-LVLTα, 
suggesting that further cytokines may be required in addition. Also, increased CXCL13 CSF 
concentration is associated with other inflammatory CNS conditions, including 
neuroborreliosis, viral meningitis and encephalitis (Krumbholz et al., 2006; Rupprecht et al., 
2009), in which TLOs have not been observed in spite of meningeal inflammation. This 
suggests that a unique milieu of cytokines and chemokines may exist in SPMS, or that a pre-
existing autoimmune response may be required to result in TLO formation and maintenance 
due to the constant presence of autoantigen stimulating a response, preventing resolution of 
inflammation.   
We suggest that LTα is primarily acting via TNFR1 on endothelial cells in subarachnoid 
vessels to induce upregulation of adhesion molecules and inflammation and as has been 
shown previously in vivo, but further studies using concomitant blockade of TNFR1 would be 
necessary to confirm this (Sacca et al., 1998). Systemic delivery of an anti-TNFR1 monoclonal 
antibody has recently shown promise in ameliorating clinical EAE in vivo (Williams et al., 
2014). Subarachnoid delivery of this antibody together with acute subarachnoid injection of 
LTα and/or IFNγ would be expected to severely reduce pathology, if LTα is signalling through 
TNFR1. Chronic intrathecal delivery via a catheter would elucidate the mechanism of action of 
LTα in the chronic model, but systemic administration would give more valuable information on 
the potential of this treatment as a therapy in SPMS. Since we have shown that LTα alone is 
insufficient to maintain organised immune cell infiltrates, further studies will investigate the 
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effect of co-injection of LVLTα with vectors for CXCL13 or IFNγ, which may be more 
representative of the inflammatory milieu of the CSF in MS, as both of these cytokines are 
upregulated in SPMS. Further work will also seek to characterise CNS gene expression 
changes in LVLTα-injected animals more fully than was possible in the current study, to 
understand the mechanisms behind meningeal infiltrate resolution and the requirements for 
formation of self-sustaining TLOs.  
7.2.5 LTα mediates different effects to TNF – channels and TLOs 
Our work demonstrated formation of substantial immune cell infiltrates in the subarachnoid 
space following injection of LTα with IFNγ, in contrast to the less pronounced meningeal 
inflammation observed following TNF with IFNγ previously (Gardner et al., 2013), suggesting 
that LTα has non-redundant roles in inflammation in this model. In addition, the large 
meningeal infiltrates observed following injection of LTα with IFNγ contained many channels of 
variable diameter, indicative of lymphangiogenesis, in which LTα is suggested to play a role 
(Mounzer et al., 2010), or which may indicate the formation of HEVs, as has been described in 
TLOs formed by ectopic expression of LTα (Kratz et al., 1996). Further work will seek to 
establish the identity of these vessels through IF for the LYVE-1 marker of lymphatic vessels. 
Identification of HEVs using the MAdCAM or PNAd markers would require fresh tissue, since 
we were unable to optimize either of these antibodies on the fixed tissue available during our 
studies. The presence of lymphatic channels and HEVs has not been reported in meningeal 
TLOs in MS, but has only been investigated by one small study to our knowledge (Serafini et 
al., 2004). 
7.3 Final conclusions 
The data presented in this thesis has demonstrated that chronic elevation of a pro-
inflammatory cytokine in the CSF, in the context of an autoimmune response, results in 
chronic subpial demyelination, accompanied by widespread, fulminant microglial activation 
and meningeal inflammation reminiscent of type III cortical GMLs observed in SPMS. This is 
the first report, to our knowledge, of a model of chronic demyelination driven by meningeal 
inflammation, and as such holds promise for use in developing novel therapeutics aimed at 
preventing the progression of pathology in SPMS. We have identified the lymphoid cytokine 
LTα as a potential contributor to meningeal inflammation and GML pathogenesis in SPMS, 
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and our data provides support for the development of pharmaceutical agents designed to 
specifically inhibit TNFR1 signalling in the meninges, to reduce meningeal inflammation and 
the associated GM pathology in SPMS. In addition, we have shown that CXCL13 expression 
in the meninges and CSF is associated with the presence of TLOs in SPMS, supporting further 
investigation into its use as a potential biomarker for meningeal inflammation, and early 
therapeutic intervention to minimise meningeal infiltration. We hope that investigation of 
pathogenic mechanisms of disease progression, and testing of novel therapeutics using our 
model of chronic demyelination, will result in discoveries that will ultimately benefit SPMS 
patients.  
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